Page 1

IN THE UNITED STATES DISTRICT COURT
FOR THE WESTERN DISTRICT OF LOUISIANA MONROE DIVISION

STATE OF MISSOURI ex rel. ERIC S. SCHMITT,
Attorney General, et al.,

Plaintiffs,
vs.
JOSEPH R. BIDEN, JR.,
in his official capacity
as President of the United
States, et al.,
Defendants.

THE VIDEOTAPED DEPOSITION OF CAROL CRAWFORD
November 15, 2022
9:24 a.m. to 5:33 p.m.

Office of General Counsel
Centers for Disease Control and Prevention 1600 Clifton Road NE Atlanta, Georgia

Reporter:
Maureen S. Kreimer, CCR-B-1379, CRR

INDEX TO EXAMINATIONS
Examination
CAROL CRAWFORD
Cross-Examination by Mr. Vecchione
DESCRIPTION OF EXHIBITS
Plaintiffs'
EXHIBIT
DESCRIPTION
Exhibit 1 Deposition Notice for Carol Crawford

Exhibit 2 Emails ending 2/7/20 Subject FB
Coordination
MOLA_DEFSPROD_00004442-4445

```
Exhibit 3 Emails ending 3/5/20 Facebook's
COVID-19 Response Efforts MOLA_DEFSPROD_0004060-4061
```

Exhibit 4 Emails ending 3/31/20 CDC brief on 38 ways to reach high-risk and frequent travelers MOLA_DEFSPROD_00003872 and MOLA_DEFSPROD $\overline{0} 0015014-15017$

Exhibit 5 Emails ending 3/30/20 CDC brief on 43 ways to reach high-risk and frequent travelers MOLA_DEFSPROD_00015018--19
Exhibit 6 Emaīls ending 1/26/21 CrowdTangle 49 COVID-19 reports for WHO MOLA_DEFSPRDO_00002595-96
Exhibit 7 Emaīls ending 5/26/21 CrowdTangle
COVID-19 reports MOLA_DEFSPROD_00002591-94
Exhibit 8 Emails ending 3/31/21 re: This
week's meeting
MOLA-DEFSPROD-00003031-33
(CONTINUED NEXT PAGE)

Page 3

Exhibit 9
Emails ending 5/6/21 Misinfo on two issues MOLA_DEFSPROD_00002686-2688

Exhibit 10
emails ending 5/10/21 CV19 misinfo reporting channel MOLA_DEFSPROD002684-2685

Exhibit 11
Emails ending 5/20/21 Agenda item for CDC call this week MOLA-DEFSPROD_00002659-2660

Exhibit 12 Lancet April 2021 article. Bell's 112 palsy and SARS-CoV-2 vaccines

Lancet September 2021 article 112
Bell's palsy and SARS-CoV-2
vaccines - an unfolding story
Document titled Infection fatality 113 rate of COVID-19 in
community-dwelling populations with emphasis on the elderly: An overview

Emails ending 6/2/21 RE It was this 118 list sorry!
MOLA-DEFSPROD_00002538-2541
Emails ending 6/3/21 RE It was this 126 list, sorry!
MOLA-DEFSPROD 00002532-33
Emails $7 / 26 \overline{/} 21$ FB Misinformation
Claims_Help Debunking
MOLA_DEFSPROD_00002478
Emāils endin̄ 7/20/21 CrowdTangle
141
COVID-19 reports
MOLA-DEFSPROD_00002487-2489
Exhibit 19
emails ending 8/18/21 CrowdTangle
145
COVID-19 reports
MOLA-DEFSPROD-00002438-440
Exhibit 20
Emails ending 8/19/21 VAERS talking
150
points 8.15_AH_PM_CLEAN COPY.docx
MOLA-DEFSPROD_00002434-435
(CONTINUED NEXT PAGE)

Page 4

Exhibit 21
9/1/21 Email BOLO: CDC lab alert \& 152 misinformation
MOLA-DEFSPROD 00002249
Exhibit 22 Emails ending 11/2/21 New Claims \& Policy updates following EAU authorization for 5-11 year olds MOLA-DEFSPROD_000011778-779

Exhibit 23
Emails ending 11/8/21 New Claims \& 163 Policy updates following EAU authorization for 5-11 year olds MOLA DEFSPROD_00001774-775

$$
\text { Blōomberg ařticle Frequent Boosters } 164
$$ Spur Warning on Immune Response

Emails ending 2/3/22 Vaccine 166
Misinformation Questions for CDC MOLA_DEFSPROD_00001683-1686

Exhibit 27

Exhibit 28

Exhibit 29

Exhibit 30
Emails ending 4/12/21 Followup on 187
mis-info conversation
MOLA_DEFSPROD_00002936
Emails ending 12/21/21 Omicron page 188 MOLA_DEFSPROD_00001719-21

Emails ending 4/9/21 Request for 196 problem accounts
MOLA_DEFSPROD_00002971
Emails ending 4/14/21 Request for 200 problem accounts
MOLA_DEFSPROD_00002807
(CONTINUED NEXT PAGE)

| 1 | Exhibit 34 | Emails ending 6/30/21 COVID Misinformation | 205 |
| :---: | :---: | :---: | :---: |
| 2 | Exhibit 35 | MOLA DEFSPROD 00002496-500 <br>  | 219 |
| 3 |  | misinformation <br> MOLA-DEFSPROD 00002200 |  |
| 4 | Exhibit 36 | Emails ending 4/15/21 Call or VC Facebook weekly sync with CDC | 221 |
| 5 | Exhibit 37 | MOLA_DEFSPROD_00002806 <br> Emāils endī̄g 4/29/21 CDC Guides | 226 |
| 6 |  | and this week's meeting <br> MOLA_DEFSPROD_00002694-95 |  |
| 7 | Exhibit 38 | Emāils ending 4/30/21 WY issue MOLA DEFSPROD 00002690-91 | 237 |
| 8 | Exhibit 39 | Emails ending 5/6/21 Join with New | 239 |
| 9 |  | Info E call or VC MOLA_DEFSPROD_00002689 |  |
| 10 | Exhibit 40 | 5/10/21 Email COVID BOLO meetings | 241 |
| 11 |  | ```on misinformation MOLA_DEFSPROD_00002683-2682``` |  |
| 12 | Exhibit 41 | Emails ending 6/10/21 CDC COVID_19 | 247 |
| 13 |  | BOLO Meeting <br> MOLA_DEFSPROD_00002521-22 |  |
| 14 |  |  |  |
|  | Exhibit 42 | Emails ending 10/28/21 Booster | 249 |
| 15 | Exhibit 43 | Shots MOLA_DEFSPROD_00001827-29 6/29/22 émail Claìms review | 254 |
| 16 |  | MOLA_DEFSPROD_00001556 |  |
| 17 | Exhibit 44 | Emails ending 3/10/21 Themes that | 257 |
| 18 |  | have been removed for misinform |  |
| 19 |  | MOLA_DEFSPROD_00003159-161 |  |
| 20 |  |  |  |
| 21 | (REPORTER'S NOTE: Original Plaintiffs' Exhibits 1 through 24 and 26 through 44 have been attached to the original deposition transcript.) |  |  |
| 22 |  |  |  |
| 23 |  |  |  |
| 24 |  |  |  |
| 25 |  |  |  |

Page 6

| 1 | APPEARANCES OF COUNSEL: <br> On behalf of the Plaintiff State of Missouri: |
| :---: | :---: |
| 2 | D. JOHN SAUER, ESQ. <br> Missouri Attorney General's Office |
| 3 | Supreme Court Building 221 W. High Street |
| 4 | $\begin{aligned} & \text { P.O. Box } 899 \\ & \text { Jefferson City, Missouri } 65101 \end{aligned}$ |
| 5 | John.sauer@ago.mo.gov (877) 696-6775 |
| 6 7 | On behalf of the Plaintiffs Dr. Jayanta Bhattacharya, Dr. Martin Kulldorff, Dr. Aaron Kheriaty, and Jill Hines: |
| 8 | JOHN J. VECCHIONE, ESQ. |
| 9 | New Civil Liberties Alliance |
| 10 | 1225 19th Street N.W. |
| 11 | Suite 450 |
| 12 | Washington, DC 20036 |
| 13 | John.vecchione@ncla.legal |
| 14 | (202) 869-5210 |
| 15 | On behalf of Centers for Disease Control and |
| 16 | Prevention: |
| 17 | JAMES GILLIGAN, ESQ. |
| 18 | KYLA SNOW, ESQ. |
| 19 | U.S. Department of Justice |
| 20 | 1100 L Street N.W. |
| 21 | Washington, DC 29530 |
| 22 | 202-353-3098 |
| 23 | James.gilligan@usdoj.gov |
| 24 | Kyla.snow@usdoj.gov |
| 25 | (Continued next page) |

Page 7

```
    On behalf of U.S. Department of Health & Human
    Services:
        ANANT KUMAR, ESQ.
        U.S. Department of Health & Human Services
        200 Independence Avenue S.W.
        Washington, DC 20201
        Anant.kumar@hhs.gov
    Also Present:
    Kenya S. Ford, Esq.
    Sudevi N. Ghosh, Esq.
    Centers for Disease Control & Prevention
            Melissa Thombley, Esq (via Zoom)
            U.S. Department of Health and Human
            Services
            Joseph Foster, Esq. (via Zoom)
            Centers for Disease Control & Prevention
                    Legal videographer: Jason Silling, Lexitas Legal
                        (Pursuant to Article 10(B) of the Rules and
                        Regulations of the Georgia Board of Court Reporting,
                        disclosure was presented to all counsel present at
                        the proceeding and a written copy is attached
                        hereto.)
```

Page 8

THE VIDEOGRAPHER: We are on the record. Today's date is November 15, 2022. The time is 9:24. This is the video-recorded deposition of Carol Crawford in the matter of the State of Missouri versus Joseph R. Biden in the U.S. District Court for the Western District of Louisiana.

This deposition is being held at the CDC. The reporter's name is Maureen Kreimer. My name is Jason Silling. I am the legal videographer. We are with Lexitas Legal. Would the attorneys present please introduce themselves and the parties they represent.

MR. VECCHIONE: I am John Vecchione. I represent the individual plaintiffs Jay Bhattacharya, Aaron Kheriaty, and Jill Hines and Martin Kulldorff.

MS. SNOW: My name is Kyla Snow. I'm with the Department of Justice representing the defendants in this case. And defendants reserve their right to review, read, review and sign the transcript.

MR. GILLIGAN: James Gilligan, also with the Department of Justice representing the defendants.

MR. KUMAR: Anant Kumar with the Office of

Page 9

1 General Counsel in HHS, and I also represent the 2 defendant. I represent the HHS defendants.

BY MR. VECCHIONE:
Q. Good morning, Ms. Crawford. Have you ever been deposed before?
A. No, I have not.
Q. All right. So I'm going to lay out some ground rules. We have to -- the court reporter and everything else can only pick up verbal cues. In normal conversation, we nod our heads like you're doing now and all that, but for the record we have to say things out loud. And that also, to keep a clear record, we have to try not to talk over each other. And that's really something the lawyers, we say to the lawyers, because they're the ones who interrupt, not the witness. But keep that in mind.

If you don't -- I will be asking

1 questions. If you don't understand the question, you can ask me to rephrase, or say you don't understand. Don't answer a question that you think you don't understand. If during the course of this, your counsel -- which of you is defending this one? You're going to defend it?

MS. SNOW: Yes.

## BY MR. VECCHIOINE:

Q. So your counsel will make objections. Wait for the objections to fade, and then answer the question unless $I$ rephrase or something like that, unless she instructs you not to answer.

Let's see. So do you agree with all that? Do you understand the process?
A. I understand. Could you speak up a little, though? It's hard for me to hear you.
Q. I can. You know what, I didn't turn on this. I was dealing with the other mic that $I$ have on my tie.
A. Thank you.
Q. But in any event, so.

All right. Are you taking any
medications, or do you have any condition that would impact your ability to testify truthfully today? A. No.

Page 11
Q. All right. For the record please state your name.
A. Carol Young Crawford.
Q. And what's your current employment?
A. I work for the CDC.
Q. What's your title?
A. I am the division director for the division of Digital Media within the CDC Office of the Associate Director for Communication, which we call OADC.
Q. Give me the term again. Office of?
A. The Associate Director for Communication.
Q. And what are your duties in that role?
A. Our division provides leadership for CDC's web presence. We provide leadership for CDC's social media presence. We have -- we lead the development operations of CDC's 800-number, which is our Contact Center. We also provide graphics and visual design services for the Agency.
Q. And what do you do?
A. I'm the director of that work. I determine strategy, objectives, oversee work.
Q. Do you have any -- well, why don't we start. Go back a little bit.

Could you briefly outline your education

Page 12

1 and employment history up until now?
A. Yes. I started work at CDC when $I$ was 18. So I have been here 34 years. I went to school -- I have a bachelor's in business and a master's in public administration, and I have been working at CDC within digital communications, web, social media, for really as long as those things existed at CDC.
Q. And where are your degrees from?
A. University of -- the University of Georgia for the master's, Georgia State for the bachelor.
Q. Okay. So have you always been at CDC here in Atlanta?
A. Yes.
Q. Did you have any back- -- do you have any background in medicine, sciences, or epidemiology?
A. No.
Q. And is there anything else about the role of the division of Public Affairs' place within CDC that you haven't told me? Is there anything --
A. Can you repeat?
Q. Yeah. You have told me a little bit about what the division of Public Affairs does, I believe, or was that only what OADC does?
A. I was referring to the division of Digital

Page 13

Media.
Q. Okay.
A. Which was created in April of 2022. Or maybe March 2022. Sorry.
Q. On or about, as we say.
A. Yes.
Q. Now -- well, let's go back to that, the division. The division of Public Affairs, you're within that at the CDC?
A. There is no division of Public Affairs in OADC any longer.
Q. What happened there?
A. The reorganization of OADC occurred in March or April of 2022, and there's -- that division does not exist anymore.
Q. Prior to this changeover what did that division do?
A. The division had three branches. The division -- I mean, the branch of Digital Media, where I was, the branch for News Media, and a branch for Employee Communications.
Q. And then what did the reorganization do with each of those three? Where did they go?
A. The -- well, Digital Media became the division of Digital Media, and parts from other

Page 14

1 divisions came to join the work that we were already

1 organization that had that role before April of March of 2022?
A. I was the branch chief of the Digital Media Branch within the Division of Public Affairs, and most of the roles that our division currently performs, web and social media, were in that branch.
Q. Thank you. Did anyone else have overlap before?
A. No.
Q. All right. So what is the current duty of the Division of Digital Media?
A. The current?
Q. Duties?
A. Of the division of Digital Media? We provide leadership for CDC's website. We provide leadership for CDC's social media efforts. We provide graphic support for the entire agency, and we manage the 800-number, the Contact Center.
Q. Okay. And what's -- what is leadership; when you use that word, what do you mean?
A. We, for web, for example, we convene a web council with people across CDC to manage the governance of the website. We manage the web content management system. We draft policies and guidelines around it.

Page 16
Q. In your current role since April or March of 2022 --
A. Mm-hmm (affirmative).
Q. -- have you had any contact with major technology companies such as Twitter, Facebook, LinkedIn, Microsoft or Google?
A. Yes.
Q. In your previous role before the reorganization, did you have such contacts?
A. Yes.
Q. Generally what type of contacts are those when you started them?
A. We started regular contact with the groups at the beginning of the COVID outbreak to exchange information about COVID, and most of the contact since then has been around COVID or other high-priority things, but mostly COVID.
Q. Okay. Let's get some timeline down. Is the beginning of COVID, would you think, February or March of 2019?
A. 2020 .
Q. 2020. Excuse me.
A. Yes.
Q. Okay. For our purposes. All right.
A. $M m-h m m$ (affirmative).
Q. So before that, social media had been around for a while, I mean, but did -- you didn't have contact with them before COVID?
A. I had periodic occasional contact with the platforms, depending on maybe they would reach out to CDC for something, or we would be trying to reach out to them for assistance with something. I didn't have regular meetings. They were -- they were very occasional.
Q. All right. COVID hits, let's say, early spring of 2020.
A. Mm-hmm (affirmative).
Q. How did you instigate contact with these systems? Generally, I'm speaking. I know there may be some differences, but generally how did you initially instigate contacts with them?
A. I don't recall who initiated contact.
Q. Does that mean you don't know who within CDC, or does that mean you don't know if they called you?
A. I don't recall if they called us first, or we called them first. It could have differed also depending on the platform.
Q. From media company to media company?
A. There was a lot going on at that time, so.
Q. Do you have a present recollection of when you first spoke to any media platform about COVID, or email, when I say -- had communications with?
A. I believe, my recollection is, is that we started talking to some of them in February and March of 2020.
Q. And what was the nature of the discussions?
A. My memory of our first interactions were around getting out CDC-credible information. For instance, $I$ know Facebook was looking at making it easier to find COVID information from the CDC and WHO on a platform, and they wanted to use our public domain content and they were similar in conversations with platforms.
Q. Got it. And did you take the initiative in these meetings, or did someone direct you to go do these meetings, or contacts?
A. I would say I took initiative on the meetings. But there were a lot of people asking staff, or other staff, are we -- were we in contact with the groups, and do we have any arrangements.
Q. In your current role who do you report to?
A. In my current role I report to the director of OADC, which is Kevin Griffis.
Q. And who did you report to prior to the reorganization? That a good word.
A. Yes.
Q. Can $I$ call it a "reorg"?
A. Yes, you can.
Q. Prior to the reoorg, who did you report to?
A. I reported to the division director for the division of Public Affairs, who was Michelle Bonds.
Q. All right. So during the beginning of the pandemic your direct report would be Michelle Barnes [sic]?
A. I was her direct report.
Q. Yes, that's what I meant.
A. Yes.
Q. You would directly report to her?
A. $M m-h m m$ (affirmative).
Q. All right. So do you recall her talking to you about what to do with the social media companies early on?
A. I don't believe we discussed it.
Q. And why don't you believe that?
A. It was an extremely busy time, and it was within the scope of work $I$ would normally handle.
Q. All right. Let's look at the early spring of 2020. What were the types of contacts you had with the social media companies? And I'm going to go through some, and you tell me if you had them.

Electronic email, or other communications that are electronic?
A. Yes.
Q. Telephonic?
A. Yes.
Q. And in person?
A. No.
Q. Okay. Who did -- if they're telephonic, who were you speaking to? I have a hard time getting any of these people on the phone. How did you get -- who did you telephonically speak to at any of these social media companies?
A. I had points of contact at several of them, and we would have meetings when we needed to talk. So we arranged calls.
Q. Do you recall any particular points of contact?
A. Yes.
Q. Who are they?
A. At Facebook my primary point of contact was Payton Iheme. I-H-E-M-E. At Google my two

Page 21

```
points of contact were Jan Antonaros, and -- forgive
    me. I'm blanking on this.
    Q. We'll be looking at emails. If you see
    the name, will you --
    A. Yes, mm-hmm.
    Q. Who else?
    A. A contact we had at Twitter was Todd
    O'Brien [sic], though I spoke to him very rarely.
    We had other contacts at Twitter, but I don't know
    their names too. I don't recall the names of other
    platforms. I didn't talk to them as regularly.
        (Plaintiffs' Exhibit 1 marked.)
        BY MR. VECCHIONE:
```

            Q. Okay. Can you take a look at Exhibit 1.
        If counsel would hand it to her, please.
            And have you seen this document before?
            A. Yes, I think I did.
            Q. So this is the Notice of Video Deposition
        to be here today; right?
            A. Yes.
            Q. You're here pursuant to this notice?
            A. Yes.
            Q. All right. And I'll just make one
        correction. We're not at Building 21. We're in
        Building 19?
    Page 22
A. That's correct.
Q. All right. Thank you. You can put that aside.

MR. VECCHIONE: I'm going to hand to counsel a packet of Exhibit 2, if I might. And if you could give -- and if you could give the witness an original, and there are two for your purposes.
(Plaintiffs' Exhibit 2 marked.)
BY MR. VECCHIONE:
Q. I'll give you a moment to read through it. Do you recognize this?
A. Yes.
Q. All right. What is it?
A. An email chain with Facebook around COVID.
Q. Yeah. Early February 2020?
A. Yes.
Q. Let's get -- just so we can get onto the same page, the way this email chain works is the oldest part is in the back; right? And then it reads up.
A. Yes.
Q. And let's go to the back. In the first part of the chain, as far as $I$ can see, it says from Carol Y. Crawford?
A. Yes.

Page 23
Q. All right. And there is a -- there is an email there. Well, could you read that for me, your email?
A. "Payton, just looping you in on something."
Q. Oh. No, no, no. I mean, I want to get the email down. I think it's C -- because of your -- I think it's @CDC.gov?
A. Mm-hmm (affirmative).
Q. Am I correct about that?
A. That's mine, yes.
Q. Okay. And is that the only email, government email, you used over this whole period, or is there a different one?
A. There is a -- it's the same email box, but there is also @CDC.gov. It's like an alias for @CDC.gov. It's the same box.
Q. They all go to the same place?
A. Yes.
Q. It's just how the computer reads it, or?
A. It's just an easier email address for someone to give people --
Q. Quicker to write?
A. -- than
Q. Do you have any other government --

Page 24
A. No.
Q. And how about have you contacted any of the social media companies with a personal email?
A. Never.
Q. Okay. So and then this is -- I believe this is a fellow we identified earlier; right? Who's Payton Iheme?
A. Yes.
Q. And if I see @ fb.com, that's your understanding that's Payton Iheme --
A. Yes.
Q. -- that's his email? And then it says cc $\square$, and then there is an $\square$ Facebook [sic]
@CDC.gov". Who is that?
A. Jay Dempsey worked -- works now and within my branch as the social media lead, and he reported to me.
Q. Okay. And his has nothing to do with Facebook as in Payton's email; right --
A. No.
Q. -- it's just a coincidence?
A. It's his user ID, yes.
Q. All right. Thank you. And what was his role?
A. He was the social media lead within my

Page 25
branch.
Q. Okay. And what do you state here in this email to Payton?
A. (As read) Just looping you in on something Jay and I had awareness of. Are you in the loop with this.
Q. All right. And what is this? What have you attached here?
A. I don't remember this part of the chain at all, but it appears to be a note from Facebook to someone at the State Department outlining some Facebook work on COVID.
Q. And let's get some terms down here. The reason you believe that, is that just from your memory, or is that because it's Shelley Thakral -it's from them to a person in the State Department?
A. I don't know any of the names on the email.
Q. Okay.
A. I read this. This is the first thing I read when you handed --
Q. Yeah.
A. -- me the document.
Q. Got it.
A. I started at the back.

Page 26
Q. So I'm just trying to be clear. You don't have a present recollection of what this is --
A. No.
Q. -- what you just told me you got because that's what it says; right?
A. No. I don't remember that part of the chain, no. No.
Q. And were you asking Mr . Iheme whether he knew about this, or was he responsible for it? Which what does it mean "in the loop about it"?
A. As a note, Payton is female.
Q. Okay.
A. I mean, I'm reading what I wrote: Just looping you on something Jay and I had awareness on. Are you in the loop with this?

That's all I know. It's what I typed.
Q. You don't have any other understanding than that?
A. No.
Q. All right. Let's move to the next part of the chain.
(REPORTER'S NOTE: Mr. Sauer enters deposition.)

BY MR. VECCHIONE:
Q. I see it's from Payton, from Ms. Iheme, to

Page 27

1 you and cc'ing Dempsey; right?
A. Yes.
Q. And he's responding to your request about the loop. What does he say there?
A. At 3:35 for Payton is what you're asking me?
Q. Yes, I am. Thank you.
A. Okay. (As read) Let me know if you're -you would like to speak to our teams working on these items.

Do you want me to read the whole email?
Q. Yes, please.
A. Okay. (As read) Our teams at Facebook have been working to identify how we can support efforts to provide users with accurate and timely information about coronavirus. We would like to get CDC's feedback on a few key initiatives that we are considering launching in the coming days, weeks. I have outlined the specifics below, and would greatly appreciate your thoughts on the tactics and proposed design/content. We would be happy to jump on a quick call today or tomorrow if that would be easier as well."
Q. All right. That's great. That's -- okay. And then he has a bunch of proposals, like three

Page 28

1 proposals; correct?
A. Yes.
Q. All right. And you respond to him the next day?
A. Yes.
Q. All right. And you say "sorry for the delay."

Were you in the habit of responding to him faster than less than 24 hours on these matters at that point in time?
A. Payton is female.
Q. Yeah, I heard. Thank you.
A. It's okay.
Q. You know what Payton I'm thinking of?
A. No.
Q. The football player.
A. Oh, sorry.

I don't know. At this time $I$ believe we were working a lot of hours, and a few hours seemed like a long time. I don't think I -- I don't think Payton and I had known each other via email very long at this point, so I can't speculate on how quick I normally email her.
Q. Okay. And you say in here in item one: As well, if can rotate messages, there might be
times we might want to address widespread myths like mask use or new issues.

At this time what was the myth of mask use?
A. My general memory of mask use was that there was confusion about whether people should wear masks or not.
Q. And what was CDC's view at that time?
A. I really can't speak to our recommendations. I probably don't have the specific recall of the timelines.
Q. Okay. And then your next sentence: "This could and should replace flu shot messaging."

And was that messaging that the platforms were already doing about flu prior to COVID?
A. This was one of the occasional interactions that $I$ recall having with Facebook. They had -- I believe -- I believe they approached CDC about flu messaging that prior flu season, and we had had a few phone calls with them and our flu division. And my recollection is that we provided them with some public domain content for them to highlight.
Q. Okay. And then the next one is you're still trying to get this phone call together. And

Page 30

1 eventually you get a phone call together; right?
A. It looks like it from this chain, yes.
Q. Okay. Can you tell us who was on that call besides Payton and you?
A. I don't recall the specific calls from that time period.
Q. Okay. And do you know what was said on the call at all, what you discussed?
A. On that specific call, I do not.
Q. Do you have any notes, calendars, or other

```
9:57.
```

Page 31
(Recess 9:57 a.m. - 10:09 a.m.)
THE VIDEOGRAPHER: We are back on the record at 10:09.

MS. SNOW: If I could just --
MR. VECCHIONE: Go ahead.
MS. SNOW: Defendants just wanted to note that at the request of plaintiffs' counsel we've forwarded a Zoom link with a call-in number for counsel, for plaintiffs' counsel, who could not be here at the deposition to listen in. And with the agreement of the parties, the Zoom link will not be shared with others beyond the three plaintiffs' counsel who are listening in and the Zoom, the deposition will not be recorded using the phone, the call-in number.

MR. VECCHIONE: Remotely by them. Just by him. (Indicating videographer.)

MS. SNOW: Yes, yes. Exactly, yes. Thank you. And then we also just wanted to -- the witness wanted to clarify a point during the last round of questioning. BY MR. VECCHIONE:
Q. Go right ahead.
A. In reviewing this email, it refreshed my memory about roles.

Page 32
Q. Are you looking at Exhibit 3 or 2, for my purposes?
A. 2 .
Q. Thank you.
A. I recalled that during the time of these emails, I was actually serving as the acting director for the division of Public Affairs. I served in that role for, $I$ think, five or six months.
Q. Was that an add-on to your other duties, or instead of, or like was it -- how did that come about?
A. Michelle Bonds had gone on a detail somewhere else. I don't recall where. Sorry. But I was still really -- especially when COVID hit, I really started also focusing on digital in-depth. So that's why I was still involved. I mean, digital was still part of the division of Public Affairs, so it was still part of my portfolio, but I had the expertise on it, so.
Q. All right. Thank you for that. And during the day if there is any -- you have further recollection as further documents get put in front of you, feel free to interrupt me and tell me that.
A. Okay.

MR. VECCHIONE: Does the witness have
Exhibit 3 in front of her?
MS. SNOW: There you go.
(Plaintiffs' Exhibit 3 marked.)
MR. VECCHIONE: This is a short one. Take
a second to take a look at it.
BY MR. VECCHIONE:
Q. Do you recognize this document?
A. No.
Q. Can you tell me what the subject line is of the first email on the chain?
A. Facebook COVID-19 Response Efforts.
Q. All right. And it's from Ms. Iheme that we've spoken about before to you; correct?
A. Yes.
Q. And it says: "Apologies for the late note," she says to you. I want to ensure you -- "I want to ensure you are aware that Mark just shared our ongoing work to support government."

Who's Mark?
A. I don't know for sure, but I'm assuming this was Mark Zuckerberg.
Q. And she says to you: "Our goal is to help organizations to get their safety message out to the public, remove misinformation, and support overall

Page 34

1 community efforts in areas where we can be of help;" 2 right?
A. Yes.
Q. Now, the next thing I see is above that it says on "March 5, 2020, at 8:55 a.m. Crawford, Carol Y...wrote," is that an email, is that a reply email from you to her?
A. Yes.
Q. You say there: "We want to do a very controlled Q\&A and would like to know our best options."

What are you referring to there, what's going on?
A. I believe this is in reference to a Facebook Live event that we were trying to plan, and it was going to be -- we expected it to be pretty big, and we were asking for help in setting it up in the best practices.
Q. Was that from a technological standpoint, like, how it was going to work, or did you need their input on information?
A. My memory is that it was mostly about how it would work. We had not done many big Facebook Lives before then, and we were worried about having, like, thousands of $Q \& A$ that we couldn't possibly

Page 35

1 answer.
Q. All right. And the next thing you say there is: "Our lead POC" -- is that point of contact, when I see POC?
A. Yes.
Q. Is Kat Turner at $\square$-- I'll say
A. $\quad$.
Q. @CDC.gov. So who is that?
A. Kat was a social media coordinator in one of our centers that was willing to help manage this effort.
Q. In the original email from Payton Iheme what was your understanding of why she was sending you this information?
A. I don't recall the specific email, or -there looks like there is a link -- or what it said, or what it was about. But they would often forward posts from their corporations for awareness for us. So I assume that was probably what this was about.
Q. Okay. And then your final email on the chain you send your -- that's your phone number at work, I take it?
A. It's actually my personal cell that $I$ use as a what CDC calls "bring your own device."
Q. Got it.

Page 36

1
A. Yes, but it was the cell phone.
Q. It's your cell number you use?
A. Yes.
Q. Did you message through that cell to any of the social media companies?
A. The only time $I$ recall using my cell phone to message anyone was like we're late for the meeting, or the contact number didn't work or something like that. We didn't have any kind of conversations on texting.
Q. Do you recall whether you spoke to Payton Iheme at this time?
A. No.
Q. Now, this is -- from my understanding is this call that you're referring at the top, your last part, is that to arrange the Facebook meeting, or is that the Facebook meeting, the $Q \& A ?$

MS. SNOW: Objection. Vague.
BY MR. VECCHIONE:
Q. Okay. So let me tell you -- the reason it's vague is because $I$ don't understand something.

Here's what I'm trying to understand from information. Originally Ms. Iheme writes to you about this information. And then you say you want a controlled Q\&A; right? On Facebook. And then

1 somehow you're going to -- you're going to arrange that with them and Kat Turner.

And then you say I'll -- here's my number, and Kat knows it, $I$ have an appointment.

Did you have a conversation is what I'm getting about besides the Facebook Q\&A?
A. I don't know. But we talked pretty regularly around this time, so I imagine we probably did talk. But $I$ don't know that for sure.
Q. All right. What was your understanding of Ms. Iheme's statement that the -- Facebook was going to help organizations remove misinformation?
A. I don't recall a recollection of discussing misinformation with Payton around this time, so I can't speculate.
Q. You don't have a present recollection of what that meant?
A. No.
Q. All right. And once again for this call that you had, and maybe Kat Turner was on it, maybe she wasn't, do you have any record of that call, or what might have been said?
A. It doesn't look like this had an appointment associated with it, so I don't think there's an appointment, and I don't know -- I don't

Page 38
remember the call, so I don't recall if there were notes. But $I$ know in general very little notes were kept.
Q. Now, you said you don't recall many conversations about removing misinformation at that time. When do you recall such conversations?
A. I remember it becoming occasionally discussed in the fall of 2020 perhaps.
Q. Okay. And what do you recall being discussed at that time?
A. I can recall us generally saying things to the effect of -- I don't remember any specifics, but misinformation is really growing, or, you know, what do you think we could be doing to address it? That kind of conversation.
Q. All right.
A. Very general.
(Plaintiffs' Exhibit 4 marked.)
BY MR. VECCHIONE:
Q. Fair enough. Let's move on to Exhibit 4.
A. Okay.
Q. All right. And I'll give you a moment to take a look at that.

All right. Have you had a chance to review?

Page 39
A. Yes.
Q. Do you recall this email?
A. No.
Q. All right. Well, let's talk about it and who these people are because I think we have some new folks.

So what's the subject line of the first, the email there at the top?
A. CDC brief on ways to reach high-risk and frequent travelers.
Q. All right. And what is the CDC brief? What does that refer to?
A. I don't -- I don't recall what the brief was.
Q. Okay. But as -- my question is a little broader than that. We're lawyers.
A. Mm-hmm (affirmative).
Q. We write briefs all the time; right? They are actually physical pieces of a paper that we put forth our arguments for. Sometimes people use that term as bullet points, or sometimes their positions, even just orally stated.

What I'm trying to get at is what does "brief" mean in this context?
A. To me, a brief probably was a one- or

```
two-page summary of something that we, or they, were
```

trying to do.
Q. Now, this email exchange I think occurred sometime at the end of March 31st; is that correct?
A. Yes.
Q. All right. And it was between you and Kevin Hatcher, and his email is @fb.com?
A. That's what the email says.
Q. All right. Who is Kevin Hatcher?
A. Oh. That says -- I don't have a clear recollection. There was a lot going on during this time beyond any of this work. But I think that Kevin Hatcher might have been some type of instructional designer with Facebook that I -looking at the units and the Unit 1 and Unit 2, there was an effort to put together like learning modules that communities could use. I think that that might have been what this was about, and that that was Kevin's role.
Q. All right.
A. I cannot be sure, though.
Q. All right. But from your understanding of what this says --
A. Mm-hmm (affirmative).
Q. -- and how it worked, that is your best

Page 41

1 understanding right now; whether it's right or wrong

1 in a way $I$ we don't. If ARTF doesn't suggest an edit, we can."

Do you know who ARTF is?
A. I don't. But I believe it's probably a CDC task force. TF would be task force. I don't know what AR is.
Q. Got it. Do you know what Mr. Hatcher was referring to where it says: "Emergency warning signs include difficulty breathing"? Do you know what that was referring to?
A. I only know what I'm reading here.
Q. Right.
A. The unit that he was developing must have had this wording, and he was asking for clarification on what the wording should be.
Q. All right. And do you have an understanding, or do you know, why Mr. Hatcher was asking whether Facebook should add extreme before emergency warning signs?
A. I have no recollection of it.
Q. Okay. Do you know why Mr. Hatcher asked whether he should replace: Older people are at high risk from severe illness from COVID to people over 65? Do you know if there was any messaging from CDC at that time?

Page 43
A. I do not know.
Q. All right. Do you know now sitting here whether there is any preference by digital media at CDC's digital output right now, for either of those terms?
A. I do not know because our office does not write the content.
Q. Okay. You can put that aside.
A. Okay.
(Plaintiffs' Exhibit 5 marked.)
BY MR. VECCHIONE:
Q. Take a minute, take a look at that.
A. Okay.
Q. You've got it?
A. Mm-hmm (affirmative).
Q. So I think we don't have any new players; right? These are all the same people we talked about before, you and Ms. Iheme and Mr. Hatcher.

Can you tell me what the subject of this email string was?
A. CDC brief on ways to reach high-risk and frequent travelers.
Q. Okay. And I think this is March 30th?
A. 2020, yes.
Q. And so I guess it's before the one I

1 showed you that was March 31st, Exhibit 4?
A. I don't have that exhibit, but I assume that's correct.
Q. Okay. We can compare it.

Can you go to the very beginning of the string on this?
A. $\mathrm{Mm}-\mathrm{hmm}$ (affirmative).
Q. There is a blacked out "from," and then it says: "When: 3:30-4:30, Subject: CDC brief on ways to reach high-risk and frequent travelers."

Do you see that?
A. Yes.
Q. What is that?
A. It looks like an appointment for a phone call.
Q. Okay.
A. But I'm not -- it's not fully there.
Q. Yeah. Would Facebook be sending that to you, or is that just at the bottom of his email? Do you have any understanding of how it works?
A. They have a different email system than we have, but it looks similar to someone forwarding on an appointment and using the chain as an email, though I don't know that for sure.
Q. Got it. And this starts at a March 27th

Page 45
email from him to him -- or from her to herself and you; correct?
A. Yes.
Q. And then there is a Margaret E. Silver. Who is that?
A. She was with our Travelers Health group. I believe that's where she was.
Q. And what was the Travelers Health group?
A. We have a unit at CDC that focuses on traveler's health. There is a website on traveler's health.
Q. And who's Caroline Seman?
A. I believe she was also with Travelers Health.
Q. All right. And then I see Dempsey. Is that the same Dempsey we saw before?
A. Yes, yes.
Q. Does that -- and then
A. That's still Jay Dempsey.
Q. Still Dempsey, it's just split; right?
A. Mm-hmm (affirmative).
Q. So Ms. Iheme says to you: "Hi, Carol and team. As relayed on the call, we're happy to target additional populations such as youth as the content becomes available. Just let us know. For the first
wave, we'd like to move forward with launching this next week," I think it's "ideally April 3rd to the groups for which you already produced content (older adults, HIV plus, asthma and pregnant women)."

Do you know whether that's for travelers, or just general populations?
A. That was for general populations.
Q. All right. And how do you know that?
A. I have some recollection of this project.
Q. Okay.
A. It was like units of information on COVID that Facebook communities could attach to their groups. And I'm not 100 percent sure about this, but I think we asked about travel, and then they mentioned the idea of this project and said if you have content for -- that would help other groups, we could do similar things.
Q. Okay. And then he then asks how you want this to read on the Facebook's sites, whether sourced from CDC, or authored by CDC?
A. Yes, I see that.
Q. Do you know what the answer was to that?
A. I don't recall which one we picked, but I'm pretty sure it was one of the sources.
Q. Okay. Let's go up to the next, the March

1 27th, 3:01 p.m. testimony and the document. BY MR. VECCHIONE:
Q. Okay. You can answer.
A. I don't have the attachments or the documents, so I don't know what we were editing or not editing. But we had content on the website, but the format of the units was slightly different. So we had to take the content from our website and have it fit in the units.
Q. Okay.
A. And they requested CDC's review of that.

Page 48
Q. All right. Do you know why in the part where he says: "If we don't launch next week we'll be pulled onto other COVID-19 projects, hence the urgency," do you know why he's asking you about when they should launch?
A. I don't think he was asking me about when we should launch. I think he's letting us know if we don't launch they may not get to it.
Q. All right. And do you know if those, if he's referring to other COVID projects he has with CDC, or just generally?
A. I don't know for sure.
Q. You can put that aside.
A. Okay.
Q. Just one more question about that. Is he creating a Facebook page for CDC, or just for Facebook, do you know?
A. My recollection of what this project was, it was like units that would exist in Facebook that like if you're in a group on travel that the group administrator could provide a link to these units if people wanted additional COVID information. They are not up any longer and my memory is vague on them.

MR. VECCHIONE: Got it. Thank you.

Page 49
(Plaintiffs' Exhibit 6 marked.)
BY MR. VECCHIONE:
Q. Take a moment to look at this. This is Exhibit 6. The mark may look like a 4, but I assure you it's Exhibit 6.

All right. Do you recognize this
document?
A. No.
Q. But do you know what it is?
A. Yes.
Q. What is it?
A. It's a discussion about access to or for Facebook giving us CrowdTangle COVID reports.
Q. All right. And let's talk about this a little bit. We're more forward in time; right? This is sometime in January 2021?
A. Correct.
Q. And I think both dates say January 26 , 2021. Would you agree with me there?
A. Yes. Well no, the first one is January 25th.
Q. All right. See, that's why we have witnesses.

All right. The first thing is what's CrowdTangle?

Page 50
A. I have not used CrowdTangle personally, but I've seen it demonstrated. But it is to my -my description of it is it's a social media listening tool for Meta properties.
Q. What are Meta properties?
A. Like Instagram and Facebook.
Q. Okay. So by Meta properties you mean properties of the company Meta, not on some other level of?
A. No.
Q. Okay.
A. Their platforms.
Q. Got it. Thank you.

Let's look at that January 25th email, because I think we have some new people here.

There is Payton Iheme, and you. It's from her to you. And you cc Lauren Balog Wright at Facebook. Do you know who that is?
A. I think that Lauren, just from reading this, she was the person that was the CrowdTangle expert and was going to provide the reports.
Q. Okay. And Priya Gangolly?
A. Priya Gangolly I interpreted to be like an assistant to Payton.
Q. And Kelly Perron?

Page 51
A. And from this email I believe Kelly was also going to provide the CrowdTangle reports.
Q. And it says: Subject CrowdTangle COVID-19 reports for WHO.

Not to channel Abbott and Costello, but who is that?
A. World Health Organization.
Q. And why were they asking you about information to WHO?
A. Well, I do have -- after reading this I do recall the conversation a bit. But what they are saying in this email is we provide this report to WHO, and we can provide it to you as well.
Q. Okay. What do you remember of the conversation?
A. Just that they -- I believe they mentioned on a call that they could possibly do this, and this is a followup email. And they shared the reports and occasionally they would ask me on the call if these reports were helpful.
Q. And let's see what he says here, what she says here. "Hi, Carol, I am following up on our conversation several weeks ago about providing more detailed reporting from our CrowdTangle team. I wanted to share our first CrowdTangle COVID content

1 report with you courtesy of Lauren and Kelly on this cc. They are providing these to WHO, thought it helpful for CDC's teams as well." And then she says what the time period of it is, and that these are going to be biweekly.

What kind of information was in the CrowdTangle? What did it provide you?
A. Well, I don't have a clear recollection of the reports because I sent the reports to other teams. But typically social media listening reports show themes and -- of discussion on social media channels.
Q. Okay. And so if you look down further I'll just ask you again some words that I think I know what they mean, but we might as well put on the record.
(As read) Lauren, can you -- can do that "distro."

That's distribution?
A. Yes.
Q. And "the full report is attached but some highlights the CrowdTangle team would like to call to your attention are: Top engaged COVID and vaccine-related content overall across Pages and Groups." And it says "largely a mix of educational
posts, reports of successful vaccinations," and it goes on. And then "news/commentary on COVID and vaccination rollout."

So does this -- is this like an algorithm that shows you where -- what people are talking about?
A. I wouldn't characterize it as an algorithm. But it's a search of content on social media, and a summary of the higher volume conversations. It's helpful for communicators to know what is being discussed because it helps improve our communication materials.
Q. All right. And then he says: "However, posts falling into the following themes, all of which have potential risks, also garnered high engagement." And then he has reports of healthcare workers refusing the vaccine; right?
A. Yes.
Q. And he says there was an article in Forbes about it?
A. Yes.
Q. Posts about alleged vaccine-related deaths?
A. Yes, I see that, too.
Q. And: "News and reports of severe vaccine

Page 54

1 side effects included both first- and secondhand 2 reports in Groups, with users sharing photos and 3 video." effectively that we need to adjust.
Q. All right. Again, pardon me -- but on that feed?
A. Can you clarify what you're referring to with groups?
Q. He says number 3 -- number -- well, in 1 , 2 and 3 he uses the words "groups." In 1 he says: Worker-centric groups, groups especially anti-vaccination groups. And then in 3 he has secondhand reports in groups. So I'm just asking for the record --
A. Yeah.
Q. -- that if I am on Facebook I can belong to various groups and get information that that group gets?
A. I cannot -- I can't say for sure that this report was about the Facebook groups, but it seems likely that that's what that is reference to and you are describing them correctly.
Q. Thank you. And then he tells -- you tell in the next -- in January 26 th you write to Ms. Iheme and you say -- you say: "It looks wonderful and much appreciated," and then send, send them to you. It says: "One group we'll be adding is the Census group who hopefully will soon start their project."
"Also, the wide group of those looking at misinfo will want this."

Page 56

First, what's the Census group within CDC? Or is that not within CDC? What is that, Census group?
A. This is the Census Bureau.
Q. Okay. And they would be on this CDC list?
A. It appears $I$ was suggesting that, yes.
Q. Okay. And then who's the wide group of those looking at -- well, first let's go back. Misinfo is misinformation?
A. Yes.
Q. Who's the wide group of those looking at misinformation?
A. I don't know specifically what $I$ was referring to there.
Q. Do you know generally?
A. I suspect that it was probably people working on communication materials or developing reports about gaps and areas of confusion.
Q. Okay. Do you have notes or other records of the phone call he refers -- she refers to: "I'm following up on our conversation several weeks ago"?
A. I doubt I have notes.
Q. Okay.
A. If I did, they would have been electronic.
Q. Do you know who took part in the

## 1 conversation?

A. I don't know. But typically I was on the call, sometimes Jay was as well, Jay Dempsey. But I don't recall the specific meeting.
Q. Did you instruct Ms. Iheme or anyone else at Facebook to do anything with the biweekly reports other than send them to you?

MS. SNOW: Objection. Mischaracterizes
testimony.
BY MR. VECCHIONE:
Q. You did ask Ms. Theme to send you the biweekly reports, didn't you?
A. She offered to send me the biweekly reports, and I agreed that would be good.
Q. Did you instruct her to do anything else regarding the biweekly reports?
A. Not that I recall.
Q. Do you know who decided the reports would be developed biweekly?
A. I don't recall. But this email seems to suggest that they were already doing biweekly ones.
Q. For the -- for your purposes, what was the purpose of the reports, receiving them?
A. They would help us understand what was being discussed on social media about COVID, which

Page 58
helps us look for gaps in information, confusion about facts, things that we might need to adjust our communication materials for.
Q. Had you prior to this email discussed with Ms. Iheme such items as reports of healthcare workers refusing the vaccine, posts about alleged vaccine-related deaths, and news and reports of severe vaccine side effects? Did you ever report to her that those would be of interest to the CDC?
A. I don't recall reporting or discussing these with them specifically. I do recall generally discussing misinformation with Facebook around this time and --
Q. And those could have been included within that discussion?
A. Possibly.
Q. Why did you add Census to the distribution of this?
A. They were going to start working with the CDC regarding misinformation.
Q. So what did -- what did the wide group of those looking at misinformation do with the reports?
A. I don't know what they did with the reports. However, I do know two things that were likely done with the reports. We had -- we have

Page 59

1 part of our Joint Information Center in the Emergency Response a research team that compiles all the themes of discussion on news and social media. And I know that they received these reports, and they use a lot of sources to develop a summary for the response for all the reasons I just described about why this is helpful.

I believe at this time it was also part of a publicly-available vaccine confidence report that also looked across themes, what was being discussed, and where areas of confusion were so that they could update vaccine communication and other issues. Those are posted on CDC's website.
Q. Did you do anything with the reports besides forward them on to Census and to this wide group?
A. Anything with the CrowdTangle reports, I didn't personally do anything else with the CrowdTangle reports.
Q. Do you know if anyone else did anything besides what you've described with the CrowdTangle reports?
A. I would assume that it was used by people to look in background of conversations similar to what I have described.

Page 60

MR. VECCHIONE: All right. You can put that aside.
(Plaintiffs' Exhibit 7 marked.)
BY MR. VECCHIONE:
Q. All right. So what is the subject line of this email chain?
A. "Crowd Tangle COVID-19 Reports."
Q. All right. Let's take a look at the February $21,2021,8: 39$. Who is this from and who's the recipient?
A. Kelly Perron at Facebook, and I'm the recipient.
Q. All right. And we've discussed her before. She was going to be one of the contacts with CrowdTangle; right?
A. Yes.
Q. And what is the summary that Perron reports?
A. She attached the report, which is not here, but and then summarized the high points.
Q. Okay. And why is she reporting this to you? Is this part of the biweekly report that you agreed to earlier?
A. Yes.
Q. And this would be a summary of a report
that's probably attached, but it's not here?
A. Correct.
Q. All right. And what did you do with this information?
A. We created a mail group, and this was forwarded on by -- I either forwarded it, or over time I had an assistant that started forwarding them.
Q. All right. So the same groups within the CDC and the Census we talked about before?
A. At some point I recall adding Census to the distro. I am sure by May or March there were several time periods they were probably included. The distribution list likely changed a bit because people deployed into the response and out of the response, but, yes.
Q. Okay. Can you take a look at the emails dated Tuesday, February 16 and 17th, 2021 at 9:00 p.m.?
A. Yes.
Q. So who is that from, and who is that to?
A. That's Kelly Perron at Facebook to me.
Q. And what is she summarizing here? What is the summary that she reports?
A. It's the -- it looks like the next
biweekly report. And it looks attached, but it's not in the exhibit. And she summarized it in the body of the email.
Q. All right. And she's highlighted, some things are highlighted, right, in dark black?
A. Some things are bolded.
Q. Bolded. That's right. Reports of deaths post-vaccination?
A. Yes, that's in bold.
Q. Double masking?
A. Yes, that's bold.
Q. And personal reports of vaccination?
A. Yes, that's bold.
Q. Why did she report this to you, those highlights?
A. There again, they are using CrowdTangle to do a summary of the themes that are being discussed on Facebook and Instagram channels, and this is a summary of that.
Q. Okay. And what did you do with this information?
A. As mentioned, we had a distribution list that this was forwarded to.
Q. You just sent it on?
A. $M m-h m m$ (affirmative).

Page 63
Q. Can you look at the email dated Monday March 1st? And who is this to?
A. Kelly at Facebook to me.
Q. All right. And she added someone. She says she added Chelsey Lepage at Facebook. Who is that?
A. I think that she may have been --
Q. I'm cheating a little. I went above what I told you to look at.
A. Yes. I'm sorry. I see that now. But I believe Chelsey was another assistant to Payton, I think.
Q. Okay. And then on the one I did direct your attention to, March 1st at 5:47, again she says Hi -- Kelly Perron says: Hi, Carol. And she attached the latest CrowdTangle insights report for February 10th to 24, and she says it's attached.
A. $\mathrm{Mm}-\mathrm{hmm}$.
Q. And then she does a summary. And there again there are certain points she's bolded: COVID-19 and mental health, vaccine refusal, testing positive post-vaccination.

Do you know whether those were bolded because those were of particular concern to the CDC?
A. No. That's the format of all the reports.
Q. Okay. So bolding them was -- your testimony is bolding them is not because they were of particular interest to the CDC, that's just how she did it?
A. I really couldn't say what her thinking was when she bolded them.
Q. Okay. When you received it did you have any understanding about the bolded portions?
A. No.
Q. Were the bolded portions things that you had particularly spoken with Facebook before in your telephone conversations?
A. I don't believe so.
Q. All right.
A. Well, can $I$ clarify that a little bit?
Q. Yes, please.
A. I'm sure -- I don't remember discussing these in terms of the CrowdTangle report or the things in bold. I am sure that general discussions that there was a lot of information on vaccines, which is one of the bolded words, for example. I am sure that did occur.
Q. Thank you. On March 15 Kelly sends you at 6:19 p.m.
A. Yes.

Page 65
Q. Sort of goes over, she keeps Chelsey Lepage in there, and then she -- this time she summarizes slightly different items:

Post-vaccination guidelines and protocols, vaccine ingredients and vaccine side effects.
A. I see that.
Q. And your testimony is the same as to why they are bolded as before, as far as you know?
A. Correct.
Q. And you did the same thing with them as you did before that you've testified?
A. I believe so, yes.
Q. Let's see. And then at the bottom of that March 15, she says: This week we also are including a one off content insights report we did looking at Spanish language content relative to the U.S. we thought might be interesting for you.

She asks you not to share it externally.
Do you recall any other times you got Spanish language-specific material?
A. No. But I didn't recall this time either until I read it.
Q. Okay. And then I'll just -- to finish up, March -- May 25th. Now, there doesn't seem to be something for April. Do you know why there would be
a break in the two-week reporting?
A. No. I don't recall unless she just sent it separate from the chain.
Q. And then here she's bolded vaccination in children, healthcare workers and masks and vaccination; right?
A. I see that, too.
Q. And do you recall whether you spoke to her about those things, or that was just her choice to highlight those?
A. We did not discuss with them the issues we wanted in the CrowdTangle report.
Q. All right. And then you say "thanks" in response to this on 5:26. But we've got a new person here. Tyler Woods. Who is that?
A. I think, but I'm not positive, that he took over the reports later, so perhaps he was starting to come in on their team.
Q. Okay. We've been going about an hour. I always give the witness a chance to break if she wants.
A. I'm okay.
Q. Okay.
A. Thank you for checking.

MR. GILLIGAN: Can I ask one question,

Page 67

```
John?
```

    MR. VECCHIONE: Yeah.
    MR. GILLIGAN: What is the number of your
    last exhibit?
MR. VECCHIONE: 42.
MR. GILLIGAN: Thank you.
And I actually -- that was -- I do have
one that's unmarked that $I$ may use.
MR. GILLIGAN: Okay. Just to add a little
suspense. Thank you.
MR. VECCHIONE: Mm-hmm (affirmative).
(Plaintiffs' Exhibit 8 marked.)
BY MR. VECCHIONE:
Q. All right. Do you recognize Exhibit 8?
A. I haven't finished reading it.
Q. Okay. Go ahead.
A. Sorry. Okay. Sorry.
Q. It's all right.
A. Can you repeat the question?
Q. Can you identify this document?
A. I recognize the first page chain of
emails, but not the previous chain.
Q. So you don't -- tell me where -- the first
page at the back?
A. Oh, I'm sorry. No, the first page of the

1 packet.
Q. Got it.
A. I remembered this email more -- I don't have a recollection of this previous back and forth.
Q. Got it. Well, what's the subject line?
A. "This week's meeting."
Q. Okay. And by this time were you meeting with them every week?
A. We were -- we were meeting weekly during parts, so I imagine we were.
Q. All right. And can you read the email
from Ms. Iheme to you about the meeting on March 30th, 2021, 2:42 p.m.?
A. Yes. "Hi, Carol, hope all is well as it can be. At least spring is making an appearance. I wanted to surface any misinfo questions your team may have for the team that I had briefing last time. They are available to attend again, but also want to make sure that we are answering any of your team's questions."
Q. All right. What's the briefing she refers to?
A. I don't recall the briefing specifically, but $I$ do recall her bringing in people from their Trust and Safety or Misinformation teams -- I'm not

1 sure what they called the team -- to talk to us about misinformation at some weekly meetings. I think that's probably what this is in reference to.
Q. Why is she offering to surface misinfo questions and to answer your team's questions?
A. Because I think -- I can't say for sure what she was thinking.
Q. What's your understanding?
A. But I think it was because we -- we had asked questions about what they were seeing in terms of misinformation and inquired about any activities they were undertaking. And I believe this was an offer to sort of get back to us on any of those questions.
Q. All right. That you had?
A. Yes.
Q. Given her. Thank you.
A. Yes.
Q. Let's clean up the record a little. That you had -- the questions that you had proposed to her?
A. I think it was questions asked within the meeting, but.
Q. Got it.
A. I'm not 100 percent sure because I don't

Page 70
know the timing of that meeting, but I believe that's what this is in reference to.
Q. And can you read your response at 3:08 p.m.?
A. "Hope all is well, too. I plan to join and listen to the 3:30 meeting, FYI. I added this part in yellow to our chain on turn.io so you probably missed it. Did you have thoughts on how we can regularly meet with Census? I will also check back with others to see if they have other Qs that went unanswered and get back to you."

Do you want me to keep reading?
Q. No, you can stop.
A. Okay.
Q. But what is "turn.io"?
A. This was another project that we were working on with WhatsApp.
Q. And what was that project?
A. I believe this was using WhatsApp to -- so people could use it, they could look up ZIP codes to find vaccines.

## Q. Okay.

A. And maybe, I'm speculating, there was also
a Spanish offering for vaccine information on WhatsApp. It was one of those.

Page 71
Q. Got it. Why is Census involved in your coordination with Facebook at this time?
A. We had entered an IAA with Census to help advise on misinformation.
Q. And an IAA is?
A. Interagency agreement.
Q. All right. Did the CDC ever use any software programs developed by Census that enabled the CDC to track the viewpoints of U.S. citizens?
A. No.
Q. Did the CDC ever gain access to or in any way receive information about the viewpoint of U.S. citizens on COVID masking or vaccination from Census?
A. We likely did because they provided reports on misinformation that they were seeing to us.
Q. Did the CDC ever share data on the viewpoints of U.S. citizens with the Census?
A. I don't recall if we did.
Q. You did share the CrowdTangle with them?
A. Yes. Can you reask the question?
Q. I will. Did the CDC ever share the data on the viewpoint of -- the viewpoints of U.S. citizens that CDC was seeing with the Census?

Page 72
A. You refer to it as data. I don't recall sharing data. I do recall sharing social media listening reports such as this, or the publicly available vaccine confidence reports that talk about what people are talking about, and probably the JIC's research, you know. They had a standing summary of what was being discussed. I suspect I shared that, too, with Census.
Q. The JIC? What kind of research, the?
A. I mentioned the JIC research team that looked at what the conversations were on news, social media and did summaries of that for everyone in the response.
Q. All right. And did information come back from the Census to CDC about what they were finding?
A. My recollection is that the Census did provide us with the key themes they were seeing around misinformation during the times that they were looking at it.
Q. Who was at the meeting that Ms. Iheme references and that you refer to in the next email?
A. The next email, which email?
Q. So above it. It says -- oh, hang on. I'll tell you in a second.
"Yes, I did see and will know in a few
hours."
Hang on for a second.
So I took it to mean that this March 30th, 3:16 email that she says: "Hi, Carol, Yes, I did see and will know in a few hours, I'm told if we plan to present for Census Thursday or if it needs more work."

And then you say that "I didn't ask Census if they had questions."

Do you know if there was a meeting with Census on or about that time?
A. I don't --
Q. Okay.
A. -- remember enough detail to answer the question. Sorry.
Q. So in this March 30th, 2021 at 7:38.
A. Yes.
Q. There you say: "I didn't ask Census if they had questions, but I know they were hoping to go over the deck they had."

And is that the one you sent them or Facebook sent them, or did they create that themselves?
A. I don't know for sure. I'm interpreting from this email that the Census created it, but I do

Page 74

1 not know.
Q. All right. "And discuss how to engage on a more regular basis."

Do you know if they ever decided to engage on a more regular basis?
A. With -- about their activity, or about CDC?
Q. Yeah, with Facebook.
A. I don't know what Census did directly with Facebook.
Q. And then I'll ask you to take a look at the 3:16 again. She says: It would be great to have questions that may not have been answered from your team on misinformation. She says "misinfo", but I'm using the full word.

And is she looking -- is it your understanding she's looking for those answers from Census that you didn't have, CDC?
A. Let me reread this chain.
Q. Go ahead.
A. Sorry. Can you repeat the question?
Q. I will withdraw the question for a moment.
A. Okay.
Q. Just take a look at March 30th, 7:46 as well. She writes to you, Carol: "Hi, Carol. Yes,

1 I think it's good to have questions from Census to make sure we have the right person. I can ask Liz to join again so she can be asked questions/provide more information about influencers and I have noted your question about removals and will tee that up as well."

What was your question about removals?
A. I -- reading in this email?
Q. Yeah.
A. I'm saying -- the email before this I'm

11
12 about how you analyze the data on removals. And my general recollection where this question came from was that we -- the -- that $I$ think there was wondering if they delete the info will we know those myths or information so we could update communication activity. So if they were deleting content would we know what the themes were.
Q. And did you ask them to remove any content?
A. No. This was -- this was when -- this was a meeting where we were just asking what -- how that worked and would there be data, would we be able to see in CrowdTangle or other reports like what kind of themes were removed so we would still have the

1 full picture of areas of confusion.
Q. All right. And if you look at your March 31st, 2:07 p.m., and you say what "Census mentioned they'd like to discuss." "It looks like the post from last week's deck about infertility and side effects have all been removed. Were those re-evaluated by the moderation team or taken down for another reason?"

What are you saying there?
A. It looks to me like I cut and pasted this from something that Census had said, and I don't have good recollection of what this was on March 31st.
Q. Then you've also cut and pasted: "One of the main themes we're seeing and from the CrowdTangle report is local news coverage of deaths after receiving the vaccine. What's the approach for adding labels to those stories?"

Why would you or Census want them to add labels to those stories?

MS. SNOW: Objection. Calls for speculation and mischaracterizes the testimony -- or the document. BY MR. VECCHIONE:
Q. You can answer.

Page 77
A. I don't think we were asking them to add labels, from what I'm reading here. We were asking them what their approach for labels were.
Q. Then they have asked: "Can we add the Census team to CrowdTangle?"

Hadn't it already been added to CrowdTangle by this time? Haven't we established that?
A. There were two different offerings for CrowdTangle. They had allowed us to directly log into CrowdTangle and run our own reports or searches. I believe that started back in, you know, March or April 2020. Then they sent the reports. So this appears to be to log in to CrowdTangle.
Q. Then what did you mean by your team is going to consider how you might want to engage with CDC Census team routinely and get back to us?
A. I don't know specifically this day this email what I meant. But I do know that we generally discussed, you know, how we should talk about misinformation because they had already been working with Census, on their own Census misinformation, and I wanted to know what was best for them for engaging on any topics that we might want to discuss.
Q. All right. Do you know what Facebook was

1 told previously about engaging with CDC and Census 2 on this?
Q. It's okay. You can answer if you understand. I'm trying to understand. It seems that Facebook has been talking to CDC and Census throughout for a while now. And yet here is a request that they want a different CrowdTangle, as you've explained.

Page 79

MS. SNOW: Objection. It assumes facts not in evidence. BY MR. VECCHIONE:
Q. You can still answer. I'm trying to understand what is happening in this series of emails, since they have already been sending you the CrowdTangle information. You've explained that there was a different CrowdTangle information that Census might want; right? That is --
A. I think it was the log-in to the CrowdTangle.
Q. Okay. Well, I'll give you an example. So Ms. Iheme asks: Yes, I think it's good -- this is at 7:46 on March 30th, said: "I think good to have question from Census so we make sure we have the right person."

So my question is, is that the right person to answer those questions to the Census from Facebook? What's your understanding?
A. I don't know this chain of emails specifically, but I believe it was likely in reference to just me mentioning to Payton that we were partnering with the Census to learn more. We had been discussing things, and we were going to have some collective questions that we would like to

Page 80

1 discuss at a future meeting.
Q. Okay. What's the amplification side at March 30th at 7:38? You are going to ask Liz about what is being done on the amplification side. What does that mean?
A. I don't know why $I$ was asking that.
Q. And why did you want to get a better understanding of how Facebook was working with influencers?
A. I don't remember the meeting before that, so I'm not sure what that is in reference to.
Q. And it says the team's interested in more info on how you analyze the data on removals.

Why are you asking about how Facebook operates on removals?

MS. SNOW: Objection. Asked and answered.
A. I did answer it previously.

BY MR. VECCHIONE:
Q. I don't believe I have directed you to that exact portion of this, and I would ask the witness to answer unless she's being instructed not to.

MS. SNOW: No, you may answer.
A. Okay. What I think this was about was I believe the teams that were looking at, like, our
research reports, or our vaccine confidence report were wondering if the data was removed if it would show up in the report, so would they be missing gaps or information because the posts were removed. That's what I believe that this question is about. BY MR. VECCHIONE:
Q. All right. CDC wasn't concerned that they weren't removing materials fast enough?
A. That's not what $I$ believe was being discussed here. This was about the data that we could get so we had a full picture on confusion so that we could adjust communication materials, or ways that we were communicating. That's what I believe that that's in reference to.

And you know what, $I$ have a clarification.
Q. Go right ahead.
A. You asked me what the amplification side --
Q. Yes.
A. -- and the influencers. Now that I'm remembering this, $I$ think that it it was likely about how to promote how to get a vaccine, or where to get a vaccine and $I$ think that was all part of that conversation.
Q. All right. Let's go to the March 31st,

2021 at 2:07, the one you've told me you've cut and pasted from Census, at least those bullet points.
A. You mean March 31st?
Q. March 31st at 2:07.
A. Yes.
Q. It says: "Were those reevaluated by the moderation team or taken down for another reason?"

Do you know if that refers to a moderation team at CDC or Facebook?
A. It must have been Facebook because we don't have a moderation team at CDC.

I'd also like to clarify that I think I probably cut and pasted it. I don't know for sure that I did.
Q. That's fine. Got it. I follow you.

Why do you -- do you know why you wanted to know what the approach for adding labels to the stories about deaths after receiving the vaccine was?

MS. SNOW: Objection. Asked and answered.
A. I don't remember this specific set of conversation, or why we were asking about that any longer.

BY MR. VECCHIONE:
Q. Okay. Do you know -- so you're discussing

Page 83
talking to Census at some point. Do you know whether that conversation ever happened, a conversation with -- regarding this string of emails with Census, CDC and at Facebook?
A. I don't know that we were discussing the string of emails, but there were meetings where Census, myself and Facebook were on calls.
Q. Okay. And do you recall what you discussed?
A. My memory is we had general conversations about what were opportunities to address misinformation. And things like in this chain $I$ believe were probably discussed, but I don't have specific memory of it.
Q. Do you know who your contact was at Census, like who was the main person at Census on this aspect of the CrowdTangle and dealing with Facebook?
A. There were a couple of people from Census that we were talking with. I only remember two of the names. One was Christopher Lewitzke, who I believe was a contractor for them. And then Jen Shopkorn, I think I'm saying it correctly. I believe she was their director for digital.
Q. Thank you.
A. But there were a couple of others that typically participated.
Q. And then March 31st at 2:18 Ms. Iheme writes you: "Hi, Carol we are working on a proposal how set up sharing partnership on the misinformation items, what would it look like, so we can discuss Thursday. Lots of team members out the last two weeks due to all the holidays, but that is the plan so we can discuss on the Thursday call."

Do you know whether that meeting, the Thursday meeting, to set up sharing partnerships on misinformation occurred?
A. I don't remember if this specific meeting occurred.
Q. Would you have a calendar that would tell you?
A. Yes.

MR. VECCHIONE: I would ask counsel to produce that calendar of the date of that meeting.

MR. GILLIGAN: We'll take your request under advisement.

MR. VECCHIONE: Thank you. BY MR. VECCHIONE:
Q. And once again would you have notes or recordings of that conversation?

Page 85

10 you to identify it and tell me the date of the 11 email.
A. The subject is Misinfo on two issues. And the date of the email is May 6, 2021.
Q. All right. You can continue to read it.
A. Read the email?
Q. Yeah.
A. "Payton, Genelle" --
Q. No, no. I mean, to yourself.
A. Oh.
Q. Just scan through it.
A. Sorry. Thank you.
Q. I want you to be a little familiar with 23 it.
A. We never recorded the calls. If I had -I didn't take many notes, but if there was anything it would be in Word or email.

MR. VECCHIONE: You can put 8 aside, Exhibit 8 aside.
(Plaintiffs' Exhibit 9 marked.)
BY MR. VECCHIONE:
Q. In this, if you'll just an initial look at it you can tell me. I just ask you to -- I'd like

MR. GILLIGAN: Good clarification.
A. Okay.

Page 86

```
BY MR. VECCHIONE:
```

Q. All right. So can you tell us why you were flagging misinformation about the vaccines for Facebook?

MS. SNOW: Objection. Mischaracterizes the document. BY MR. VECCHIONE:
Q. Well, let's take a look at it for a moment. It's from you; right?
A. Yes.
Q. And then it's to Ms. Iheme under a new name Gennelle Adrien. Do you know her and what her role was?
A. I think she was one of Payton's assistants.
Q. All right. And then you're cc'ing Sam Huxley at @Reingold.com. Do you know who that is?
A. Yeah, now that $I$ see the name. Sam was a contractor for Census that was often on our phone calls with Christopher and Jen.
Q. And that's Christopher Lewitzke; right?
A. Yes.
Q. And then Jennifer Shopkorn, I apologize if you told me who that was, but who was that?
A. She's with Census, and I believe she's the director for their digital team.
Q. And Lynn Sokler?
A. Lynn Sokler is a counterpart of mine in OADC who was working on this partnership with Census along with myself.
Q. All right. And then it says:
"Payton/Genelle. As mentioned, here are two issues we are seeing a great deal of misinfo on that we wanted to flag for you all -- vaccine shedding and microchips"; right? You wrote that?
A. Yes.
Q. Can you tell us why you were flagging misinformation about the vaccines for Facebook?
A. Because we had had conversations with Facebook about ways that we could address misinformation, and my recollection is that one suggestion that was -- that came up in that conversation was to let them know if we were seeing major themes that CDC had scientific information on, or had web content that would address.

I believe that is why I was sending these, because these were two large areas of misinformation.
Q. What did you mean by the term "flag" or

## flagging?

A. Pointing out.
Q. What was the expectation of what Facebook would do when something was flagged?
A. I don't recall having a specific recollection of what I thought that they would do.

I do know that the platforms have a variety of ways to address misinformation. They might tag it as something that people should look more into. I think that they have the -- I think, but I do not know, that they have the ability to control how often some of these things show up in peoples' feeds. And I do know that removing them is an option that they could consider.

So I didn't know exactly what they might do with it, but I felt like it was worth pointing out what we knew, that we had seen these myths and that we were going to have information up soon.
Q. All right. And what was the consequence to Facebook if they didn't do anything with your flagging of these items?
A. Nothing.
Q. All right. What were you hoping to accomplish by flagging these items for Facebook?
A. I mean, our goal always is to be sure that

Page 89
people have credible health information so that they can make the correct health decisions for themselves. There were a lot of things circulating that were not accurate information about COVID. And so we were trying to point out and make the credible information more available to users.
Q. How did you decide on these particular posts?
A. I don't remember specifically this conversation, or what made us decide. But I do know generally that these were two very high-volume misconceptions online at the time about vaccines.
Q. All right. Do you recall whether you had any criteria in determining which posts to flag?
A. I don't recall that we had any criteria on what we pointed out to Facebook other than it had to be something that was in CDC's lane that we had information for, you know, to offer about it, and something that had been -- you know, was high volume, that was worth pointing out to this entity.
Q. Did you or anyone at CDC have concerns about the government working with Facebook and telling them what should be flagged or not?

MS. SNOW: Objection. Mischaracterizes testimony, calls for speculation.

Page 90

BY MR. VECCHIONE:
Q. You can answer.
A. Can you rephrase the question again, or say it again?
Q. Yeah. Did you or anyone at CDC have any concerns about CDC or the government flagging materials for Facebook when you knew they took some things down?
A. I can't speculate what others at CDC might have thought about it. Personally, because I didn't believe we were asking them to remove content specifically, I did think getting credible information out was important.
Q. Where did this information about microchips and the shedding, what kind of information did the Census team have on those posts at that time?
A. My recollection is that we were pointing out to Facebook that there were these themes going around pretty heavily, and these probably came from the social listening tools, you know, that can consolidate examples. And we provided some examples of what we meant.
Q. Okay. You can put that aside.
A. Thank you.

Page 91
(Plaintiffs' Exhibit 10 marked.)
BY MR. VECCHIONE:
Q. And, again, I'll give you a chance to read it, but if you could just identify the document and the subject line?

MR. GILLIGAN: The document being Exhibit 10?

MR. VECCHIONE: Exhibit 10.
A. It says: Subject CV19 misinfo reporting channel. May 10, 2021.

BY MR. VECCHIONE:
Q. All right. What is -- I presume CV19 is COVID-19?
A. Yes.
Q. "Misinfo" is misinformation?
A. Yes.
Q. All right. What is the COVID-19
misinformation channel?
A. Well, I don't think I -- just rereading this email, I don't think I understood this at first, what she was referring to. I think I thought that this was CrowdTangle, just by reading the chain, but $I$ now know what it was was Facebook apparently has a portal or reporting channel where you can report misinformation or threats or things

Page 92

1 from a specific log-in that $I$ believe they only provide to like federal agencies.
Q. All right. And who used it at the CDC?
A. To my recollection, the only person that ever logged in at CDC was Brook Aspinall.
Q. Who was that?
A. She was part of our social media team.
Q. For what?
A. For COVID.
Q. For what did she log on?
A. Oh. Why did she log on?
Q. Yeah.
A. My memory is that we log on one time to see what it was -- what the system was and understand what we could do in it. And she logged on one time, and I think reported two or three -- I don't remember what they were -- two or three posts or threats or one or the other.
Q. All right. Would you have a record of what she put on there?
A. I believe so. But I only really remember this from pulling documents at some point related to this litigation earlier in the process. I recall there was an email that listed it, but I don't remember what they said. But I believe that there

Page 93
is a record of it because $I$ recall seeing it during that process.
Q. All right.

MR. VECCHIONE: I would request that as well, Counsel. But I'll put it in writing. BY MR. VECCHIONE:
Q. Well, I'll just ask this question. I usually ask this question earlier, but I might as well. In preparation for your deposition today, did you review any documents?
A. No. Well, we -- the only one I reviewed happened to be one of the ones you had during our practice.
Q. Good. All right. That's fine. Do you know which one it was?

MS. SNOW: Objection.
A. Oh, sorry.

MS. SNOW: To the extent this calls for --
MR. GILLIGAN: Does call for.
MS. SNOW: The question calls for
information that's covered by the attorney-client privilege. So I direct the witness not to answer.

MR. VECCHIONE: No, it doesn't. What she's reviewed I'm allowed to know. That's --

MR. GILLIGAN: Not if it didn't refresh

Page 94

```
her recollection.
```

MS. SNOW: Yeah.
MR. VECCHIONE: Doesn't matter. She
reviewed it. I'm allowed to know it.

MR. GILLIGAN: No, you're not.
MS. SNOW: Not if it did not refresh her recollection about the facts.

MR. VECCHIONE: She's been shown the
document today. I'm allowed to know which one she
reviewed if she's been shown it today.

MS. SNOW: You're asking about documents

```
that --
```

MR. VECCHIONE: That she saw today.
MS. SNOW: -- she reviewed in

```
preparation --
```

MR. VECCHIONE: Yeah.
MS. SNOW: -- for the deposition?
MR. VECCHIONE: Yes.
MS. SNOW: Yes, that is covered by attorney-client.

MR. VECCHIONE: She said she's been shown it today. There is no attorney-client privilege for that.

MR. GILLIGAN: I don't know that -- I don't know that she said that she was shown it BY MR. VECCHIONE:
Q. I'll ask. Were you shown it today?
A. One of them, yes.

MR. GILLIGAN: It's still --
MR. VECCHIONE: It's an improper
objection, but it's not that important, so I'm going
to let it go for now.
MR. GILLIGAN: All right. Well, if you care to raise the issue again later, we'll be happy to discuss it later.

BY MR. VECCHIONE:
Q. All right. So who's responsible for creating this channel, this COVID-19 channel?
A. Well, I have a small recollection of this channel, and I never looked at it myself to my memory. But it's, to my understanding, you log onto Facebook as an administrator, and it's something that they make available to you as a federal agency.
Q. Okay. So Facebook made it?
A. Yeah. It's like a place you can go and report something. I -- "channel" does feel like an odd description of it to me.
Q. Okay. How do you know that it was made available to, like, law enforcement? Do you know

Page 96
that from this document, or do you know that from your own memory?

MS. SNOW: Objection. Facts not in evidence.

MR. VECCHIONE: She testified to it a minute ago.

MS. SNOW: Okay. Sorry. My apologies. missed that. Sorry. BY MR. VECCHIONE:
Q. So how do you know that? Like, why is that your understanding?
A. I guess I can't say I know that. I have a vague recollection of it being described to me as something that other, like, official groups could use to report, that it wasn't something that was generally available. But $I$ might be wrong.
Q. Okay.
A. I don't know for sure.
Q. That's fine. Now, at the end of this email there is a list of other email lists; right? She says: Thank you, Genelle. And then she lists some government people and some Census people and CDC people and Reingold again.
A. I see it.
Q. So those -- and she asks you to confirm if
the below emails are correct for onboarding to the reporting channel; right?
A. Yes.
Q. All right. Are any of those people the Ms. Aspinall I think you told me before?
A. Those emails are so difficult, I don't know. Perhaps it's $\square$ or $\square$ or $\square$, but I don't know peoples' user IDs, so I can't answer.

I would also like to clarify that when I was reviewing this based on this chain, I thought this was about CrowdTangle access.
Q. Okay. At that time?
A. At this -- yes, so.
Q. You don't believe that now, but that's what you thought when you received it?
A. Yes. I can see in this chain that that's what I thought was happening with this.
Q. All right. Do you know how this list of employees, whether you recognize them or not, do you know how the people for access were selected, like --
(REPORTER'S NOTE: Loud audio noise heard over loud speakers in room.) (Comments off the record.) MR. VECCHIONE: Let's go off record.

THE VIDEOGRAPHER: Off record at 11:51.
(Comments off the record.)
THE VIDEOGRAPHER: Back on record at
11:53.
BY MR. VECCHIONE:
Q. All right. So the question is, the question on the floor, before we were so rudely interrupted, was how was this list of employees or contractors selected?
A. I don't know. Maybe from a meeting invite. Maybe people that were on a meeting, but I don't know.
Q. Do you know whether there was any training involved in using this COVID-19 misinformation channel?
A. I don't remember any training. The email looks like perhaps there was.
Q. Do you know whether CDC employees or contractors asked to flag or report certain kinds of information to Facebook?
A. Yes. On occasion there were people saying "we saw this." Usually they were around threats that they wanted us to report, which you can do as an administrator for Facebook now.

In terms of this, $I$ only remember the one

Page 99

1 occasion that $I$ mentioned a minute ago.
Q. Was Facebook asked to flag certain types of material to report to CDC or to Census?

MS. SNOW: Objection. Vague.
BY MR. VECCHIONE:
Q. I mean, I have asked whether or not CDC asked to flag things to Facebook, and you've answered that question. Did Facebook ask CDC to flag things to them?
A. Well, the way $I$ have been using "flag" in these emails is to point out.
Q. Right.
A. I don't recall asking them to point anything out to us, but $I$ can maybe recall us saying something are you seeing this too, are y'all considering this too?
Q. Do you know whether or not we have any documents that were given to CDC staff or contractors regarding the training on this COVID-19 channel?
A. I don't recall.
Q. Okay. Did the meeting -- I think it was from May 18th. Let me look at the document for a second.

Okay. You had a meeting that she -- that

Page 100

Genelle Adrienne refers to on May 7, 2021, 11:27
a.m. "Hi, Carol following up from our meeting yesterday it looks like Monday May 17th at 12 will work for onboarding meeting."

Do you know whether that onboarding meeting ever occurred for this channel?
A. I don't have any recollection of the onboarding meeting.
Q. And once again would you have a calendar mark for that onboarding meeting, if it occurred?
A. If I was invited I would.

MR. VECCHIONE: And once again, I'll put
that in a letter to you, Counsel.
MS. SNOW: We'll note that document
discovery has closed, but we'll take it under advisement.

MR. VECCHIONE: I got you.
BY MR. VECCHIONE:
Q. And you can put Exhibit 10 aside.

Oh, you know, might need it for this, but I don't know if you do.

The Reingold contractors. Why did CDC need contractors? What were they doing? Did they have concern -- let me withdraw the question.

Why did CDC have the contractors, the

Page 101

1 Reingold contractors, involved in this?

MS. SNOW: Objection. Mischaracterizes
testimony.
BY MR. VECCHIONE:
Q. Was it Census?

MS. SNOW: Objection. Vague.
BY MR. VECCHIONE:
Q. Why were the Reingold contractors involved in all this?
A. They were contractors working with Census.
Q. Okay. Did you know why they were contractors and not Census directly?
A. No.
Q. Do you know if their duties involve content moderation?
A. I don't.
Q. Do you know whether their duties involve flagging or reporting on certain kinds of opinions expressed by U.S. citizens?

MS. SNOW: Objection. Vague, calls for speculation. BY MR. VECCHIONE:
Q. You can answer.
A. I really don't know. I wouldn't know what they had them do.

Page 102

MR. VECCHIONE: All right. That's it for 10. I could go on to 11, and or we could break here and fix the sound. You go -- you could have lunch. Decide what the witness --

MR. GILLIGAN: It's up to the witness to break.

THE WITNESS: Let's break. Let's break.
MR. VECCHIONE: There you go.
THE VIDEOGRAPHER: Off record at 11:59. (Lunch recess 11:59 a.m. - 12:51 p.m.)

THE VIDEOGRAPHER: Back on record at 12:51.

MS. SNOW: And, defense counsel, just like to note that we've reestablished the Zoom connection and shared a call-in phone number again, which is being forwarded to plaintiffs' counsel pursuant to the previous agreement that it not be shared, the Zoom link not be shared beyond plaintiffs' counsel or the Zoom, or the call recorded using the Zoom call-in number.

MR. VECCHIONE: That's fine.
(Plaintiffs' Exhibit 11 marked.)
BY MR. VECCHIONE:

```
Q. All right. Ms. Crawford, I have handed you -- once again can you identify Exhibit 11 and
```

CAROL CRAWFORD 11/15/2022
Page 103
then tell me what the subject matter of the -- what the subject line is, and then you can continue to read it.
A. Agenda item for CDC call this week. May 20th, '21. Okay.
Q. Can you tell me who Liz Lagone is?
A. My understanding is that Liz is on their Trust and Safety team, or the Misinformation team, which $I$ don't know what the official name of it is.
Q. Meaning Facebook's?
A. Yes, Facebook's. Sorry.
Q. And in these emails Ms. Lagone identified the, quote, "Content Policies" of Facebook as guiding which posts get removed; right?
A. It says "we may reduce, remove or inform."
Q. And I think she describes these policies as evolving?
A. Yes, I see that.
Q. Okay. Did you or anyone at the CDC participate in the crafting of the content policy of Facebook?
A. No.
Q. Did you or anyone at CDC contribute to the terms of service or community standards of Facebook?

Page 104


Page 105
Q. Same question for other social media. Did you ever -- did you or anyone at CDC help any other social media company on how they should apply their policies to -- toward a particular post?
A. No. We didn't -- I have never seen their policies.
Q. Did you or anyone at CDC ever discuss with Ms. Lagone any manner relating to any enforcement of the policies that she's discussing here?

MS. SNOW: Objection. Vague.
BY MR. VECCHIONE:
Q. Well, she's discussing these policies here. Did you ever discuss with her their development and enforcement?
A. No. We did not discuss the development of their policies, or the enforcement of their policies. What we did provide was scientific information that $I$ did assume that they might use to do those things.
Q. Okay. I'd like you to take a look at one of -- she -- Payton Iheme lays out a number of items that I think she says at May 19th, 4:19: To help with scoping on your end for Thursday, here's some of the COVID content items that Liz will be flagging for you the CDC team.

Page 106

And here she seems to be flagging items for you at CDC. And then she goes through them. And what did you do when they flagged some of these to you? What -- why was she flagging those to you, and then what did you do in response?

MS. SNOW: Objection. Compound. BY MR. VECCHIONE:
Q. You can answer.
A. So why were they flagging this to us?

First part. They were wanting our feedback on whether these things were true or false statements that they were seeing. Did the CDC have science around this, did we have content on our website.

Can you refresh me on the second part of the question?
Q. And what did you do in response to the flagging?
A. Typically what we would do is try to let -- if we knew, if we had something or we had science on these items, we would point to it or provide them an answer. If we didn't, we wouldn't provide it.

My recollection, this might have been one of the first times they asked in this type of format. And I think we talked about that on the

Page 107

1 call, like, who knew -- some of these people, I 2 thought, could help answer whether -- what we had on
Q. All right. And you had -- and let's, since you just pointed out, we'll just say --
A. Mm-hmm (affirmative).
Q. -- your response was: Thanks for the additional info. And then you say you're going to have these folks joining.

And you've got the Census team members joining this. Cynthia Jorgensen, director of Comms for NCIRD. What's that?
A. National Center for Immunization and Respiratory Diseases at CDC.
Q. "And our joint information center co-lead." So is she that as well? She's the joint information center co-lead, or is that a different person?
A. She was serving both roles. She -- we deployed to the response, and she was -- at this point in time was deployed as the co-lead for the joint information center, but her regular job is the ADCS. So she had a lot of knowledge regarding this topic.
Q. And then you've got Rosie

Page 108

Bretthauer-Mueller and Demi Haynes. And they are co-leads for consumer vaccine content development. Is that content development on your website at CDC?
A. Yes.
Q. Okay. And they say: "I'm not going to have SME join."

Is that subject matter experts?
A. Yes.
Q. What are those?
A. That would have been like an actual scientist that studied these issues, or knew what the science was on it. When I -- I believe when I scanned this I thought we probably had readily answered -- we probably had a lot of this already addressed on the website, and the content folks would be able to point that out. We didn't have to have the expert on the call.
Q. I have -- if you look at 11.
A. $M m-h m m$ (affirmative).
Q. "Is the claim 'COVID-19 manmade' false, unproven, unsupported by evidence, or true?"

Do you know whether or not CDC ever
responded to that inquiry?
A. I don't know for sure, but $I$ doubt we

Page 109

1 would have.
Q. And why do you think that?
A. I don't recall us having any information on this posted on our website. I know it came up a lot, but $I$ don't remember us having it like an FAQ on it.
Q. All right.
A. But I'm not an expert on all the content we had on the web. I don't develop the content.
Q. I understand.
A. Okay.
Q. I'm just -- I appreciate the information and why you thought it.

I have a -- so this -- Census is now in. Is this after the IAA you mentioned to me yesterday? Earlier today. It's not yesterday yet. Before lunch?
A. Yes.
Q. Okay. So what is the -- what's your understanding of what an interagency memo is, or an interagency agreement is?
A. I'm definitely not an expert on IAAs. But it's an agreement between two agencies to conduct some kind of work between them. Sometimes you're given fundings to do it. Usually you are. I

Page 110

```
    1 don't -- I wasn't -- I didn't create the IAA, so I
2 don't have a lot of details on what was in it.
Q. Have you seen it?
A. I do believe I saw it.
Q. Is it related just to COVID, or is it broader than that?
MS. SNOW: Objection. Assumes facts not in evidence.
BY MR. VECCHIONE:
```

Q. Okay. Is it related to COVID?
A. I cannot say for sure what was stated in the IAA, but we were only engaging on COVID misinformation. But we were learning about how they operated a general misinformation team along the way to --
Q. How Census did?
A. How Census did it, yes.
Q. And did you -- was part of the IAA -well, I'll ask it in two parts first. Was part of -- was the purpose of the IAA so that CDC could learn what they did and perhaps replicate it?
A. Was that the purpose of the IAA? No, I

23 wouldn't say it. I think that we were learning from

Page 111
Q. Okay. What was your understanding of what the AII was about?
A. To let us partner with the Census to learn how they handled misinformation and help us with the COVID misinformation. We were shorthanded. They seemed to have more knowledge than we did.
Q. All right. And do you know if the IAA is still in place?
A. Well, we haven't been working with Census in quite some time. I don't know the actual date on the end of the IAA, though.
Q. All right. If you look at item eight of the items flagged: "COVID-19 vaccine cause bell's palsy." Do you see that?
A. Yes.
Q. Do you know whether you gave any input on that question?
A. I don't recall.
Q. And how about item number nine: "COVID-19 has $99.96 \%$ survival rate"?
A. I don't remember what we said about that one.
Q. All right.

MR. VECCHIONE: I will hand over these all at once because I'm going to ask the same question

Page 112

1 about them.

MR. GILLIGAN: 31?
MR. VECCHIONE: 12. No, no, no, 12 through 14, how about that?
(Plaintiffs' Exhibit 12 and Exhibit 13 marked.)

BY MR. VECCHIONE:
Q. And you don't have to read through these. You can just look at them all at once. I'll let counsel look at them for a second, and then I'll ask the question.

Now, I'll just represent to you what these are, unless you can tell me you've seen them before.
A. I haven't seen them before.
Q. All right. So Exhibit 12 is a scientific paper on the relationship between Bell's palsy and SARS CoV-2, as is 13.

Do you know whether or not in relationship to Exhibit 11 and Bell's palsy, that whether or not any of these scientific articles or others on Bell's palsy were flagged by CDC to Facebook?

MS. SNOW: Objection. Calls for speculation. Lack of foundation. BY MR. VECCHIONE:
Q. You can answer, if you know.

Page 113
A. I wouldn't know. I mean, I didn't flag them.
(Plaintiffs' Exhibit 14 marked.)
BY MR. VECCHIONE:
Q. Okay. And then on 14, Plaintiffs' Exhibit 14, have you seen this before?
A. No.
Q. And this is another scientific paper on the percentage survival rate of COVID patients.

Do you know whether this was flagged by CDC to Facebook or other social media?
A. We didn't flag this, or specific things. We provided CDC content.
Q. All right. And that means things that either CDC had on its website, or it knew internally?
A. I think primarily it was things that were on CDC's site, but $I$ can't say that for sure. I did not, not -- none of the communicators answered the questions directly.
Q. Okay.
A. Unless we had it on our website.
Q. So what you do is would you refer them to subject matter experts?
A. Those questions would -- if they were on

Page 114

1 an email, they would go, you know, we would -- I 2 didn't.
Q. Right.
A. People in the response would ask the SMEs about them. That's my understanding of what happened when they were circulated.
Q. So I'm trying to get the trail of how they get -- how Facebook or the other social media get information. You're the contact point oftentimes. They send you things like this?
A. Mm-hmm (affirmative).
Q. Then somebody -- and we've already determined, you're not -- you don't do science, you're a communicator, right? And a tech person? So where do you send this material to get those answers if it's not on the website? Because you've told me if it's on the website we just send it over to them.
A. I didn't even always check to see if it was on the website myself or in my office. I would let the communicator that was assigned to whatever the area was. For instance, Rosie on the Exhibit 11 was working with this area, and she would have the contacts with the experts.
Q. Okay.

Page 115
A. I don't know what they -- how they got the answers back in every instance.
Q. Because you weren't always the person to send the answer back?
A. I sent the answers back, but I didn't collect them. Usually they required multiple experts.
Q. Okay. All right. And in Exhibit 11 again -- you can put 12 to 14 aside. Do you know if Cynthia Jorgensen and Rosie Bretthauer-Mueller and Demi Haynes joined the meeting, as indicated?

MS. SNOW: Objection. Vague.
MR. VECCHIONE: They're the people she's going to bring in for the meeting.
A. I think they probably did. I don't know if all three of them did. BY MR. VECCHIONE:
Q. And what is -- do you know what the role is of a co-lead for consumer vaccine content development is?
A. She would help write all the materials on vaccines that were on the website, or in a fact sheet.
Q. And do you recall this meeting taking place?

Page 116
A. I don't recall the specific meeting. I do recall meetings such as -- like this. I mean, maybe it's this one I have in my mind. I don't know for sure.
Q. Well, if it's -- what was discussed at the meeting, to the best of your recollection?
A. Sometimes in these meetings they would ask do we know if this is true or false, which is what they were doing. And then if we knew, the communicators knew the answer, we would provide it. If not, I would say, we would say, I'll have to get back to you later, we'll talk to our SMEs.

And then that's why $I$ was referring to not going to have an SME going, but we can go back to the group after the meeting if needed was the gist.
Q. Do you have notes or other records of what was said on the call?
A. I didn't take notes. I don't believe notes were taken.
Q. But once again, on a calendar you might have that calendared?
A. I would have -- the appointment would be there, but it wouldn't necessarily say if Cynthia joined or not. She would have been invited.
Q. All right. And we discussed earlier today

Page 117
your conversations with at least Facebook, but some social media on misinformation. And you said it was on -- I think you said it was on a general level, you couldn't remember anything specific.

After looking at these documents, has anything changed in your response? Do you remember any specific misinformation you discussed with the social media organizations around here, around 2021?
A. I mean, I remember seeing this list before now that you've showed it, but I don't remember what we sent back, or what we said on the phone specifically about each of these items.
Q. And did you -- did CDC -- when I say "you" here I mean you or anyone you know at CDC.
A. $M m-h m m$ (affirmative).
Q. Ever monitor whether Facebook or other social media company took down material that you have indicated was false?
A. I do think that Census was at least periodically checking on things that they had flagged, or they had seen come up.
Q. Okay. Thank you. And why do you believe that?
A. Because I have vague recollections of them mentioning it or asking it in the meetings, and I

Page 118
believe that was in one of these exhibits.
Q. Got it. That you reviewed during this deposition, or before?
A. In this one.
Q. Okay. You can put Exhibit 11 aside.
A. Okay.
(Plaintiffs' Exhibit 15 marked.)
BY MR. VECCHIONE:
Q. And let's go to Exhibit 15.

MR. GILLIGAN: Just a moment, Counsel,
before you ask your next question.
(REPORTER'S NOTE: Mr. Gilligan conferring with witness.)

MR. VECCHIONE: The witness has conferred
with counsel.
BY MR. VECCHIONE:
Q. And, again, I'd just ask you to identify it by the subject of the re: line and the date, and then continue reviewing it.

MR. GILLIGAN: Referring to Exhibit 15?
BY MR. VECCHIONE:
Q. Referring to Exhibit 15.
A. "It was this list, sorry. Agenda item for CDC call this week." It was June 2nd, 2021.
Q. Now, please take a look.

Page 119
A. Okay.
Q. All right. Now, I think the end of this email is pretty much the same as the one that was Exhibit 14; right?
A. It is.
Q. So let's just start with the email that's from Liz Lagone to you on May 24 at 1:57 p.m., and she ccs Carrie Adams at Facebook, it looks like, from the email. Who's Carrie Adams?
A. She was part of Liz -- of Payton's team, now Carrie is my main point of contact at Facebook, Payton has since left.
Q. And can you tell me -- so she says on this email: "Thanks so much again for you and team's help in debunking a few COVID-19 and vaccine misinformation claims for us. As a followup to our meeting, please see the list of claims below with notes from our conversation last Thursday morning."

So if this is Monday May 24th, is it fair to say that the meeting was Thursday May 20th, if that's the Thursday of the previous week?
A. It appears that way to me too.
Q. Okay. So do you recall who met at that meeting, and where it was?
A. Well, as we were discussing on the other

Page 120

1 exhibit, it was a phone conference, and I think that Cynthia and Rosie and Demi may have attended. I can't say for sure all three of them attended, but I know that they were at least two of them were probably on the line.
Q. All right. And she's listed a number of those items that we saw before that they had questions about. And the first one that she lists, although it's not in the same order, she sent it to you earlier; right?
A. It does appear in a different order, yes.
Q. But, she says: "Is the claim, quote, 'COVID-19 is manmade' false, unproven, unsupported by evidence or true?" And the answer's:

Inclusive [sic] -- inconclusive; right?
And then she also goes on to say: It's probably from animals jumping to humans.

And my question here is she says: The CDC director in her testimony yesterday said being manmade was technically possible because we did not know the origin still.

And was that the CDC dir- -- I think I
saw Walensky in this email beforehand. Is that your understanding of who that is?
A. In May that would be Walensky.

Page 121
Q. Okay. Now, why is Liz Lagone sending this email to you about -- why is she sending this email to you to confirm the conclusions below about the COVID vaccine?

MS. SNOW: Objection. Calls for speculation. BY MR. VECCHIONE:
Q. You can answer.
A. I don't know why Liz specifically sent it for sure. But I -- because I just mentioned -- when we were talking about the other exhibit -- that we were communicators and not experts, there were probably -- I'm sure we were saying we're pretty sure this is correct. We might have to go back and check on stuff. And I think she was trying to give us something to go and follow up.

And I can see I said let's -- I'd like to note that we have no scientific experts on the call so these are our thoughts, but we'll definitely check on this on our end.
Q. Okay. So you didn't -- but you didn't respond that she had misheard anything on the conversation; right? You just said you needed to check with scientists; right?
A. Correct. That's what $I$ said in the email.

Page 122
Q. Okay. And then $I$ will just to -- later on the COVID-19 vaccine causes various things, these things had been proposed: Alzheimer's, Prion's, cytokine storm. And you respond inconclusive. We don't know right now; right? You just didn't have anything at hand?
A. That appears to be what we said on the call, and that Liz, in theory, wrote down what we said correctly.
Q. Right.
A. That's not clear from this chain.
Q. And then --
A. But how I'm interpreting it.
Q. And then once again the survival rate, they say it's inconclusive but it's a hard number to prove, and -- correct, that's what she says?
A. "Not able to debunk now, inconclusive. Scientists would be hesitant to attach a correct number to the survival rates," so.
Q. Okay. Yes. And then it says "Note, this claim is tied to the VAERS issue."

What's VAERS?
A. VAERS is a Vaccine Adverse Events Reporting system.
Q. And is it your understanding that doctors

CAROL CRAWFORD 11/15/2022
Page 123

1 around the country report adverse events for

Page 124

1 assigned to the topic group such as Rosie who was the communicator for vaccines. She was talking to the SMEs.
Q. All right. And then would she talk -could she talk directly to Facebook or the other social media after that?
A. Almost always she'd send back to me, and I would consolidate responses and send them back. Sometimes if I was out, Rosie would respond directly with a copy to me or something. I don't know that that happened ever, but it might have.
Q. All right. Now, on May 24 at 1:57 she does thank you for your and your team's help in debunking a few COVID-19 and vaccine misinformation claims; correct?
A. Where do you see the thank you?
Q. On May 24th, 2021 at 1:57. The Bates stamp at the bottom ends in 539.
A. Sorry. I'm on the wrong --
Q. Yeah.
A. Yeah, she does say that. But then I note that we haven't had scientific experts review this yet right after she sent that to clarify.
Q. All right. But you were going to check with them so that it could be debunked; correct?

Page 125
A. Correct. If it was supposed to be debunked.
Q. If it --
A. Yes.
Q. Yes, if it was. I thought -- I'm not seeing it now. One second.

Ah, here it is on the very first page of Exhibit 15. Liz Lagone refers to a Sam. "Also I meant to ask in my email earlier but I recall it was either you or Sam mentioning that you could share a transcript." Who's Sam?
A. I assume that was Sam with the Census team.
Q. Got it. And have we talked about him before? Is he --
A. We mentioned that he was one of the Census folks. I didn't remember his name until the exhibits, but yes.
Q. And do you know if the transcript of Dr. Walensky was just her testimony to Congress, or something else?
A. In re-reading this, my recollection is is that they asked about this, and several of us said I think we heard her address this in the press event, or maybe it was the testimony. I'm not sure. I

Page 126

1 guess it was the testimony because I was looking for
2 the transcript, and we mentioned it. And we were looking for it because that was the only thing that 4 we knew of that might exist to help them with their 5 question.

6
7 6:58, that's from you; right?

Page 127

$$
1
$$

$$
2
$$

$$
3
$$

```
A. Yes.
Q. And that's to Liz Lagone; right?
A. Yes.
Q. And what -- could you read what you say to her?
A. "Notes below on some. I hope this helps. I will let you know when we have cleared points."
Q. And then stop there.
A. Okay.
Q. Then "COVID-19 vaccines causing
magnetism." And, surprisingly, "debunked."
Then you'll say "will have cleared TP soon." What's TP?
A. Talking point.
Q. How does a talking point get cleared? Well, I'll withdraw that. What is a talking point?
A. Usually it's a bullet or a paragraph on whatever the subject is that one could refer to.
Q. And how does it get cleared? What's the process?
A. I mean, I'm not sure why I was looking for \(T P\) instead of web content. I don't know if that was just a mistype or not, but -- or maybe -- maybe it was going to be a talking point. But usually any content that's going outside of the agency goes
```

Page 128
through a very specific clearance process. There was a clearance process for COVID. I wasn't -- I rarely cleared things myself, but there -- many people have to sign off on content before it leaves the Agency.
Q. Got it. And I'll just notice -- I'll just point out that the bottom about the COVID-19 vaccines causing erectile dysfunction, again, you say "will have a cleared TP soon"; right?
A. Yeah. I believe thinking more about why I said TP, we often provide media with talking points when they ask questions. And that was -- we were also looking at things that we were providing to media in addition to web content because that was similar, there were similar questions coming. So perhaps that's why this says TP instead of web content.
Q. All right.
A. I can't say for 100 percent sure, but I think that might be likely.
Q. And you use web content in other -- in other of these points. So my question there is with respect to items 3, 4 and 6, which, I think if you look at it, that's what they are.
A. Mm-hmm (affirmative).

CAROL CRAWFORD 11/15/2022
Page 129
Q. What does it mean that, quote, "web content to debunk is in clearance"?
A. Well, I think what we were referring to is posting a more specific kind of $F A Q$ or myth. We had a myths page where we would more directly address the myth. You know, sometimes answers to things were buried in guidance or scientific papers, and we were trying to make it easier for people to understand the myths. So I think this is in reference to adding a myth or an FAQ to the site.
Q. All right. And then you said -- well, my next question: So what does CDC do to debunk the claims that -- I'll make it more specific here. What did CDC do to debunk each of these claims? What process does it go through to debunk them?
A. I can't -- I can't answer what the -because that's a scientific process that I'm not part of.
Q. Okay. So they give these questions to you, and you send it out to a scientist or a subject matter expert, let's call them.
A. $M m-h m m$ (affirmative).
Q. I take it -- I take it from the responses there is a number of different $C D C$ answers. One is inconclusive. You say that a number of times. They

Page 130

1 didn't have the information at that time, is that fair?
A. That's my assumption of what was meant by that.
Q. Okay. And sometimes they'd say inconclusive, but give here's what we know now?
A. Mm-hmm (affirmative).
Q. And then in other times it's just debunked.

What did you get from the subject matter experts when they send that back? Did they just send back "debunked," or do they have some reference or explanatory note?
A. On -- I think it varied. For this one I'm not sure. I don't remember if $I$ saw all the explanations, or if they were discussed in meetings with the experts. I've seen some that seemed to have a little more description when $I$ have asked it, but -- or well, maybe when $I$ was asking the SME they might have given me, but $I$ was really the one discussing it directly with the SME.
Q. Now you've also described already some things they'd already done and put on your website?
A. Yes.
Q. All right. So do you know if CDC

Page 131

1 conducted any experiment or processes to debunk any of these items?
A. I wouldn't know.
Q. Do you know whether they did surveys of the medical literature of the vaccines?

MS. SNOW: Objection. Vague.
BY MR. VECCHIONE:
Q. In order to debunk claims do you know whether they checked medical literature, or what they reviewed?
A. I wasn't part of the scientific process, so I wouldn't even want to speculate.
Q. So I think if you look at Exhibit 15.
A. Yes.
Q. Do you have it? If you go to the second-to-last page it's where they start. And Payton Iheme sends you this list of a number of claims. And the date of that is May 19th; right?
A. Yes.
Q. And then if you look at 16 by June 3rd at 2021, 2:57 you write about the last ones that you hadn't told her about: "Yes, they are debunked and we will also have content on it soon"; correct?
A. I see that, yes.
Q. All right. So that is about two weeks'

Page 132

1 time to debunk these claims that?
A. That seems like the dates, yes.
Q. So given that short time frame, would you agree with me that CDC didn't do any experiment to debunk these proposals?

MS. SNOW: Objection. Mischaracterizes the documents and the testimony.
A. I feel like it took us two weeks to respond back to Facebook. I don't think it was fair to characterize it as the time it took CDC to potentially collect science on this. BY MR. VECCHIONE:
Q. Thank you. Do you know who -- when you give your initial proposals to Facebook, when -like the discussions we saw earlier where you said those were our discussions but we have to check with the subject matter experts, who in that conversation, when you're meeting with them, who makes those proposals? Is that you, or is that one of the co-chairs we mentioned?

MS. SNOW: Objection. Vague.
A. What do you mean by proposals? BY MR. VECCHIONE:
Q. Well, they put together these matters to be debunked; right? And we saw -- and you can put

Page 133

15 next to 16. And if you look at 15 , as we discussed earlier, Liz Lagone sends you: This is the conversation we had. It's kind of --

MR. GILLIGAN: Which page?
MR. VECCHIONE: Page -- on page 15 [sic], second page.

MR. GILLIGAN: Thank you.
MR. VECCHIONE: Exhibit 15.
BY MR. VECCHIONE:
Q. So she says, and we've discussed this before: "Please confirm the conclusions I have noted below based on our discussion."

So you had a discussion and she got these impressions. But who gave her these impressions? In other words, who was the person in the room who could say, nah, I don't think that's right, but we'll get back to you with the subject matter expert?
A. I don't remember this call specifically in any kind of detail, but $I$ do believe it was one of the first times they had sent us a list, and I think that Cynthia and Rosie or Demi, who had a lot more knowledge of the content, piped in mostly on what they thought was available.
Q. Okay.

Page 134
A. But I believe we characterized it during the call that we would need the expert, and I followed up that way at the end.
Q. In the subsequent emails?
A. Yes.
Q. And then -- so then finally there is at the end: "Yes, these are debunked" --
A. Mm-hmm (affirmative).
Q. -- and you'll "have content on it soon."

And that content, is that talking points, or is that web content when you use that term?
A. When I use what term?
Q. Content.
A. Web content, it could have been a FAQ on the web, it could have been a myth, it could have been a fact sheet on the web. Anything on the web --
Q. All right.
A. -- that was for consumers.
Q. But you considered that debunked by the CDC by June 3rd, 2021?

MS. SNOW: Objection. Vague. BY MR. VECCHIONE:
Q. Well, she says: "Yes, they are debunked and we will also have content on it soon" in

Page 135

Plaintiffs' Exhibit 16, June 3rd, 2021.
A. We reported to Facebook that they were debunked at this time.

MR. VECCHIONE: Thank you. Exhibit 17.
You know what, take this one, too, because it will be real quick, I hope.

BY MR. VECCHIONE:
Q. So I'll -- one more question on 16. On that June 3rd date where you said these are debunked, who makes the final calls that they are debunked before you send it Facebook?
A. The communicators or the SME that I'm working with would decide if it was okay to send it back to Facebook. The communicator would get that from the SME that they were working with.

For instance, my team posts the web, but I don't know how every piece is exactly cleared, but yet when they send it to us to post it there were trusted people that send it to me, and we assume that it's cleared and we post it.

It's very similar. Rosie was also in charge of clearing other things, and so she would assure to me that she had discussed it with the SMEs of authority.
Q. Okay. And do you know of any, the names

Page 136

1 of any of these SMEs?
A. No, not off the top of my head. I mean, people were in and out of the response, and I don't recall.
Q. All right. I'll ask you to take a look at Plaintiffs' Exhibit 16 again.
A. Okay.
Q. Can you read item seven, and the answer on -- it's Bates stamped 533. It's on the second page.
A. Of which exhibit?
Q. Exhibit 16.
A. Of 533.
Q. The bottom at the number is called a Bates stamp.
A. Oh, sorry.
Q. That page, if you go up -- yeah, not everybody knows that and I have to say that -MR. GILLIGAN: Nobody actually uses a Bates stamp any more either.

MR. VECCHIONE: What do they do?
MR. GILLIGAN: They're all electronically applied.

MR. VECCHIONE: I gotcha. I remember. BY MR. VECCHIONE:
Q. In any event, could you read item 7 from

Page 137

```
    1 the email that you sent?
    A. "People who are receiving COVID-19
vaccines are subject to medical experiments."
    Q. And then the answer at 7 (a)?
    A. "Debunked. CDC notes this likely stems
from the vaccines only having EUA now and equating
    lack of full authorization as being involuntary part
of a medical experiment."
    Q. And WhatsApp EUA?
    A. Emergency use authorization.
    Q. All right. And that's when the FTC -- FDA
has given an emergency use authorization for certain
medicines?
    A. This is not my area of expertise, but yes,
    I believe that's --
    Q. That's your understanding?
    A. Yes.
    Q. So were you aware at this time that
vaccine mandates had been employed by governments,
employers and colleges as a condition of maintaining
employment or enrollment?
                            MS. SNOW: Objection. Assumes facts not
in evidence.
BY MR. VECCHIONE:
Q. Have you ever heard of such a thing?
```

Page 138
A. Yes. I don't know --
Q. Does getting a vaccine as a requirement of maintaining employment or enrollment affect voluntariness?

MS. SNOW: Objection. Calls for speculation, assumes facts not in evidence, argumentative.
A. This is really not my area of expertise of any account. I don't have anything really to provide on that. BY MR. VECCHIONE:
Q. Did you instruct Facebook to do anything with debunked claims?
A. No.
Q. Did you have an understanding of what they were going to do with any claims that the CDC said were debunked?
A. I knew that they had options, but I think we also discussed on a previous exhibit, which is to inform people, to maybe reduce it in the algorithm, or to remove it. I -- they probably had other options, but $I$ knew of at least those.
(Plaintiffs' Exhibit 17 presented.)
Q. Thank you. Exhibit 17. And, again, just tell me the subject line and the date.

Page 139
A. "FB misinformation claims help debunking," misspelled. The date is 7/26/2021.
Q. So on July 26, 2021 it's Liz Langone to you again; right?
A. Yes.
Q. And she says: "Our Misinformation Policy Team," meaning Facebook's do you believe?
A. Yes.
Q. "Has identified some claims that we were hoping your team could help us understand if they are false and can lead to harm"; right?
A. Yes.
Q. And she has spike proteins in COVID-19 vaccines, Guillain-Barre syndrome -- which I will use GBS from now on as well -- is possible side effect, and heart inflammation as a possible side effect of all COVID-19 vaccines.

Those were the questions that she sent you; right?
A. Yes.
Q. Do you know why she's asking you, or do you have an understanding? I'll withdraw it.

Do you have an understanding of why she's asking you at CDC whether the claims are true or false?

Page 140
A. Because CDC would have credible health information about the claims or scientific information that would benefit their policy making is the way I understood it.
Q. Okay. And she then asks you she was "wondering if your team was aware of any global source of truth/database for vaccine adverse effects including possibly vaccine-related deaths." Do you see that?
A. Yes.
Q. Did there ever come a time when WHO or some foreign medical health agency differed with the CDC on any of these vaccine topics that you recall?
A. That's not my area of expertise, and I don't recall any specifics.
Q. Do you know whether on these three requests that you did another response on debunking, inconclusive, or not known like you did in the previous one, exhibits we looked at?
A. I don't remember what I specifically answered with this.
Q. Okay.
A. I know generally what I -- how I handled them, but not what $I$ did with this.
Q. Okay. And generally how you handled them

Page 141
we've already discussed?
A. Yes.
Q. And you have nothing different to add on this particular request?
A. No.
(Plaintiffs' Exhibit 18 presented.)
Q. Okay. You can go to Exhibit 18. And once again could you please give me the subject line and the date of Exhibit 18?
A. Yes. CrowdTangle COVID-19 reports. 7/20/21.
Q. Okay. And please take a look at it.
A. I've scanned this one.
Q. Who's -- at the top, at the very end, I guess I should say the end, the very top?
A. $M m-h m m$ (affirmative).
Q. It's Carol Crawford to Tyler Woods. Who is that?
A. Tyler Woods was a name on another exhibit. I mentioned at that time I'm pretty sure that Tyler Woods took over the reporting from Kelly Perron, and that appears to be the case here. There is a transfer on the first page saying -- from Kelly saying Tyler is going to be sending the reports in the future.

Page 142
Q. Okay. And once again these are the CrowdTangle reports that $I$ think we discussed at one point you were receiving biweekly?
A. Yes.
Q. And were you doing anything different with this information at this time than you've described to me earlier?
A. Not that I recall.
Q. Okay. And at this time, June 9th, 2021, are they reporting this to you for the same reasons as you've described previously when we first mentioned CrowdTangle?
A. That's my recollection of it.
Q. On the very last page, which is the beginning of it, June 8th, 2021, 8:13 p.m.,
"vaccination lawsuits" --
A. I see it.
Q. -- highlighted. Do you know what they are referring to there?
A. Sounds like the lawsuits around the mandates that you mentioned previously.
Q. Okay. Like the OSHA mandate or CMS mandates?

MS. SNOW: Objection. Assumes facts not in evidence. Calls for speculation.

Page 143
A. I really am speculating.

BY MR. VECCHIONE:
Q. You're not sure?
A. I don't know. This is not really an area of my expertise. This is simply a report of conversations that are occurring on social media.
Q. All right. When you received it, did you have an understanding of what the vaccine lawsuits they were referring to were?
A. I had a recollection of that from watching the news in my personal life.
Q. Okay. On that same page "Deciding to Get Vaccinated" she's highlighted.

Why does the CDC need to be updated on the statements of public physicians?

MS. SNOW: Objection. Mischaracterizes testimony and the document. BY MR. VECCHIONE:
Q. Why were you updated on those statements?
A. Again, these are reports that characterize the overall conversation of social media. They are not -- I don't believe these were picked out specifically for CDC. I think these are a report of the trends of conversation on social media.
Q. And I'd like you to turn to the next page

Page 144
where Tyler Woods takes over and he sends a June 22nd, 4:43 p.m. summary to you.
A. Okay.
Q. At the end of it it says: "Let us know if you have any questions or specific keywords/topics you'd like us to explore in the next report. As always, please do not share."

Did there come a time that you shared keywords or topics with Facebook that you wanted them to check in?
A. I don't recall doing it.
Q. All right. Turn to the first page of Exhibit 18. Once again, this is Tyler Woods to you?
A. Yes. Sorry.
Q. Thank you. The very, very mistake on my instructions at the beginning. You're to be commended, because it usually happens a lot more until now.

So the last, the last item that's highlighted: Door-to-door vaccines. Do you know whether he's referring to any public statements made on this topic by any plaintiff in this case, including Governor Mike Parson?
A. I wouldn't know.

MR. VECCHIONE: You can put that aside.

Page 145
(Plaintiffs' Exhibit 19 marked.)
BY MR. VECCHIONE:
Q. And once again please identify it to me by subject matter and date of Exhibit 19, and then please read it to yourself.
A. CrowdTangle COVID-19 reports, 8/18/21. I didn't hear your last part of to yourself, what.
Q. Just read it to yourself. In other words, you get to review the document but you don't have to read it out loud?
A. I'm sorry about that. Okay.
Q. I'm not caught up to you.

Okay. So as we've discussed, this, once again, is one of the CrowdTangle reports but that Tyler Woods is now sending; correct?
A. Yes.
Q. Let's go back to the August 3rd exchange on this. So on August 3rd Tyler Woods writes to you at 6:16 p.m.?
A. Yes.
Q. And once again the purpose of this you've already testified to; it hasn't changed, why you're getting these?
A. Correct.
Q. All right. So did the CDC at this time

Page 146
have proof that, quote, "the recent uptick in hospitalizations and deaths is being driven by unvaccinated individuals"?
A. I'm not an expert in that area and I wouldn't be able to answer that question.
Q. All right. Do you know whether subsequent evidence the CDC had supported that view?
A. I'm not an expert in this area, and I don't feel comfortable. I don't know.
Q. The email exchange that Tyler would send you on July 20th, 2021, the Bates stamp number at the bottom is 2440 of this document.
A. I see it.
Q. You there? So, once again, when he sends you material from CrowdTangle concerning allowing people to return to religious services, that's because it's appearing on CrowdTangle and not because you asked for it?
A. Correct.
Q. And let's go to the first page here, but I'll ask you to take a look at the August 17th exchange. Once again, Tyler Woods sending you the CrowdTangle reports?
A. Yes.
Q. Now, by August 17th, 2021 are you still

Page 147

1 using CrowdTangle for the same purposes you
Q. But just to clarify.

Page 148
A. Yes.
Q. So these are reports from Facebook to you?
A. Yes.
Q. As we've discussed?
A. Yes.
Q. I might ask you if something's changed, but you've already testified to that. But within CDC you had access to CrowdTangle, and created your own reports?
A. That we could -- I don't know that we created reports. I know that we did searches in CrowdTangle, the same way we do searches in other social media and listening tools that we have to create, to understand what's being discussed in the environment, to update our communication material, as $I$ was explaining this morning.
Q. Okay. So on this particular one that we're discussing, once again Facebook has sent you their CrowdTangle summary. And I-- the COVID 19 mandates at the bottom there that's highlighted. It says: "On the other hand, many conservative politicians are calling for an end to government mandated restrictions and vaccinations."

And my question is do you know whether or not there was any CrowdTangle information about

Page 149

```
either Attorney General Schmitt or Attorney General
```

Landry in these CrowdTangle briefings?
A. I'm not -- I wouldn't even say I flipped open this -- every report. I don't know. I couldn't remember any of the details. They did often put pictures of the posts, of a post as examples.
Q. Oh, okay.
A. But $I$ don't know.
Q. That they're finding? Sort of like that that attachment we saw earlier where they were asking you about the wording? Like, in other words, it wouldn't look like this. It would be some something they had taken off Facebook?
A. Yeah. But that was -- those samples I feel like you're referencing are different. This would just be like they are saying a lot of people are talking about COVID-19 mandates; they might put a few example posts someone put in the slide deck to show what they were talking about.
Q. Got it. Thank you.

MR. VECCHIONE: Exhibit 20.
THE WITNESS: After Exhibit 20, could we take a short break?

MR. VECCHIONE: Let's take one now.

Page 150

THE WITNESS: Could we take one now?
THE VIDEOGRAPHER: Off record at 2:06. (Recess 2:06 p.m. - 2:19 p.m.)
THE VIDEOGRAPHER: We are back on the record at 2:19.
(Plaintiffs' Exhibit 20 marked.)
BY MR. VECCHIONE:
Q. Okay. Ms. Crawford, have you had a chance to look at Plaintiffs' Exhibit 20?
A. I did.
Q. All right. And could you tell me the subject line and who's it from, who's it to and what the date is?
A. Yes. The subject is VAERS policy consultation on 8/19, 2021. The first email is from me to Carrie Adams at Facebook.
Q. All right. What's your understanding of why the CDC was asking to meet with the VAERS experts for consultation about misinformation?
A. I don't recall a lot of the details, but VAERS, the topic of VAERS was an area that was widely discussed on social media, and there was a lot of areas of confusion about what VAERS data was. There was myths about VAERS data, and there was misinformation about VAERS data. So it was always

Page 151

1 one of the things that rose to the top in terms of volume of discussion of people were very confused about VAERS.
Q. And do you know whether this meeting ever took place?
A. I don't remember if the one we were discussing at this time took place and the Singapore team attended for sure. But we did have a session with the VAERS experts with Facebook.
Q. Okay.
A. Probably as a result of this, I feel like it might have dragged out a little bit after this for a few weeks.
Q. And do you know what was discussed at that meeting? First, did you attend it?
A. I did attend it.
Q. And do you recall what was discussed at that meeting?
A. We had one of the experts for VAERS, and -- maybe it was two experts for VAERS and a couple of their communication experts on the line with Facebook's team. I believe it was like their misinformation and policy type team like that Liz was part of, but $I$ don't know who -- I don't remember specifically who was on there. And we

Page 152
offered the SME just to answer their questions about what VAERS was and what it wasn't.

And my recollection is they asked a lot of questions like, you know, what does -- what does -who can report something on VAERS and things like that during the session.
Q. Okay. Do you know who the subject matter experts on VAERS were at CDC?
A. Goodness. I'm just totally blanking on their names. I'm sorry.
Q. If you recall during the course of this deposition, please let me know.
A. Okay.

MR. VECCHIONE: We can move on to the next document.
(Plaintiffs' Exhibit 21 marked.)
A. Thank you.

BY MR. VECCHIONE:
Q. And once again if you could just read the subject line, and then who -- what the date was and then read it to yourself.

MS. SNOW: Is this for Exhibit 21?
MR. VECCHIONE: 21.
A. Subject BOLO, CDC lab alert and misinformation. September 1st. It's from me to

Page 153

```
Carrie Adams at Facebook.
    I have read it.
BY MR. VECCHIONE:
```

Q. Okay. So do you recall this email?
A. I do now that I'm seeing it, yes.
Q. What are you telling Adams in this email?
A. I can't see the attachment. But there was a misinterpretation of a lab alert that we issued, and so I think we put together a deck -- a power point or a two-page just saying what the facts were about this lab alert.
Q. Okay. What is a lab alert?
A. I don't know if this was a HAN alert or if was some other kind of alert they sent straight to laboratory. So I don't remember the details.
Q. What is a HAN alert?
A. A health advisory alert. We send it -no, Network. Health Advisory Network alert. Sorry.
Q. And you have: "Carrie - BOLO."

What's BOLO?
A. Be on the lookout.
Q. Why were you concerned about this?
A. Similar to all the other BOLOs, we still thought it was good to point out if we had facts around something that was widely circulating as a

Page 154

1 cause of misinformation to the platforms to assist them in whatever they were going to do with their policy or not do. And this was one that was kind of growing, and we had a lot of facts about it, and the team was concerned about this, this misunderstanding.
Q. Do you recall whether Facebook did anything upon receiving this information from you?
A. I don't recall.
Q. How did you know that it was a small but growing area of misinformation?
A. I vaguely recall that we ran some Meltwater reports, and that people -- that conversation regarding this topic -- Meltwater is sort of like CrowdTangle but for all the platforms -- and that the conversation around this was growing.
Q. Got it. Now, tell me about Meltwater. Does it aggregate all the platforms and you search across them?
A. Yes. And social media listening tools are used by every social media team, I believe. I mean, it's widely common practice, and, yes, it will search. The CrowdTangle can see more on the Meta properties. So it's nicer if you're just looking at

Page 155

1 Meta properties. Meltwater gives you social media at large. The Meta platforms, to clarify.
Q. Do you know what the nature of the misinterpretation was? I know we don't have the attachment, but do you know?
A. I don't recall any longer.
(Plaintiffs' Exhibit 22 marked.)
BY MR. VECCHIONE:
Q. Go to Exhibit 22. So what -- before we look at that exhibit --
A. Mm-hmm (affirmative).
Q. -- when you said "be on the lookout," what did you expect them to do once they were on the lookout for Facebook?
A. The same thing I have been describing. I knew that they had various options. They could have just used it to inform people. They could have considered it in their algorithm, I believe. I did understand that potentially removing posts was something that they might do.
Q. So if you could, just please identify Exhibit 22 to me the same way by its re: line --
A. Okay.
Q. -- and its date and then read it to yourself.

Page 156
A. November 2nd, 2021. Subject New Claims and Policy Updates Following EUA Authorization for 5 to 11-year-olds.

It's from me to a group, but $I$ think primarily it was to Facebook. Also -- never mind. I thought I missed part of the subject. Sorry. Okay.
Q. All right. So this is the first one that -- she actually signs off with Meta this time; right? So I guess whatever he did took place --
A. I see that.
Q. -- changed over by then.

All right. The -- can you read the first two paragraphs she writes to you on November 2nd, 1:22 p.m. into the record?
A. Yes. "Kristen, thanks so much for confirming the ability for the claims in question last week having the risk of causing vaccine refusals. And thank you all so much for your input over the last week on our many questions about vaccine misinformation relative to the EUA."
Q. And second paragraph?
A. (As read) I wanted to share that as a result of our work together, when the FDA give emergency use authorization to the Pfizer vaccine

Page 157

1 for children last week, we immediately updated our policies globally to remove false claims about the COVID-19 vaccine for children, e.g., the COVID vaccine is not safe for kids, we also launched a new feature on Instagram where accounts that repeatedly post content that violates our polices on COVID-19 or vaccine misinformation may now lose the ability
to be tagged or mentioned or may see pop-ups asking
if they'd like to delete certain posts that violate our policies.
Q. And then she goes on to say: Now we've identified new claims; right? And then she lists them?
A. Yes.
Q. And she asks you could you tell her whether the claim is false, and if believed this claim could contribute to vaccine refusals; right?
A. Yes.
Q. All right. And this is similar to the other lists she had sent you earlier that we looked at to be debunked or not?
A. This is similar. This time, though, they -- I think -- I don't know if this is the first time, but this added the whole "could this contribute to vaccine refusals" element that $I$ don't

Page 158
think we had on the last one.
Q. Okay. What was your understanding of why she was reporting to you Meta's policies on childhood vaccines?

MS. SNOW: Objection. Mischaracterizes the document. BY MR. VECCHIONE:
Q. You can answer.
A. Would you reask the question?
Q. Yeah. What was your understanding of why she was telling you what Meta's policy was on pediatric vaccines?
A. Well, I don't know what -- why she was doing it specifically because I can't speculate on that, but $I$ received it as a thank you for assisting with the claims or the facts about this that we could provide.
Q. And then why did you think she was asking you to tell her which claims were true and which were false on that further list?

MS. SNOW: Objection.
A. Sorry?

MS. SNOW: Mischaracterizes the document. BY MR. VECCHIONE:
Q. Okay. You can answer.

Page 159
A. Ask the question again.
Q. Yeah. What was your understanding of what Langone was asking -- why she was asking you to tell her which of these claims were true and which were false, and, as you said, which would lead to vaccine hesitancy?
A. It was still my interpretation that she was asking to inform their policies. They were looking for CDC, who would have the scientific facts, to provide them with scientific facts.
Q. And didn't this email give you a pretty good idea that when CDC said something was false that Meta was going to take it down?

MS. SNOW: Objection. Calls for speculation. BY MR. VECCHIONE:
Q. You can answer.
A. I did not have a recollection of this email, and -- when I think about the work we did, but it definitely says here that they updated the policy globally to remove additional false claims.
Q. All right. Upon getting your information; correct?
A. It doesn't say upon getting our information. It just says that when the FDA gave

Page 160

1 the emergency use authorization we immediately updated our policies. It doesn't say upon getting our information.
Q. She goes on to say: I wanted to share that as a result of our work together; right?
A. Yes. But I assume this was -- I mean, I don't -- I'm reading it now. I don't have memory of this email. I'm interpreting it more of like the ongoing work for us to provide the facts to them. It could have been something specific, but I don't remember something specific regarding the -- this.
Q. Do you know whether -- and then you say -hang on. I'll get back to it.

You then respond to her on 11/2. I think it's 2:54:26. It's down to the second. "Got it, Liz. I'm going to work on this one with some other vaccine staff and take this one off of Kristen." So who are the other vaccine staff?
A. Kristen Nordlund is a press officer for the National Center -- or at the time was a press officer for the National Center for Immunization, Respiratory Diseases where the vaccine work was, and she was very involved in the COVID response.

And I don't see it in this chain, and I cannot be sure, but what I think happened was that

Page 161

1 Kristen helped on some questions regarding this in a 2 previous set of emails or maybe a conversation.
Q. All right. And then you say: "I hope we can do it by Monday."

So it's going to take a little less than a week. But you're going to hope to get back to her by then. This is a Tuesday.
A. Yes. I see that, yes.
Q. But then you say: "Thank you so much for the feedback on what you've been able to do. This is very good to know." Right?
A. I do say that, yes.
Q. So you're approving of her taking down the COVID vaccine is not safe for kids off the Meta platforms; right?

MS. SNOW: Objection. Mischaracterizes document and testimony. BY MR. VECCHIONE:
Q. You can answer.
A. I did not mean it generally. I never felt that my role, or CDC's role, was to determine what to do with the scientific information that we provided. But I'm happy that providing the scientific information led to less spread of misinformation. In this email I think what's what I

Page 162
was reflecting.
Q. So you were pleased that people who believed that the COVID vaccine was not safe for kids were taken off the platforms of Meta? MS. SNOW: Objection. Mischaracterizes testimony.
A. I don't think that's what she's saying in here.

BY MR. VECCHIONE:
Q. (As read) We immediately updated our policies globally to remove additional false claims about COVID vaccine for children, e.g. the COVID vaccine is not safe for kids.

That doesn't tell you that she's removing those people from the platform?

MS. SNOW: Objection. Mischaracterizes
document.
A. No.

BY MR. VECCHIONE:
Q. What is she doing then?
A. I understand that she's removing claims that have -- that are not scientifically accurate.
Q. Okay. Well, let me put it another way. People who post that statement will have that statement removed from Meta; correct?

Page 163

MS. SNOW: Objection. It calls for speculation, mischaracterizes the document. BY MR. VECCHIONE:
Q. That was your understanding of this email; right?
A. I think we'd have to just look at what's written here.
Q. And it is in English; right?

MS. SNOW: Objection.
MR. GILLIGAN: Argumentative.
A. I don't think you're characterizing it correctly. Sorry.
(Plaintiffs' Exhibit 23 marked.) BY MR. VECCHIONE:
Q. Move on to Exhibit 23. And once again I'd like you to just read the subject line and the date, and then read the rest to yourself.
A. New claims and policy updates following EAU authorization for 5 to 11-year olds.

This is on November 8th, 2021 from me to Liz and some others at CDC.

Okay.
Q. All right. So once again in Exhibit 23 she's asking you a number of questions, particularly number one was COVID-19 vaccines weaken the immune

Page 164

1 system. And then the same question she's asked before: "Is this false? Could this lead to vaccine refusals?" Right?
A. Yes.
Q. And you've -- and you've responded, "false"; right? "COVID vaccination will help people from getting COVID-19. Adults and children may have some side effects from vaccine which is normal signs that their body is building protection. These side effects may affect their ability to do daily activities but they should go away in a few days. Some people have no side effects, and allergic reactions are rare. Learn how mRNA vaccines work." Right? That's your response to her?
A. That I received from the content teams, yes.
(Plaintiffs' Exhibit 24 marked.) BY MR. VECCHIONE:
Q. Okay. I'm going to give you Exhibit 24. I'll just represent to you this is a report about European's Medicines Agency.

Do you know whether or not CDC looked to other worldwide agencies' view of the vaccines in order to inform Facebook on what was true and false? A. That's completely out of my expertise or

Page 165
knowledge.
Q. Have you seen this document before?
A. No.
Q. And you don't know whether it was used to formulate any response you gave to Ms. Lagone?
A. No.

MS. SNOW: Objection. Asked and answered.
BY MR. VECCHIONE:
Q. That's fine. You said no.
A. (Nods head.)
Q. And then let's look at -- I think I tossed my document aside. Yeah.

I'll direct you to item number six that you responded to Lagone about breast milk from vaccinated parents, harmful to babies and children.

MR. GILLIGAN: What document you referring to again, John?

MR. VECCHIONE: It's number 23. It's number six of the Lagone proposals.

MR. GILLIGAN: Thank you.
MR. VECCHIONE: You know what, I'm going to let that -- we're going to move on.

MR. GILLIGAN: Okay. No objection. BY MR. VECCHIONE:
Q. All right. We're going to Exhibit 26.

Page 166

1 We're going to skip Exhibit 25. there?
A. (As read) I hope your team are well and staying healthy. Thank you so much for the information you provided on claims we asked about last month. Since we last spoke, I wanted to share updates we made as a result of our work together. I also wanted to ask for your assessment of a few

Page 167
things, including three additional claims we've become aware of from our regular monitoring; how FDA EUA authorization for children under five might impact our policies; and three, CDC's insights regarding deaths from vaccines. As always, please do let me know if it's easier to set up a time to talk. Otherwise could we get input before February 9.
Q. Okay. Time to talk through any of these live; right?
A. Excuse me?
Q. I think you just --
A. Oh, did I miss a sentence?
Q. I think you just skipped.
A. Sorry. "Set up a time to talk through any of these live." I apologize.
Q. So what was your understanding of what she meant by as a result of our work together?
A. I believe the result of the work together is us providing the scientific information for the questions that they were asking us periodically like these in this email.
Q. All right. And if you'd look -- I'd ask you to go to the back of the document, the very back. And the first at three, she says: "COVID-19

Page 168
vaccines have caused thousands/millions of deaths."
And she says: (As read) Under our current policy, we remove posts that claim that COVID-19 vaccines kill people or lead to death. We removed these posts on the grounds that the claim is false and that it's harmful because people believe it, it might make them less likely to get vaccinated; right?
A. Yes.
Q. And then she notes that: In fact, vaccines -- some people might have an adverse reaction that leads to death; right?

MS. SNOW: Objection. Mischaracterizes the document.
A. I also can't -BY MR. VECCHIONE:
Q. Okay.
A. I'm not a scientist.
Q. I understand that. But she's telling you her understanding. Putting millions and thousands of deaths aside, we have this -- she's bringing to you a problem now.
A. Okay. If you'd -- I lost where you're reading from.
Q. Okay. So on the last page she says: We

Page 169

1 understand that in general COVID-19 vaccines do not cause death. However, we are aware that some deaths have been linked to COVID-19 vaccination such as detailed in this correspondence in The Lancet... reporting death rates from TTS following AstraZeneca vaccination in a number of countries.

And then she's saying we're going to reconsider our policies, and she's asking you for your advice; correct?

## A. She's asking us for scientific

information.
Q. I'll ask you to go to the second page of this document, which is Bates stamped 1684 at the bottom. And in the middle of the page under number 2 of the Claims about COVID vaccines for children under five years of age.

And she says: We understand the FDA is considering giving emergency use authorization for COVID-19 vaccine for children under five in coming weeks. We are considering how our existing policy on COVID-19 vaccines (see below) should apply to claims about children 6 months to 4 years once the vaccine is approved for use. Can you please assess for each claim whether it is false for children in this age range and if believed, likely to contribute

Page 170
to vaccine hesitancy or refusal?

And then: Please let us know if it's easiest to set up a time to meet and discuss each one.

And then she tells you what their policies are; correct?
A. No. I don't -- I haven't interpreted any of this as being the policies. These are the claims.
Q. Okay.
A. These are the things or -- they're saying are these true or false or unknown.
Q. Well, at the first one we read, though, they -- she did tell you under our current policy, remove posts that claim COVID-19 vaccines kill people or lead to death; right?
A. But the policy is not the same as the claims. The claims are the -- what she's asking us about, which is I know that they're using our scientific information to determine their policy, but they're asking us about the science.
Q. Okay. And your response was: "PS - the update is very helpful. Thank you for including that." Right?
A. Yes.

Page 171
Q. But and in this you don't respond on whether anything's debunked or not?
A. Yes. I don't remember if we did or not.
Q. And what did you find helpful about this?
A. I think what I think is helpful for us is to have her ask us specifically what she needs input on. So it's been helpful when she started just sending us the things she's wanting us to do.

I also think it is helpful to know that they're actually using the responses that we have in some form or fashion because it takes time to put them together.
Q. Thank you. You can put that aside.
A. Okay.
(Plaintiffs' Exhibit 27 marked.)
BY MR. VECCHIONE:
Q. And just again tell me the subject matter, the date, and then read it to yourself.
A. Okay.

MS. SNOW: What exhibit is it?
MR. VECCHIONE: Exhibit 27.
A. Have five minutes to chat. E: Vaccine

Misinformation questions for CDC February 4th, 2022.
Okay.
(Reporter clarifying exhibit number.)

CAROL CRAWFORD 11/15/2022
Page 172

1 BY MR. VECCHIONE:
Q. All right. And I think this is the same, at least part of the email is the same, as the last one we looked at; right?
A. I agree.
Q. But there is a different chain on top of hers saying she -- the part where she says she hopes you and your team are well and staying healthy.
A. Can I see 26?
Q. When you say on February 3rd at 5:21:

I'll talk to the vaccine program and see what I can do -- or what we can do. Excuse me. You say: I will talk to the vaccine program and see what we can do; right?
A. Yes.
Q. Is that to have a meeting on these questions that she'd presented?
A. Well, I mean, I guess it could have been a meeting, but $I$ was -- I was meeting -- I'll see if they could -- it was a lot of claims she gave in this email.
Q. Right.
A. And I was thinking I don't know that we're going to be able to address all of these. So I think I was thinking $I$ would talk to them and see if

Page 173
would even be willing to look at this many of them because she's asking for input on them within a couple of days.
Q. And it would be difficult to give input on all those questions that quickly?
A. I thought so.
Q. And do you know if this phone call occurred that you say at the very top of it in Exhibit 27?
A. I don't know for sure. I think that she called, and $I$ just said, look, $I$ don't think that we're going to be able to -- I was going out of town. I do remember that much. I think I -- I think she may have called, or I had emailed her separately when we didn't catch up, and said I don't think we're going to have it this quickly, it probably will be when $I$ return.

MR. VECCHIONE: Aren't you glad you came? MR. KUMAR: Make myself useful, yeah.
(Plaintiffs' Exhibit 28 marked.)
BY MR. VECCHIONE:
Q. And once again I'd ask you to read, for Exhibit 28 read the subject line and the date and read it to yourself.
A. Okay. COVID Misinfo Project. 3/23/2021.

Page 174

Okay.
Q. Okay. We have a new cast of characters. I'd like you to take a look at the bottom here, the March 18, 2021 portion of the email chain.
A. Yes.
Q. And that's from you to Stanley Onyimba at a Google -- it's $\square$ @google.com and Jan Antonaros at -@google.com. Do you recognize those names?
A. Yes. And Stanley was the name I couldn't remember when you asked me who my POCs were at Google.
Q. Okay. Stanley.

So you wrote to them on March 18 -- well, read that out loud to me what you wrote to them: "Stanley/Jan"?
A. (As read) As I believe we discussed previously, CDC is now working with Census to leverage some of their infrastructure to help identify and address COVID vaccine misinfo. As I understand it from the Census team, when they were doing this for the Census project last year, they met regularly with a Google/YouTube Trust team. Is it possible for us to start regular meetings on this topic or maybe use our existing time? Let us know

Page 175
if you want to discuss in more depth.
Q. All right. So what did you mean by CDC is now working with Census to leverage some of their infrastructure to help identify and address COVID vaccine misinfo?
A. That was the work of the IAA with Census to help consult and work with us on the COVID misinformation information. I just -- put COVID information one time. That's what I'm referring to here. This is more specific. This is when I refer to infrastructure, $I$ was referring to the fact that Christopher ran those reports and looked for misinformation on these areas for us.
Q. All right. And you refer to the Census project last year in which they met -- meet regularly with Google YouTube Trust team.

Was that a different project?
A. That was their -- I believe this was the 2020 Census.
Q. And that's what you think you're referring to there?
A. Yes.
Q. Do you know whether or not the Census engaged in content moderation with Google?
A. I don't know.

Page 176
A. Yes. But before I do, I want to go back

MS. SNOW: Objection. Vague.
BY MR. VECCHIONE:
Q. So and here I am not using censorship -anyways, still drawing objections.

All right. Let's take a look at March 23rd, 2021. Jan Antonaros to you, and cc's Stanley Onyimba. Can you read that response out to the clarification that she objected. When you asked me did Census do content moderation, I assumed you meant for the Census project, and I answered for that.
Q. Okay. How about for --
A. I wondered if there was more vagueness to --
Q. And how about for the COVID-19 vaccine project?
A. Not to my knowledge either.
Q. Okay.
A. But I thought you were referring to their project.
Q. All right. So please read Mr. Antonaros' response to you.
A. Hey, Carol -- or "Hi, Carol, Thank you for

Page 177
your patience as we identified the right colleagues from Google to pull into this effort. Would it be possible to schedule a call for later this week to learn more about how the $C D C$ and Census envision working together on this important topic."
Q. What was your understanding of what Antonaros meant by the right colleague from Google to pull into this effort?
A. I believe she was going to ask people on their trust team, or whatever their name for their, that kind of team is.
Q. Okay. Did you -- do you know now or did you know then who these people were and what their titles were, or are?
A. No. I mean, I might have known then. They may have participated in the meeting.
Q. But you can't remember now?
A. But I don't know their names now.
Q. And what's your response to him?
A. "Sounds good to check in first -- would Friday around 3:30 work?"
Q. All right. And do you know whether or not you had that call with him?
A. I don't remember.
Q. All right. So you don't recall who was on

CAROL CRAWFORD 11/15/2022
Page 178

```
the call besides you, if it took place?
    MS. SNOW: Objection. Mischaracterizes
testimony.
    A. I --
        MS. SNOW: Sorry.
        (Inaudible crosstalk.)
        MR. VECCHIONE: I'll rephrase.
    BY MR. VECCHIONE:
    Q. You don't recall whether the call happened
and who was on it?
    A. Correct.
    Q. All right. And do you know whether you'd
have a calendar with that call on it, by any chance?
    A. If we had a call, we typically had a
calendar appointment.
Q. Okay. All right. And what was -- you say "sounds good to check in first."
What did you want to check in with him for? What were you -- what did you want to talk about first?
A. I mean, I'm doing this from reading the email. I think she's saying let's check in before our regular meeting.
Q. Okay.
A. I think that's what -- I mean, that's how
```

CAROL CRAWFORD 11/15/2022
Page 179

1 I interpreted the "check in first."
A. Okay. Okay. Subject line's: Followup on meetings to go over things with Census, or what is

Page 180

```
preferred? I wasn't clear how interested you all
were on this effort or who the players are on your
end."
```

Q. So what were the regular 4:00 p.m. meetings you refer to?
A. I think -- because $I$ still have a 4:00 p.m. meeting every other Monday with Google. I think that these were the same every-other-week check-in meetings. Sometimes we wouldn't have them. Sometimes we would have them and discuss things.
Q. Did you have similar regular meetings with the other platforms we've been discussing, Face- -Meta and Twitter?
A. We -- you asked some of this earlier.
Q. I did.
A. The same answer. So we had regular meetings with Google, and we had regular meetings with Meta. Most -- you know, the frequency changed. So, you know, I don't meet as often. I mean, Google we meet every other week. Right now with Meta it's more ad hoc.

## Q. Okay.

A. We had had a regular meeting with Pinterest for a short period of time, and we had my memory was just more ad hoc meetings on occasion

Page 181
with Twitter.
Q. So on the regular meetings with either Google or Facebook?
A. Mm-hmm (affirmative).
Q. Well, let me ask the question this way. From the CDC end, were the same people usually attending those meetings with each social media?
A. It could vary. I mean, I was always -- I mean, with Google, it was typically me and Fred Smith, who's our technical lead, because often the Google questions would be more about technical implementations that we might have to work on. We were usually always on it. Sometimes I would -depending on the subject, I would bring in other people.

With Meta, I was pretty much always on there. Jay typically listened in. And then $I$ would bring people in depending on the subject.
Q. All right. And what were the -- were the topics typically misinformation, or technical subjects?
A. They -- by and large, they were mostly about things other than misinformation; though misinformation was discussed in the meetings. But they were originated about getting our credible

Page 182

1 information out to our audiences and some of the examples I gave this morning.
Q. Okay. And what did you mean by with we're going to check with -- "to go over things with Census, or what is preferred"? What does that mean?
A. I don't -- I don't have direct memory of it. I'm only assuming that -- what $I$ recall doing is asking through this chain is like is it okay if we bring Census in? Do you like -- what format is best to talk about misinformation?

Maybe we didn't resolve it on this call from the previous exhibit. I can't say for sure what I meant by it.
Q. Okay. And then could you read Onyimba's response to you on that, following that on March 29th?
A. (As read) We would like to follow up on our discussion with your colleague, Cynthia, on vaccine information a few months ago. Specifically, we plan to share a new list of common vaccine misinformation claims and would love it if Cynthia or other vaccine experts can join. We can also save a few minutes for me, you and Jan to discuss potential next steps regarding Census, but will not need the broader team for that discussion.

Page 183
Q. So who's Cynthia?
A. Cynthia Jorgensen, which was on a previous exhibit. She was the -- I mean, at the time of the other exhibits, she was the co-lead and the associate director for communication. I don't know what role she was -- she was definitely the ACS during this. I don't know if he was in their JIC during this period of time.
Q. Do you know what vaccine information she provided to Google?
A. I don't recall specifically. But they -so they were trying to be sure that they had the right information when someone Googled something. When you Google COVID, for instance, there are these little tabs that come up. They'll say, like, symptoms, treatment, vaccines. And that content, some of the things came from the CDC website. So from time to time they wanted to update information like that, and would ask us to have an expert on that could talk about it.
Q. Got it.
A. I don't remember this question, but I'm sure that's what it's in reference to.
Q. All right. Do you know what Google did with the list of common vaccine misinformation

CAROL CRAWFORD 11/15/2022
Page 184

```
1 claims?
```

A. I don't remember the list of claims, or what the format was or what they asked us about it. Maybe if you have future exhibits I'll remember, but I don't recall from this.
Q. All right. And then he says and -- "can save a few minutes for you, me and Jan to discuss potential next steps regarding the Census but will not need the broader team for the discussion."

Is that your understanding that it's a discussion about Census, or with Census, like are they there?
A. I don't know for sure what this was in reference to. But it -- I think that it is in reference to discussing how to engage on an ongoing basis about misinformation and the Census suggestion that we have regular meetings with them just on that topic.
Q. I got it. And you respond that you're going to get those subject matter experts on the next call?
A. Yes.
Q. I think I might as well add, and Census won't be there, but you'll discuss how to engage with them. Is that the meaning of that, that they

CAROL CRAWFORD 11/15/2022
Page 185
are not going to be at the next meeting but we'll talk about them?
A. That's my assumption.
Q. Okay.
A. I don't know if it's because they weren't available, or if there was some reason we didn't invite them.
Q. Do you recall what your discussion with Census was about Google at that time?
A. I don't recall, but I still believe this is just about how to engage more regularly about misinformation, or whatever -- whatever Census had done with Google and YouTube, should we have a similar structure with CDC. I believe that is what is not resolved in these chains.
Q. All right. And then Mr. Onyimba asked you another question on Friday April 2nd, 2021.
A. $\quad \mathrm{Mm}-\mathrm{hmm}$ (affirmative).
Q. He says: "Thanks again for your time this week. Attached are some of the claims we discussed for your reference," and they are not attached so we can't see those. But it says: "On a separate but related note would you happen to know if the CDC has statistics on hospitalization or death for people in the 40-49 age category who do not have underlying

Page 186
health conditions or co-morbidities?"
You see that?
A. Yes.
Q. Do you know why he was asking you that?
A. No, I don't know why he was asking me that.
Q. And you responded on April 5th that you couldn't respond over the weekend, but then you -- I think you sent him this chart?
A. Yes.
Q. What is that chart?
A. I thought that this chart would answer his question. It's the -- it was from the CDC's data tracker. It's a chart on hospitalizations.
Q. But it's a chart of people with asthma; right?
A. That's -- the link worked -- you could -that's a drop-down where you can pick anything you want I think I'd screenshot so he'd know what was going to be on the link.
Q. So you could pick without asthma if you wanted?
A. Yeah. I think I just was showing him what it was.
Q. Okay.

Page 187
A. But the link was more interactive.
Q. Okay. And so if he went there, if you go to this website, theoretically he can take out asthma and put in whatever age range he wants?
A. Mm-hmm (affirmative). And you could pick a different major category or an age.

MR. VECCHIONE: Thank you. Put that aside.
(Plaintiffs' Exhibit 30 marked.)
BY MR. VECCHIONE:
Q. Plaintiffs' Exhibit 30. Again, could you just tell us the subject matter and the date and then read it to yourself.
A. Subject: Follow up on mis-info conversation. 4/12/21. 4 -- yeah, 2021. Sorry. Okay.
Q. So would you agree with me that this is also, if you look at Plaintiffs' Exhibit 29, that bottom link you had sent is the same link, and then there is just a new chain on the top of this?
A. Yes.
Q. And then you ask him: "Can you give me an idea what topics we'll be covering? But yes, I'll ask them to attend."

I guess we ought to read. Could you

Page 188

1 please read to me what question he asked you?
A. "For tomorrow's call would it be possible to include Cynthia or other COVID-19 treatment SMEs to follow up on some additional questions?"
Q. And then you say: "Can you give me an idea of what topics we'll be covering? But, yes, I'll ask them to attend"?
A. Yes.
Q. Was this a BOLO meeting or a regular meeting? Like, was this for something that had just occurred that you wanted to alert them to, or was this a regular meeting?
A. I don't believe this was a BOLO meeting because I don't think we had started BOLO meetings in April. I think we started those in May. I don't know for sure, but $I$ don't feel like that's what this was.

I -- without that attachment, I don't remember what it was, but it wasn't uncommon for them to have just general questions about things and ask us to bring people to a meeting to help go over it. Maybe they were trying to display something in the search or whatever. I just -- I don't remember this context.
(Plaintiffs' Exhibit 31 marked.)

CAROL CRAWFORD 11/15/2022
Page 189

1 BY MR. VECCHIONE:
Q. All right. Go to Exhibit 31.
A. Thank you.
Q. Once again for Exhibit 31 could you tell me the date and the subject matter line, and then read it to yourself.
A. Subject: Omicron page. Sent December 21, 2021.

Okay.
Q. All right. We can go to the back again, the last page. And you have an email exchange you sent on December 21, 2021 at 10:38?
A. Yes.
Q. Who did you send it to?
A. That's -- I -- probably to Jan and Stanley.
Q. Okay. And why are you sending information about Omicron-specific pages to them?
A. Very similar to how I described how we've been working with them. This was a really big thing at the time, and they are trying to also be sure that people can find things in the search results, and they were -- they were highlighting CDC content and what they -- I call it the knowledge panel, those little tabs on Google.

Page 190

So, if something big like this was
happening I would let them know if we had new key pages that they were likely getting a high number of searches on. And I'm pretty sure everyone was searching for Omicron around December of 2021. So that is why I sent it to them so they would have awareness of this brand new piece of content, and because I was seeing this -- I know. I have a point.
Q. Right.
A. This is a screenshot of what I call the knowledge panel with the tabs, and it wasn't coming up with the newer piece of content. So I wanted to alert them to it.
Q. Okay. So what you've cut and pasted I think in there, says, like, coronavirus virus disease, and then there is overview statistic symptoms?
A. Yes.
Q. And then below it has the information on variants.
A. Mm-hmm (affirmative).
Q. All right. So let me understand this, because I'm not quite sure I'm getting it.

You say: "I see our main Variant page."

Page 191


Page 192
sure you were aware that this Omicron specific page is maturing and I expect further updates."

What does that mean, the Omicron-specific page is maturing? The one at CDC?
A. Yes. This was our page, like -- you know, this is pretty early in the Omicron, I believe, I don't have the timetable in it, but -- so we're always updating our web pages as situations changes. So I don't think this -- at the time I sent it I had just tons of concrete information, but it -- we were going to add to it, and I thought it was a better place to send people that were searching for Omicron.
Q. And what did you want them to do with it?
A. Well, they have always been clear that the search results are not something that they mess with, but this part, the knowledge panel, is something that they manually assembled and worked with us on. So I thought they might want to switch this. (Indicating.)
Q. Got it. And then he responds -- at least it looks like Jan Antonaros responds to you; right?
A. Jan does, yes.
Q. "Thanks for heads up. Our health team, including our Chief Health Officer, is tracking U.S.

Page 193
federal announcements today closely. Stanley and I will take this back to our team."

Do you know who the chief health officer was?
A. I think -- I think it may be Karen DeSalvo.
Q. Okay.
A. But on their end. That's their chief health officer. I think that's her title.
Q. And when he says tracking U.S. federal announcements today closely, does he mean on Google? What does he mean by that, in your understanding?

MS. SNOW: Objection. Calls for
speculation.
BY MR. VECCHIONE:
Q. What did you understand that term?
A. I don't remember. I'm guessing there was some announcements then, but $I$ don't recall.
Q. Had Google been instructed by the CDC to update following the CDC guidance?
A. To update what?
Q. To update their search engine, or for their panels to follow the CDC guidance?

MS. SNOW: Objection. Compound. BY MR. VECCHIONE:

Page 194
Q. You could answer if you understand.
A. We did not instruct Google to update their search engines, or their panels. But I did suggest that -- and he said about CDC guidance. This was -this wasn't about -- this was a consumer page about what people would need to know about Omicron. I -it was more of just correcting what $I$ thought was a better link in the panels that we had provided input on before.

Google is already -- has always made it clear that the search engine is sacred. There is nothing we can say to have them fix their search engine, or change their search engine to something else.
Q. All right. But how about the panel itself? What -- I guess what I'm trying to understand is what -- you send them this panel -because apparently it's going to the wrong place on the CDC -- if you put in certain search terms, it's going to the wrong place on the CDC website?
A. So I think what's hard to understand about this is this is not a typical way that Google presents things. You will have to ask Google how they considered when they added it. But my perception is that because of the substantial demand

Page 195

1 of searches for COVID, they added this that I call a knowledge panel. I think they may have another word for it. So that there is this layer before the search results come up, and it looks like this screenshot.
Q. What you're pointing --
A. But normally when you search, you don't get that on other topics. I think they do have it for a few other topics, but $I$ rarely run into it when I do searches.
Q. Okay. And then on December 21st I think Stanley Onyimba writes to you?
A. Yes.
Q. And he again said he explains how it's working and what they are going to do; right?
A. Yes.
Q. And then he says again: "As Jan mentioned, we are tracking announcements closely and will continue to update our products to reflect the latest guidance."

What did you understand that to mean?
A. I think he is saying -- I -- gosh, I don't remember what was happening the week of December 21. There seems to be a reference to announcements that I just, at this moment I'm not sure. So I think I'm

CAROL CRAWFORD 11/15/2022
Page 196
missing some context to what he's saying.
Q. And at the top?
A. Mm-hmm (affirmative).
Q. Then you say: "Glad you all are tracking." You sign off.
A. That would mean I'm glad you're watching what's happening, but I don't -- unfortunately, I can't remember what was happening that week that they're referencing. But when they say reflect the latest guidance, what $I$ believe he's referring to is what I said before is that we helped populate some of these tabs.
Q. You can put that aside.
A. Okay.
(Plaintiffs' Exhibit 32 marked.)
BY MR. VECCHIONE:
Q. Exhibit 32. And once again I'll ask you for Exhibit 32 to read the subject line and the date, and then read it to yourself.
A. Subject: Request for problem accounts. Sent April 9, 2021.

Okay.
Q. All right. This is from you to Todd O'Boyle at the top. And then it's from Todd O'Boyle to you at the bottom, right, on April 8th, 2021?

Page 197
A. Yes.
Q. Can you read what he writes to you, and then your response?
A. "Hi, Carol, I'm looking forward to setting up regular chats; my team has asked for examples of problematic content so we can examine trends. All examples of misinformation are helpful, but in particular, if you have examples of fraud such as fraudulent COVID cures, fraudulent vaccine cards, et cetera, that will be very helpful."

And I said: "Yes, we will get back to you early this week."
Q. "Thanks for checking in"; right?

So did you -- had you talked to Todd O'Boyle before this exchange?
A. I don't recall. But $I$ think this is around the time that census was helping us, and I believe I asked Todd, similar to I asked the other ones, like: Is there a good way that we should start engaging on misinformation? And this is probably a followup to either that email or phone call.
Q. And so first, who's Todd O'Boyle? And he says at Twitter.com, so I assume he's at Twitter?
A. Yes, Todd's at Twitter. And I know he was

CAROL CRAWFORD 11/15/2022
Page 198

1 a point of contact that $I$ received for the topic of misinformation. I don't know what his title was specifically.
Q. Okay. Have you ever met him in person?
A. No. And as a clarification, I think I called him Todd O'Brien when you asked me earlier who the POCs were. Until I see this, I didn't remember his name correctly.
Q. So O'Boyle, different, yes.
A. Yes.
Q. That's fine. At this time did you set up regular meetings with Twitter?
A. My memory is is that we never got regular meetings with Twitter set up. I mean, around this time. I know they participated in the BOLO meetings, but $I$ don't recall any kind of regular schedule with them. I don't remember many occasions we actually got on a phone call and discussed anything during COVID. There was a couple, but not many.
Q. How many BOLO meetings did you have with the social media companies from the beginning of COVID to, say, now?
A. I think that we only had two. And then I think that $I$ sent one time $a$-- in lieu of a meeting

Page 199

```
    1 \text { a PowerPoint. And I didn't recall it but we sent}
2 \text { another PowerPoint regarding that lab issue that was}
```

```
Q. Excuse me. Do you know who directed him to ask you for examples of misinformation?
A. No.
Q. And do you know whether you sent him any?
A. No.
Q. Okay.
A. Could --
Q. Yeah, go ahead.
A. Can I get you to clarify? What do you mean by directed him to?
Q. I just wanted to -- I'll put it this way. Todd O'Boyle was your point of contact with Twitter?
A. Yes.
Q. Was -- did you know of anyone over him telling him to do things?
A. That's how I interpreted it. No.
```

CAROL CRAWFORD 11/15/2022
Page 200
Q. He says that examples of misinformation are helpful, particularly fraud. Do you know what he was doing that it would be helpful to him to get this information?
A. I don't remember the exact context of this email, but I believe, as I mentioned before, this was probably part of me saying how could we work together on misinformation.

And it sounds like he's kind of wondering what we're seeing that we want to bring up, and he's asking for some examples. This is how I'm reading it now. And it sounds familiar based on what we, you know, my memory of this time.

MR. VECCHIONE: You can put that aside.
(Plaintiffs' Exhibit 33 marked.)
BY MR. VECCHIONE:
Q. Exhibit 33. And once again please read the subject matter and the date, and then read it to yourself for Exhibit 33.
A. Twitter CDC examples. 4-13-21 xlsx is the extension. 4/14/2021.
Q. Can you read his request to you, and then your response?
A. This is the same email from before. "I'm looking forward to setting up regular chats. My

Page 201
team has asked for examples of problematic content so we can examine trends. All examples of misinformation are helpful, but in particular, if you have examples of fraud such as fraudulent COVID cures, fraudulent vaccine cards, et cetera, that would be very helpful."
Q. And then this time you respond, though?
A. Yes. I didn't recall if we sent them, but we did.
Q. And what do you say?
A. "The Census team put together this spreadsheet with four examples. Is this what you had in mind?"
Q. And then you have examples: Vaccines aren't FDA approved. Fraudulent cures. VAERS data taken out of context and infertility; right?
A. Yes.
Q. What did you mean by the subject word -what was your understanding of the subject "request for problem accounts"?
A. I don't know --
Q. Okay.
A. -- why the subject read that. But what he asked for in the email is for examples of misinformation.

Page 202

```
Q. Okay. And when you met with him, did you have a spreadsheet like this?
A. I don't -- we, we sent him a spreadsheet.
```

```
    I don't remember meeting with Todd --
```

    I don't remember meeting with Todd --
    Q. Okay.
A. -- besides the BOLO meetings. We might have, but $I$ don't recall.
Q. And if -- and if you look at this email --
A. Mm-hmm (affirmative).
Q. -- it has attachments?
A. Yes.
Q. And it's Twitter CDC examples. So you've attached the spreadsheet to this?
A. Right.
Q. Okay.
A. I thought you were asking about when we met with him --
Q. No --
A. -- did we have spreadsheets.
Q. -- that's -- I was asking that.
A. Okay.
Q. Do you know who in the Census put this spreadsheet together?
A. I don't know for sure, but likely it was Christopher.

```

Page 203
```

Q. Christopher, remind me.
A. Lewitzke.
Q. Lewitzke, yes. I got it.
A. Something close to that name.
Q. We discussed him earlier. He appears on
those emails?
A. Yes.
Q. Not a new guy?
A. No. I feel like we're saying his name wrong, though.
Q. I think that's correct. Lewitzke.
(Comment off the record.)
BY MR. VECCHIONE:
Q. Do you know whether that Census team had any medical professionals on it?
A. No.
Q. And what was the definition of fraudulent cures?
A. I don't remember what that was.
Q. And what is the category: Vaccines aren't FDA approved? Is that a claim, or is that a statement about vaccines that you're making? What is that?
A. I'm interpreting this whole list as things that they saw that were being stated as

```

CAROL CRAWFORD 11/15/2022
Page 204
misinformation, that there were claims that vaccines aren't FDA approved.
Q. All right. And as far as VAERS data taken out of context, is your understanding that that's the same problem we discussed earlier with VAERS reports?
A. Yes.
Q. All right. It's not something different?
A. Yes.
Q. Let me rephrase. No, it's not something different?
A. I believe this VAERS data taken out of context is the same kind of thing we were discussing earlier.
Q. Thank you. And what do you believe "infertility" is?
A. I'm assuming this was people claiming that getting the vaccines led to infertility.
Q. Okay. And why did you give this chart and this information to Mr . O'Boyle?
A. He asked for examples. And I believe he was asking for these examples in this email because he was wondering what we would -- what would come up in BOLO meetings, or what we would be discussing. I think he wanted some sense of what we would be

Page 205
bringing to point out. That's my memory of it.
Q. You can put that aside.

MS. SNOW: Can we take like a five-minute break?

MR. VECCHIONE: Sure, sure. We have --
we're -- I was cooking with gas, though, so, you
know --
(Comments off the record.)
THE VIDEOGRAPHER: Off the record at 3:37.
(Recess 3:37 p.m. - 3:51 p.m.)
THE VIDEOGRAPHER: Back on record at 3:51. BY MR. VECCHIONE:
Q. And I will again direct the witness to read the subject line and the date, and then read this one. And this one is a little more hefty. You may want to take a look through it.

MS. SNOW: What exhibit?
MR. VECCHIONE: Exhibit 34.
(Plaintiffs' Exhibit 34 marked.)
A. Subject line is COVID Misinformation. Sent 6/30/2021.

MS. SNOW: Mine is stapled out of order, I just realized. I want to make sure, it might just be mine, if you want to clarify.

MR. VECCHIONE: Let's do the Bates stamps.

Page 206

1 The bottom right \(I\) have it ends 496, 497, 498, 499 2 and 500.

MS. SNOW: I think I have all those. They are just out of order. I just want to make sure no one else's was.

MR. VECCHIONE: No, I appreciate that.
MS. SNOW: Yeah.
MR. GILLIGAN: Is Carol's right?
MS. SNOW: Yeah.
A. Mine was correct.

BY MR. VECCHIONE:
Q. Tell me when you're ready.
A. I'm ready.
Q. All right. Can you identify Exhibit 34 for me?
A. The subject line is COVID misinformation. 6/30/2021.
Q. Do you recognize this document?
A. This, yes, feels familiar to me.
Q. And what is it?
A. It's a discussion about accessing

Twitter's partner support portal where you can flag information to be reviewed by Twitter.
Q. Let's take a look. As usual, these chains start at the back.

CAROL CRAWFORD 11/15/2022
Page 207
A. Mm-hmm (affirmative).
Q. I think the first one in this chain is May 10, 2021 at 1:50 p.m. and is that from you to Todd O'Boyle?
A. Yes.
Q. And I think that we've seen this list of items before to other -- to other social media outlets about --
A. Yes.
Q. And it's concerned -- it's mainly concerned about shedding?
A. And microchips.
Q. And microchips. And you attach sort of a chart. Could you tell us what that chart is?
A. Just a table of example posts regarding this, those two issues, vaccine shedding and microchips. It's not really a chart. It's just formatted in a table.
Q. Okay. Could you read what you say to him right above the table?
A. (As read) We wanted to point out two issues that we are seeing a great deal of misinfo about, vaccine shedding and microchips. These are -- the below are just some example posts. We do plan to post something shortly to address vaccine

Page 208

1 shedding, and I can send that link too. Our Census team copied here has much more info on it if needed.
Q. Okay. And so you have copied the Census team that we've discussed earlier.
A. Yes.
Q. And then you say -- could you read what you say next?
A. (As read) We're -- also we're standing up a BOLO COVID misinformation meeting and inviting all tech platforms. We are shooting for \(12 \mathrm{p} . \mathrm{m}\). on Friday for our first meeting. I'll include you on the invite but if you'd like to propose an alternate approach or would like me to include others, just let me know.
Q. All right. Tell us. We discussed a little bit the BOLO meetings that you had with the tech companies. And this BOLO COVID meeting, is this the first one? Where does it stand amongst those you've discussed?
A. I -- without having the date --
Q. Right.
A. -- in front of me, \(I\) think this is in reference to the very first meeting.
Q. Okay. And BOLO, we said, is be on the lookout. And this was -- you were sending this to

Page 209

1 Mr . O'Boyle so that he would be on the lookout for 2 these things appearing on Twitter?
A. Yes.
Q. Did you have a prior conversation with him about this before you sent it, do you know?
A. I don't think I had a prior conversation about vaccine shedding and microchips, and these are examples of that. I mean, we saw on the other one we had sort of general conversations about how we could -- how we should have meetings or not have meetings. And I probably asked about the BOLO, like is the BOLO format, since it was used previously, a good format.
Q. Okay. And what is that format? So it's just -- we've seen the previous one, you said to him I'll include you on the invite, but if you'd like to propose an alternative approach, or would like me to include others, just let me know.

Did you have some view of whether Twitter wanted to meet alone, or separately? Is that what that means?
A. No. But I had a view that I couldn't tell if the platforms wanted to do the BOLO meetings the way Census had done them for their own work, so I was checking.

Page 210
Q. Had you been at any -- invited to any of the Census BOLOs?
A. No. I don't think they were doing BOLOs by the time that we were meeting.
Q. So they had done that for the Census?
A. That's my understanding.
Q. And it had been in relation to the 2020

\section*{Census?}
A. That's my understanding.
Q. All right. Did you talk to anyone at Census about how they ran BOLO meetings?
A. Yes.
Q. Okay. In order to create your own?
A. Yes.
Q. And what did they tell you?
A. Well, they explained how they did it. In fact, they drafted the slide deck. We talked about this earlier. They drafted it and showed me how they thought that we should do it, and that it was just we would give examples, we would give the science, and then they -- people could follow up separately. I mean, I believe we changed some of the format of the PowerPoint, what we did for CDC of course, but they -- you know, they kind of told us how they had done it in the past.

Page 211
Q. Okay. Let's go to his response to you. He says to you -- and here we see Mr. Lewitzke's name spelled correctly; right?
A. Yes.
Q. Okay. So Todd O'Boyle writes to you on May 10, 2021 on Exhibit 34. "Hi, Carol. Thanks for sharing this."

And you took that to mean your chart, right, or table, you called it?
A. Yes.
Q. "Agree these are important trends to note. A quick scan shows that at least some of these have been previously reviewed and actioned. I will now ask the team to review the others."

What did you take that to mean?
A. I don't know how Todd meant it specifically, but I interpreted it as Twitter made decisions about the areas of misinformation based on whatever policy they had.
Q. And he says: "Carol, remind me: Did you have a chance to enroll in our partner support portal? In the future that's the best way to get a spreadsheet like this reviewed."

So you mentioned that Partner Support Portal. What is that?

Page 212
A. My understanding of it, and I don't believe \(I\) ever successfully got into it, but it's similar to what I described for Meta. It's an offering where you log in and you can report misinformation or threats or problematic posted content in this portal, and it puts it in a system for review.
Q. Did you know what happened at Twitter to reports that were deemed actionable?
A. I assume similar to Meta that they probably had multiple options. I am sure some were removed. I am sure some may have had -- were flagged. I see flags all the time on the Twitter posts. I am sure some were just maybe -- I don't know what they do, but maybe they weren't distributed as much on peoples' feeds.
Q. Where do you see Twitter? Do you have a Twitter?
A. Yeah. I mean, my responsibility is social media for CDC, so I do look at Twitter, and we have Twitter accounts at CDC.
Q. And CDC -- well, I'll just go back for one second. You -- prior -- on May 10 you were discussing a Friday meeting that you'd invited Mr. O'Boyle to. And do you know whether that

Page 213

1 meeting occurred?
A. I mean, I think we set up the first BOLO meeting in May. And this was May 10 th, and the Friday was there so I suspect it did occur.
Q. Okay. And you said you didn't use the portal. Did anyone else at CDC use the portal?
A. No, I don't -- I don't recall anyone else trying to get access besides myself.
Q. Had you talked to him about the partner support portal beforehand, before this email chain?
A. I don't remember. I'm inferring from this chain that perhaps not.
Q. All right. Had you talked to Census about the portal?
A. I don't recall if we discussed the Twitter portal per se. But \(I\) did know from discussions with them that one technique \(I\) think that they used was using portals to -- for their work to report information. I don't remember if we discussed Twitter or not.
Q. Okay.
A. Or if it was all about Meta.
Q. But it was your understanding that Census did use such devices when offered?
A. That, or they told me it was an option for

Page 214

1 us. I'm worried I'm mischaracterizing their work
with very little actual memory on it.
Q. Okay. And you respond to him: "Todd, I don't think we have info on how to enroll, but we'd be happy to get on it if you'd send some info"; right?
A. Yes.
Q. And he responds that -- on May 10 th at 8:51, he says he's happy to enroll you, and it allows you a special, expedited reporting flow in the Twitter Help Center. That's the purpose of it.
A. Yes, I see that.
Q. What's the Twitter Help Center?
A. The portal is part of their help center somehow. I mean, I'm not an expert, but I -- it's seeming -- I think the screenshot might even show how it's part of it.

No, it doesn't. But \(I\) believe it's like a link on the help center page.
Q. And he says it worked very well with Census colleagues last year; right?
A. Well, there we go.
Q. Yeah.
A. That's why he came up with that.
Q. Okay. And did you give him a Twitter

Page 215

\section*{1 account to enroll?}
A. I asked him -- I can see that I asked him does it have to be our official CDC account, or is it supposed to be personal. And I gave him my personal one.
Q. Okay. And what was your problem with using -- did you have a technical problem with using it? What happened?
A. It was not a priority for me, for one. I wasn't thinking that we would probably want to use this portal on a regular basis. I thought that let me just myself, instead of asking my staff to get involved, I want to see what the portal is myself because I wasn't able to look at the Meta portal myself because you had to be administrator.

So I wanted to look at it and see what it it looked like, but I -- it wasn't a priority. So every now and then \(I\) would try to get on it, and I don't remember ever solving the problem. All I know is I think when I clicked it nothing happened, or I didn't get drop-downs. That's -- and I felt like maybe I wasn't in the right place.
Q. Okay.
A. But I am --
Q. Okay.

CAROL CRAWFORD 11/15/2022
Page 216

1
A. -- unclear of what exactly was wrong. Sorry.
Q. I got it. But here's -- so then I see May 24th, 2021, 2:28 email from Christopher Lewitzke that I think Todd forwards it to you. Is that how that works? How does that page -- could you tell me what's happening on this page?
A. The way the reply works from the email it's unclear if \(I\) was copied or not, so \(I\) can't say. But I definitely was copied on Todd's response to Christopher. I'm not sure if Christopher copied me on his email to Todd, which is what I think you're asking me.
Q. Okay. But on May 24 th at least it looks like Lewitzke sent a note to Todd?
A. Mm-hmm (affirmative). And then 30 minutes later Todd hit reply with everyone on it.
Q. Okay. And Carol says I had -- (as read) Carol and I had a sidebar, and I requested her account be enrolled. Your email reminds me that the process should have been completed by now. I'll check with the team to make sure it's properly enrolled.

And that's your recollection that's how it occurred?

Page 217
A. That's my recollection. I don't recall the sidebar, but \(I\) do know that \(I\) wanted it to be CDC people in these portals versus Census. I felt like that was more appropriate.
Q. And remind me, who's Christopher Lewitzke?
A. He's a -- he's a Census contractor.
Q. Okay. With this Reingold outfit we talked about?
A. \(\mathrm{Mm}-\mathrm{hmm}\).
Q. He says: We want to have at least some CDC accounts whitelisted. What does whitelisted mean?
A. Let me read this. I'm not sure.
Q. You've never heard that term before?
A. I have heard of whitelisted. I don't understand it in this context.
Q. What was your understanding of whitelisted meaning?
A. Like my under -- my general understanding of whitelisting is you can have kind of a list of things that maybe -- of servers that are allowed or not allowed is an example of a list of whitelist.
Q. Okay. And then do you know which Census accounts had access to this portal?
A. My memory was that none. And I think this

CAROL CRAWFORD 11/15/2022
Page 218

1 email supports my memory, and that Todd responding 2 that I'm going to be the account that's enrolled.
Q. Oh.
A. For CDC.
Q. For CDC.
A. For CDC at least.
Q. But do you know which Census accounts?
A. Oh, no.
Q. Okay.
A. I wouldn't have any knowledge of what they did.
Q. Okay. And then let's read up to May 27 th, 2021, 2:30. And you say haven't seen anything come through. And then Todd says: You should now be up -- should be fully -- and period. You should be fully period, he says.

Then he says: "When you visit the Twitter help center logged in with your account you should see additional reporting options."

Do you know what he meant by that?
A. Yes. This portal, like I think when
anyone goes to the health center -- help center, I think there is, like, you can flag threats and things, I believe. I think he was saying I would have had something more. But I never could locate

CAROL CRAWFORD 11/15/2022
Page 219

1 that.
Q. Okay. And you tell him: "Hi, Todd. I have been trying to enter info but I realize I have been unclear on where to enter them. I went to /forms and there is a drop down on things to submit, but none of them seem relevant to misinformation. Am I in the right place?"

So is that the problem you had?
A. I -- based on this email I think it was one of the problems. I don't -- I think at the beginning I didn't get the links, I couldn't find it on the help center. There's probably additional chains, I suspect, regarding this.
Q. Okay. But you don't recall what they were?
A. No.

MR. VECCHIONE: All right. Put that aside.
(Plaintiffs' Exhibit 35 marked.)
BY MR. VECCHIONE:
Q. 35. And once again for Exhibit 35 tell me what the subject line is and what's the date at the top.
A. The subject line: BOLO CDC lab alert misinformation. Sent September 2nd, 2021.

Page 220
Q. And I think we've seen this alert before for another social media recipient, am I correct about that?
A. You're correct.
Q. All right. Is this anything different than when you testified last time about this BOLO?
A. The only difference is this email is going to Twitter.
Q. Okay. And what was your intent in telling Twitter through O'Boyle to be on the lookout for misinformation about PCR testing?
A. I mean, I, again, I think CDC's role is to provide the facts around issues. We saw this confusion about this alert brewing and more posts were going up with confusion, and we thought it would be a good idea to provide the platforms with the facts before it became something bigger.
Q. And what did you believe he'd do with the information?
A. I believed that they would consider it in their -- I knew their policy teams or their trust teams or misinfo teams, whatever they -- whatever they called their teams, would evaluate it.
Q. And perhaps remove it?
A. I knew that removal was one of the options

Page 221

1 that they had, yes.

MR. VECCHIONE: You can put that aside.
(Plaintiffs' Exhibit 36 marked.)
BY MR. VECCHIONE:
Q. Exhibit 36. And once again, if you could, for Exhibit 36 tell me the date and the subject line, and then read it to yourself.
A. Subject: Call or VC-Facebook weekly sync with CDC (CDC to invite other agencies as needed.) And this was sent on April 15, 2021.
Q. And then please read it to yourself.
A. Okay.
Q. All right. Do you know who created the meeting agenda there?
A. I think Payton probably inserted these agenda items because it was her appointment.
Q. And what was on that agenda?
A. New attendees intro, CDC needs/questions, FB product updates/feedback requests. (COVID-HUB). And then COVID-19 projects, and several are listed CMU/FB data survey. Update -- data survey update. Excuse me. Misinfo collab status. Others.
Q. Let's go through this. What's COVID-HUB?
A. I believe the COVID-HUB is what they called when I mentioned you're on Facebook and you

Page 222

1 could search for COVID, they actually provided in-app content on COVID that they pulled from WHO, CDC and other sources and I believe they call that internally the COVID-HUB.
Q. All right. And I think we have some new names here in the middle. Let's see if we see most of them. Kang-Xing Jin. Do you know who that was?
A. Looks like a Facebook employee, but I don't recall.
Q. And I think we've discussed Raena Saddler, but I've forgotten. Do you recall?
A. I mean, she's with Facebook, or he is with Facebook, but I don't know who they are.
Q. All right. And then she cc'd a number of people. Do you recognize any of those names besides Liz Lagone?
A. Yes, Airton, the first name.
Q. Yeah.
A. He was definitely with Facebook, and he seemed to be an expert on like Facebook ads how to run Facebook ads.

Julia Eisman is someone we talked to regularly. I think she's in, like, their public relations type office. She occasionally would be on the calls with Payton. Kate Thornton, I don't

Page 223

1 recall. Carrie Adams, I mentioned is the new point of contact I have now. And Ursula Phoenix Weir was -- is someone at CDC. I assume that for this meeting she was probably deployed in a -- something that was related to what \(I\) thought was going to be discussed here.
Q. And what was her title?
A. Ursula's?
Q. Yeah.
A. I'm not sure. When people deploy into something -- Ursula probably had several roles during COVID, as many of us did. I just don't -- I can't tell why I invited her to this meeting from looking at this.
Q. Where was she normally?
A. I believe -- I believe. I believe she's in the National Center for Birth Defects.
Q. Now, the subject says "Call or VC," I assume that's voice chat?
A. Yes.
Q. "Facebook weekly sync." That's synchronization with CDC?
A. That's how I interpret sync, yes.
Q. CDC to invite other agendas as -- agencies as-needed. Okay.

Page 224

What did you understand CDC needs questions to be about in this agenda?
A. I think that that was often just listed. I mean, it would just be if we had a question that we needed, we wanted to ask Facebook about, or if we had something that we -- was upcoming that we wanted their assistance with or something. I know, like, for instance, Airton's on this because sometimes we'd have technical questions about how to run an ad or the live chat, that kind of -- that we talked about earlier, how to make it work.
Q. All right. And then the COVID-19 projects, she seems to have split them up. Were they split up this way within CDC or within Facebook, to your knowledge?
A. No. I think it's just a list of things that were just put together in one area. But I don't recall.
Q. What's your understanding of CMU/FB?
A. I think this was -- oh, gosh. I think this was about some surveying that Facebook was doing regarding COVID maybe, and they wanted to just let us know they were doing it. But I'm very fuzzy on that, on the details of it.
Q. All right. And is data and survey

Page 225
\begin{tabular}{|c|c|}
\hline 1 & separate? \\
\hline 2 & A. I think that's all one update. CMU at \\
\hline 3 & slash FB data survey update. That's how I believe \\
\hline 4 & this to be. \\
\hline 5 & Q. All right. And misinformation. "Misinfo" \\
\hline 6 & is misinformation? \\
\hline 7 & A. "Collab status" is one thing. \\
\hline 8 & Q. Oh, that's one thing? \\
\hline 9 & A. Yeah. \\
\hline 10 & Q. Okay. And "collab" is collaboration? \\
\hline 11 & A. Yes. \\
\hline 12 & Q. And then others, I take it, is everything \\
\hline 13 & else? \\
\hline 14 & A. Yes. \\
\hline 15 & Q. So when this meeting took place do you \\
\hline 16 & know if there is any notes or recordings of it? \\
\hline 17 & A. We didn't record them. I don't -- like \\
\hline 18 & I've been saying, I rarely took notes. If something \\
\hline 19 & was jotted down, it would have been in an email or a \\
\hline 20 & Word doc. \\
\hline 21 & Q. Do you recall if all these agenda items \\
\hline 22 & were discussed on this call? \\
\hline 23 & A. No. \\
\hline 24 & Q. What do you remember about that meeting? \\
\hline 25 & A. I don't remember the specific meeting at \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
Page 226

1 all.

MR. VECCHIONE: Okay. You can put that aside.
(Plaintiffs' Exhibit 37 marked.)
BY MR. VECCHIONE:
Q. 37. And once again for Plaintiffs' Exhibit 37 please read the date and the subject line of, and then read it to yourself, please.
A. Subject line: CDC "guides," in quotes, and this week's meeting. And that was sent on 4/29/2021.

Okay.
Q. All right. And can you identify what this is?
A. This is an email chain about -- that's called "CDC 'Guides' and this week's meeting."
Q. Okay. And at this time -- I think we've talked about biweekly meetings. At this time could you have been having weekly meetings with Facebook?
A. We might have. There definitely were times that we were talking weekly.
Q. All right. Let's do it -- let's go to the back, the last page.

She writes to you: "Hi, Carol, we want to flag a couple of items for you this week," right?

CAROL CRAWFORD 11/15/2022
Page 227

1 And she says: "Instagram Guides Promotion
2 Opportunity. Our Instagram team is looking to run promotion to amplify vaccine-related Instagram Guides. We saw that \(C D C\) has a great one on its feed." And then she provides a link; is that right? Am I correct? Did I read that correctly?
A. Yes.
Q. What is an Instagram Guides? I --
A. I honestly don't remember. I noticed I added our social lead to pipe in more of the guides. I think it might have been like a reel, like the little video snippets you can see on Instagram. But I honestly cannot remember what they were at the time.
Q. Okay.
A. I don't know that Instagram guides still exist.
Q. Let's talk about it just for a moment, though, because we talked about various types of social media. Instagram is usually like a photo and then some words under it?
A. That is one type of Instagram post, and then there is more like a video version of it.
Q. Okay. And how long -- does the video run a long time like YouTube, or is it short?

CAROL CRAWFORD 11/15/2022
Page 228

1 A. No, it's short.
Q. And then she says: "The team is planning to launch an in-feed promotion of the Guides on Monday."

What's an in-feed promotion?
A. If I'm not sure what they meant by in-feed promotion. But what I'm -- as reading this at this moment, I believe they were -- it would, you know, it would get highlighted more often in a user's feed. They would -- the content would be promoted more to the users in their scrolling.
Q. Okay. And then it says that this launch in-feed promotion would run for three weeks, and the anticipated reach is 60 to 80 percent of the people in the U.S. on Instagram.

So that's 60 to 80 percent of the people that -- the United States people on that platform, is that your understanding?
A. Yes.
Q. And then she says: (As read) "We wanted to know if the Guide above is up-to-date, or if you'd be willing to update it (if needed) and if it is something" you can include in the -- "we can include in the promotion. Happy to discuss further if this is something you may be interested in, or if

CAROL CRAWFORD 11/15/2022
Page 229

1 you have any questions."
        Did I read that correctly?
A. Yes.
Q. Who decides whether the guide is up to date or not?
A. That would be us because it's our post.
Q. Okay.
A. Like if the guide is like a story -- I called it a reel earlier, but a story is better for Instagram. It's something that CDC has posted, so it's our content to update.
Q. Got it.
A. And I'll add, to clarify, I can see on the url it says "/CDC gov." So it's definitely something we have posted, and if I'm incorrect about the format of it I still can tell it's something we've posted.
Q. Okay. Then also "FYI", which I think is for your information, "we are hoping for an update on our COVID-19 misinfo reporting, but that is not ready for this week."

What did you -- did I read that correctly?
A. You read it correctly.
Q. And what did you take that to mean?
A. I am not sure, but I'm -- it might have

Page 230

1 been about those CrowdTangle reports and sending 2 them to us.

CAROL CRAWFORD 11/15/2022
Page 231

1 do anything on vaccine.gov or vaccinefinder. What's
2 "vaccinefinder"?

MS. SNOW: Objection, calls for speculation. BY MR. VECCHIONE:
Q. And you wrote down: "Are you being asked by the White House?" You asked her that. Why did you do that?
A. I --

MR. GILLIGAN: You asked her why she suspected something. BY MR. VECCHIONE:
Q. Why did you -- why did you ask whether the

Page 232

1 White House had asked her to do anything?
A. I don't remember specifically. But it was not uncommon because there was multiple major agencies such as the White House working on things. And so Payton had meetings with lots of federal agencies, and we were -- the vaccine.gov site was something CDC, HHS and the White House were collaboratively working on.

So it might have been me just trying to understand if we were about to promote vaccines.gov on -- maybe it was in the guides; maybe \(I\) was just trying to see if she knew something related to what we were doing. We did overlap from time to time and ask Payton similar things.
Q. So you knew that Facebook could also have been being contacted by other agencies besides CDC?
A. Yes. They -- she -- I'm fairly confident that she was speaking to several federal agencies during the COVID response.
Q. Including HHS?
A. I believe so, yes.
Q. And including the White House?
A. I think. I believe so, yes. I don't -- I didn't ask her her meeting schedule, but she often would be up to date.

Page 233
Q. Did she ever mention to you who her contact was at the White House?
A. No.
Q. Do you know that of your own knowledge from some other source?
A. No.
Q. Were you ever on a call with any of the agencies in the White House?
A. Yes. Sometimes what I remember was that when vaccines.gov was coming out, that was involving multiple agencies including people at the White House and the U.S. Design System team and HHS and CDC, and I do believe there might have been some joint calls to discuss some of the promotion of vaccine.gov.
Q. All right. And U.S. Design are the people who design the websites for the government?
A. Yes. I think in my mind when \(I\) say White House, they are the people in the White House that I'm talking about because that's my counterparts in the White House are digital people. I should have clarified. I should have clarified that earlier.
Q. All right. And do you know of anyone, any names?
A. There was several of them that were

CAROL CRAWFORD 11/15/2022
Page 234

1 involved with vaccines.gov.
Q. Okay. Do you recall any names?
A. I really don't.
Q. All right. Did anyone from the White House, any office in the White House, direct you to engage with social media companies independent of your supervisor at the CDC?
A. No.
Q. All right. Let's take a look at the next one. Payton to you on April 29 at 6:23. Can you read her response to you?
A. (As read) Thank you, Carol. Regarding vaccines.gov -- or vaccine.gov -- we haven't had any specific requests from the White House on this. We've been working at the state level on our vaccine finders tools and promotions. I also want to followup on our COVID-19 misinfo reporting. Our team is looking to schedule a training with CDC and Census colleagues who will be reporting content through the tool. It will cover Community Standards, COVID-19 misinformation and harm policies and a walkthrough of the reporting tool.
Q. Let's stop there.
A. Okay.
Q. Did that training occur with CDC?

CAROL CRAWFORD 11/15/2022
Page 235
A. To my recollection, that training never occurred. But I might not have been a part of it, and that's why I don't recall it.
Q. Do you recall whether or not Census was involved in such a training?
A. No, because I'm not sure that we had the training, so I don't know who would have attended it.
Q. Okay. And then could you continue reading where you have the asterisks?
A. "Could you share back some times that may work to schedule? We'll probably need 1.5 hours to cover. If needed, we can break the training up if a longer block is hard to schedule."
Q. All right. And then you'll respond that you'll check with Census; right?
A. Yes.
Q. But do you know whether or not you checked with Census?
A. No.
Q. Do you recall anything more than what you've told me about this training?
```

    A. I recall that when this -- well, can I ask
    my -- can I ask counsel a question first?
MR. GILLIGAN: Yes, you may.

```

Page 236
(Witness conferring with counsel.)
MR. VECCHIONE: Let the record reflect that the witness has consulted with counsel. BY MR. VECCHIONE:
Q. Can you answer my question?
A. Oh. Yes. When we went through discovery, I was pulling documents for discovery, and I was asked if we had used the portal by I believe the CDC lawyer that I have been working with, and I could not recall.

So I went through a lot of emails at that time, and I concluded that my memory was correct that we really did not use the portal more than the one time that I mentioned earlier, and that's why I don't believe the training occurred. I don't have any memory of going through the training, or setting up the training. But it's pos- -- I mean, I have a lot of emails, but that was what \(I\) thought after \(I\) did discovery. BY MR. VECCHIONE:
Q. Right. And that's what you think now sitting here?
A. Yes.
Q. All right. Thank you. You can put that aside.

Page 237
A. Okay.
(Plaintiffs' Exhibit 38 marked.)
BY MR. VECCHIONE:
Q. And, again, for Exhibit 38 just tell me the date and the subject line, and then read it to yourself.
A. I'm sorry. The subject, Wyoming issue. April 30th, 2021. Okay.
Q. So let's start from the back again.

On April 23rd you write to Payton Iheme again. Can you write what you say to her?
A. (As read) The Wyoming Department of Health mentioned to one of our groups that the algorithms that Facebook and other social media are apparently using to screen out postings by sources of vaccine misinformation are also apparently screening out valid public health messaging, including Wyoming Health communications. They were looking for advice about how to work with social media networks to ensure that verifiable information sources are not blocked. Do you have someone that she could talk to -- sorry. Do you have someone that could perhaps talk to the state about this?
Q. And then before you get a response you say on top: "Anything you all can do to help on this?"

CAROL CRAWFORD 11/15/2022
Page 238

1 I guess -- you say that five days later, is that why you sent it again?
A. They hadn't responded.
Q. Okay. Who decided what a verifiable information source was at this time?
A. I don't know.
Q. Now, on April 28th at 6:37 you get an email back from Adrien Genelle, I think or Genelle Adrien. Excuse me.
A. Yes.
Q. And she says that her colleague can solve this problem?

MS. SNOW: Objection, mischaracterizes document.

BY MR. VECCHIONE:
Q. Did she direct you to another person to take care of the problem?
A. She looped in another colleague to provide additional guidance, or to connect directly with the state health department that asked.
Q. Okay. And then you say, you tell her that you don't have an email chain to loop anyone in because it was received via meeting. Do you know what meeting it was received in?
A. Yes. Well, no, I don't know exactly which

Page 239
meeting it was in, but it was just relayed to me during one of the COVID internal meetings that, hey, we got a call from Wyoming, do we know anyone to connect them with.
Q. And you connected to Holly Scheer? Is that what you're doing there?
A. Yes.
Q. And do you know anything more about Eva Guidarini than what she states here about her? Did you ever deal with her?
A. No.

MR. VECCHIONE: You can put that aside.
Exhibit 39. I believe they are all
one-pagers, and they are all stapled together, so give me one moment.
(Plaintiffs' Exhibit 39 marked.)
BY MR. VECCHIONE:
Q. Once again, could you just read the -- 39, could you read the subject line and the date?
A. Join with new info E: Call or VC-Facebook weekly sync with CDC (CDC to invite other agencies as needed). May 6, 2021.
Q. Okay. Tell me when you're ready.
A. Oh, I'm ready. I'm sorry.
Q. And I think we've seen this meeting

CAROL CRAWFORD 11/15/2022
Page 240
before, but \(I\) just want to make sure it's not a separate one. Was -- this was just with Facebook; right?
A. This was.
Q. Okay. And the -- and we've already discussed the items that were -- that were on the agenda; right?
A. We did. But I'm just now noticing that the items in the agenda might be a cut-and-paste from the same thing and maybe weren't updated regularly.
Q. I see. That's my question. All right. So do you have any memory of this particular meeting?
A. I don't.
Q. And you don't recall what was said one way or another?
A. Don't recall, excuse me?
Q. Okay.
A. I didn't catch -- I'm sorry. I didn't catch what you asked me.
Q. Oh, oh. Do you recall anything that was said at that meeting?
A. On May 6? No.
Q. And do you know if the format was in Zoom,

Page 241

1 or what the format, or Microsoft Teams, or in person, or?
A. It was always on either teams or they had BlueJeans that we used occasionally.
Q. Okay. What's BlueJeans?
A. It's something like a Teams or a Zoom.
Q. Okay. And, once again, do you know if there is any notes or record kept of the meeting?
A. I did not take any notes at the meeting that I recall. I mean, same answer I have been giving. If there were any, it was minor and they would have been in Word or email.
Q. Okay.

MR. VECCHIONE: 40.
MR. GILLIGAN: I remember when everybody
just used Skype when it was simpler times.
(Plaintiffs' Exhibit 40 marked.)
BY MR. VECCHIONE:
Q. Exhibit 40. Once again the date and the subject line, and then read it to yourself.
A. Subject line: COVID BOLO meetings on misinformation, sent on May 10, 2021.

Okay.
Q. All right. Let's go back to the back page of this that's Bates number 682.

Page 242
A. Okay.
Q. Now, this is -- I think we've said this date. It's May 10th of 2021?
A. Yes.
Q. And you send to Facebook the COVID BOLO misinformation meeting request; right?
A. Yes.
Q. And could you please read that for me?
A. (As read) We would like to establish COVID BOLO meetings on misinformation and invite all platforms to join the meetings. We are aiming for the first one on Friday at noon. I know you were considering a possible process on your end, but we wanted to start here just as an interim first step. Are there direct POCs on your end I should include on the invite? I'm happy to chat if better, thanks.
Q. All right. Now, so this is the first BOLO meeting. Does that comport with your recollection?
A. This is a note that I'm about to send an appointment for the first BOLO meeting and asking them who to include.
Q. All right. And we've already said POCs -A. Yes.
Q. -- are the point of contacts; right?
A. \(M m-h m m\) (affirmative).

Page 243
Q. And you said: "I know you are considering possible process on your end."

What did you mean by that?
A. As I mentioned, that \(I\) was engaging with the platform saying what format would be best for us to talk about this. And I think there were references in the exhibit a couple of times where they said they were thinking internally about what would be best. So I think I was just referencing that I knew that they were considering it as well.
Q. Do you know what the topics -- did you know what the topics for the BOLO were when you sent this out?
A. I don't know if \(I\) did or not.
Q. All right. Let's go to the next page back where we have -- I believe this is from Jan Antonaros to you, but he includes your email to him; right?
A. This -- the bottom part --
Q. Mm-hmm (affirmative).
A. -- is where I sent a similar note to Google, which is Jan.
Q. Okay.
A. And I was telling her that we would like to invite the digital platforms to attend the BOLO.

Page 244

1 I think it was me sending the appointment or a 2 heads-up that it was coming. I can't -- it looks
```

    like maybe I -- this is an actual appointment.
    ```
Q. Okay.
A. But I tried to send each of them a personal note that we were doing it.
Q. And in this one you actually spelled out be on the lookout; right?
A. I did.
Q. And was that because you hadn't discussed it with them before, or did you have some concern they wouldn't know what it was?
A. I don't know why I didn't do it that time.
Q. All right. And there is Kevin Kane here with the email address @Google.com. Who is that?
A. I don't remember Kevin, but this indicates that he was from YouTube.
Q. Okay. And do you recall having discussions with YouTube?
A. YouTube would occasionally -- people from YouTube would occasionally be on our regular meetings, depending on what we talked about. And because YouTube has the most content, like, hosting, they -- they were at the -- they were a part of the

Page 245

BOLO meetings, I believe, that Kevin attended probably, or someone from YouTube did.
Q. And you responded: "Great. I was going to ask about Kevin."
A. Yeah. Maybe I remembered who Kevin was at the time.
Q. Okay. And then finally the front page.
A. That's a repeat of -- oh, no, that's not. I apologize. I'm looking at the wrong one.
Q. And here you're sending this to the Google folks?
A. Yes.
Q. Why don't you read it for the record?
A. "We would like to establish COVID BOLO meetings on misinformation and invite all platforms to join the meetings. We were aiming for the first one on Friday at noon. We heard through the grapevine that Kevin Cain at YouTube would want to join. Are there other POCs on your end I should include on the invite?"
Q. All right. You said YouTube. Who's YouTube related to, is it Google or Facebook?
A. YouTube is a Google property.
Q. Okay.
A. Or platform.

Page 246
Q. And is it your recollection that you did have a meeting on Friday?
A. I think we did, but \(I\) don't have the exact date. But \(I\) believe we had -- that's when we had the first BOLO meeting.
Q. All right. And do you have any list of who actually showed up and was an attendee?
A. No.
Q. All right. And, once again, it would be on your calendar as far as if it happened?
A. Now, to clarify I don't remember keeping a list of who attended. Maybe Census might have because this is something they were arranging. But I don't recall it being sent to me. It could have been, but \(I\) don't believe so.
Q. So they were helping you arrange this because they'd done it before, this particular meeting?
A. Yes. I mean, I mentioned that they drafted the slides.
Q. Right.
A. And, you know, Chris participated in the meeting.
Q. Okay. Chris. Remind me his last name? A. Lewinsky, Lewitzke.

CAROL CRAWFORD 11/15/2022
Page 247
Q. Lewitzke. I'm glad he's not here because we've done terrible things to his name, and I apologize for that. My name is Vecchione. I have no excuses for this.

All right. I think you can put that aside.
(Plaintiffs' Exhibit 41 marked.) BY MR. VECCHIONE:
Q. Let's go to Exhibit 41. And once again please tell me the headline, subject line, and the date, and then read it to yourself.
A. Subject, CDC COVID-19 BOLO meeting. 6/10/2021.
Q. Okay. So let's go back -- well, the first item on here, it says "On Wednesday June 9, 2021 at 4:23 PM Crawford, Carol wrote."

Can you read that to -- into the record?
A. Yes.
"We would like to invite digital platforms
to attend our third short 'Be On The Lookout' meeting on COVID. Let us know if you have questions and feel free to forward this message to anyone in your organization that should attend."
Q. And did you send these out separately to all the -- withdrawn.

CAROL CRAWFORD 11/15/2022
Page 248

You sent this particular one to Todd O'Boyle at Twitter; right?
A. The formatting of the email is odd. But I don't believe I did that. I believe I had one appointment and I blind copied everyone, so the emails -- I think that's just because he replied, it looks like it's just him.
Q. Okay. But you think when you sent these out you sent them out to all the social media places at once?
A. I do. And I think when we were looking at the other exhibit I wondered the same thing, but I think that was the situation.
Q. All right. That explains it for me.

And did you -- do you know if this meeting in June, I think it would be, ever took place?
A. I don't believe it did. And this is a morning question. I'm starting to think maybe Juneteenth was a new holiday we weren't expecting that conflicted with the third BOLO meeting and maybe that is why we didn't end up having it and we sent the materials out via email.
Q. All right. And who tasked you with sending out the BOLO messages? Why were you doing it?

Page 249
\begin{tabular}{|c|c|}
\hline 1 & A. Because I was the main person that was the \\
\hline 2 & CDC point of contact to talk to Facebook, Twitter \\
\hline 3 & and the platforms since our job was to lead digital \\
\hline 4 & media. \\
\hline 5 & MR. VECCHIONE: Okay. You can put that \\
\hline 6 & aside. \\
\hline 7 & (Plaintiffs' Exhibit 42 marked.) \\
\hline 8 & BY MR. VECCHIONE: \\
\hline 9 & Q. Exhibit 42. \\
\hline 10 & MR. VECCHIONE: And I feel that someone \\
\hline 11 & has added 43 in here, so I do apologize. That's a \\
\hline 12 & late addition. \\
\hline 13 & MR. GILLIGAN: I thought it was Carnac \\
\hline 14 & time. \\
\hline 15 & MR. VECCHIONE: No. \\
\hline 16 & BY MR. VECCHIONE: \\
\hline 17 & Q. So, once again, please just name the date \\
\hline 18 & and the subject matter, and then take a look at it. \\
\hline 19 & A. Yeah. Subject: Booster shots, regarding \\
\hline 20 & booster shots. It was sent on 10/28/2021. \\
\hline 21 & Okay. \\
\hline 22 & Q. All right. Do you recognize this \\
\hline 23 & document? \\
\hline 24 & A. Not specifically. \\
\hline 25 & Q. Can you describe what it is? \\
\hline
\end{tabular}

Page 250
A. It's a conversation about some booster guidance updates that are occurring and some requests from Google to review some of the changes that they were considering on the search result pages.
Q. All right. And the date is -- I think it starts, if you look at the last page, on September 30th, 2021.
A. Yes.
Q. And that's from Stanley Onyimba to Fred Smith.

Who is Fred Smith? He's new.
A. He's a direct -- he reports to me. He was the technical person I mentioned who usually attended the Google meetings with me. I was out of town this date, so \(I\) wasn't on the email.
Q. All right. And he -- well, I think he sends you the email?
A. Yeah.
Q. Just you're cc'd?
A. Maybe. I don't believe I was in town, though --
Q. Okay.
A. -- when this was occurring. I don't see myself cc'd on Stanley's email to Fred.

Page 251
Q. All right. Why is -- do you have any knowledge why is Stanley Onyimba sending this to Fred? What is the purpose of this?

MS. SNOW: Objection. Calls for speculation.
A. Are you going to re-ask the question? BY MR. VECCHIONE:
Q. No.
A. I mean --
Q. What's your understanding of why he's sending this --
A. Yes.
Q. -- to CDC?
A. Well, I don't -- because the screenshots are not available that are attached or put in here, I can't directly explain this, but sometimes on those Google panels that I mentioned they would highlight specific things like, they would -- they would, you know, before the search results came up, they would highlight a link. And I think that they were considering -- considering taking some words that they saw on vaccines.gov and add it to that panel, and they wanted to be sure it was right and they were asking us.
Q. All right. And then Fred responds that it

CAROL CRAWFORD 11/15/2022
Page 252

1 looks okay to him, but he's not the -- he's not an expert on this?
A. Correct.
Q. All right. And so -- and then Mr. Smith writes -- now, after that -- after that, you know, I don't know, I'm going to go check with some people, Mr. Smith writes back: "Hi, Stanley, I heard back from some folks. No heartburn over the messages proposed. Cheers, Fred."

Do you see that?
A. Yes.
Q. Did I read that correctly?
A. Yes.
Q. Do you know who "some folks" are? Who did he check with?
A. I don't know who he checked with.
Q. Okay. And then the next -- I'm having a hard time -- I can read the message. Do you know when that was sent, the next message up?
A. The one from Jan and Megan?
Q. Yeah.
A. It looks like October 28, 2021.
Q. So you go all the way up to the next -- on page 1 , and then you read down?
A. That's what it appears, mm-hmm.

Page 253
Q. All right. Why don't you take -- so can you -- you came back, apparently, and emailed Antonio [sic] -- Jan and Stanley and the folks at Google on October 28th at 5:11; right?
A. Yes.
Q. Okay. And you said: "This looks good, thanks for checking," in the middle there?
A. \(M m-h m m\) (affirmative).
Q. The next part?
A. (As read) Yes. We can discuss the pediatric vaccines early next week but let me give you some general info: ACIP is likely to vote on this on November 2nd. CDC is likely to start posting final information on November 3rd...if that helps to know. There will be many updates so the changes might span over a few days. We are also looking ahead and misinformation and hope to have a BOLO type meeting later that week with the platforms that are interested.
Q. And who's ACIP?
A. The Advisory Council for Immunization Practices, I believe, I think that's right.
Q. And do you know whether you had a BOLO meeting for this?
A. I don't -- I don't believe that we ever

Page 254

1 had one.
Q. So the email states that --

You can put that aside.
(Plaintiffs' Exhibit 43 marked.)
BY MR. VECCHIONE:
Q. Let's go to -- yeah, let's go to the last, 43.

Once again for Exhibit 43 please state the subject matter line, and then the -- and who it -what the date of it is?
A. Subject: Claims review. 6/29/2022.

I have read it.
Q. Okay. So can you read the -- well, who is Rachel Gruner?
A. She is my new point of contact at Google. She replaced Jan Antonaros.
Q. And who's Lindsay Steele?
A. Lindsay Steele replaced Stanley.
Q. Onyimba?
A. "○".
Q. Okay. And they're both -- their emails are here in the to line; right?
A. Yes.
Q. All right. And if you could read the after Hi, Carol, Hi, Fred from Rachel, what does she

Page 255

Page 256

\section*{COVID-19 or vaccines?}
A. It definitely didn't have anything to do with COVID-19 or vaccines.
Q. Do you know why it was sent to you?
A. Well, as COVID's -- our focus is not solely on COVID. We're focusing on other topics. I think Rachel thought that we might be able to help with this topic as well.
Q. Okay. Do you know who you sent it, what agency you sent it to, if any?
A. I -- I didn't know. I called one of our centers and asked if this was something that CDC dealt with. I didn't think that we did, and they confirmed that we do not. And I don't think they had a suggestion on where to refer this to, but I can't recall for sure.

MR. VECCHIONE: All right. I would like to take a brief break and have the court reporter put my last exhibit together and give you copies and then --

MR. GILLIGAN: There is a 44, too?
MR. VECCHIONE: -- confer, confer with counsel, and \(I\) think we'll be finishing up. (Comments off the record.)

THE VIDEOGRAPHER: Off the record at 5:07.

CAROL CRAWFORD 11/15/2022
Page 257
(Recess 5:07 p.m. - 5:19 p.m.)
THE VIDEOGRAPHER: Back on the record at
5:19.
(Plaintiffs' Exhibit 44 marked.)
BY MR. VECCHIONE:
Q. All right. Ms. Crawford, this is going to be Exhibit 44. And it will have -- once again, read the subject line and then tell me what the date was.
A. Subject: "Themes that have been removed from misinform." I am sure that was typo. 3/10/2021.

Okay.
Q. All right. Let's go to the back end of the exhibit. And the first email chain is from March 10th, 2021 from you to Payton Iheme; is that correct?
A. Yes.
Q. And it says: "Themes that have been removed for misinfo." And I think we've established that's misinformation; correct?
A. Yes.
Q. And you say to her: "We mentioned this on a call last week and you said you'd be sending something as other had asked -- is that available yet by chance?"

CAROL CRAWFORD 11/15/2022
Page 258

What were you telling her? What did you mean?
A. This is what \(I\) was referencing on a previous exhibit that one of our teams that was doing those vaccine confidence reports and those research reports, they were wondering if we -- if they had info on the -- on the types of posts that were removed and the themes because they were worried that we could only see the live posts and so we wouldn't know if there was also confusion about other areas that had been removed.
Q. And she --
A. I feel pretty confident that that is what this is about.
Q. And she responds to you. "Are you looking for types of COVID-19 misinfo we remove"; right?
A. Yes.
Q. "I think it may be worth a separate meeting to have some of our leads discuss the approach/what they are seeing and doing. Would that work?" That's what you said?
A. Yes.
Q. And what are her leads; what was your understanding?
A. Just like I would bring people that were

Page 259
```

1 in charge of different areas, sometimes she would
2 bring people that had more expertise. Payton and I

```
```

    did not know everything in our respective
    organizations, so I assume it was a lead for
    something, someone in this area.
    Q. All right. And then you respond to her on March 10th at 9:24; correct?
A. Yes.
Q. "Yes." And you say "you mentioned that" -- is that White House?
A. Yes.
Q. "And HHS"?
A. Yes.
Q. "Had asked so you'd get it to us"; right?
A. Yes.
Q. "I think it is wanted as part of
analysis -- so are you thinking there is no report/file to send?"
Is that your question to her?
A. Yes.
Q. All right. And what you say there is when White House and HHS ask Facebook for this information, they assumed that Facebook would provide it to them; correct?
MS. SNOW: Objection. Calls for

```

CAROL CRAWFORD 11/15/2022
Page 260

1 speculation.
```

BY MR. VECCHIONE:

```
Q. You can answer.
A. Well, I think it was poorly worded by myself and kind of typo maybe. But what this was was I recall we asked on the meeting if they had this data, like, because we wanted it. And I think she said, Oh, we did something like this for the White House or HHS.

This is my memory of it.
Q. Okay. This is one of your weekly meetings, or a BOLO?
A. I think it was at a weekly meeting.
Q. All right. And then the next thing she says back to you is: (As read) It wasn't a report, but rather a discussion. We were setting up a meeting with White House and HHS to discuss more likely later this week or early next week. Perhaps the CDC rep could participate or HHS share out? Is that what she says?
A. Yes.
Q. What does HHS share out mean? That they'd give it to you?
A. Yes. Oh.

MS. SNOW: You're good. You're good.

Page 261

BY MR. VECCHIONE:
Q. So let's clean up the record a little. What is an HHS share out? Does that mean they give you whatever they are provided?
A. Yes.
Q. All right. So it was your understanding that Facebook was having the same kind of meetings you were having with them with White House and HHS?
A. I don't know that in relation to this email. I was assuming that. But I do think that they did have meetings with the agencies.
Q. And could you read what you respond to her on May 10th at 9:30 a.m.?
A. "Oh, I assumed it was a report. Who at HHS is in the meeting?"
Q. And what did she respond to you at 9:32?
A. (As read) Josh Peck would be the HHS rep once a meeting is confirmed based on that I see him at a previous discussions or meetings with the White House.
Q. Do you know who he is?
A. Yes.
Q. Who is he?
A. I don't know his specific title, but he, I believe, during this time was running the HHS COVID

Page 262

1 communication marketing campaign.

Page 263

Wilhelm on the vaccine confidence team is what is needed if Facebook is willing to do it. Doesn't seem to me like that would be -- like it should be part of the White House HHS meeting.
Q. Who's Lis Wilhelm?
A. She is the group that was creating those vaccine confidence reports that was wondering if they had all the data reflected in them, and what the people were worried about, or confused about. And she was thinking that if the data -- if we knew the kinds of things that were removed, it might give a fuller picture for those reports.
Q. Okay. And then you discuss a time for another meeting, and I think it ends at -- this chain ends at 3:10, 9:54 a.m.: Let's plan on next Thursday then.

Do you know whether you ever had that meeting?
A. I think we did.
Q. And do you know what was discussed there?
A. I think that the vaccine confidence team came, and I don't -- and we discussed what they might have that would give them that fuller picture.
Q. You can put that aside. I have got a few followup questions.

Page 264
A. Okay.
Q. At any of your -- in flagging any material for any of the social media issues, themes, facts, whatever you flag, can you say whether or not you flagged any information from the Great Barrington Declaration?
A. I don't know what that is.
Q. Okay. How about Jay Bhattacharya?

Anything from him?
A. I don't know who that is.
Q. Marty Kulldorff. Anything from him?
A. I don't know who that is.
Q. Aaron Kheriaty. Anything from him?
A. I don't know who that is.
Q. Jim Hoft, or Gateway Pundit?
A. I don't know who that is.
Q. All right. And Jill Hines?
A. I don't know who she is.
Q. All right. And I think I have asked you before, but bear with me. Have you flagged anything from Governor Michael Parson?
A. I -- well, I may or may not have known the name of the governor. But \(I\) don't recall any specific who posted anything we flagged. That might be a better way to answer these questions.

Page 265
Q. Okay. And that's --
A. I don't remember anybody associated with the example posts that we sent.
Q. Okay. And that would include -- I'm doing this for the record, you understand. I understand your answer.
A. Yes.
Q. That would include Eric Schmitt, Jeff Landry and John Bel Edwards?
A. Yes.
Q. Thank you. And now, finally, on the BOLO meetings, who ran the BOLO meetings?
A. I ran the BOLO meetings.
Q. In what manner? How did you do it?
A. I opened up the meeting, introduced myself, gave context for why we were doing the BOLO meeting in brief. And then \(I\) believe that Christopher went through the slide decks, and I occasionally piped in on them.
Q. Lewitzke?
A. Yes.
Q. And so he -- these slide decks, would they be like the table you showed me or that we looked at with examples of the shedding and the microchips in the bloodstream?

Page 266
A. They were similar to the table, but they were more like this is a theme, and then there'd be maybe a little info about what the theme was and then maybe a couple of example posts. And then there would be a slide maybe with CDC links or information related to that theme.
Q. All right.
A. So it was more than just a table. It had more context to it.
Q. How long did the meetings go?
A. They were short. I mean, maybe they were 20 minutes.
Q. And what did you and Mr. -- well, first, what did you hope to accomplish by those meetings?
A. The same thing that I've been referencing.

I mean, our goal is to be sure that credible information about COVID was out there. A lot of people seek information on platforms. We thought that by giving the platform scientific information it might help in our goals to being sure that credible information could be found.
Q. And uncredible information would not be found; correct?

MS. SNOW: Objection, mischaracterizes testimony.

Page 267

1 BY MR. VECCHIONE:
Q. You can answer.
A. I did want the credible information to be found in advance of the uncredible information.
Q. You at least wanted upgraded over --
A. Yes.
Q. -- uncredible information?
A. Yes.
Q. Do you recall anything anyone at any of the social media platforms asked at any of these BOLO meetings?
A. They weren't able to ask questions during the BOLO meetings.
Q. Why was that? Tell me how it ran.
A. I think we talked about that this morning. They are muted because the thought was they're competitors, and they could ask questions individually later.
Q. Got it. One second.
(Mr. Vecchione conferring with Mr. Sauer.)
BY MR. VECCHIONE:
Q. Did they ask any questions individually later that you recall?
A. No, I don't think that they did.

MR. VECCHIONE: All right. I have no

Page 268
further questions at this time.
MS. SNOW: Okay. Nothing further. No questions for defense.

MR. VECCHIONE: And you already said you'll read, right, at the beginning?

MS. SNOW: I said that at the beginning, so I didn't want to forget at the end.

MR. VECCHIONE: All right.
THE VIDEOGRAPHER: Okay. I've got to ask on the record, what about video copies for everybody? Anybody?

MR. SAUER: We want video as soon as it's available.

THE VIDEOGRAPHER: So you want synced, non-synced?

MR. SAUER: I think synced syncs the video to the transcript?

THE VIDEOGRAPHER: Yes, I believe so.
MR. VECCHIONE: And we -- I think what we've been doing, we're going to do is give the originals to her to put the record together, the transcript together, the original exhibits.

MR. GILLIGAN: The original exhibits, yes.
MR. SAUER: So there should be -- that stack of exhibits should go to the court reporter in

CAROL CRAWFORD 11/15/2022
Page 269
\begin{tabular}{|c|c|}
\hline 1 & front of the witness. \\
\hline 2 & THE VIDEOGRAPHER: Do you want a copy also \\
\hline 3 & for your group? \\
\hline 4 & MR. SAUER: No, just one. We're both \\
\hline 5 & plaintiffs. \\
\hline 6 & MR. VECCHIONE: And there is no Exhibit. \\
\hline 7 & 25 that's the one we skipped. So don't be thinking \\
\hline 8 & it's lost. \\
\hline 9 & MS. SNOW: But, yeah, we would like a copy \\
\hline 10 & of the video as well. \\
\hline 11 & THE VIDEOGRAPHER: Okay. A synced copy? \\
\hline 12 & MS. SNOW: Yes. \\
\hline 13 & THE VIDEOGRAPHER: So how about you, sir? \\
\hline 14 & MR. GILLIGAN: She's with us. \\
\hline 15 & THE VIDEOGRAPHER: So just one for each. \\
\hline 16 & MS. SNOW: Yeah. \\
\hline 17 & THE VIDEOGRAPHER: Got you. Thank you. \\
\hline 18 & And we are off the record at 5:33. \\
\hline 19 & (Concluded at 5:33 p.m.) \\
\hline 20 & (Signature reserved.) \\
\hline 21 & \\
\hline 22 & \\
\hline 23 & \\
\hline 24 & \\
\hline 25 & \\
\hline
\end{tabular}

Page 270

C ERTIFICATE
STATE OF GEORGIA:
DEKALB COUNTY:
I, Maureen S. Kreimer, a Certified Court Reporter for the State of Georgia, before whom the foregoing deposition was taken, do hereby certify:

That CAROL CRAWFORD, the witness whose deposition is hereinbefore set forth in pages 1 to 269, was duly sworn by me and that such deposition is a true record of the testimony given by the witness.

I further certify that I am not related to any of the parties to this action by blood or marriage, and that I am in no way interested in the outcome of this matter.

IN WITNESS HEREOF, I have hereunto set my hand this 18th day of November, 2022.


MAUREEN S. KREIMER, CCR-B-1379
Notary Public in and for the
State of Georgia. My Commission
Expires August 14, 2024.

Page 271

LEXITAS LEGAL

November 17, 2022

KYLA SNOW, ESQ.
U.S. Department of Justice
\[
1100 \text { L Street N.W. }
\]

Washington, DC 29530
IN RE: STATE OF MISSOURI ex rel. ERIC S. SCHMITT, Attorney General, et al. v. JOSEPH R. BIDEN, JR., in his official capacity as President of the United States, et al.

Dear Ms. Snow:
Please find enclosed your copies of the deposition of CAROL CRAWFORD taken on November 15, 2022 in the above-referenced case. Also enclosed is the original signature page and errata sheets.

Please have the witness read your copy of the transcript, indicate any changes and/or corrections desired on the errata sheets, and sign the signature page before a notary public.

Please return the errata sheets and notarized signature page within 30 days to our office at 711 N 11th Street, St. Louis, MO 63101 for filing.

Sincerely,

Lexitas Legal

Enclosures

Page 272
\begin{tabular}{|c|c|}
\hline 1 & ERRATA SHEET \\
\hline & Witness Name: CAROL CRAWFORD \\
\hline 2 & Case Name: STATE OF MISSOURI ex rel. ERIC S. SCHMITT, Attorney General, et al. v. JOSEPH R. \\
\hline 3 & BIDEN, JR., in his official capacity as President of the United States, et al. \\
\hline 4 & Date Taken: NOVEMBER 15, 2022 \\
\hline 5 & Page \#__ Line \# \\
\hline 6 & Should read: \\
\hline 7 & Reason for change: \\
\hline 8 & \\
\hline 9 & Page \#__ Line \# \\
\hline 10 & Should read: \\
\hline 11 & Reason for change: \\
\hline 12 & \\
\hline 13 & Page \#___ Line \# \\
\hline 14 & Should read: \\
\hline 15 & Reason for change: \\
\hline 16 & \\
\hline 17 & Page \#___ Line \# \\
\hline 18 & Should read: \\
\hline 19 & Reason for change: \\
\hline 20 & \\
\hline 21 & Page \#___ Line \# \\
\hline 22 & Should read: \\
\hline 23 & Reason for change: \\
\hline 24 & \\
\hline 25 & Witness Signature: \\
\hline
\end{tabular}

Page 273
\begin{tabular}{|c|c|}
\hline 1 & STATE OF \\
\hline 2 & \\
\hline 3 & COUNTY OF \\
\hline 4 & \\
\hline 5 & I, CAROL CRAWFORD, do hereby certify: \\
\hline 6 & That I have read the foregoing deposition; \\
\hline 7 & That I have made such changes in form \\
\hline 8 & and/or substance to the within deposition as might \\
\hline 9 & be necessary to render the same true and correct; \\
\hline 10 & That having made such changes thereon, I \\
\hline 11 & hereby subscribe my name to the deposition. \\
\hline 12 & I declare under penalty of perjury that the \\
\hline 13 & foregoing is true and correct. \\
\hline 14 & Executed this ___ day of ___ , \\
\hline 15 & 20 \(\qquad\) , at \(\qquad\) \\
\hline 16 & \\
\hline 17 & \\
\hline 18 & \\
\hline 19 & \\
\hline 20 & CAROL CRAWFORD \\
\hline 21 & \\
\hline 22 & \\
\hline 23 & NOTARY PUBLIC \\
\hline 24 & My Commission Expires: \\
\hline 25 & \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline A & accounts & add-on 32:10 & administ. & 62:25 \\
\hline a.m1:15 & 4:18, 21 & added 63: 4, 5 & 48:21 & 67:11 \\
\hline 31:1,1 & 157:5 & \(70: 677: 6\) & 95:18 & 107:6 \\
\hline \(34: 5100: 2\) & 196:20 & 157:24 & 98:24 & 108:20 \\
\hline 102:10 & 201:20 & 194:24 & 215:15 & 114:11 \\
\hline 261:13 & 212:21 & 195:1 & Adrien \(86: 12\) & 117:15 \\
\hline 263:15 & 217:11,24 & 227:10 & 238:8,9 & 128:25 \\
\hline Aaron 6:6 & 218:7 & 249:11 & Adrienne & 129:22 \\
\hline 8:15 & accurate & adding 55:21 & 100:1 & 130:7 \\
\hline 264:13 & 27:15 89:4 & 61:11 & ads 222:20 & 134:8 \\
\hline Abbott 5 & 162:22 & 76:18 & 222:21 & 141:16 \\
\hline ability & ACIP \(253: 12\) & 82:17 & adults 46:4 & 155:11 \\
\hline 10:24 & 253:20 & 129:10 & 164:7 & 166:13 \\
\hline 88:11 & ACS 183: 6 & addition & advance & 181:4 \\
\hline 156:17 & acting 32:6 & 128:14 & 267:4 & 185:18 \\
\hline 157:7 & action & 249:12 & adverse & 187:5 \\
\hline 164:10 & 270:12 & additional & 122:23 & 190:22 \\
\hline able 75:23 & actionable & 45:24 & 123:1,10 & 196:3 \\
\hline 108:17 & 212:9 & 48:22 & 140:7 & 202:9 \\
\hline 122:17 & actioned & 78:10 & 168:11 & 207:1 \\
\hline 123:9 & 211:13 & 107:8 & advice 169:9 & 216:16 \\
\hline 146:5 & activities & 159:21 & 237:19 & 242:25 \\
\hline 161:10 & 69:11 & 162:11 & advise 71:4 & 243:20 \\
\hline 172:24 & 164:11 & 167:1 & 104:22 & 253:8 \\
\hline 173:12 & activity & 188:4 & advisement & age 169:1 \\
\hline 215:14 & 41:3,4 & 218:19 & 84:21 & 169:25 \\
\hline 256:7 & 74:6 75:17 & 219:12 & 100:16 & 185:25 \\
\hline 267:12 & actual & 238:19 & advisory & 187:4,6 \\
\hline abortion & 108:11 & 255:5 & 153:17,18 & agencies \\
\hline 255:10,15 & 111:10 & address & 253:21 & 92:2 \\
\hline above-re.. & 214:2 & 23:21 29:1 & Affairs & 109:23 \\
\hline 271:11 & 244:3 & 38:14 & 12:23 13:8 & 221:9 \\
\hline access 49:12 & ad 180:21, 25 & 83:11 & 13:10 & 223:24 \\
\hline 71:11 & 224:9 & \(87: 16,21\) & 14:10 15:4 & 232:4,6,16 \\
\hline 97:11,20 & Adams 119:8 & 88:8 & 19:9 32:7 & 232:18 \\
\hline 147:12 & 119:9 & 125:24 & 32:18 & 233:8,11 \\
\hline 148:8 & 150:16 & 129:5 & Affairs' & 239:21 \\
\hline 213:8 & 153:1,6 & 172:24 & 12:19 & 261:11 \\
\hline 217:24 & 223:1 & 174:20 & affect 138:3 & agencies' \\
\hline accessing & ADCS 107:23 & 175:4 & 164:10 & 164:23 \\
\hline \[
206: 21
\] & add 42:18 & 207:25 & affirmative & agency 11:19 \\
\hline accomplish & 58:17 67:9 & 244:15 & 16:3,25 & \[
15: 17
\] \\
\hline 88:24 & \(76: 19 \quad 77: 1\) & addressed & 17:12 & 95:19 \\
\hline 266:14 & \(77: 478: 15\) & 108:16 & 19:18 23:9 & 127:25 \\
\hline account & 141:3 & adds 262:11 & 39:17 & 128:5 \\
\hline 138:9 & 184:23 & adjust 54:20 & 40:24 & 140:12 \\
\hline 215:1,3 & 192:11 & 58:2 81:12 & 41:23 & 164:21 \\
\hline 216:20 & 229:13 & administ... & \(43: 1544: 7\) & 255:23 \\
\hline 218:2,18 & 251:22 & 12:5 & 45:21 & 256:10 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline agenda 3: 4 & 271:7,8 & Anant 7:2 & answer's & 247:3 \\
\hline 103:4 & 272:2,3 & 8:25 & 120:14 & 249:11 \\
\hline 118:23 & alert 4:1 & Anant.ku.. & answered & apparently \\
\hline 126:15 & 5:2 152:24 & 7:4 & 41:8 74:13 & 91:24 \\
\hline 221:14,16 & 153:8,11 & and/or & 80:16 & 194:18 \\
\hline 221:17 & 153:12,13 & 271:13 & 82:20 99:8 & 237:15,16 \\
\hline 224:2 & 153:14,16 & 273:8 & 108:15 & 253:2 \\
\hline 225:21 & 153:17,18 & animals & 113:19 & appear \\
\hline 240:7,9 & 188:11 & 120:17 & 140:21 & 120:11 \\
\hline agendas & 190:14 & announce & 165:7 & appearance \\
\hline 223:24 & 219:24 & 193:1,11 & 176:12 & 68:15 \\
\hline aggregate & 220:1,14 & 193:18 & answering & APPEARANCES \\
\hline 154:19 & algorithm & 195:18,24 & 68:19 & 6:1 \\
\hline ago 51:23 & 53:4,8 & answer 10:3 & answers & appearing \\
\hline 56:21 96:6 & 138:20 & 10:10,12 & 74:17 & 146:17 \\
\hline 99:1 & 155:18 & \(35: 146: 22\) & 114:16 & 209:2 \\
\hline 182:19 & algorithms & 47:17 & 115:2,5 & appears \\
\hline agree 10:13 & 237:14 & 54:11 69:5 & 129:6,24 & 25:10 \\
\hline 49:19 & alias 23:16 & 73:14 & anti-vac. & 41:16 56:6 \\
\hline 132:4 & alleged & \(76: 25\) 78:6 & 55:6 & 77:14 \\
\hline 172:5 & 53:22 58:6 & \(78: 20 \quad 79: 4\) & anticipated & 119:22 \\
\hline 187:17 & allergic & 79:18 & 228:14 & 122:7 \\
\hline 211:11 & 164:12 & 80:17, 21 & Antonaros & 141:22 \\
\hline 230:11 & Alliance 6:9 & 80:23 90:2 & 21:1 174:8 & 203:5 \\
\hline agreed 47:9 & allowed & 93:22 97:8 & 176:6 & 252:25 \\
\hline 57:14 & 77:10 & 101:23 & 177:7 & applied \\
\hline 60:23 & 93:24 94:4 & 106:8, 21 & 192:22 & 136:22 \\
\hline agreement & 94:9 & 107:2 & 243:17 & apply 104:23 \\
\hline 31:11 71:6 & 217:21,22 & 112:25 & 254:16 & 105:3 \\
\hline 102:17 & allowing & 115:4 & Antonaros' & 169:21 \\
\hline 109:21,23 & 146:15 & 116:10 & 176:23 & appointment \\
\hline Ah 125:7 & allows & 121:8 & Antonio & 37:4,24,25 \\
\hline ahead 31:5 & 214:10 & 129:16 & 253:3 & 44:14, 23 \\
\hline 31:23 & alternate & 136:8 & anybody & 116:22 \\
\hline 67:16 & 208:12 & 137:4 & 265:2 & 178:15 \\
\hline 74:20 & alternative & 146:5 & 268:11 & 221:16 \\
\hline 81:16 & 209:17 & 152:1 & anymore & 242:20 \\
\hline 104:13 & Alzheimer's & 158:8,25 & 13:15 & 244:1,3 \\
\hline 199:17 & 122:3 & 159:17 & anything's & 248:5 \\
\hline 253:17 & amplific... & 161:19 & 171:2 & appointm. \\
\hline AII 111:2 & 80:2,4 & 180:16 & anyways & 30:13 \\
\hline aiming & 81:17 & 186:12 & 176:4 & appreciate \\
\hline 242:11 & amplify & 194:1 & apologies & 27:20 \\
\hline 245:16 & 227:3 & 236:5 & 33:16 96:7 & 109:12 \\
\hline Airton & analysis & 241:10 & apologize & 206:6 \\
\hline 222:17 & 259:17 & 260:3 & 41:13 & appreciated \\
\hline Airton's & analyze & 264:25 & 86:24 & 55:20 \\
\hline 224:8 & 75:12 & 265:6 & 167:16 & approach \\
\hline al 1: 4, 10 & \(80: 13\) & 267:2 & 245:9 & 76:17 77:3 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 276 of 334 PageID \#: 11220
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 82:17 & 259:1 & asked 14:11 & 48:4,6 & assigned \\
\hline 208:13 & argument. & 42:21 & 51:8 55:7 & 114:21 \\
\hline 209:17 & 138:7 & 46:14 & 75:22 77:1 & 124:1 \\
\hline approach... & 163:10 & 69:10,22 & 77:2 78:15 & assist 154:1 \\
\hline 258:20 & arguments & 75:3 77:4 & 80:6,14 & assistance \\
\hline approached & 39:20 & 80:16 & 82:22 & 17:7 224:7 \\
\hline 29:18 & arrange & 81:17 & 90:11 & assistant \\
\hline appropriate & 36:16 37:1 & 82:20 & 94:11 & 50:24 61:7 \\
\hline 217:4 & 246:16 & 98:19 99:2 & 99:13 & 63:11 \\
\hline approved & arranged & 99:6,7 & 117:25 & assistants \\
\hline 169:23 & 20:19 & 106:24 & 123:25 & 86:15 \\
\hline 201:15 & arrangem. & 125:23 & 130:19 & assisting \\
\hline 203:21 & 18:22 & 130:18 & 139:21,24 & 158:15 \\
\hline 204:2 & arranging & 146:18 & 149:12 & associate \\
\hline approving & 246:13 & 152:3 & 150:18 & 11:9,12 \\
\hline 161:13 & ARTF 42:1,3 & 164:1 & 157:8 & 183:5 \\
\hline April 3:6 & article 3:6 & 165:7 & 158:18 & associated \\
\hline 13:3,14 & 3:7 4:7 & 166:22 & 159:3,3,8 & 37:24 \\
\hline 15:1 16:1 & 7:19 53:19 & 174:11 & 163:24 & 265:2 \\
\hline 46:2 65:25 & articles & 176:11 & 167:21 & assume 35:19 \\
\hline 77:13 & 112:20 & 180:14 & 169:8,10 & 44:2 59:23 \\
\hline 185:17 & as-needed & 184:3 & 170:18,21 & 105:18 \\
\hline 186:7 & 223:25 & 185:16 & 173:2 & 125:12 \\
\hline 188:15 & aside \(22: 3\) & 188:1 & 182:8 & 135:19 \\
\hline 196:21,25 & 43:8 48:13 & 197:5,18 & 186:4,5 & 160:6 \\
\hline 221:10 & 60:2 85:4 & 197:18 & 200:11 & 197:24 \\
\hline 234:10 & 85:5 90:24 & 198:6 & 202:16,20 & 212:10 \\
\hline 237:8,10 & 100:19 & 201:1,24 & 204:22 & 223:3,19 \\
\hline 238:7 & 115:9 & 204:21 & 215:12 & 259:4 \\
\hline AR \(42: 6\) & 118:5 & 209:11 & 216:13 & assumed \\
\hline area 114:22 & 126:7 & 215:2,2 & 230:25 & 176:11 \\
\hline 114:23 & 144:25 & 230:13,24 & 231:13 & 259:23 \\
\hline 137:14 & 165:12 & 230:25 & 242:20 & 261:14 \\
\hline 138:8 & 168:21 & 231:18,19 & 251:24 & assumes 79:1 \\
\hline 140:14 & 171:13 & 231:22 & asks 46:18 & 110:7 \\
\hline 143:4 & 179:8 & 232:1 & 65:18 & 137:22 \\
\hline 146:4,8 & 187:8 & 236:8 & 79:13 & 138:6 \\
\hline 150:21 & 196:13 & 238:20 & 96:25 & 142:24 \\
\hline 154:11 & 200:14 & 240:21 & 140:5 & assuming \\
\hline 224:17 & 205:2 & 256:12 & 157:15 & 33:21 \\
\hline 259:5 & 219:18 & 257:24 & aspect 83:17 & 182:7 \\
\hline areas 34:1 & 221:2 & 259:14 & Aspinall & 204:17 \\
\hline 56:18 & 226:3 & 260:6 & 92:5 97:5 & 261:10 \\
\hline 59:11 76:1 & 236:25 & 264:19 & assembled & assumption \\
\hline 87:23 & 239:12 & 267:10 & 192:18 & 130:3 \\
\hline 150:23 & 247:6 & asking 9:25 & assess & 185:3 \\
\hline 175:13 & 249:6 & 18:20 26:8 & 169:23 & assure 49:4 \\
\hline 211:18 & 254:3 & 27:5 34:17 & assessment & 135:23 \\
\hline 258:11 & 263:24 & 42:14,18 & 166:25 & asterisks \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 235:10 & 63:14 & 192:1 & 237:9 & 12:23 14:5 \\
\hline asthma 46:4 & Attorney 1:4 & awareness & 238:8 & 18:4 19:22 \\
\hline 186:15,21 & 6:2 149:1 & 25:5 26:14 & 241:24,24 & 19:23 24:5 \\
\hline 187:4 & 149:1 & 35:18 & 243:15 & 25:14 \\
\hline AstraZeneca & 271:7 & 190:7 & 247:14 & 28:18 \\
\hline 169:5 & 272:2 & & 252:7,7 & 29:18,18 \\
\hline Atlanta 1:18 & attorney & B & 253:2 & 30:12 \\
\hline 12:13 & 93:21 & babies & 255:23 & 34:14 42:4 \\
\hline attach 46:12 & 94:20,22 & 165:15 & 257:2,13 & 45:7,13 \\
\hline 122:18 & attorneys & bachelor & 260:15 & 51:1,16 \\
\hline 207:13 & 8:10 & 12:11 & back-12:15 & 59:8 63:11 \\
\hline attached & audiences & bachelor's & background & 64:13 \\
\hline 5:22 7:22 & 182:1 & 12:4 & 12:16 & 65:12 \\
\hline 25:8 52:21 & audio 97:22 & back 11:24 & 59:24 & 69:12 70:1 \\
\hline \(60: 1961: 1\) & August & 13:7 22:19 & Balog 50:17 & 70:19 \\
\hline 62:1 63:16 & 145:17,18 & 22:22 & Barnes 19:12 & 77:12 \\
\hline 63:17 & 146:21,25 & 25:25 31:2 & Barrington & 79:21 \\
\hline 185:20,21 & 270:25 & 41:18 56:8 & 264:5 & 80:19, 25 \\
\hline 202:13 & authored & \(67: 2468: 4\) & based 97:10 & 81:5, 9, 14 \\
\hline 251:15 & 46:20 & 69:13 & 133:12 & 83:13,22 \\
\hline attachment & authority & 70:10,11 & 200:12 & 83:24 87:1 \\
\hline 149:11 & 135:24 & 72:14 & 211:18 & 87:22 \\
\hline 153:7 & authoriz & 77:12,17 & 219:9 & 90:11 92:1 \\
\hline 155:5 & 4:3,6 & 98:3 & 261:18 & 92:21, 25 \\
\hline 188:18 & 137:7,10 & 102:11 & basis 74:3,5 & 97:14 \\
\hline attachments & 137:12 & 115:2,4,5 & 184:16 & 108:13 \\
\hline 47:18 & 156:2,25 & 116:12,14 & 215:11 & 110:4 \\
\hline 202:10 & 160:1 & 117:11 & Bates 124:17 & 116:18 \\
\hline attend 68:18 & 163:19 & 121:14 & 136:9,13 & 117:22 \\
\hline 151:15,16 & 167:3 & 124:7,8 & 136:19 & 118:1 \\
\hline 187:24 & 169:18 & 126:17 & 146:11 & 123:9,13 \\
\hline 188:7 & available & 130:11,12 & 169:13 & 128:10 \\
\hline 243:25 & 45:25 & 132:9 & 205:25 & 133:20 \\
\hline 247:20,23 & 68:18 72:4 & 133:17 & 241:25 & 134:1 \\
\hline attended & 89:6 95:19 & 135:14 & bear 264:20 & 137:15 \\
\hline 120:2,3 & 95:25 & 145:17 & becoming & 139:7 \\
\hline 151:8 & 96:16 & 150:4 & 38:7 & 143:22 \\
\hline 235:7 & 133:24 & 160:13 & beginning & 147:18 \\
\hline 245:1 & 185:6 & 161:6 & 16:14,19 & 151:22 \\
\hline \(246: 12\) & 251:15 & 167:24,25 & 19:11 44:5 & 154:22 \\
\hline 250:15 & 257:24 & 176:9 & 142:15 & 155:18 \\
\hline attendee & 268:13 & 189:10 & 144:16 & 167:19 \\
\hline 246:7 & Avenue 7:3 & 193:2 & 198:22 & 168:6 \\
\hline attendees & aware 33:18 & 197:11 & 219:11 & 174:17 \\
\hline 221:18 & 137:18 & 205:11 & 268:5,6 & 175:18 \\
\hline attending & 140:6 & 206:25 & behalf 6:1, 6 & 177:9 \\
\hline 181:7 & 167:2 & 212:22 & \(6: 1571\) & 185:10,14 \\
\hline attention & 169:2 & 226:23 & Bel 265:9 & 188:13 \\
\hline 52:23 & 191:23 & 235:11 & believe & 192:6 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 196:10 & 211:22 & bloodstream & 267:11,13 & brewing \\
\hline 197:18 & 243:5,9 & 265:25 & BOLOs 153:23 & 220:14 \\
\hline 200:6 & better 80:7 & Bloomberg & 210:2,3 & brief 2:12 \\
\hline 204:12,15 & 192:11 & 4:7 & Bonds 19:10 & 2:15 39:9 \\
\hline 204:21 & 194:8 & BlueJeans & 32:13 & 39:11,13 \\
\hline 210:22 & 229:9 & 241:4,5 & booster 5:14 & 39:24,25 \\
\hline 212:2 & 242:16 & Board 7:20 & 249:19,20 & 43:21 44:9 \\
\hline 214:18 & 264:25 & body 62:3 & 250:1 & 256:18 \\
\hline 218:24 & beyond 31:12 & 164:9 & Boosters 4:7 & 265:17 \\
\hline 220:18 & 40:12 & bold 62:9,11 & bottom 44:19 & briefing \\
\hline 221:24 & 102:18 & 62:13 & 65:13 & 68:17,21 \\
\hline 222:3 & Bhattach . & 64:19 & 124:18 & 68:23 \\
\hline 223:16,16 & 6:6 8:15 & bolded 62: 6 & 128:7 & briefings \\
\hline 223:16 & 264:8 & 62:7 63:20 & 136:13 & 149:2 \\
\hline 225:3 & Biden 1:7 & 63:23 64:6 & 146:12 & briefly \\
\hline 228:8 & 8:5 271:8 & 64:8,10,21 & 148:20 & 11:25 \\
\hline 230:20 & 272:3 & 65:8 66:4 & 169:14 & briefs 39:18 \\
\hline 232:21,23 & big 34:17,23 & bolding 64:1 & 174:3 & bring 35:24 \\
\hline 233:13 & 189:20 & 64:2 & 187:19 & 115:14 \\
\hline 236:8,15 & 190:1 & BOLO 4:1 5:2 & 196:25 & 181:14,18 \\
\hline 239:13 & bigger & 5:10,13 & 206:1 & 182:9 \\
\hline 243:16 & 220:17 & 152:24 & 243:19 & 188:21 \\
\hline 245:1 & Birth 223:17 & 153:19,20 & box 6:4 & 200:10 \\
\hline 246:4,15 & bit 11:24 & 188:9,13 & 23:15,17 & 258:25 \\
\hline 248:4,4,17 & 12:22 & 188:14 & branch 13:19 & 259:2 \\
\hline 250:21 & 49:15 & 198:15,21 & 13:20,20 & bringing \\
\hline 253:22,25 & 51:11 & 202:6 & 14:4,12,17 & 68:24 \\
\hline 261:25 & 61:14 & 204:24 & 15:3,4,6 & 168:21 \\
\hline 265:17 & 64:15 & 208:9,16 & 24:16 25:1 & 205:1 \\
\hline 268:18 & 151:12 & 208:17,24 & branches & Broadcast \\
\hline believed & 208:16 & 209:11,12 & 13:18 & 14:7 \\
\hline 157:16 & biweekly & 209:23 & brand 190:7 & broader \\
\hline 162:3 & 52:5 57:6 & 210:11 & break 30:20 & 39:16 \\
\hline 169:25 & 57:12,13 & 213:2 & 66:1,20 & 110:6 \\
\hline 220:20 & 57:16,19 & 219:24 & 102:2,6,7 & 182:25 \\
\hline bell's 3:6,8 & 57:21 & 220:6 & 102:7 & 184:9 \\
\hline 111:13 & 60:22 62:1 & 241:21 & 149:24 & Brook 92:5 \\
\hline 112:16,19 & 142:3 & 242:5,10 & 205:4 & building 6:3 \\
\hline 112:20 & 226:18 & 242:17,20 & 235:13 & 21:24,25 \\
\hline belong 54:24 & 262:20 & 243:12,25 & 256:18 & 164:9 \\
\hline 55:10 & black 62:5 & 245:1,14 & breaking & bullet 39:21 \\
\hline benefit & blacked 44:8 & 246:5 & 41:24 & 82:2 \\
\hline 140:3 & blanking & 247:12 & breast & 127:17 \\
\hline best 34:10 & 21:2 152:9 & 248:20,24 & 165:14 & bunch 27:25 \\
\hline 34:18 & blind 248:5 & 253:18,23 & breathing & Bureau 56:4 \\
\hline 40:25 & block 235:14 & 260:12 & 41:11 42:9 & buried 129:7 \\
\hline 77:23 & blocked & 262:8 & Bretthau. & business \\
\hline 116:6 & 237:21 & 265:11,12 & 108:1 & 12:4 \\
\hline 182:10 & blood 270:12 & 265:13,16 & 115:10 & busy 19:24 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 279 of 334 PageID \#: 11223
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline C & 190:11 & 233:14 & 141:22 & 42:24 \\
\hline C 23:7 270:1 & 195:1 & 251:4 & 144:22 & 43:21 44:9 \\
\hline 270:1 & 197:22 & 259:25 & 271:11 & 45:9 46:20 \\
\hline Cain 245:18 & 198:18 & campaign & 272:2 & 46:20 \\
\hline calendar & 221:8 & 262:1 & cast174:2 & 47:12 \\
\hline 30:12 & 222:3 & capacity 1:8 & catch 173:15 & 48:11,16 \\
\hline 84:15,19 & 223:18 & 271:8 & 240:20,21 & 54:6,13 \\
\hline 100:9 & 225:22 & 272:3 & category & 56:1,2,5 \\
\hline 116:20 & 233:7 & cards 197:9 & 185:25 & 58:9,20 \\
\hline 178:13,15 & 239:3,20 & 201:5 & 187: 6 & 61:10 \\
\hline 246:10 & 257:23 & care 95:10 & 203:20 & 63:24 64:3 \\
\hline calendared & call-in 31:8 & 238:17 & caught & 71:7,9,11 \\
\hline 116:21 & 31:15 & Carnac & 145:12 & 71:18,23 \\
\hline calendars & 102:15,20 & 249:13 & cause 111:13 & 71:25 \\
\hline 30:10 & called 17:19 & Carol 1:13 & 154:1 & 72:15 74:7 \\
\hline call 3:5 5:4 & 17:21,22 & 2:3,7 8:4 & 169:2 & 74:18 \\
\hline 5:9 11:10 & 69:1 & 9:5 11:3 & caused 168:1 & 77:17 78:1 \\
\hline 19:4 27:22 & 136:13 & 22:24 34:5 & causes 122:2 & 78:9,22 \\
\hline 29:25 30:1 & 173:11,14 & 45:22 & causing & 81:7 82:9 \\
\hline 30: 4, 8, 9 & 198:6 & 51:22 & 78:11,13 & 82:11 83:4 \\
\hline 30:11 & 211:9 & 63:15 & 127:10 & 87:20 \\
\hline 36:15 & 220:23 & 68:14 73:4 & 128:8 & 89:21 90:5 \\
\hline 37:19,21 & 221:25 & 74:25,25 & 156:18 & 90:6,9 \\
\hline 38:1 44:15 & 226:16 & 84:4 100:2 & cc 24:12 & 92:3,5 \\
\hline 45:23 & 229:9 & 126:19 & 50:17 52:2 & 96:23 \\
\hline 51:17,19 & 231:3 & 141:17 & cc'd 222:14 & 98:18 99:3 \\
\hline 52:22 & 256:11 & 166:18 & 250:20,25 & 99:6,8,18 \\
\hline 56:20 57:3 & calling & 176:25,25 & cc'ing 27:1 & 100:22,25 \\
\hline 84:9 93:19 & 148:22 & 197:4 & 86:16 & 103:4,20 \\
\hline 102:19 & calls 20:19 & 211:6,20 & Cc's 176:6 & 103:24 \\
\hline 103:4 & 29:20 30:5 & 216:18,19 & CCR-B-1379 & 104:8,22 \\
\hline 107:1 & 35:24 & 226:24 & 1:20 & 105:2,7,25 \\
\hline 108:18 & 76:21 78:3 & 234:12 & 270:22 & 106:2,12 \\
\hline 116:17 & 83:7 85:1 & 247:16 & ccrawfor & 107:14 \\
\hline 118:24 & 86:21 & 254:25 & 23:16 & 108:4,23 \\
\hline 121:18 & 89:25 & 270:7 & ccs 119:8 & 110:20 \\
\hline 122:8 & 93:18,20 & 271:11 & CDC 2:12,15 & 112:21 \\
\hline 126:16 & 101:20 & 272:1 & 3:5 4:1,9 & 113:11,13 \\
\hline 129:21 & 112:22 & 273:5,20 & \(5: 2,4,5,12\) & 113:15 \\
\hline 133:19 & 121:5 & Carol's & 8:7 11:5,8 & 117:13,14 \\
\hline 134:2 & 123:3 & 206:8 & 12:2,6,8 & 118:24 \\
\hline 173:7 & 135:10 & Caroline & 12:12,19 & 120:18,22 \\
\hline 177:3,23 & 138:5 & 45:12 & 13:9 15:22 & 126:16 \\
\hline 178:1,9,13 & 142:25 & Carrie 119:8 & 17:6,19 & 129:12,14 \\
\hline 178:14 & 159:14 & 119:9,11 & 18:12 & 129:24 \\
\hline 182:11 & 163:1 & 150:16 & 29:19 & 130:25 \\
\hline 184:21 & 193:13 & 153:1,19 & 35:24 39:9 & 132:4,10 \\
\hline 188:2 & 222:25 & 223:1 & 39:11 & 134:21 \\
\hline 189:24 & 231:15 & case 8:19 & 41:17 42:5 & 137:5 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 280 of 334 PageID \#: 11224
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 138:16 & 236:8 & 79:23 82:2 & 214:11,13 & 257:14 \\
\hline 139:24 & 239:21,21 & 83:1, 4, 7 & 214:14,19 & 263:15 \\
\hline 140:1,13 & 247:12 & 83:16,16 & 218:18,22 & chains \\
\hline 143:14,23 & 249:2 & 83:19 & 218:22 & 185:15 \\
\hline 145:25 & 251:13 & 86:20 87:1 & 219:12 & 206:24 \\
\hline 146:7 & 253:13 & 87:5 90:16 & 223:17 & 219:13 \\
\hline 148:8 & 255:4 & 96:22 99:3 & centers 1:17 & chance 38:24 \\
\hline 150:18 & 256:12 & 101:5,10 & 6:15 7:6 & 66:20 91:3 \\
\hline 152:8,24 & 260:19 & 101:12 & 7:12 35:10 & 150:8 \\
\hline 159:9,12 & 266:5 & 107:10 & 256:12 & 178:13 \\
\hline 163:21 & CDC's 11:14 & 109:14 & certain & 211:21 \\
\hline 164:22 & 11:15,17 & 110:16,17 & 63:20 & 257:25 \\
\hline 166:7 & 15:15,16 & 111:3,9 & 98:19 99:2 & change \\
\hline 171:23 & 27:17 29:8 & 117:19 & 101:18 & 194:13 \\
\hline 174:18 & 43:4 47:25 & 125:12,16 & 137:12 & 272:7,11 \\
\hline 175:2 & 52:3 59:13 & 174:18,21 & 157:9 & 272:15,19 \\
\hline 177:4 & 89:17 & 174:22 & 194:19 & 272:23 \\
\hline 181: 6 & 113:18 & 175:3,6,14 & Certified & changed \\
\hline 183:17 & 126:23 & 175:19,23 & 270:4 & 61:14 \\
\hline 185:14,23 & 161:21 & 176:11,12 & certify & 117:6 \\
\hline 189:23 & 167:4 & 177:4 & 270:6,11 & 145:22 \\
\hline 192:4 & 186:13 & 179:25 & 273:5 & 148:6 \\
\hline 193:19,20 & 191:1,16 & 182:5,9,24 & cetera & 156:12 \\
\hline 193:23 & 220:12 & 184:8,11 & 197:10 & 180:18 \\
\hline 194:4,19 & CDC-cred. & 184:11,16 & 201:5 & 210:22 \\
\hline 194:20 & 18:10 & 184:23 & chain 22:14 & changeover \\
\hline 200:20 & cell 35:23 & 185:9,12 & 22:18,23 & 13:16 \\
\hline 202:12 & 36:1,2,4,6 & 197:17 & 25:9 26:7 & changes 47:9 \\
\hline 210:23 & censorship & 201:11 & 26:21 30:2 & 192:8 \\
\hline 212:20,21 & 176:3 & 202:22 & 33:11 & 250:3 \\
\hline 212:22 & Census 55:22 & 203:14 & 35:21 & 253:16 \\
\hline 213:6 & 56:1,2,4 & 208:1,3 & 44:23 60:6 & 271:13 \\
\hline 215:3 & 58:17 & 209:24 & 66:3 67:21 & 273:7,10 \\
\hline 217:3,11 & 59:15 & 210:2,5,8 & 67:22 70:7 & channel 3:3 \\
\hline 218:4,5,6 & 61:10,11 & 210:11 & 74:19 & 51:5 91:10 \\
\hline 219:24 & 70:9 71:1 & 213:13,23 & 79:20 & 91:18,24 \\
\hline 221:9,9,18 & 71:3,8,14 & 214:21 & 83:12 & 95:14,14 \\
\hline 222:3 & 71:19,25 & 217:3,6,23 & 91:23 & 95:16, 22 \\
\hline 223:3,22 & 72:8,15,16 & 218:7 & 97:10,16 & 97:2 98:15 \\
\hline 223:24 & 73:6,8,11 & 234:19 & 122:11 & 99:20 \\
\hline 224:1,14 & 73:18,25 & 235:4,16 & 160:24 & 100:6 \\
\hline 226:9,16 & 74:9,18 & 235:19 & 172: 6 & channels \\
\hline 227:4 & 75:1 76:3 & 246:12 & 174:4 & 52:12 \\
\hline 229:10,14 & 76:11,19 & center 11:18 & 182:8 & 62:18 \\
\hline 230:20 & 77:5,17,22 & 14:2 15:18 & 187:20 & characte. \\
\hline 232:7,16 & 77:22 78:1 & 59:1 & 207:2 & 53:7 \\
\hline 233:13 & 78:9,14,15 & 107:13,15 & 213:10,12 & 132:10 \\
\hline 234:7,18 & \(78: 22\) 79:9 & 107:17,22 & 226:15 & 143:20 \\
\hline 234:25 & 79:15,18 & 160:20,21 & 238:22 & characte... \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 134:1 & 66:24 & @CDC. & 198:5 & 221:21 \\
\hline characte. & 117:20 & 23:8,17 & clarified & 224:19 \\
\hline 163:11 & 197:13 & claim 108:21 & 233:22,22 & co-chairs \\
\hline characters & 209:25 & 120:12 & clarify & 132:20 \\
\hline 174:2 & 253:7 & 122:21 & 31:20 55:1 & co-lead \\
\hline charge & Cheers 252:9 & 157:16,17 & 64:15 & 107:16,17 \\
\hline 135:22 & Chelsey 63:5 & 168:3,5 & 82:12 97:9 & 107:21 \\
\hline 259:1 & 63:11 65:1 & 169:24 & 104:12 & 115:19 \\
\hline chart 186:9 & chemical & 170:15 & 124:23 & 183:4 \\
\hline 186:11,12 & 255:9,15 & 203:21 & 147:8,25 & co-leads \\
\hline 186:14,15 & chief 15:3 & 255:8,13 & 155:2 & 108:2 \\
\hline 204:19 & 192:25 & claiming & 199:18 & co-morbi \\
\hline 207:14,14 & 193:3,8 & 204:17 & 205:24 & 186:1 \\
\hline 207:17 & childhood & claims 4:2,5 & 229:13 & code 231: 9 \\
\hline 211:8 & 158:4 & 5:15 & 246:11 & codes 70:20 \\
\hline chat 4:11 & children & 119:16,17 & clarifying & coincidence \\
\hline 171:22 & 66:5 157:1 & 124:15 & 171:25 & 24:21 \\
\hline 223:19 & 157:3 & 126:22 & clean 69:19 & collab \\
\hline 224:10 & 162:12 & 129:13,14 & 261:2 & 221:22 \\
\hline 242:16 & 164:7 & 131:8,18 & clear 9:21 & 225:7,10 \\
\hline chats 197:5 & 165:15 & 132:1 & 26:1 40:10 & collabor. \\
\hline 200:25 & 167:3 & 138:13,16 & 52:8 & 225:10 \\
\hline cheating & 169:15,19 & 139:1,9,24 & 122:11 & collabor. \\
\hline 63:8 & 169:22,24 & 140:2 & 180:1 & 232:8 \\
\hline check 41:12 & choice 66:9 & 156:1,17 & 192:15 & colleague \\
\hline 70:9 & Chris 246:22 & 157:2,12 & 194:11 & 177:7 \\
\hline 114:19 & 246:24 & 158:16,19 & clearance & 182:18 \\
\hline 121:15,20 & Christopher & 159:4,21 & 128:1,2 & 238:11,18 \\
\hline 121:24 & 83:21 & 162:11,21 & 129:2 & colleagues \\
\hline 124:24 & 86:21,22 & 163:18 & cleared & 177:1 \\
\hline 132:16 & 175:12 & 166:22 & 127:7,12 & 214:21 \\
\hline 144:10 & 202:25 & 167:1 & 127:15,19 & 234:19 \\
\hline 177:20 & 203:1 & 169:15,22 & 128:3,9 & collect \\
\hline 178:17,18 & 216:4,11 & 170:9,18 & 135:17,20 & 115:6 \\
\hline 178:22 & 216:11 & 170:18 & clearing & 132:11 \\
\hline 179:1 & 217:5 & 172:20 & 135:22 & collective \\
\hline 182: 4 & 265:18 & 182:21 & clicked & 79:25 \\
\hline 216:22 & circulated & 184:1,2 & 215:20 & colleges \\
\hline 235:16 & 114:6 & 185:20 & Clifton 1:17 & 137:20 \\
\hline 252:6,15 & circulating & 204:1 & close 203:4 & come 32:11 \\
\hline 255:21 & 89:3 & 254:11 & closed & 66:18 \\
\hline check-in & 153:25 & 255:3,4,7 & 100:15 & 72:14 \\
\hline 180:9 & citizens & Claims_Help & closely & 117:21 \\
\hline checked & 71:9,13,19 & 3:15 \({ }^{-}\) & 193:1,11 & 140:11 \\
\hline 123:22 & 71:25 & clarific. & 195:18 & 144:8 \\
\hline 131:9 & 101:19 & 42:15 & closer 78:14 & 183:15 \\
\hline 235:18 & City 6:4 & 81:15 & CMS 142:22 & 195:4 \\
\hline 252:16 & Civil 6:9 & 85:24 & CMU 225:2 & 204:23 \\
\hline checking & 23:24 & 176:10 & CMU/FB & 218:13 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 146:9 & 124:2 & concern 54 : 6 & confirm & 243:1,10 \\
\hline coming 27:18 & 135:14 & 54:13 & 96:25 & 250:4 \\
\hline 128:15 & communic. & 63:24 & 121:3 & 251:21,21 \\
\hline 169:19 & 53:10 & 100:24 & 133:11 & consolidate \\
\hline 190:12 & 54:16 & 244:11 & confirmed & 90:22 \\
\hline 191:3 & 113:19 & concerned & 256:14 & 124:8 \\
\hline 233:10 & 116:10 & 81:7 & 261:18 & consult \\
\hline 244:2 & 121:12 & 153:22 & confirming & 175:7 \\
\hline commended & 123:25 & 154:5 & 156:17 & consulta \\
\hline 144:17 & 135:12 & 207:10,11 & conflicted & 150:15,19 \\
\hline Comment & communities & concerning & 248:20 & consulted \\
\hline 203:12 & 40:17 & 146:15 & confused & 236:3 \\
\hline commented & 46:12 & concerns & 151:2 & consumer \\
\hline 41:17 & community & 89:21 90:6 & 263:9 & 108:2 \\
\hline 255:5 & 34:1 & 255:19 & confusion & 115:19 \\
\hline comments & 103:25 & concluded & 29:6 54:19 & 194:5 \\
\hline 41:6,12,14 & 234:20 & 236:12 & 56:18 58:1 & consumers \\
\hline 41:15,20 & communit & 269:19 & 59:11 76:1 & 134:19 \\
\hline 97:24 98:2 & 3:10 & conclusions & 81:11 & contact \\
\hline 205:8 & companies & 121:3 & 150:23 & 11:18 14:2 \\
\hline 256:24 & 16:5 19:21 & 133:11 & 220:14,15 & 15:18 16:4 \\
\hline Commission & 20:3,16 & concrete & 258:10 & 16:13,15 \\
\hline 270:24 & 24:3 36:5 & 192:10 & Congress & 17:3,4,13 \\
\hline 273:24 & 198:22 & condition & 125:20 & 17:17 \\
\hline common & 208:17 & 10:23 & connect & 18:21 \\
\hline 154:23 & 234:6 & 137:20 & 238:19 & 20:17,21 \\
\hline 182:20 & company & conditions & 239:4 & 20:24 21:1 \\
\hline 183:25 & 17:24,24 & 186:1 & connected & 21:7 35:4 \\
\hline Comms 107:11 & 50:8 104:6 & conduct & 123:15 & 36:8 83:15 \\
\hline communic. & 105:3 & 109:23 & 239:5 & 114:9 \\
\hline 54:19 & 117:17 & conducted & connection & 119:11 \\
\hline 81:13 & compare 44:4 & 131:1 & 102:14 & 198:1 \\
\hline communic. & competitors & confer & consequence & 199:21 \\
\hline 11:9,12 & 267:17 & 256:22,22 & 88:19 & 223:2 \\
\hline 14:8 53:12 & compiles & conference & conserva & 233:2 \\
\hline 56:17 58:3 & 59:2 & 120:1 & 148:21 & 249:2 \\
\hline 59:12 & completed & conferred & consider & 254:15 \\
\hline 75:17 & 216:21 & 118:14 & 77:16 & contacted \\
\hline 81:12 & completely & conferring & 88:14 & 24:2 \\
\hline 148:15 & 164:25 & 118:12 & 220:20 & 232:16 \\
\hline 151:21 & component & 236:1 & considered & contacts \\
\hline 183:5 & 14:10 & 267:20 & 134:20 & 16:9,11 \\
\hline 262:1 & comport & confidence & 155:18 & 17:16 \\
\hline communic. . & 242:18 & 59:9 72:4 & 194:24 & 18:18 20:2 \\
\hline 12:6 13:21 & Compound & 81:1 258:5 & considering & 21:9 60:14 \\
\hline 18:3 20:5 & 106:6 & 263:1,7,21 & 27:18 & 114:24 \\
\hline 237:18 & 193:24 & confident & 99:16 & 242:24 \\
\hline communic... & computer & 232:17 & 169:18,20 & content \\
\hline 114:14,21 & 23:20 & 258:13 & 242:13 & 15:24 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 18:14 & 196:1 & 56:21 57:1 & COPY. docx & 227:6 \\
\hline 29:22 43:7 & 200:5 & 81:24 & 3:23 & 229:2,22 \\
\hline 45:24 46:3 & 201:16 & 82:22 83:2 & coronavirus & 229:23 \\
\hline 46:16 47:8 & 204: 4,13 & 83:3 84:25 & 27:16 & 252:12 \\
\hline 47:13,20 & 217:16 & 87:19 & 190:16 & correspo \\
\hline 47:22 & 230:18 & 89:10 & corporat. & 169:4 \\
\hline 51:25 & 255:6 & 119:18 & 35:18 & Costello \\
\hline 52:24 53:8 & 265:16 & 121:23 & correct 22:1 & 51:5 \\
\hline 65:15,16 & 266:9 & 132:18 & 23:10 28:1 & council \\
\hline 75:18,20 & continue & 133:3 & 33:14 40:4 & 15:22 \\
\hline 87:21 & 85:14 & 143:21,24 & 44:3 45:2 & 253:21 \\
\hline 90:11 & 103:2 & 154:14,16 & 49:17 61:2 & counsel 1:16 \\
\hline 101:15 & 118:19 & 161:2 & 65:9 89:2 & 6:1 7:21 \\
\hline 103:14,21 & 195:19 & 179:15 & 97:1 & 9:1,8 10:5 \\
\hline 105:24 & 235:9 & 187:15 & 121:14,25 & 10:9 21:15 \\
\hline 106:13 & Continued & 209:4,6 & 122:16,18 & 22:5 31:7 \\
\hline 108:2,3,16 & 2:25 3:25 & 250:1 & 124:15,25 & 31:9,9,13 \\
\hline 109:8,9 & 4:24 6:25 & conversa & 125:1 & 84:18 93:5 \\
\hline 113:13 & contractor & 18:15 & 131:23 & 100:13 \\
\hline 115:19 & 83:22 & 36:10 38:5 & 145:15,24 & 102:13,16 \\
\hline 127:22,25 & 86:20 & 38:6 53:10 & 146:19 & 102:18 \\
\hline 128: 4,14 & 217:6 & 54:17 & 159:23 & 112:10 \\
\hline 128:17,21 & contractors & 59:24 & 162:25 & 118:10,15 \\
\hline 129:2 & 98:9,19 & 64:12 & 169:9 & 235:24 \\
\hline 131:23 & 99:19 & 72:11 & 170:6 & 236:1,3 \\
\hline 133:23 & 100:22,23 & 83:10 & 178:11 & 256:23 \\
\hline 134:9,10 & 100:25 & 87:15 & 203:11 & counterpart \\
\hline 134:11,13 & 101:1,8,10 & 117:1 & 206:10 & 87:4 \\
\hline 134:14,25 & 101:12 & 143:6 & 220:2,4 & counterp. \\
\hline 157:6 & contribute & 209:9 & 227:6 & 233:20 \\
\hline 164:15 & 103:24 & cooking & 236:12 & countries \\
\hline 175:24 & 157:17,25 & 205:6 & 252:3 & 169:6 \\
\hline 176:11 & 169:25 & coordina. & 257:16,20 & country \\
\hline 183:16 & contributed & 2:9 71:2 & 259:7,24 & 123:1 \\
\hline 189:23 & 104:3 & coordinator & 266:23 & COUNTY 270:3 \\
\hline 190:7,13 & control 1:17 & 35:9 & 273:9,13 & 273:3 \\
\hline 191:16 & 6:15 7:6 & copied 208:2 & correcting & couple 83:19 \\
\hline 197:6 & 7:12 88:12 & 208:3 & 194:7 & 84:1 \\
\hline 201:1 & controlled & 216:9,10 & correction & 151:21 \\
\hline 212:6 & 34:10 & 216:11 & 21:24 & 173:3 \\
\hline 222:2 & 36:25 & 248:5 & corrections & 198:19 \\
\hline 228:10 & convene & copies & 271:13 & 226:25 \\
\hline 229:11 & 15:21 & 256:19 & correctly & 243:7 \\
\hline 234:19 & conversa. & 268:10 & 55:16 & 266:4 \\
\hline 244:24 & 4:13,15 & 271:10 & 83:23 & course 10:4 \\
\hline context & 9:18 37:5 & copy 7:22 & 122:9 & 123:2 \\
\hline 39:24 & 38:15 & 124:10 & 163:12 & 152:11 \\
\hline 126:22 & 51:11,15 & 269:2,9,11 & 198:8 & 210:24 \\
\hline 188:24 & 51:23 & 271:13 & 211:3 & 262:13 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 284 of 334 PageID \#: 11228
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline court 1:1 & 161:14 & 127:10 & 148:14 & 141:10 \\
\hline 6:3 7:20 & 162:3,12 & 128:7 & 210:13 & 142:2,12 \\
\hline 8:6 9:3,16 & 162:12 & 137:2 & created 13:3 & 145:6,14 \\
\hline 256:18 & 164:6 & 139:13,17 & 61:5 73:25 & 146:15,17 \\
\hline 268:25 & 169:15 & 141:10 & 148:8,11 & 146:23 \\
\hline 270:4 & 173:25 & 145:6 & 221:13 & 147:1,4,5 \\
\hline courtesy & 174:20 & 149:18 & creating & 147:10,13 \\
\hline 52:1 & 175:4,7,8 & 157:3,6 & 48:16 & 148:8,12 \\
\hline CoV-2 112:17 & 183:14 & 163:25 & 95:14 & 148:19,25 \\
\hline cover 234:20 & 195:1 & 164:7 & 263:6 & 149:2 \\
\hline 235:13 & 197:9 & 167:25 & credible & 154:15,24 \\
\hline coverage & 198:19,23 & 168:3 & 89:1,5 & 230:1 \\
\hline 76:16 & 201:4 & 169:1,3,19 & 90:12 & 262:14,20 \\
\hline covered & 205:20 & 169:21 & 140:1 & CRR 1:20 \\
\hline 93:21 & 206:16 & 170:15 & 181:25 & cues 9:17 \\
\hline 94:19 & 208:9,17 & 176:17 & 266:16,21 & cures 197:9 \\
\hline covering & 222:1,2 & 188:3 & 267:3 & 201:5,15 \\
\hline 187:23 & 223:12 & 221:20 & criteria & 203:18 \\
\hline 188: 6 & 224:22 & 224:12 & 89:14,15 & current 11: 4 \\
\hline COVID 4:11 & 231:5,9 & 229:20 & Cross-Ex. & 15:10,12 \\
\hline 5:1,10 & 232:19 & 234:17,21 & 2:4 & 16:1 18:23 \\
\hline 16:14,15 & 239:2 & 247:12 & crosstalk & 18:24 \\
\hline 16:16,17 & 241:21 & 256:1,3 & 178:6 & 168:2 \\
\hline 16:19 17:3 & 242:5,10 & 258:16 & Crowd 60:7 & 170:14 \\
\hline 17:10 18:2 & 245:14 & COVID-HUB & CrowdTangle & 262:14 \\
\hline 18:12 & 247:21 & 221:19,23 & 2:17,19 & currently \\
\hline 22:14 & 255:4 & 221:24 & 3:16,19 & 15:5 \\
\hline 25:12 & 256:6 & 222:4 & 49:13,25 & cut 76:10,14 \\
\hline 29:15 & 261:25 & COVID_19 & 50:1,20 & 82:1,13 \\
\hline 32:15 & 266:17 & 5:12 & 51:2,3,24 & 190:15 \\
\hline 42:23 & COVID's & crafting & 51:25 52:7 & 191:17 \\
\hline 46:11 & 256:5 & 103:21 & 52:22 & cut-and- \\
\hline 48:10,22 & COVID-19 & Crawford & 59:17,19 & 240:9 \\
\hline 49:13 & 2:11,18,20 & 1:13 2:3,7 & 59:21 & CV19 3:2 \\
\hline 51:25 & 3:9,17,20 & 8:4 9:5,12 & 60:15 & 91:9,12 \\
\hline 52:23 53:2 & 33:12 48:3 & 11:3 22:24 & 62:16 & Cynthia \\
\hline 57:25 & 51:3 60:7 & 34:5 & 63:16 & 107:11 \\
\hline 71:13 89:4 & 63:21 & 102:24 & 64:18 & 115:10 \\
\hline 92:9 & 91:13,17 & 141:17 & 66:12 & 116:23 \\
\hline 105:24 & 95:14 & 150:8 & 71:21 & 120:2 \\
\hline 110:5,10 & 98:14 & 247:16 & 75:24 & 133:22 \\
\hline 110:12 & 99:19 & 257:6 & 76:16 77:5 & 182:18,21 \\
\hline 111:5 & 108:21 & 270:7 & 77:7,10,11 & 183:1,2 \\
\hline 113:9 & 111:13,19 & 271:11 & 77:14 & 188:3 \\
\hline 121:4 & 119:15 & 272:1 & 78:16,24 & cytokine \\
\hline 128:2 & 120:13 & 273:5,20 & 79:7,8,11 & 122:4 \\
\hline 148:19 & 122:2 & create 73:22 & 83:17 & \\
\hline 157:3 & 124:14 & 110:1 & 91:22 & D \\
\hline 160:23 & 126:22 & 147:17 & 97:11 & D 6:2 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline daily 164:10 & 237:5 & 167:5 & deck 73:20 & 120:2 \\
\hline dark 62:5 & 239:19 & 168:1,21 & 76:5 & 133:22 \\
\hline data 71:18 & 241:19 & 169:2 & 149:19 & demonstr. \\
\hline 71:23 72:1 & 242:3 & debunk & 153:9 & 50:2 \\
\hline \(72: 275: 12\) & 246:4 & 122:17 & 210:17 & Dempsey \\
\hline 75:23 & 247:11 & 129:2,12 & decks 265:18 & 24:15 27:1 \\
\hline 80:13 81:2 & 249:17 & 129:14,15 & 265:22 & 45:15,16 \\
\hline 81:10 & 250:6,16 & 131:1,8 & Declaration & 45:19, 20 \\
\hline 150:23,24 & 254:10 & 132:1,5 & 264:6 & 57:3 \\
\hline 150:25 & 257:8 & debunked & declare & department \\
\hline 186:13 & 272:4 & 124:25 & 273:12 & 6:19 7:1,2 \\
\hline 201:15 & dated 61:18 & 125:2 & deemed 212:9 & 7:8 8:18 \\
\hline 204:3,12 & 63:1 & 127:11 & Defects & \(8: 23\) 25:11 \\
\hline 221:21,21 & dates 49:18 & 130:9,12 & 223:17 & 25:16 \\
\hline 224:25 & 132:2 & 131:22 & defend 10:6 & 237:12 \\
\hline 225:3 & day 28: 4 & 132:25 & defendant & 238:20 \\
\hline 260:7 & 32:22 & 134:7,20 & 9:2 & 271:5 \\
\hline 263:8,10 & 47:10 & 134:24 & defendants & depending \\
\hline date 8:2 & 77:18 & 135:3,10 & 1:11 8:19 & 17:5,23 \\
\hline 84:19 & 230:4 & 135:11 & 8:19,24 & 181:14,18 \\
\hline 85:10,13 & 270:16 & 137:5 & 9:2 31:6 & 244:23 \\
\hline 111:10 & 273:14 & 138:13,17 & defending & deploy \\
\hline 118:18 & days 27:18 & 157:21 & 10:5 & 223:10 \\
\hline 126:11 & 164:11 & 171:2 & defense & deployed \\
\hline 131:18 & 173:3 & debunking & 102:13 & 61:15 \\
\hline 135:9 & 238:1 & 3:15 & 268:3 & 107:20,21 \\
\hline 138:25 & 253:16 & 119:15 & definitely & 123:23 \\
\hline 139:2 & 271:17 & 124:14 & 109:22 & 223:4 \\
\hline 141:9 & DC 6:12, 21 & 126:23 & 121:19 & deposed 9:13 \\
\hline 145:4 & 7:3 271:6 & 139:1 & 159:20 & deposition \\
\hline 150:13 & deal 87:9 & 140:17 & 183:6 & 1:13 2:7 \\
\hline 152:20 & 207:22 & December & 216:10 & \(5: 23\) 8:3,7 \\
\hline 155:24 & 239:10 & 189:7,12 & 222:19 & 21:18 \\
\hline 163:16 & dealing & 190:5 & 226:20 & 26:23 \\
\hline 166:5 & 10:18 & 195:11,23 & 229:14 & 31:10,14 \\
\hline 171:18 & 83:17 & decide 89:7 & 256:2 & 93:9 94:17 \\
\hline 173:23 & dealt \(256: 13\) & 89:10 & definition & 118:3 \\
\hline 179:12 & Dear 271:9 & 102:4 & 203:17 & 152:12 \\
\hline 187:12 & death 168:4 & 135:13 & degrees 12:9 & 270:6,8,9 \\
\hline 189:5 & 168:12 & decided & DEKALB 270:3 & 271:10 \\
\hline 196:19 & 169:2,5 & 57:18 74:4 & delay 28:7 & 273:6,8,11 \\
\hline 200:18 & 170:16 & 238:4 & delete 75:15 & depth 175:1 \\
\hline 205:14 & 185:24 & decides & 157:9 & DeSalvo \\
\hline 208:20 & deaths 53:23 & 229:4 & deleting & 193:6 \\
\hline 219:22 & 58:7 62:7 & Deciding & 75:17 & describe \\
\hline 221:6 & 76:16 & 143:12 & demand & 249:25 \\
\hline 226:7 & 82:18 & decisions & 194:25 & described \\
\hline 229:5 & 140:8 & 89:2 & Demi 108:1 & 47:5 59:6 \\
\hline 232:25 & 146:2 & 211:18 & 115:11 & 59:21,25 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 96:13 & 42:13 & 15:11,14 & 100:15 & 203:5 \\
\hline 130:22 & 56:17 & 32:16,17 & 236:6,7,19 & 204:5 \\
\hline 142:6,11 & development & 43:3,4 & discuss & 208:4,15 \\
\hline 189:19 & 11:17 & 83:24 87:2 & 66:11 74:2 & 208:19 \\
\hline 212:3 & 105:14,15 & 233:21 & 76:4 77:24 & 213:15,19 \\
\hline describes & 108:2,3 & 243:25 & 80:1 84:6 & 222:10 \\
\hline 103:17 & 115:20 & 247:19 & 84:9 95:11 & 223:6 \\
\hline describing & device 35:24 & 249:3 & 105:7,13 & 225:22 \\
\hline 55:16 & devices & dir-120:22 & 105:15 & 240:6 \\
\hline 155:15 & 213:24 & direct 18:17 & 170:3 & 244:10 \\
\hline description & differed & 19:12,14 & 175:1 & 263:20,22 \\
\hline 2:5,6 50:3 & 17:22 & 63:13 & 180:10 & discussing \\
\hline 95:23 & 140:12 & 93:22 & 182:23 & 37:14 \\
\hline 130:18 & difference & 165:13 & 184:7,24 & 58:10,12 \\
\hline design 11:19 & 220:7 & 166:11 & 228:24 & 64:17 \\
\hline 233:12,16 & differences & 182: 6 & 233:14 & 79:24 \\
\hline 233:17 & 17:15 & 205:13 & 253:10 & 82:25 83:5 \\
\hline design/c. & different & 234:5 & 258:19 & 105:9,12 \\
\hline 27:21 & 23:14 & 238:16 & 260:17 & 119:25 \\
\hline designer & 44:21 & 242:15 & 263:13 & 130:21 \\
\hline 40:14 & 47:21 65:3 & 250:13 & discussed & 148:18 \\
\hline desired & 77:9 78:24 & directed & 19:22 30:8 & 151:7 \\
\hline 271:14 & 79:8 & 80:19 & 38:8,10 & 180:12 \\
\hline detail 32:13 & 107:17 & 199:4,10 & 53:11 & 184:15 \\
\hline 73:14 & 120:11 & 199:19 & 57:25 58:4 & 204:13,24 \\
\hline 133:20 & 129:24 & directly & 59:10 & 212:24 \\
\hline detailed & 141:3 & 19:17 74:9 & 60:13 & 230:19 \\
\hline 51:24 & 142:5 & 77:10 & 62:17 72:7 & discussion \\
\hline 169:4 & 147:10,20 & 101:12 & 77:20 & 49:12 \\
\hline details & 147:24 & 113:20 & 78:11 & 52:11 \\
\hline 110:2 & 149:16 & 123:25 & 81:10 83:9 & 58:15 59:3 \\
\hline 149:5 & 172:6 & 124:5,9 & 83:13 & 133:12,13 \\
\hline 150:20 & 175:17 & 129:5 & 116:5,25 & 151:2 \\
\hline 153:15 & 187: 6 & 130:21 & 117:7 & 182:18,25 \\
\hline 224:24 & 198:9 & 147:11,12 & 130:16 & 184:9,11 \\
\hline determine & 204:8,11 & 238:19 & 133:2,10 & 185:8 \\
\hline 11:22 & 220:5 & 251:16 & 135:23 & 206:21 \\
\hline 110:24 & 259:1 & director & 138:19 & 260:16 \\
\hline 161:21 & difficult & 11:7,9,12 & 141:1 & discussions \\
\hline 170:20 & 97:6 173:4 & 11:21 & 142:2 & 18:8 64:19 \\
\hline determined & difficulty & 18:25 19:8 & 145:13 & 132:15,16 \\
\hline 114:13 & 42:9 & \(32: 783: 24\) & 147:2 & 213:16 \\
\hline determining & digital 11:8 & 87:2 & 148:4,14 & 244:20 \\
\hline 89:14 & 12:6,25 & 107:11 & 150:22 & 261:19 \\
\hline develop 59:5 & 13:19,24 & 120:19 & 151:14,17 & disease 1:17 \\
\hline 109:9 & 13:25 & 183:5 & 174:17 & 6:15 7:6 \\
\hline developed & 14:12,14 & disclosure & 181:24 & 7:12 \\
\hline 57:19 71:8 & 14:17,20 & 7:21 & 185:20 & 190:17 \\
\hline developing & 14:24 15:3 & discovery & 198:18 & Diseases \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 107:14 & 161:17 & doses 255:13 & 147:2 & 76:6 140:7 \\
\hline 160:22 & 162:17 & Double 62:10 & 149:11 & 164:8,10 \\
\hline display & 163:2 & doubt 56:22 & 157:20 & 164:12 \\
\hline 188:22 & 165:2,12 & 108:25 & 180:14 & effort 35:11 \\
\hline distributed & 165:16 & Dr 6:6,6,6 & 198:6 & 40:16 \\
\hline 212:16 & 167:24 & 125:20 & 203:5 & 177:2,8 \\
\hline distribu. & 168:14 & draft 15:24 & 204:5,14 & 180:2 \\
\hline 52:19 & 169:13 & drafted & 208:4 & efforts 2:11 \\
\hline 58:17 & 206:18 & 210:17,18 & 210:18 & 15:16 \\
\hline 61:14 & 238:14 & 246:20 & 224:11 & 27:15 \\
\hline 62:22 & 249:23 & drafts 41:17 & 229:9 & 33:12 34:1 \\
\hline District 1:1 & documents & dragged & 233:22 & eight 111:12 \\
\hline 1:1 8:5,6 & 32:23 & 151:12 & 236:14 & Eisman \\
\hline distro 52:18 & 47:19 & drawing & early 17:10 & 222:22 \\
\hline 61:12 & 92:22 & 176:4 & 19:21 20:1 & either 43:4 \\
\hline division 1:2 & 93:10 & driven 146:2 & 22:15 & 61:6 65:21 \\
\hline 11:7,8,14 & 94:11 & drop 219:5 & 147:13 & 104:22 \\
\hline 12:19,23 & 99:18 & drop-down & 192:6 & 113:15 \\
\hline 12:25 13:8 & 117:5 & 186:18 & 197:12 & 125:10 \\
\hline 13:8,10,14 & 132:7 & drop-downs & 253:11 & 136:19 \\
\hline 13:17,18 & 236:7 & 215:21 & 260:18 & 147:7 \\
\hline 13:19,25 & doing 9:19 & due 84:8 & easier 18:12 & 149:1 \\
\hline 14:4,20,24 & 14:2 29:15 & duly 9:6 & 23:21 & 176:19 \\
\hline 15:4,5,11 & 38:14 & 270:9 & 27:22 & 181:2 \\
\hline 15:14 19:8 & 57:21 & duties 11:13 & 129:8 & 197:21 \\
\hline 19:9 29:21 & 100:23 & 15:13 & 167:6 & 230:22 \\
\hline 32:7,18 & 116:9 & 32:10 & easiest & 241:3 \\
\hline divisions & 142:5 & 101:14,17 & 170:3 & elderly 3:10 \\
\hline 14:1 & 144:11 & duty 15:10 & EAU 4:3,5 & electronic \\
\hline doc 225:20 & 158:14 & dysfunction & 163:19 & 20:5,6 \\
\hline doctors & 162:20 & 128:8 & edit 42:2 & 30:17 \\
\hline 122:25 & 174:22 & & editing & 56:24 \\
\hline document 3:9 & 178:21 & E & 47:12,19 & electron. \\
\hline 21:16 & 182:7 & E 5:9 45:4 & 47:20 & 136:21 \\
\hline 25:23 33:8 & 200:3 & 171:22 & education & element \\
\hline 41:22 & 210:3 & 239:20 & 11:25 & 157:25 \\
\hline 47:15 49:7 & 224:22,23 & 270:1,1 & educational & else's 206:5 \\
\hline 54:9 67:20 & 232:13 & e.g 157:3 & 52:25 & email 4:1 \\
\hline 76:23 & 239:6 & 162:12 & Edwards & 5:2,10,15 \\
\hline 78:18 86:6 & 244:6 & earlier 24 : 6 & 265:9 & 18:3 20:5 \\
\hline 91: 4,6 & 248:24 & 60:23 & effect 38:12 & 22:14,18 \\
\hline 94:9 96:1 & 258:5,20 & 92:23 93:8 & 139:16,17 & 23:2,3,7 \\
\hline 99:23 & 265:4,16 & 109:16 & 231:8 & 23:12,13 \\
\hline 100:14 & 268:20 & 116:25 & effective & 23:15,21 \\
\hline 143:17 & domain 18:14 & 120:10 & 255:14 & 24:3,12,19 \\
\hline 145:9 & 29:22 & 125:9 & effectively & 25:3,18 \\
\hline 146:12 & Door-to- & 132:15 & 54:20 & 27:11 \\
\hline 152:15 & 144:20 & 133:2 & effects 54:1 & 28:21,23 \\
\hline 158: 6, 23 & dosage 255:8 & 142:7 & 58:8 65:5 & 30:17 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 33:11 34:6 & 201:24 & emergency & 77:23 78:1 & errata \\
\hline 34:6 35:12 & 202:8 & 42:8,19 & 78:8 & 271:12,14 \\
\hline 35:15,20 & 204:22 & 59:2 & 110:12 & 271:16 \\
\hline 39:2,8 & 213:10 & 137:10,12 & 197:20 & 272:1 \\
\hline 40:3,7,8 & 216:4,8,12 & 156:25 & 243:4 & especially \\
\hline 43:20 & 216:20 & 160:1 & engine & 32:15 55:5 \\
\hline 44:19,21 & 218:1 & 169:18 & 193:22 & Esq 6:2, 8, 17 \\
\hline 44:23 45:1 & 219:9 & emphasis & 194:11,13 & 6:18 7:2,5 \\
\hline 50:14 51:1 & 220:7 & 3:10 & 194:13 & 7:6,7,11 \\
\hline 51:12,18 & 225:19 & employed & engines & 271:4 \\
\hline 57:20 58:4 & 226:15 & 137:19 & 194:3 & establish \\
\hline 60:6 62:3 & 230:15 & employee & English & 242:9 \\
\hline 63:1 68:3 & 238:8,22 & 13:21 14:8 & 163:8 & 245:14 \\
\hline 68:11 & 241:12 & 222:8 & enroll & established \\
\hline 72:21,22 & 243:17 & employees & 211:21 & 77:7 \\
\hline 72:22 73:4 & 244:15 & 97:19 98:8 & 214:4,9 & 257:19 \\
\hline 73:25 75:8 & 248:3,22 & 98:18 & 215:1 & et 1: 4,10 \\
\hline 75:10 & 250:16,18 & employers & enrolled & 197:10 \\
\hline 77:19 85:3 & 250:25 & 137:20 & 216:20,23 & 201:5 \\
\hline 85:11,13 & 254:2 & employment & 218:2 & 271:7,8 \\
\hline 85:15 & 257:14 & 11:4 12:1 & enrollment & 272:2,3 \\
\hline 91:20 & 261:10 & 137:21 & 137:21 & EUA 137:6,9 \\
\hline 92:24 & emailed & 138:3 & 138:3 & 156:2,21 \\
\hline 96:20,20 & 173:14 & enabled 71:8 & ensure 33:17 & 167:3 \\
\hline 98:16 & 253:2 & enclosed & 33:18 & European's \\
\hline 114:1 & emails 2:8 & 271:10,11 & 237:20 & 164:21 \\
\hline 119:3,6,9 & 2:10,12,15 & Enclosures & enter 219:3 & Eva 239:8 \\
\hline 119:14 & 2:17,19,22 & 271:25 & 219:4 & evaluate \\
\hline 120:23 & 3:1,2,4,11 & ends 124:18 & entered 71:3 & 220:23 \\
\hline 121:2,2,25 & 3:13,14,16 & 206:1 & enters 26:22 & event 10:21 \\
\hline 123:19,21 & 3:19,22 & 263:14,15 & entire 15:17 & 34:15 \\
\hline 125:9 & 4:2,5,8,10 & enforce & entity 89:20 & 123:10 \\
\hline 126:21 & 4:11,13,15 & 104:23 & environment & 125:24 \\
\hline 137:1 & 4:17,18,20 & enforcement & 148:15 & 136:25 \\
\hline 146:10 & 5:1,4,5,7 & 95:25 & envision & events \\
\hline 150:15 & 5:8,12,14 & 105:8,14 & 177:4 & 122:23 \\
\hline 153: 4, 6 & 5:17 21:3 & 105:16 & epidemio... & 123:1 \\
\hline 159:11,19 & 32:6 61:17 & engage 74:2 & 12:16 & eventually \\
\hline 160:8 & 67:22 79:6 & 74:4 77:16 & equating & 30:1 \\
\hline 161:25 & 79:20 83:3 & 184:15,24 & 137:6 & every-ot. \\
\hline 163:4 & 83:6 97:1 & 185:11 & equity & 180:8 \\
\hline 166:12 & 97:6 99:11 & 234:6 & 230:11,17 & everybody \\
\hline 167:22 & 103:13 & engaged & 230:21 & 136:17 \\
\hline 172:3,21 & 134:4 & 52:23 & erectile & 241:15 \\
\hline 174:4 & 161:2 & 175:24 & 128:8 & 268:11 \\
\hline 178:22 & 203:6 & engagement & Eric 1:3 & evidence \\
\hline 189:11 & 236:11,18 & 53:16 & 265:8 & 79:2 96:4 \\
\hline 197:21 & 248:6 & 78:11,14 & 271:7 & 108:22 \\
\hline 200:6,24 & 254:21 & engaging & 272:2 & 110:8 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 120:14 & 204:21,22 & 100:19 & 199:3 & experiment \\
\hline 137:23 & 209:8 & 102:22,25 & 200:15,17 & 131:1 \\
\hline 138:6 & 210:20 & 112:5,5,15 & 200:19 & 132:4 \\
\hline 142:25 & 265:24 & 112:19 & 205:17,18 & 137:8 \\
\hline 146:7 & exchange & 113:3,6 & 205:19 & experiments \\
\hline evidence. & 16:14 40:3 & 114:22 & 206:14 & 137:3 \\
\hline 255:3 & 145:17 & 115:8 & 211:6 & expert 50:21 \\
\hline evolving & 146:10,22 & 118:5,7,9 & 219:19,21 & 108:18 \\
\hline 103:18 & 189:11 & 118:20,22 & 221:3,5,6 & 109:8,22 \\
\hline ex 1:3 271:7 & 197:15 & 119:4 & 226:4,7 & 123:5 \\
\hline 272:2 & excuse 16:22 & 120:1 & 237:2,4 & 129:21 \\
\hline exact 80:20 & 167:11 & 121:11 & 239:13,16 & 133:18 \\
\hline 200:5 & 172:12 & 125:8 & 241:17,19 & 134:2 \\
\hline 246:3 & 199:10 & 126:8,12 & 243:7 & 146:4,8 \\
\hline exactly & 221:22 & 126:14 & 247:7,9 & 183:19 \\
\hline 31:18 & 238:9 & 131:13 & 248:12 & 214:15 \\
\hline 88:15 & 240:18 & 133:8 & 249:7,9 & 222:20 \\
\hline 135:17 & excuses & 135:1,4 & 254:4,8 & 252:2 \\
\hline 216:1 & 247:4 & 136:6,10 & 256:19 & expertise \\
\hline 238:25 & Executed & 136:11 & 257:4,7,14 & 32:20 \\
\hline Examination & 273:14 & 138:19,23 & 258:4 & 137:14 \\
\hline 2:2 9:10 & exhibit 2:6 & 138:24 & 269:6 & 138:8 \\
\hline EXAMINAT & 2:7,8,10 & 141:6,7,9 & exhibits 2:5 & 140:14 \\
\hline 2:1 & 2:12,15,17 & 141:19 & 5:21 118:1 & 143:5 \\
\hline examine & 2:19,22 & 144:13 & 125:18 & 164:25 \\
\hline 197:6 & 3:1,2,4,6 & 145:1,4 & 140:19 & 259:2 \\
\hline 201:2 & 3:7,9,11 & 149:22,23 & 183: 4 & experts \\
\hline examined 9:6 & 3:13,14,16 & 150:6,9 & 184:4 & 108:8 \\
\hline example & 3:19,22 & 152:16,22 & 268:22,23 & 113:24 \\
\hline 15:21 & 4:1,2,5,7 & 155:7,9,10 & 268:25 & 114:24 \\
\hline 64:21 & 4:8,10,11 & 155:22 & exist 13:15 & 115:7 \\
\hline 79:12 & 4:13,15,17 & 163:13,15 & 48:19 & 121:12,18 \\
\hline 149:19 & 4:18, 20 & 163:23 & 126:4 & 123:20,20 \\
\hline 207:15,24 & 5:1,2,4,5 & 164:17,19 & 227:17 & 124:22 \\
\hline 217:22 & 5:7,8,10 & 165:25 & existed 12:7 & 130:11,17 \\
\hline 265:3 & \(5: 12,14,15\) & 166:1,2,6 & existing & 132:17 \\
\hline 266:4 & 5:17 21:12 & 171:15,20 & 169:20 & 150:19 \\
\hline examples & 21:14 22:5 & 171:21,25 & 174:25 & 151:9,19 \\
\hline 90:22,22 & 22:8 30:22 & 173:9,20 & expect & 151:20,21 \\
\hline 149:7 & 32:1 33:2 & 173:23 & 155:13 & 152:8 \\
\hline 182:2 & 33:4 38:18 & 179:9,11 & 192:2 & 182:22 \\
\hline 197:5,7,8 & 38:20 & 182:12 & expectation & 184:20 \\
\hline 199:11 & 43:10 44:1 & 183:3 & 88:3 & Expires \\
\hline 200:1,11 & 44:2 49:1 & 187:9,11 & expected & 270:25 \\
\hline 200:20 & 49:4,5 & 187:18 & 34:16 & 273:24 \\
\hline 201:1,2,4 & 60:3 62:2 & 188:25 & expecting & explain \\
\hline 201:12,14 & 67: 4, 12,14 & 189:2,4 & 248:19 & 251:16 \\
\hline 201:24 & 85:5,6 & 196:15,17 & expedited & explained \\
\hline 202:12 & 91:1,7,8 & 196:18 & 214:10 & 78:25 79:7 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 210:16 & 55:10,14 & 222:8,12 & 53:14 & 61:18 \\
\hline explaining & 57:6 58:12 & 222:13,19 & false 106:11 & 63:17 \\
\hline 148:16 & 60:11 & 222:20,21 & 108:21 & 166:8,15 \\
\hline explains & 61:22 & 223:21 & 116:8 & 167:8 \\
\hline 195:14 & 62:18 63:3 & 224:5,15 & 117:18 & 171:23 \\
\hline 248:14 & 63:5 64:11 & 224:21 & 120:13 & 172:10 \\
\hline explanat. & 71:2 73:22 & 226:19 & 139:11,25 & federal 92:2 \\
\hline 130:16 & 74:8,10 & 231:13 & 157:2,16 & 95:19 \\
\hline explanatory & 77:25 & 232:15 & 158:20 & 193:1,10 \\
\hline 130:13 & 78:22 & 237:14 & 159:5,12 & 232:5,18 \\
\hline explore & 79:19 80:8 & 240:2 & 159:21 & feed 54:25 \\
\hline 144:6 & 80:14 82:9 & 242:5 & 162:11 & 227:5 \\
\hline expressed & 82:10 83:4 & 245:22 & 164:2,6,24 & 228:10 \\
\hline 101:19 & 83:7,18 & 249:2 & 168:5 & feedback \\
\hline extension & 86:4 87:14 & 259:22,23 & 169:24 & 27:17 \\
\hline 200:21 & 87:16 88:3 & 261:7 & 170:12 & 106:10 \\
\hline extent 93:18 & 88:20,24 & 263:2 & 255:5 & 161:10 \\
\hline externally & 89:16,22 & Facebook's & familiar & feeds 88:13 \\
\hline 65:18 & 90:7,19 & 2:10 46:19 & 85:22 & 212:16 \\
\hline extreme & 91:23 & 103:11,12 & 200:12 & feel 32:24 \\
\hline 42:18 & 95:18,20 & 139:7 & 206:19 & 95:22 \\
\hline extremely & 98:20,24 & 151:22 & FAQ 109:5 & 132:8 \\
\hline 19:24 & 99:2,7,8 & fact 115:22 & 129:4,10 & 146:9 \\
\hline & 103:14,22 & 134:16 & 134:14 & 149:16 \\
\hline F & 103:25 & 168:10 & far 22:23 & 151:11 \\
\hline F 270:1 & 104:2,23 & 175:11 & 65:8 204:3 & 188:16 \\
\hline Face-180:12 & 112:21 & 210:17 & 246:10 & 203:9 \\
\hline Facebook 5:4 & 113:11 & facts 58:2 & fashion & 247:22 \\
\hline 16:5 18:11 & 114:8 & 79:1 94:7 & 171:11 & 249:10 \\
\hline 20:24 & 117:1,16 & 96:3 110:7 & fast 81:8 & 258:13 \\
\hline 22:14 & 119:8,11 & 137:22 & faster 28:9 & feels 206:19 \\
\hline 24:13,19 & 124:5 & 138:6 & fatality 3:9 & fellow 24 : 6 \\
\hline 25:10,12 & 132:9,14 & 142:24 & FB 2:8 3:14 & felt 88:16 \\
\hline 27:13 & 135:2,11 & 153:10,24 & 139:1 & 161:20 \\
\hline 29:17 & 135:14 & 154:4 & 221:19 & 215:21 \\
\hline 33:12 & 138:12 & 158:16 & 225:3 & 217:3 \\
\hline 34:15,23 & 144:9 & 159:10,10 & FDA 137:11 & female 26:11 \\
\hline 36:16,17 & 148:2,18 & 160:9 & 156:24 & 28:11 \\
\hline 36:25 37:6 & 149:14 & 220:13,17 & 159:25 & filing \\
\hline 37:11 & 150:16 & 264:3 & 167:2 & 271:18 \\
\hline 40:14 & 151:9 & fade 10:10 & 169:17 & final 35:20 \\
\hline 42:18 & 153:1 & fair 38:20 & 201:15 & 135:10 \\
\hline 44:18 & 154:7 & 119:19 & 203:21 & 253:14 \\
\hline 46:12 & 155:14 & 130:2 & 204:2 & finally \\
\hline 48:16,17 & 156:5 & 132:9 & feature & 134:6 \\
\hline 48:19 & 164:24 & fairly & 157:5 & 245:7 \\
\hline 49:13 50:6 & 179:4 & 232:17 & February & 265:11 \\
\hline 50:18 & 181:3 & fall 38:8 & 16:19 18:5 & find 18:12 \\
\hline 54:23 & 221:25 & falling & 22:15 60:9 & 70:21 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 171:4 & 178:17,20 & flagging & 182:15 & forward \\
\hline 189:22 & 179:1 & 86:3 87:13 & 193:20 & 35:17 46:1 \\
\hline 219:11 & 197:23 & 88:1,21,24 & follows 9:7 & 49:15 \\
\hline 231:9,10 & 207:2 & 90:6 & followup & 59:15 \\
\hline 271:10 & 208:11,18 & 101:18 & 4:13,15 & 197:4 \\
\hline finders & 208:23 & 105:24 & 30:15 & 200:25 \\
\hline 234:16 & 213:2 & 106:1,4,9 & 51:18 & 247:22 \\
\hline finding & 222:17 & 106:17 & 119:16 & forwarded \\
\hline 72:15 & 230:16 & 264:2 & 179:14 & 31:8 41:18 \\
\hline 149:10 & 235:24 & flags 212:13 & 197:21 & 61: 6, 6 \\
\hline fine 82:15 & 242:12,14 & flipped & 234:17 & 62:23 \\
\hline 93:14 & 242:17,20 & 149:3 & 263:25 & 102:16 \\
\hline 96:19 & 245:16 & floor 98:7 & football & forwarding \\
\hline 102:21 & 246:5 & flow 214:10 & 28:16 & 44:22 61:7 \\
\hline 165:9 & 247:14 & flu 29:13,15 & Forbes 53:19 & forwards \\
\hline 198:11 & 257:14 & 29:19,19 & force 42:5,5 & 216:5 \\
\hline finish 65:23 & 266:13 & 29:20 & Ford 7:5 & Foster 7:11 \\
\hline finished & first-54:1 & focus 256:5 & foregoing & found 266:21 \\
\hline 67:15 & fit 47:23 & focuses 45:9 & 270:6 & 266:23 \\
\hline finishing & five 32:8 & focusing & 273:6,13 & 267:4 \\
\hline 256:23 & 167:3 & 32:16 & foreign & foundation \\
\hline first 9:6 & 169:16,19 & 256:6 & 140:12 & 112:23 \\
\hline 17:21,22 & 171:22 & folks 39:6 & forget 268:7 & four 201:12 \\
\hline 18:2,9 & 238:1 & 41:17 & forgive 21:1 & frame 132:3 \\
\hline 22:22 & five-minute & 107:9 & forgotten & 262:20 \\
\hline 25:20 & 30:20 & 108:16 & 222:11 & fraud 197: 8 \\
\hline 33:11 39:7 & 205:3 & 125:17 & form 171:11 & 200:2 \\
\hline 45:25 & fix 102:3 & 245:11 & 273:7 & 201:4 \\
\hline 49:20,24 & 194:12 & 252:8,14 & format 47:21 & fraudulent \\
\hline 51:25 56:1 & flag 87:10 & 253:3 & 63:25 & 197:9,9 \\
\hline 56:8 67:21 & 87:25 & follow 82:15 & 106:25 & 201:4,5,15 \\
\hline 67:23,25 & 89:14 & 121:16 & 182:9 & 203:17 \\
\hline 91:21 & 98:19 99:2 & 126:20 & 184:3 & Fred 181:9 \\
\hline 106:10,24 & 99:7,9,10 & 182:17 & 209:12,13 & 250:10,12 \\
\hline 110:19 & 113:1,12 & 187:14 & 209:14 & 250:25 \\
\hline 120:8 & 206:22 & 188:4 & 210:23 & 251:3,25 \\
\hline 125:7 & 218:23 & 193:23 & 229:16 & 252:9 \\
\hline 133:21 & 226:25 & 210:21 & 240:25 & 254:25 \\
\hline 141:23 & 264:4 & followed & 241:1 & free 32:24 \\
\hline 142:11 & flagged 88:4 & 134:3 & 243:5 & 247:22 \\
\hline 144:12 & 89:23 & following & formatted & frequency \\
\hline 146:20 & 106:3 & 4:3,5 & 207:18 & 180:18 \\
\hline 150:15 & 111:13 & 51:22 & formatting & frequent \\
\hline 151:15 & 112:21 & 53:14 & 248:3 & 2:13,16 \\
\hline 156:8,13 & 113:10 & 56:21 & forms 219:5 & 4:7 39:10 \\
\hline 157:23 & 117:21 & 100:2 & formulate & 43:22 \\
\hline 167:25 & 212:13 & 156:2 & 165:5 & 44:10 \\
\hline 170:13 & 264:5,20 & 163:18 & forth 39:20 & Friday \\
\hline 177:20 & 264:24 & 169:5 & 68:4 270:8 & 177:21 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 292 of 334 PageID \#: 11236
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 185:17 & 53:15 & getting & 121:15 & 46:25 56:8 \\
\hline 208:11 & gas 205:6 & 18:10 & 129:19 & 67:16 \\
\hline 212:24 & Gateway & 20:14 37:6 & 130:6 & 73:20 \\
\hline 213:4 & 264:15 & 90:12 & 132:14 & 74:20 \\
\hline 242:12 & GBS 139:15 & 138:2 & 141:8 & 81:16,25 \\
\hline 245:17 & Genelle & 145:23 & 156:24 & 95:8,21 \\
\hline 246:2 & 85:17 & 147:11 & 159:11 & 97:25 \\
\hline front 32:23 & 96:21 & 159:22,24 & 164:19 & 102:2,3,8 \\
\hline 33:2 & 100:1 & 160:2 & 173:4 & 104:13 \\
\hline 166:17 & 238:8,8 & 164:7 & 187:22 & 114:1 \\
\hline 208:22 & general 1: 4 & 181:25 & 188:5 & 116:14 \\
\hline 245:7 & 1:16 9:1 & 190:3,24 & 204:19 & 118:9 \\
\hline 269:1 & 29:5 38:2 & 204:18 & 210:20,20 & 121:14,16 \\
\hline FTC 137:11 & 38:17 46:6 & Ghosh 7:6 & 214:25 & 126:17 \\
\hline full 52:21 & 46:7 54:15 & Gilligan & 239:15 & 129:15 \\
\hline 74:15 76:1 & 64:19 & 6:17 8:22 & 253:11 & 131:15 \\
\hline 81:11 & 75:13 & 8:22 66:25 & 256:19 & 136:16 \\
\hline 137:7 & 83:10 & 67:3,6,9 & 260:23 & 141:7 \\
\hline fuller & 110:14 & 84:20 & 261:3 & 145:17 \\
\hline 263:12,23 & 117:3 & 85:24 91:6 & 262:16 & 146:20 \\
\hline fully 44:17 & 149:1,1 & 93:19,25 & 263:11,23 & 147:12 \\
\hline 218:15,16 & 169:1 & 94:5,24 & 268:20 & 155:9 \\
\hline fundings & 188:20 & 95:5,9 & given 69:17 & 164:11 \\
\hline 109:25 & 191:19 & 102:5 & 99:18 & 166:12 \\
\hline further & 209:9 & 112:2 & 109:25 & 167:24 \\
\hline 32:22,23 & 217:19 & 118:10,12 & 130:20 & 169:12 \\
\hline 52:13 & 253:12 & 118:20 & 132:3 & 176:9 \\
\hline 126:21 & 271:7 & 133: 4,7 & 137:12 & 179:21,25 \\
\hline 158:20 & 272:2 & 136:18,21 & 270:10 & 182:4 \\
\hline 192:2 & General's & 163:10 & gives 155:1 & 187:2 \\
\hline 228:24 & 6:2 & 165:16,20 & giving 49:13 & 188:21 \\
\hline 268:1,2 & generally & 165:23 & 169:18 & 189:2,10 \\
\hline 270:11 & 16:11 & 206:8 & 241:11 & 199:17 \\
\hline future 80:1 & 17:14,15 & 231:22 & 266:19 & 211:1 \\
\hline 141:25 & 38:11 & 235:25 & glad 173:18 & 212:22 \\
\hline 184:4 & 48:11 & 241:15 & 196:4,6 & 214:22 \\
\hline 211:22 & 56:15 & 249:13 & 247:1 & 221:23 \\
\hline fuzzy 224:23 & 58:11 & 256:21 & global 140:6 & 226:22 \\
\hline FYI 70:6 & 77:19 & 268:23 & globally & 231:7 \\
\hline 229:18 & 89:11 & 269:14 & 157:2 & 241:24 \\
\hline & 96:16 & gist116:15 & 159:21 & 243:15 \\
\hline G & 140:23,25 & give 11:11 & 162:11 & 247:9,14 \\
\hline gain 71:11 & 161:20 & 22:6,6,10 & go 11:24 & 252: 6,23 \\
\hline Gangolly & Gennelle & 23:22 & 13:7,23 & 254:6,6 \\
\hline 50:22, 23 & 86:12 & 30:21 & 18:17 20:4 & 257:13 \\
\hline gaps 54:18 & Georgia 1:18 & 38:22 & 22:22 & 266:10 \\
\hline 56:18 58:1 & 7:20 12:10 & 66:20 & 23:18 31:5 & 268:25 \\
\hline 81:3 & 12:11 & 79:12 91:3 & 31:23 33:3 & goal 33:23 \\
\hline garnered & 270:2,5,24 & 104:8 & 41:21 44:5 & 88:25 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 266:16 & 185:1 & 194:22,23 & grounds & guidance \\
\hline goals 266:20 & 186:20 & 243:22 & 168:5 & 129:7 \\
\hline goes 53:2 & 191:19 & 245:10,22 & group 14:4,7 & 193:20,23 \\
\hline 65:1 106:2 & 192:11 & 245:23 & 14:8,10 & 194:4 \\
\hline 120:16 & 194:18,20 & 250:3,15 & 41:16 45:6 & 195:20 \\
\hline 127:25 & 195:15 & 251:17 & 45:8 48:20 & 196:10 \\
\hline 157:11 & 218:2 & 253:4 & 48:20 & 238:19 \\
\hline 160:4 & 220:7,15 & 254:15 & 55:12,21 & 250:2 \\
\hline 218:22 & 223:5 & Google/Y. & 55:22, 24 & Guidarini \\
\hline going 9:15 & 236:16 & 174:23 & 56:1,3,7 & 239:9 \\
\hline 10:6 17:25 & 245:3 & Googled & 56:11 & guide 228:21 \\
\hline 20:3 22:4 & 251: 6 & 183:13 & 58:21 & 229:4,8 \\
\hline 34:13,16 & 252: 6 & gosh 195:22 & 59:16 61:5 & 230:8 \\
\hline 34:20 37:1 & 257:6 & 224:20 & 104:14 & guidelines \\
\hline 37:1,11 & 268:20 & gotcha & 116:15 & 15:25 65:4 \\
\hline 40:11 47:8 & good 9:12 & 136:23 & 124:1 & guides 5:5 \\
\hline 50:21 51:2 & 19:2 57:14 & gov 229:14 & 156:4 & 226:9 \\
\hline 52:5 58:19 & 75:1 76:12 & governance & 263:6 & 227:1,4,8 \\
\hline 60:14 & 79:13,14 & 15:23 & 269:3 & 227:10,16 \\
\hline 66:19 & 85:24 & government & groups 16:13 & 228:3 \\
\hline 77:16 & 93:14 & 23:13,25 & 18:22 46:3 & 232:11 \\
\hline 79:24 80:3 & 153:24 & 33:19 & 46:13,16 & Guides ' \\
\hline 88:18 & 159:12 & 89:22 90:6 & 52:25 54:2 & 226:16 \\
\hline 90:19 95:7 & 161:11 & 96:22 & 54:22, 22 & guiding \\
\hline 107:8 & 177:20 & 148:22 & 54:23, 24 & 103:15 \\
\hline 108:6 & 178:17 & 233:17 & 55:2,4,5,5 & Guillain. \\
\hline 111:25 & 197:19 & governments & 55:6,7,11 & 139:14 \\
\hline 115:14 & 209:13 & 137:19 & 55:14 61:9 & guy 203:8 \\
\hline 116:14,14 & 220:16 & governor & 96:14 & guys 262:23 \\
\hline 124:24 & 253:6 & 144:23 & 237:13 & H \\
\hline 127:24,25 & 260:25,25 & 264:21,23 & growing & H \\
\hline 138:16 & Goodness & grapevine & 38:13 & habit 28:8 \\
\hline 141:24 & 152:9 & 245:18 & 154:4,11 & HAN 153:13 \\
\hline 147:11 & Google 16:6 & graphic & 154:17 & 153:16 \\
\hline 154:2 & 20:25 & 15:17 & Gruner & hand 21:15 \\
\hline 159:13 & 174:7,12 & graphics & 254:14 & 22:4 \\
\hline 160:16 & 175:16,24 & 11:18 14:2 & guess 43:25 & 111:24 \\
\hline 161:5,6 & 177:2,7 & great 27:24 & 96:12 & 122:6 \\
\hline 164:19 & 179:3,6 & 74:12 87:9 & 126:1 & 148:21 \\
\hline 165:21,22 & 180:7,17 & 207:22 & 141:15 & 270:16 \\
\hline 165:25 & 180:19 & 227:4 & 156:10 & handed 25:21 \\
\hline 166:1 & 181:3,9,11 & 230:9 & 172:18 & 102:24 \\
\hline 169:7 & 183:10,14 & 245:3 & 179:22 & handle 19:25 \\
\hline 172:24 & 183:24 & 264:5 & 187:25 & handled \\
\hline 173:12,12 & 185:9,13 & greatly & 194:16 & 111:4 \\
\hline 173:16 & 189:25 & 27:19 & 238:1 & 140:23,25 \\
\hline 177:9 & 191:5,8,11 & Griffis & 262:25 & hang 72:23 \\
\hline 182: 4 & 193:11,19 & 18:25 & guessing & 73:2 \\
\hline 184:20 & 194:2,10 & ground 9:16 & 193:17 & 160:13 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline happen & 247:10 & 54:16 & 159:6 & 251:18,20 \\
\hline 185:23 & heads 9:18 & 57:24 71:3 & 170:1 & highlighted \\
\hline happened & 192:24 & 104:23 & hesitant & 62:4,5 \\
\hline 13:12 83:2 & heads-up & 105:2,22 & 122:18 & 142:18 \\
\hline 93:12 & 244:2 & 107:2 & hey 176:25 & 143:13 \\
\hline 114:6 & health 7:1,2 & 111: 4 & 239:2 & 144:20 \\
\hline 124:11 & 7:8 45:6,8 & 115:21 & HHS 9:1,2 & 148:20 \\
\hline 160:25 & 45:10,11 & 119:15 & 232:7,20 & 228:9 \\
\hline 178:9 & 45:14 51:7 & 124:13 & 233:12 & highligh. \\
\hline 212:8 & 63:21 89:1 & 126:4,23 & 259:12,22 & 189:23 \\
\hline 215:8,20 & 89:2 140:1 & 139:1,10 & 260:9,17 & highlights \\
\hline 246:10 & 140:12 & 164:6 & 260:19,22 & 52:22 \\
\hline happening & 153:17,18 & 174:19 & 261:3,8,15 & 62:15 \\
\hline 79:5 97:17 & 186:1 & 175:4,7 & 261:17,25 & Hines 6:7 \\
\hline 190:2 & 192:24,25 & 188:21 & 263:4 & 8:15 \\
\hline 195:23 & 193:3,9 & 214:11,13 & Hi 45:22 & 264:17 \\
\hline 196:7,8 & 218:22 & 214:14,19 & 51:22 & history 12:1 \\
\hline 216:7 & 230:11,16 & 218:18,22 & 63:15,15 & hit 32:15 \\
\hline happens & 230:21 & 219:12 & 68:14 73:4 & 216:17 \\
\hline 144:17 & 237:13,17 & 237:25 & 74:25 84:4 & hits 17:10 \\
\hline happy 27:21 & 237:18 & 256:7 & 100:2 & HIV 46:4 \\
\hline 45:23 & 238:20 & 266:20 & 126:19 & hoc 180:21 \\
\hline 95:10 & healthcare & helped 161:1 & 166:17 & 180:25 \\
\hline 161:23 & 53:16 58:5 & 196:11 & 176:25 & Hoft 264:15 \\
\hline 214:5,9 & 66:5 & helpful & 197: 4 & holiday \\
\hline 228:24 & healthy & 51:20 52:3 & 211:6 & 248:19 \\
\hline 242:16 & 166:21 & 53:10 59:7 & 219:2 & holidays \\
\hline hard 10:16 & 172:8 & 170:23 & 226:24 & 84:8 \\
\hline 20:13 & hear 10:16 & 171:4,5,7 & 252:7 & Holly 239:5 \\
\hline 122:15 & 145:7 & 171:9 & 254:25,25 & honestly \\
\hline 194:21 & heard 28:12 & 197:7,10 & high 6:3 & 227:9,13 \\
\hline 235:14 & 97:22 & 200:2,3 & 42:22 & hope 68:14 \\
\hline 252:18 & 125:24 & 201:3,6 & 53:15 & 70:5 \\
\hline harm 139:11 & 137:25 & helping & 60:20 & 126:19 \\
\hline 234:21 & 217:14,15 & 197:17 & 89:19 & 127: 6 \\
\hline harmful & 245:17 & 246:16 & 190:3 & 135: 6 \\
\hline 165:15 & 252:7 & helps 53:11 & 255:8,13 & 161:3,6 \\
\hline 168: 6 & heart 139:16 & 54:18 58:1 & high-pri. & 166:20 \\
\hline Hatcher 40:7 & heartburn & 127:6 & 16:17 & 230:10 \\
\hline 40:9,13 & 252:8 & 231:10 & high-risk & 253:17 \\
\hline 42:7,17,21 & heavily & 253:15 & 2:13,16 & 266:14 \\
\hline 43:18 & 90:20 & hereinbe & 39:9 43:21 & hopefully \\
\hline hate 41:11 & hefty 205:15 & 270:8 & 44:10 & 55:22 \\
\hline Haynes 108:1 & held 8:7 & HEREOF & high-volume & hopes 172:7 \\
\hline 115:11 & help 33:23 & 270:15 & 89:11 & hoping 73:19 \\
\hline he'll 230:8 & 34:1,17 & hereto 7:23 & higher 53:9 & 88:23 \\
\hline head 136:2 & 35:10 & hereunto & highlight & 139:10 \\
\hline 165:10 & 37:12 & 270:15 & 29:23 & 229:19 \\
\hline headline & 46:16 & hesitancy & 66:10 & hospital. \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 185:24 & 220:16 & 104:15 & 144:23 & influencers \\
\hline hospital & ideally 46:2 & immediately & 167:1 & 75:4 80:9 \\
\hline 146:2 & identified & 157:1 & 170:23 & 81:20 \\
\hline 186:14 & 24:6 & 160:1 & 192:25 & info 5:9 \\
\hline hosting & 103:13 & 162:10 & 232:20,22 & 75:11,15 \\
\hline 244:24 & 139:9 & immune 4:7 & 233:11 & 80:13 \\
\hline hour 66:19 & 157:12 & 163:25 & 237:18 & 107:8 \\
\hline hours 28:9 & 177:1 & Immuniza & Inclusive & 208:2 \\
\hline 28:19,19 & identify & 107:13 & 120:15 & 214:4,5 \\
\hline 73:1,5 & 27:14 & 160:21 & inconclu. & 219:3 \\
\hline 235:12 & 54:18 & 253:21 & 120:15 & 230:8,11 \\
\hline House 230:13 & 67:20 & impact 10:24 & 122: 4,15 & 230:17 \\
\hline 230:24,25 & 85:10 91:4 & 167:4 & 122:17 & 239:20 \\
\hline 231:12,19 & 102:25 & implemen. & 129:25 & 253:12 \\
\hline 232:1,4,7 & 118:17 & 181:12 & 130:6 & 258:7 \\
\hline 232:22 & 145:3 & important & 140:18 & 266:3 \\
\hline 233:2,8,12 & 155:21 & 90:13 95:7 & incorrect & inform \\
\hline 233:19,19 & 174:20 & 177:5 & 229:15 & 103:16 \\
\hline 233:21 & 175:4 & 211:11 & Independ. & 138:20 \\
\hline 234:5,5,14 & 206:14 & impressions & 7:3 & 155:17 \\
\hline 259:10,22 & 226:13 & 133:14,14 & independent & 159:8 \\
\hline 260:9,17 & IDs 97:8 & improper & 234:6 & 164:24 \\
\hline 261:8,20 & IFB 24:18 & 95:6 & INDEX 2:1 & information \\
\hline 263:4 & Iheme 20:25 & improve & indicate & 16:15 \\
\hline Human 7:1,2 & 24:7,10 & 53:12 & 271:13 & 18:10,12 \\
\hline 7:8 & 26:8,25 & in-app 222:2 & indicated & 27:16 \\
\hline humans & 33:13 & in-depth & 115:11 & 34:21 \\
\hline 120:17 & 35:12 & 32:16 & 117:18 & 35:14 \\
\hline Huxley 86:17 & 36:12,23 & in-feed & indicates & 36:23,24 \\
\hline @R... & 43:18 & 228:3,5,6 & 244:17 & 46:11 \\
\hline 86:17 & 45:22 & 228:13 & Indicating & 48:22 51:9 \\
\hline & 50:16 & Inaudible & 31:17 & 52:6 54:23 \\
\hline I & 55:19 57:5 & 178:6 & 192:20 & 54:24 \\
\hline I-- 148:19 & 57:11 58:5 & include 42:9 & individual & 55:11 58:1 \\
\hline I-H-E-M-E & 68:12 & 188:3 & 8:14 & 59:1 61:4 \\
\hline 20:25 & 72:20 & 208:11,13 & individu... & 62:21 \\
\hline IAA 71:3,5 & 79:13 84:3 & 209:16,18 & 267:18,22 & 64:20 \\
\hline 109:15 & 86:11 & 228:23,24 & individuals & 70:24 \\
\hline 110:1,12 & 105:21 & 242:15,21 & 146:3 & 71:12 \\
\hline 110:18,20 & 131:17 & 245:20 & Infection & 72:14 75:4 \\
\hline 110:22,25 & 237:10 & 265:4,8 & 3:9 & 75:16 79:7 \\
\hline 111:7,11 & 257:15 & included & inferring & 79:8 81:4 \\
\hline 175:6 & Iheme's & 54:1 58:14 & 213:11 & 87:20 \\
\hline IAAs 109:22 & 37:11 & 61:13 & infertility & 88:18 89:1 \\
\hline ID 24:22 & illness & includes & 76:5 & 89:4,6,18 \\
\hline idea 46:15 & 41:25 & 243:17 & 201:16 & 90:13,14 \\
\hline 159:12 & 42:23 & including & 204:16,18 & 90:16 \\
\hline 187:23 & imagine 37:8 & 65:14 & inflamma. & 93:21 \\
\hline 188: 6 & 68:10 & 140:8 & 139:16 & 98:20 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 107:15,17 & initially & instructed & 73:24 & 199:2 \\
\hline 107:22 & 17:16 & 80:21 & 122:13 & 237:7 \\
\hline 109:3,12 & initiated & 193:19 & 160:8 & issued 153:8 \\
\hline 114:9 & 17:17 & instruct. & 203:24 & issues 3:1 \\
\hline 123:7 & initiative & 40:14 & interrupt & 29:2 59:12 \\
\hline 126:22 & 18:16,19 & instruct. & 9:24 32:24 & 66:11 \\
\hline 130:1 & initiatives & 144:16 & interrupted & 85:12 87:8 \\
\hline 140:2,3 & 27:17 & instructs & 98:8 & 108:12 \\
\hline 142:6 & input 34:21 & 10:12 & intro 221:18 & 207:16,22 \\
\hline 148:25 & 104:8 & intent 220:9 & introduce & 220:13 \\
\hline 154:8 & 111:16 & interact. & 8:11 & 264:3 \\
\hline 159:22,25 & 156:19 & 18:9 29:17 & introduced & item 3:4 \\
\hline 160:3 & 167:7 & interactive & 265:15 & 28:24 \\
\hline 161:22,24 & 171:6 & 187:1 & invite 98:11 & 103:4 \\
\hline 166:22 & 173:2,4 & interagency & 185:7 & 111:12,19 \\
\hline 167:20 & 194:8 & 71: 6 & 208:12 & 118:23 \\
\hline 169:11 & 255:3 & 109:20,21 & 209:16 & 126:15 \\
\hline 170:20 & inquired & interest & 221:9 & 136:8,25 \\
\hline 175:8,9 & 69:11 & 58:9 64:3 & 223:24 & 144:19 \\
\hline 182:1,19 & inquiry & interested & 239:21 & 165:13 \\
\hline 183:9,13 & 108:24 & 75:11 & 242:10,16 & 247:15 \\
\hline 183:18 & inserted & 80:12 & 243:25 & items 27:10 \\
\hline 189:17 & 221:15 & 180:1 & 245:15,20 & 30:15 58:5 \\
\hline 190:20 & insights & 228:25 & 247:19 & 65:3 84:6 \\
\hline 192:10 & 63:16 & 253:19 & invited & 88:21,24 \\
\hline 200:4 & 65:15 & 270:13 & 100:11 & 105:21,24 \\
\hline 204:20 & 167:4 & interesting & 116:24 & 106:1,20 \\
\hline 206:23 & Instagram & 65:17 & 210:1 & 111:13 \\
\hline 213:19 & 50:6 62:18 & interface & 212:24 & 117:12 \\
\hline 220:19 & 157:5 & 262:2 & 223:13 & 120:7 \\
\hline 229:19 & 227:1,2,3 & interim & inviting & 128:23 \\
\hline 230:21 & 227:8,12 & 242:14 & 208:9 & 131:2 \\
\hline 237:20 & 227:16,20 & internal & involuntary & 207:7 \\
\hline 238:5 & 227:22 & 239:2 & 137:7 & 221:16 \\
\hline 253:14 & 228:15 & internally & involve & 225:21 \\
\hline 255:4 & 229:10 & 113:16 & 101:14,17 & 226:25 \\
\hline 259:23 & instance & 222:4 & involved & 240:6,9 \\
\hline 264:5 & 18:11 & 243:8 & \[
\begin{array}{ll}
32: 17 & 71: 1 \\
98: 14 &
\end{array}
\] & J \\
\hline \(266: 6,17\)
\(266: 18,19\) & 114:22 & interpret & \[
98: 14
\] & J 6:8 \\
\hline 266:18,19 & 115:2 & 223:23 & 101:1,8 & J 6:8 \\
\hline 266:21,22 & 135:16 & interpre. & 160:23 & James 6:17 \\
\hline 267:3,4,7 & 183:14 & 159:7 & 215:13 & 8:22 \\
\hline infrastr. & 224:8 & interpreted & 234:1 & James.gi \\
\hline 174:19 & instigate & 50:23 & 235:5 & 6:23 \\
\hline 175:4,11 & 17:13,16 & 170:7 & involving & Jan 21:1 \\
\hline ingredients & instruct & 179:1 & 233:10 & 174:7 \\
\hline 65:5 & 57:5,15 & 199:25 & issue 5:7 & 176:6 \\
\hline initial 85:8 & 138:12 & 211:17 & 95:10 & 182:23 \\
\hline 132:14 & 194:2 & interpre... & 122:21 & 184:7 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 189:15 & John.sau. . . & Juneteenth & 8:15 & 26:16 27:8 \\
\hline 192:22,23 & 6:5 & 248:19 & 264:13 & 28:14,18 \\
\hline 195:17 & John.vec. & Justice 6:19 & kids 157: 4 & 30:7,16 \\
\hline 243:16,22 & 6:13 & 8:18, 23 & 161:14 & 33:21 \\
\hline 252:20 & join 5:8 & 271:5 & 162:4,13 & \(34: 10 \quad 37: 7\) \\
\hline 253:3 & 14:1 70:5 & & kill 168:4 & 37:9,25 \\
\hline 254:16 & 75:3 108:7 & K & 170:15 & 38:2,13 \\
\hline & 182:22 & @ & kind 36:9 & 41:15 42:3 \\
\hline 174:8 & 239:20 & 244:15 & 38:15 52:6 & 42:6,7,9 \\
\hline January & 242:11 & Kane 244:14 & \(72: 975: 24\) & 42:11,17 \\
\hline 49:16,18 & 245:16,19 & Kang-Xing & 90:15 & 42:21,24 \\
\hline 49:21 & joined 30:20 & 222:7 & 109:24 & 43:1, 2, 6 \\
\hline 50:14 & 115:11 & Karen 193:5 & 123:17,17 & 44:24 \\
\hline 55:18 & 116:24 & Kat 35:6,9 & 129:4 & \(45: 25\) 46:5 \\
\hline Jason 7:14 & joining & 37:2,4,20 & 133:3,20 & 46:8,22 \\
\hline 8:9 & 107:9,11 & Kate 222:25 & 153:14 & 47:4,19 \\
\hline Jay 8:14 & joint 59:1 & keep 9:20, 24 & 154:3 & 48:1,4,7,9 \\
\hline 24:15 25:5 & 107:15,16 & 70:12 & 177:11 & 48:12,17 \\
\hline 26:14 & 107:22 & keeping & 198:16 & 49:9 50:18 \\
\hline 45:19 57:3 & 233:14 & 246:11 & 200:9 & 52:15 \\
\hline 57:3 & Jorgensen & keeps 65:1 & 204:13 & 53:11 \\
\hline 181:17 & 107:11 & Kelly 50:25 & 210:24 & 54:17 \\
\hline 230:7 & 115:10 & 51:1 52:1 & 217:20 & 56:13,15 \\
\hline 264:8 & 183:2 & 60:11 & 224:10 & \(56: 25\) 57:2 \\
\hline Jayanta 6:6 & Joseph 1:7 & \(61: 22\) 63:3 & 230:9 & 57:18 \\
\hline Jeff 265:8 & 7:11 8:5 & 63:15 & 260:5 & 58:23,24 \\
\hline Jefferson & 271:7 & 64:23 & 261:7 & 59:4,20 \\
\hline 6:4 & 272:2 & 141:21,23 & kinds 98:19 & \(63: 23\) 65:8 \\
\hline Jen \(83: 22\) & Josh 261:17 & Kenya 7:5 & 101:18 & \(65: 25 \quad 70: 1\) \\
\hline 86:21 & jotted & kept 38:3 & 263:11 & 72: 6, 25 \\
\hline Jennifer & 225:19 & 241:8 & knew 26:9 & 73:5,10,19 \\
\hline 86:24 & JR 1:7 271:8 & Kevin 18:25 & 88:17 90:7 & \(73: 24\) 74:1 \\
\hline 45:18 & 272:3 & 40:7,9,13 & 106:19 & \(74: 4,9\) \\
\hline & Julia 222:22 & 41: 6 & 107:1 & 75:15,18 \\
\hline 24:13 & July 139:3 & 244:14,17 & 108:12 & 77:12,18 \\
\hline JIC 72: 9, 10 & 146:11 & 245:1,4,5 & 113:15 & 77:19,20 \\
\hline 183:7 & jump 27:21 & 245:18 & 116:9,10 & 77:23,25 \\
\hline JIC's 72:6 & jumping & Kevin's & 126:4 & 78:10,16 \\
\hline Jill 6:6 & 120:17 & 40:19 & 138:18,22 & 79:20 80:6 \\
\hline 8:15 & June 118:24 & key 27:17 & 155:16 & 81:15 82:8 \\
\hline 264:17 & 126:16,18 & 72:17 & 220:21,25 & 82:13,16 \\
\hline Jim 264:15 & 126:24 & 190:2 & 232:12,15 & 82:17,25 \\
\hline Jin 222:7 & 131:20 & keywords & 243:10 & 83:1,5,15 \\
\hline job 107:22 & 134:21 & 144:9 & 263:10 & 84:10 \\
\hline 249:3 & 135:1,9 & keywords . . . & know 10:17 & 86:12,17 \\
\hline John 6:2,8 & 142:9,15 & 144:5 & 17:14,18 & 87:19 88:7 \\
\hline 8:13 67:1 & 144:1 & khatcher. & 17:19 & 88:11,13 \\
\hline 165:17 & 247:15 & 40:7 & 18:11 21:9 & 88:15 \\
\hline 265:9 & 248:16 & Kheriaty 6:6 & 25:17 & 89:10,18 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 298 of 334 PageID \#: 11242
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 89:19 & 144:4,20 & 208:14 & 111: 6 & 153:15 \\
\hline 90:21 & 144:24 & 209:5,18 & 133:23 & lack 112:23 \\
\hline 91:23 & 146:6,9 & 210:24 & 165:1 & 137:7 \\
\hline 93:15,24 & 148:10,11 & 211:16 & 176:19 & Lagone 103:7 \\
\hline 94:4,9,24 & 148:24 & 212:8,15 & 189:24 & 103:13 \\
\hline 94:25 & 149:4,9 & 212:25 & 190:12 & 105:8 \\
\hline 95:24,25 & 151:4,14 & 213:16 & 192:17 & 119:7 \\
\hline 96:1,10,12 & 151:24 & 215:19 & 195:2 & 121:1 \\
\hline 96:18 97:7 & 152: 4,7,12 & 217:2,23 & 218:10 & 125:8 \\
\hline 97:8,18,20 & 153:13 & 218:7,20 & 224:15 & 126:18 \\
\hline 98:10,12 & 154:10 & 221:13 & 233:4 & 127:2 \\
\hline 98:13,18 & 155:3,4,5 & 222:7,13 & 251:2 & 133:2 \\
\hline 99:17 & 157:23 & 224:7,23 & known 28:21 & 165:5,14 \\
\hline 100:5,20 & 158:13 & 225:16 & 140:18 & 165:19 \\
\hline 100:21 & 160:12 & 227:16 & 177:15 & 166:14 \\
\hline 101:11,14 & 161:11 & 228:8,21 & 264:22 & 222:16 \\
\hline 101:17,24 & 164:22 & 233:4,23 & knows 37:4 & Lancet 3: 6, 7 \\
\hline 101:24 & 165:4,21 & 235:7,18 & 136:17 & 169:4 \\
\hline 103:10 & 167: 6 & 238:6,23 & Kreimer 1:20 & Landry 149:2 \\
\hline 108:23,25 & 170:2,19 & 238:25 & 8:8 270:4 & 265:9 \\
\hline 109:4 & 171:9 & 239:3,8 & 270:22 & lane 89:17 \\
\hline 111:7,10 & 172:23 & 240:25 & Kristen & Langone \\
\hline 111:16 & 173:7,10 & 241:7 & 156:16 & 139:3 \\
\hline 112:18,25 & 174:25 & 242:12 & 160:17,19 & 159:3 \\
\hline 113:1,10 & 175:23,25 & 243:1,11 & 161:1 & language \\
\hline 114:1 & 177:12,13 & 243:12,14 & Kulldorff & 65:16 \\
\hline 115:1,9,15 & 177:18,22 & 244:12,13 & 6:6 8:16 & language \\
\hline 115:18 & 178:12 & 246:22 & 264:11 & 65:20 \\
\hline 116:3,8 & 180:18,19 & 247:21 & Kumar 7:2 & large 87:23 \\
\hline 117:14 & 183:5,7,9 & 248:15 & 8:25,25 & 155:2 \\
\hline 120:4,21 & 183:24 & 251:19 & 173:19 & 181:22 \\
\hline 121:9 & 184:13 & 252:5,6,14 & Kyla 6:18 & largely \\
\hline 122:5 & 185:5,23 & 252:16,18 & 8:17 271:4 & 52:25 \\
\hline 123:8,15 & 186:4,5,19 & 253:15,23 & Kyla.sno... & late 33:16 \\
\hline 123:19,21 & 188:16 & 255:18 & 6:24 & 36:7 \\
\hline 124:10 & 190:2,8 & 256:4,9,11 & 97:7 & 249:12 \\
\hline 125:19 & 191:20 & 258:10 & & latest 63:16 \\
\hline 127:7,22 & 192:5 & 259:3 & L & 195:20 \\
\hline 129: 6 & 193:3 & 261:9,21 & L 6:20 271:5 & 196:10 \\
\hline 130:6,25 & 194:6 & 261:24 & lab 4:1 5:2 & 230:8 \\
\hline 131:3,4,8 & 197:25 & 262:16 & 152:24 & launch 48:2 \\
\hline 132:13 & 198:2,15 & 263:17,20 & 153:8,11 & 48:5,7,8 \\
\hline 135:5,17 & 199:4,10 & 264:7,10 & 153:12 & 228:3,12 \\
\hline 135:25 & 199:13,23 & 264:12,14 & 199:2 & launched \\
\hline 138:1 & 200:2,13 & 264:16,18 & 219:24 & 157:4 \\
\hline 139:21 & 201:21 & knowledge & labels 76:18 & launching \\
\hline 140:16,23 & 202:22,24 & 54:18 & 76:20 77:2 & 27:18 46:1 \\
\hline 142:18 & 203:14 & 104:16,18 & 77:3 82:17 & Lauren 50:17 \\
\hline 143:4 & 205:7 & 107:23 & laboratory & 50:19 52:1 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 52:17 & let's 10:13 & letting 48:7 & 206:16 & 183:25 \\
\hline 262:15,18 & 13:7 16:18 & level 50:9 & 219:22,24 & 184:2 \\
\hline 262:19 & 17:10 20:1 & 117:3 & 221:7 & 203:24 \\
\hline law 95:25 & 22:17, 22 & 234:15 & 226:7,9 & 207:6 \\
\hline lawsuits & 25:13 & leverage & 237:5 & 217:20,22 \\
\hline 142:16,20 & 26:20 & 174:19 & 239:19 & 224:16 \\
\hline 143:8 & \(38: 20 \quad 39: 4\) & 175:3 & 241:20,21 & 246:6,12 \\
\hline lawyer 236:9 & \(46: 25\) & Lewinsky & 247:10 & listed 92:24 \\
\hline lawyers 9:22 & 49:14 & 246:25 & 254:9,22 & 120:6 \\
\hline 9:23 39:16 & 50:14 & Lewitzke & 257:8 & 221:20 \\
\hline lay 9:15 & \(51: 2156: 8\) & 83:21 & 272:5, 9, 13 & 224:3 \\
\hline layer 195:3 & \(60: 865: 13\) & 86:22 & 272:17,21 & listen 31:10 \\
\hline lays 105:21 & 69:19 & 203:2, 3, 11 & line's & 70:6 \\
\hline lead 11:16 & 81:25 86:8 & 216:4,15 & 179:14 & listened \\
\hline 24:16,25 & 97:25 & 217:5 & link 31: 8, 11 & 181:17 \\
\hline 35:3 & 102:7,7 & 246:25 & 35:16 & listening \\
\hline 139:11 & 107:4 & 247:1 & 48:21 & 31:13 50:4 \\
\hline 159:5 & 118:9 & 265:20 & 102:18 & 52:10 72:3 \\
\hline 164:2 & 119:6 & Lewitzke's & 186:17,20 & 90:21 \\
\hline 168:4 & 121:17 & 211:3 & 187:1,19 & 148:13 \\
\hline 170:16 & 126:17 & Lexitas 7:14 & 187:19 & 154:21 \\
\hline 181:10 & 129:21 & 8:10 271:1 & 194:8 & lists 96:20 \\
\hline 227:10 & 145:17 & 271:23 & 208:1 & 96:21 \\
\hline 249:3 & 146:20 & Liberties & 214:19 & 120:8 \\
\hline 259:4 & 149:25 & 6:9 & 227:5 & 157:12,20 \\
\hline leadership & 165:11 & lieu 198:25 & 251:20 & literature \\
\hline 11:14,15 & 166:12 & life143:11 & linked 169:3 & 131:5,9 \\
\hline 15:15,16 & 176:5 & Lindsay & LinkedIn & litigation \\
\hline 15:19 & 178:22 & 254:17,18 & 16:6 & 92:23 \\
\hline leads 168:12 & 179:11 & line 33:10 & linking & little 10:16 \\
\hline 258:19,23 & 205:25 & 39:7 60:5 & 41:25 & 11:24 \\
\hline learn 79:23 & 206:24 & 68:5 91:5 & links 191:23 & 12:22 38:2 \\
\hline 110:21 & 211:1 & 103:2 & 219:11 & 39:15 \\
\hline 111:3 & 218:12 & 118:18 & 266:5 & 49:15 63:8 \\
\hline 164:13 & 221:23 & 120:5 & Lis 262:25 & \(64: 1567: 9\) \\
\hline 177:4 & 222:6 & 126:11 & 263:5 & 69:19 \\
\hline learning & 226:22,22 & 138:25 & list 3:12,13 & 85:22 \\
\hline 40:16 & 227:18 & 141:8 & 56:5 61:14 & 130:18 \\
\hline 110:13,23 & 234:9,23 & 150:12 & 62:22 & 151:12 \\
\hline leaves 128:4 & 237:9 & 151:21 & 96:20 & 161:5 \\
\hline led 161:24 & 241:24 & 152:20 & 97:18 98:8 & 183:15 \\
\hline 204:18 & 243:15 & 155:22 & 117:9 & 189:25 \\
\hline left119:12 & 247:9,14 & 163:16 & 118:23 & 191:14 \\
\hline legal 7:14 & 254:6,6 & 166:5 & 119:17 & 205:15 \\
\hline 7:14 8:9 & 257:13 & 173:23 & 126:15 & 208:16 \\
\hline 8:10 271:1 & 261:2 & 179:12 & 131:17 & 214:2 \\
\hline 271:23 & 263:15 & 189:5 & 133:21 & 227:12 \\
\hline Lepage 63:5 & letter & 196:18 & 158:20 & 261:2 \\
\hline 65:2 & 100:13 & 205:14,20 & 182:20 & 266:3 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline live 34:15 & 38:23 & 172: 4 & 192:22 & 182:21 \\
\hline 167:10,16 & 43:12 49:3 & 175:12 & 195:4 & lunch 102:3 \\
\hline 224:10 & 49:4 50:14 & 215:17 & 216:14 & 102:10 \\
\hline 258:9 & 52:13 58:1 & 265:23 & 222:8 & 109:17 \\
\hline Lives 34:24 & 59:24 60:8 & looking & 244:2 & Lynn 87:3,4 \\
\hline Liz 75:2 & 61:17 63:1 & 18:11 21:3 & 248:7 & \\
\hline 80:3 103:7 & 63:9 70:20 & 32:1 40:15 & 252:1, 22 & M \\
\hline 103:8 & 74:11,24 & 55:24 56:8 & 253:6 & magnetism \\
\hline 105:24 & \(76: 284: 6\) & 56:11 & loop 25:5 & 127:11 \\
\hline 119:7,10 & 85:8 86:8 & 58:22 & 26:10,15 & mail 61:5 \\
\hline 121:1,9 & 88:9 99:23 & 65:15 & 27:4 & main 76:15 \\
\hline 122:8 & 104:9 & 72:19 & 238:22 & 83:16 \\
\hline 125:8 & 105:20 & 74:16,17 & looped & 119:11 \\
\hline 126:18 & 108:19 & 80:25 & 238:18 & 190:25 \\
\hline 127:2 & 111:12 & 117:5 & looping 23:4 & 231:8 \\
\hline 133:2 & 112:9,10 & 126:1,3 & 25:4 26:14 & 249:1 \\
\hline 139:3 & 118:25 & 127:21 & lose 157:7 & maintaining \\
\hline 151:23 & 128:24 & 128:13 & lost 168:23 & 137:20 \\
\hline 160:16 & 131:13,20 & 154:25 & 269:8 & 138:3 \\
\hline 163:21 & 133:1 & 159:9 & lot 17:25 & major 16:4 \\
\hline 166:14 & 136:5 & 191:20,22 & 18:20 & 87:20 \\
\hline 222:16 & 141:12 & 197:4 & 28:19 & 187: 6 \\
\hline local 76:16 & 146:21 & 200:25 & 40:11 59:5 & 232:3 \\
\hline locate & 149:13 & 223:14 & 64:20 89:3 & making 18:11 \\
\hline 218:25 & 150:9 & 227:2 & 107:23 & 68:15 \\
\hline \(\log 77: 10,14\) & 155:10 & 234:18 & 108:15 & 140:3 \\
\hline 92:10,11 & 163:6 & 237:19 & 109:5 & 203:22 \\
\hline 92:13 & 165:11 & 245:9 & 110:2 & manage 15:18 \\
\hline 95:17 & 167:23 & 248:11 & 133:22 & 15:22, 23 \\
\hline 212:4 & 173:1,11 & 253:17 & 144:17 & 35:10 \\
\hline log-in 79:10 & 174:3 & 258:15 & 149:17 & management \\
\hline \[
92: 1
\] & 176:5 & lookout & 150:20,23 & 15:24 \\
\hline logged 92:5 & 179:12 & 153:21 & 152:3 & mandate \\
\hline 92:15 & 187:18 & 155:12,14 & 154:4 & 142:22 \\
\hline 218:18 & 202:8 & 208:25 & 172:20 & mandated \\
\hline long 12:7 & 205:16 & 209:1 & 231:6 & 148:23 \\
\hline 28:20,22 & 206:24 & 220:10 & 236:11,18 & mandates \\
\hline 126:20 & 212:20 & 244:8 & 266:17 & 137:19 \\
\hline 166:12 & 215:14,16 & Lookout' & lots 84:7 & 142:21,23 \\
\hline 227:24,25 & 234:9 & 247:20 & 232:5 & 148:20 \\
\hline 266:10 & 249:18 & looks 30:2 & loud 9:20 & 149:18 \\
\hline longer 13:11 & 250:7 & 35:16 & 97:22,23 & manmade \\
\hline 48:23 & looked 59:10 & 44:14, 22 & 145:10 & 120:20 \\
\hline 82:23 & 72:11 & 55:19 & 174:15 & manmade \({ }^{\prime}\) \\
\hline 155:6 & 95:16 & \(61: 2562: 1\) & 176:8 & 108:21 \\
\hline 235:14 & 140:19 & 76:4,10 & Louis 271:18 & 120:13 \\
\hline look 20:1 & 147:17 & 98:17 & Louisiana & manner 105:8 \\
\hline \[
21: 14 \quad 33: 6
\] & 157:20 & 100:3 & 1:1 8:6 & 265:14 \\
\hline \(37: 23\) & 164:22 & 119:8 & love 126:23 & manually \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 301 of 334 PageID \#: 11245
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 192:18 & 166:2 & 248:22 & 161:20 & 125:9 \\
\hline March 13:4 & 171:15 & matter 8: 4 & 172:18 & 130:3 \\
\hline 13:14 15:2 & 173:20 & 94:3 103:1 & 175:2 & 167:18 \\
\hline 16:1,20 & 179:9 & 108:8 & 177:15 & 176:12 \\
\hline 18:6 34:5 & 187:9 & 113:24 & 178:21,25 & 177:7 \\
\hline 40:4 43:23 & 188:25 & 123:2,20 & 180:19 & 182:13 \\
\hline 44:1,25 & 196:15 & 129:21 & 181:8,9 & 211:16 \\
\hline \(46: 25\) 47:7 & 200:15 & 130:10 & 182:3,5 & 218:20 \\
\hline 61:12 63:2 & 205:19 & 132:17 & 183:3 & 228:6 \\
\hline 63:14 & 219:19 & 133:17 & 191:15 & media 11: 8 \\
\hline 64:23 & 221:3 & 145:4 & 192:3 & 11:16 12:7 \\
\hline 65:14, 24 & 226:4 & 152:7 & 193:11,12 & 13:1,19,20 \\
\hline 68:13 73:3 & 237:2 & 171:17 & 195:21 & 13:24,25 \\
\hline 73:16 & 239:16 & 184:20 & 196:6 & 14:3, 4, 12 \\
\hline \(74: 24 \quad 76: 2\) & 241:17 & 187:12 & 198:14 & 14:14,17 \\
\hline 76:13 & 247:7 & 189:5 & 199:19 & 14:20,25 \\
\hline 77:13 & 249:7 & 200:18 & 201:18 & 15:4,6,11 \\
\hline 79:14 80:3 & 254:4 & 249:18 & 209:8 & 15:14,16 \\
\hline 81:25 82:3 & 257:4 & 254:9 & 210:22 & 17:1,24,24 \\
\hline 82:4 84:3 & marketing & 270:14 & 211:8,15 & 18:2 19:20 \\
\hline 174:4,14 & 262:1 & matters 28:9 & 212:19 & 20:3,16 \\
\hline 176:6 & marriage & 132:24 & 213:2 & 24:3,16, 25 \\
\hline 179:23 & 270:12 & maturing & 214:15 & 35:9 36:5 \\
\hline 182:16 & Martin 6:6 & 192:2,4 & 217:12 & 43:3 50:3 \\
\hline 257:15 & 8:16 & Maureen 1:20 & 220:12 & 52:10,11 \\
\hline 259:7 & Marty 264:11 & 8:8 270:4 & 222:12 & \(53: 954: 14\) \\
\hline Margaret & mask 29:2,3 & 270:22 & 224:4 & 54:17 \\
\hline 45:4 & 29:5 & mean 13:19 & 229:24 & \(57: 25\) 59:3 \\
\hline mark 33:18 & masking & 15:20 17:2 & 236:17 & 72:2,12 \\
\hline 33:20,22 & 62:10 & 17:18,19 & 241:10 & 92:7 104:5 \\
\hline 49:4 & 71:13 & 23:6 26:10 & 243:3 & 104:24 \\
\hline 100:10 & masks 29:7 & 26:13 & 246:19 & 105:1,3 \\
\hline marked 21:12 & 66:5 & 30:12 & 251:9 & 113:11 \\
\hline 22:8 33:4 & master's & \(32: 17\) & 258:2 & 114:8 \\
\hline 38:18 & 12:4,11 & \(39: 2450: 7\) & 260:22 & 117:2,8,17 \\
\hline 43:10 49:1 & match 41: 4 & 52:15 73:3 & 261:3 & 124:6 \\
\hline \(60: 3\) 67:12 & material & 77:15 80:5 & 266:11,16 & 128:11,14 \\
\hline 85:6 91:1 & 65:20 99:3 & 82:3 85:18 & meaning & 143:6,21 \\
\hline 102:22 & 114:15 & 87:25 & 103:11 & 143:24 \\
\hline 112:6 & 117:17 & 88:25 99:6 & 139:7 & 148:13 \\
\hline 113:3 & 146:15 & 113:1 & 184:25 & 150:22 \\
\hline 118:7 & 148:15 & 116:2 & 217:18 & 154:21,22 \\
\hline 126:8 & 264:2 & 117:9,14 & means 113:14 & 155:1 \\
\hline 145:1 & materials & 127:21 & 191:1 & 181:7 \\
\hline 150:6 & 53:12 & 129:1 & 209:21 & 198:22 \\
\hline 152:16 & 56:17 58:3 & 132:22 & meant 19:15 & 207:7 \\
\hline 155:7 & 81:8,12 & 136:2 & \(37: 17\) & 212:20 \\
\hline 163:13 & 90:7 & 154:22 & \(77: 19\) & 220:2 \\
\hline 164:17 & 115:21 & 160:6 & 90:23 & 227:20 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 302 of 334 PageID \#: 11246
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 234:6 & 172:19 & 116:7 & 48:23 & 259:9 \\
\hline 237:14,20 & 177:16 & 117:25 & 83:10,14 & mentioning \\
\hline 248:9 & 178:23 & 130:16 & 92:13 & 79:22 \\
\hline 249:4 & 179:6 & 174:24 & 95:17 96:2 & 117:25 \\
\hline 264:3 & 180:7,23 & 179:3,25 & 160:7 & 125:10 \\
\hline 267:10 & 185:1 & 180:5,9,11 & 180:25 & mess 192:16 \\
\hline medical & 188:9,10 & 180:17,17 & 182:6 & message \\
\hline 131:5,9 & 188:12,13 & 180:25 & 198:13 & 33:24 36:4 \\
\hline 137:3,8 & 188:21 & 181:2,7,24 & 200:13 & 36:7 \\
\hline 140:12 & 198:25 & 184:17 & 205:1 & 247:22 \\
\hline 203:15 & 202:4 & 188:14 & 214:2 & 252:18,19 \\
\hline medications & 208:9,11 & 198:12,14 & 217:25 & messages \\
\hline 10:23 & 208:17,23 & 198:16,21 & 218:1 & 28:25 \\
\hline medicine & 210:4 & 202:6 & 236:12,16 & 248:24 \\
\hline 12:16 & 212:24 & 204:24 & 240:13 & 252:8 \\
\hline medicines & 213:1,3 & 208:16 & 260:10 & messaging \\
\hline 137:13 & 221:14 & 209:10,11 & mental 63:21 & 29:13,14 \\
\hline 164:21 & 223: 4,13 & 209:23 & mention & 29:19 \\
\hline meet 70:9 & 225:15,24 & 210:11 & 123:21 & 42:24 \\
\hline 150:18 & 225:25 & 226:18,19 & 230:22 & 237:17 \\
\hline 170:3 & 226:10,16 & 232:5 & 233:1 & met 119:23 \\
\hline 175:15 & 230:12 & 239:2 & mentioned & 174:23 \\
\hline 180:19,20 & 232:24 & 241:21 & 46:15 & 175:15 \\
\hline 209:20 & 238:23,24 & 242:10,11 & 51:16 & 198:4 \\
\hline meeting 2:23 & 239:1,25 & 244:23 & \(54: 15\) & 202:1,17 \\
\hline 5:6,13 & 240:14,23 & 245:1,15 & 62:22 & Meta 50:4,5 \\
\hline 36:8,16,17 & 241:8,9 & 245:16 & 72:10 76:3 & 50:7,8 \\
\hline 57:4 68:6 & 242:6,18 & 250:15 & 87:8 99:1 & 154:24 \\
\hline 68:7,9,12 & 242:20 & 260:12 & 109:15 & 155:1,2 \\
\hline 69:23 70:1 & 246:2,5,18 & 261:7,11 & 121:10 & 156:9 \\
\hline 70:6 72:20 & 246:23 & 261:19 & 125:16 & 159:13 \\
\hline 73:10 & 247:12,21 & 262:6 & 126:2 & 161:14 \\
\hline 75:22 80:1 & 248:15,20 & 265:12,12 & 132:20 & 162:4,25 \\
\hline 80:10 & 253:18,24 & 265:13 & 141:20 & 180:13,18 \\
\hline 84:10,11 & 258:19 & 266:10,14 & 142:12,21 & 180:20 \\
\hline 84:13,19 & 260:6,13 & 267:11,13 & 147:16 & 181:16 \\
\hline 98:10,11 & 260:17 & Megan 252:20 & 157:8 & 212:3,10 \\
\hline 99:22,25 & 261:15,18 & Melissa 7:7 & 195:17 & 213:22 \\
\hline 100:2, 4, 6 & 262:9,25 & Meltwater & 200:6 & 215:14 \\
\hline 100:8,10 & 263:4,14 & 154:13,14 & 211:24 & Meta's 158:3 \\
\hline 115:11,14 & 263:18 & 154:18 & 221:25 & 158:11 \\
\hline 115:24 & 265:15,17 & 155:1 & 223:1 & method 255:9 \\
\hline 116:1,6,15 & meetings & members \(84: 7\) & 236:14 & 255:14 \\
\hline 119:17,20 & 5:10 17:8 & 107:10 & 237:13 & mic 10:18 \\
\hline 119:24 & 18:17,18 & memo 109:20 & 243:4 & Michael \\
\hline 132:18 & 18:20 & memory 18:9 & 246:19 & 264:21 \\
\hline 151: 4, 15 & 20:18 & 25:15 29:5 & 250:14 & Michelle \\
\hline 151:18 & 30:15 69:2 & 31:25 & 251:17 & 19:9,12 \\
\hline 172:16,19 & 83:6 116:2 & 34:22 & 257:22 & 32:13 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline microchips & 161:16 & 74:14 & 241:22 & 166:13 \\
\hline 87:11 & 162:5,16 & 77:21, 22 & 242:6,10 & 181:4 \\
\hline 90:15 & 163:2 & 83:12 84:5 & 245:15 & 185:18 \\
\hline 207:12,13 & 168:13 & 84:12 86:3 & 253:17 & 187:5 \\
\hline 207:17,23 & 178:2 & 87:14,17 & 257:20 & 190:22 \\
\hline 209:7 & 199:6 & 87:24 88:8 & misinter & 196:3 \\
\hline 265:24 & 238:13 & 91:15,18 & 153:8 & 202:9 \\
\hline Microsoft & 266:24 & 91:25 & 155:4 & 207:1 \\
\hline 16:6 241:1 & mischara & 98:14 & misoprostol & 216:16 \\
\hline middle & 214:1 & 103:9 & 255:11,16 & 217:9 \\
\hline 169:14 & misconce & 110:13,14 & missed 70:8 & 242:25 \\
\hline 222: 6 & 89:12 & 111:4,5 & 96:8 156:6 & 243:20 \\
\hline 253:7 & misheard & 117:2,7 & missing 81:3 & 252:25 \\
\hline mifepris & 121:22 & 119:16 & 196:1 & 253:8 \\
\hline 255:10,15 & misinfo 3:1 & 124:14 & Missouri 1:3 & MO 271:18 \\
\hline Mike 144:23 & 3:2 4:11 & 139:1,6 & \(6: 1,2,4\) & moderation \\
\hline milk 165:14 & \(55: 25\) 56:9 & 150:19,25 & 8:5 271:7 & 76:7 82:7 \\
\hline millions & \(68: 16\) 69:4 & 151:23 & 272:2 & 82:8,11 \\
\hline 168:20 & 74:14 & 152:25 & misspelled & 101:15 \\
\hline mind 9:24 & 85:12 87:9 & 154:1,11 & 139:2 & 175:24 \\
\hline 47:5 116:3 & 91:9,15 & 156:21 & mistake & 176:11 \\
\hline 156:5 & 173:25 & 157:7 & 144:15 & modules \\
\hline 201:13 & 174:20 & 161:25 & mistype & 40:17 \\
\hline 233:18 & 175:5 & 166:7 & 127:23 & MOLA-DEF . \\
\hline mine 23:11 & 179:15 & 171:23 & misunder. & 3:21 \\
\hline 87:4 & 207:22 & 175:8,13 & 154:6 & MOLA-DEF. \\
\hline 205:22,24 & 220:22 & 179:15 & \(\boldsymbol{m i x} 52: 25\) & 2:24 \\
\hline 206:10 & 221:22 & 181:20,23 & mm-hmm 16:3 & MOLA-DEF . \\
\hline minor 241 :11 & 225:5 & 181:24 & 16:25 & 4:4 \\
\hline minute 43:12 & 229:20 & 182:10,21 & 17:12 & MOLA-DEF \\
\hline 96:6 99:1 & 234:17 & 183:25 & 19:18 21:5 & 5:3 \\
\hline minutes 4:10 & 257:19 & 184:16 & 23:9 39:17 & MOLA-DEF. \\
\hline 171:22 & 258:16 & 185:12 & 40:24 & 4:2 \\
\hline 182:23 & misinform & 197:7,20 & 41:23 & MOLA-DEF. \\
\hline 184:7 & 5:18 & 198:2 & \(43: 15\) 44:7 & 3:24 \\
\hline 216:16 & 257:10 & 199:5,11 & 45:21 & MOLA-DEF . \\
\hline 266:12 & misinfor. & 200:1,8 & 62:25 & 3:18 \\
\hline mis-info & 3:14 4:1,9 & 201:3,25 & 63:18 & MOLA-DEF . . . \\
\hline 4:13,15 & \(5: 1,3,11\) & 204:1 & 67:11 & 3:14 \\
\hline 187:14 & 33:25 & 205:20 & 107:6 & MOLA-DEF . \\
\hline mischara. & 37:12,14 & 206:16 & 108:20 & 3:12 \\
\hline 47:14 54:8 & 38:5,13 & 208:9 & 114:11 & MOLA-DEF . \\
\hline \(57: 876: 22\) & 56:9,12 & 211:18 & 117:15 & 3:5 \\
\hline \(78: 1786: 5\) & 58:12, 20 & 212:5 & 128:25 & MOLA_DEF... \\
\hline 89:24 & 58:22 & 219:6,25 & 129:22 & 2:18 \\
\hline 101:2 & \(68: 25\) 69:2 & 220:11 & 130:7 & MOLA_DEF... \\
\hline 132: 6 & 69:11 71:4 & 225:5,6 & 134:8 & 5:1] \\
\hline 143:16 & 71:16 & 234:21 & 141:16 & MOLA_DEF... \\
\hline 158:5,23 & 72:18 & 237:16 & 155:11 & 4:11 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022


Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 305 of 334 PageID \#: 11249
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 270:23 & 271:3,11 & 87:5 & occasion & offerings \\
\hline 271:14 & 272:4 & objected & 98:21 99:1 & 77:9 \\
\hline 273:23 & number 31: 8 & 176:10 & 180:25 & office 1:16 \\
\hline note 5:21 & 31:15 & objection & occasional & 6:2 8:25 \\
\hline 25:10 & 35:21 36:2 & 36:18 & 17:4,9 & 11:8,11 \\
\hline 26:11,22 & 36:8 37:3 & 47:14 54:8 & 29:16 & 14:9 43:6 \\
\hline 31:6 33:17 & 55:3,3 & 57:8 76:21 & 30:15 & 104:15 \\
\hline 97:22 & 67:3 & 78:3,17 & occasion. & 114:20 \\
\hline 100:14 & 102:15,20 & 79:1 80:16 & 38:7 51:19 & 222:24 \\
\hline 102:14 & 105:21 & 82:20 86:5 & 222:24 & 234:5 \\
\hline 118:12 & 111:19 & 89:24 & 241:4 & 271:17 \\
\hline 121:18 & 120:6 & 93:16 95:7 & 244:21,22 & officer \\
\hline 122:20 & 122:15,19 & 96:3 99:4 & 265:19 & 160:19,21 \\
\hline 124:21 & 129:24,25 & 101:2,6,20 & occasions & 192:25 \\
\hline 130:13 & 131:17 & 105:10 & 198:17 & 193:3,9 \\
\hline 185:23 & 136:13 & 106:6 & occur 64:22 & official 1:8 \\
\hline 211:11 & 146:11 & 110:7 & 213:4 & 96:14 \\
\hline 216:15 & 163:24,25 & 112:22 & 234:25 & 103:10 \\
\hline 242:19 & 165:13,18 & 115:12 & occurred & 215:3 \\
\hline 243:21 & 165:19 & 121:5 & 13:13 40:3 & 271:8 \\
\hline 244:6 & 169:6,14 & 123:3 & 84:12,14 & 272:3 \\
\hline noted 75:4 & 171:25 & 131: 6 & 100:6,10 & oftentimes \\
\hline 133:12 & 190:3 & 132: 6,21 & 173:8 & 114:9 \\
\hline notes 30:10 & 222:14 & 134:22 & 188:11 & oh 23:6 \\
\hline 30:14,14 & 241:25 & 137:22 & 213:1 & 28:17 \\
\hline 38:2,2 & nutshell & 138:5 & 216:25 & 40:10 \\
\hline 56:19,22 & 230:15 & 142:24 & 235:2 & 67:25 \\
\hline 84:24 85:2 & 97:7 & 143:16 & 236:15 & 72:23 \\
\hline 116:16,18 & & 158:5,21 & occurring & 85:19 \\
\hline 116:19 & 0 & 159:14 & 143:6 & 92:11 \\
\hline 119:18 & O254:20 & 161:16 & 250:2,24 & 93:17 \\
\hline 127: 6 & O'Boyle & 162:5,16 & occurs 54:17 & 100:20 \\
\hline 137:5 & 196:24,24 & 163:1,9 & October & 136:15 \\
\hline 168:10 & 197:15,23 & 165:7,23 & 252:22 & 149:8 \\
\hline 225:16,18 & 198:9 & 168:13 & 253:4 & 167:13 \\
\hline 241:8,9 & 199:4,21 & 176:1 & OD 14:9 & 218:3,8 \\
\hline notice 2:7 & 204:20 & 178:2 & odd 95:23 & 224:20 \\
\hline 21:18,21 & 207:4 & 193:13,24 & 248:3 & 225:8 \\
\hline 128:6 & 209:1 & 199:6 & offer 69:13 & 236:6 \\
\hline noticed & 211:5 & 231:15 & 89:18 & 239:24 \\
\hline 227:9 & 212:25 & 238:13 & offered & 240:22,22 \\
\hline noticing & 220:10 & 251:4 & 57:13 & 245:8 \\
\hline 240:8 & 248:2 & 259:25 & 152:1 & 260:8,24 \\
\hline November & O'Brien 21:8 & 266:24 & 213:24 & 261:14 \\
\hline 1:14 8:2 & 198:6 & objections & 231:10 & okay 12:12 \\
\hline 156:1,14 & OADC 11:10 & 10:9,10 & offering & 13:2 14:12 \\
\hline 163:20 & 12:24 & 176:4 & 69:4 70:24 & 14:19,21 \\
\hline 253:13,14 & 13:11,13 & objectives & 212:4 & 14:24 \\
\hline 270:16 & 14:9 18:25 & 11:22 & 230:10 & 15:19 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 306 of 334 PageID \#: 11250
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 20:12 & 101:11 & 171:24 & 235:9 & 100:9,12 \\
\hline 21:14 & 103:6,20 & 173:25 & 237:1,8 & 102:25 \\
\hline 23:12 24:5 & 105:20 & 174:1,2,13 & 238:4,21 & 111:25 \\
\hline 24:18 25:2 & 108: 6 & 176:14,20 & 239:23 & 112:9 \\
\hline 25:19 & 109:11,19 & 177:12 & 240:5,19 & 116:20 \\
\hline 26:12 27:8 & 110:10 & 178:16,24 & 241:5,7,13 & 122:14 \\
\hline 27:13,24 & 111:1 & 179:7,14 & 241:23 & 126:10 \\
\hline 28:13,24 & 113:5,21 & 179:14,19 & 242:1 & 141:7 \\
\hline 29:12,24 & 114:25 & 180:22 & 243:23 & 142:1 \\
\hline 30:3,7,23 & 115:8 & 182:3,8,14 & 244:4,19 & 144:13 \\
\hline 32:25 & 117:22 & 185:4 & 245:7,24 & 145:3,13 \\
\hline 35:20 & 118:5,6 & 186:25 & 246:24 & 145:21 \\
\hline 36:20 38:9 & 119:1,23 & 187:2,16 & 247:14 & 146:14,22 \\
\hline 38:21 & 121:1,21 & 189:9,17 & 248:8 & 148:18 \\
\hline 39:15 & 122:1,20 & 190:15 & 249:5,21 & 152:19 \\
\hline 42:21 43:8 & 123:12,19 & 191:12,25 & 250:23 & 155:13 \\
\hline 43:9,13,23 & 126:17 & 193:7 & 252:1,17 & 163:15,23 \\
\hline 44:4,16 & 127:9 & 195:11 & 253:6 & 166:4 \\
\hline 46:10,18 & 129:19 & 196:14,22 & 254:13,21 & 169:22 \\
\hline 46:25 47:2 & 130:5 & 198:4 & 256:9 & 173:22 \\
\hline 47:5,12,17 & 133:25 & 199:15 & 257:12 & 189:4 \\
\hline 47:24 & 135:13,25 & 201:22 & 260:11 & 196:17 \\
\hline 48:14 50:7 & 136:7 & 202:1,5,15 & 262:21 & 200:17 \\
\hline 50:11,22 & 140:5,22 & 202:21 & 263:13 & 219:21 \\
\hline 51:14 & 140:25 & 204:19 & 264:1,8 & 221:5 \\
\hline 52:13 56:5 & 141:7,12 & 207:19 & 265:1,4 & 226:6 \\
\hline 56:7,19,23 & 142:1,9,22 & 208:3,24 & 268:2,9 & 239:18 \\
\hline 60:21 & 143:12 & 209:14 & 269:11 & 241:7,19 \\
\hline 61:17 & 144:3 & 210:13 & older 42:22 & 246:9 \\
\hline 62:20 & 145:11,13 & 211:1,5 & 46:3 & 247:9 \\
\hline 63:13 64:1 & 147:6,9,15 & 213:5,21 & oldest 22:19 & 248:10 \\
\hline 64:7 65:23 & 148:17 & 214:3,25 & olds 4:3,6 & 249:17 \\
\hline 66:19,22 & 149:8 & 215:6,23 & 163:19 & 254:8 \\
\hline 66:23 67:9 & 150:8 & 215:25 & Omicron 4:17 & 257:7 \\
\hline 67:16,17 & 151:10 & 216:14,18 & 189:7 & 261:18 \\
\hline 68:7 70:14 & 152:7,13 & 217:7,23 & 190:5 & one-39:25 \\
\hline 70:22 & 153:4,12 & 218:9,12 & 191:22 & one-pagers \\
\hline 73:13 & 155:23 & 219:2,14 & 192:1,6,13 & 239:14 \\
\hline 74:23 & 156:7 & 220:9 & 194:6 & ones 9:23 \\
\hline 78:20 & 158:2,25 & 221:12 & Omicron- & 57:21 \\
\hline 79:12 80:2 & 162:23 & 223:25 & 189:18 & 93:12 \\
\hline 80:24 & 163:22 & 225:10 & 192:3 & 131:21 \\
\hline 82:25 83:8 & 164:19 & 226:2,12 & Omicron/. & 197:19 \\
\hline 85:25 & 165:23 & 226:17 & 191:4 & ongoing \\
\hline 90:24 & 167:9 & 227:15,24 & onboarding & 33:19 \\
\hline 95:20,24 & 168:17,23 & 228:12 & 97:1 100:4 & 160:9 \\
\hline 96:7,17 & 168:25 & 229:7,18 & 100:5,8,10 & 184:15 \\
\hline 97:12 & 170:10,22 & 230:7 & once 37:19 & online 89:12 \\
\hline 99:22,25 & 171:14,19 & 234:2,24 & 84:24 & Onyimba \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 174:6 & 117:8 & P & 192:1,4,5 & 255:10,15 \\
\hline 176:7 & 259:4 & P.m1:15 & 194:5 & parents \\
\hline 185:16 & origin & 47:1 61:19 & 214:19 & 165:15 \\
\hline 195:12 & 120:21 & \(64: 24\) & 216:6,7 & Parson \\
\hline 250:10 & original & 68:13 \(70: 4\) & 226:23 & 144:23 \\
\hline 251:2 & 5:21,23 & \(76: 3\) & 241:24 & 264:21 \\
\hline 254:19 & 22:7 35:12 & 102:10 & 243:15 & part 14:22 \\
\hline Onyimba's & 268:22,23 & 119:7 & 245:7 & 22:19,23 \\
\hline 182:14 & 271:11 & 126:19 & 250:7 & 25:9 26:6 \\
\hline open 149:4 & originally & 142:15 & 252:24 & 26:20 \\
\hline 179:24 & 36:23 & 144:2 & 271:12,14 & 32:18,19 \\
\hline opened & 231:3 & 145:19 & 271:17 & \(36: 16\) 48:1 \\
\hline 265:15 & originals & 150:3,3 & 272:5,9,13 & \(56: 25\) 59:1 \\
\hline operated & 268:21 & 156:15 & 272:17,21 & 59:8 60:22 \\
\hline 110:14 & originated & 180: 4, 7 & pages 52:24 & \(70: 7\) 81:23 \\
\hline operates & 181:25 & 205:10,10 & 189:18 & 92:7 \\
\hline 80:15 & OSHA 142:22 & 207:3 & 190:3 & 106:10,14 \\
\hline operations & ought 187:25 & 208:10 & 192:8 & 110:18,19 \\
\hline 11:17 & outbreak & 257:1,1 & 250:5 & 119:10 \\
\hline opinions & 16:14 & 269:19 & 270:8 & 129:18 \\
\hline 101:18 & outcome & P.06:4 & palsy 3:7,8 & 131:11 \\
\hline opportun & 270:13 & packet 22:5 & 111:14 & 137:7 \\
\hline 83:11 & outfit 217:7 & 68:1 & 112:16,19 & 145:7 \\
\hline Opportunity & outlets & page 2: 2, 6 & 112:21 & 151:24 \\
\hline \[
227: 2
\] & 207:8 & \[
2: 25 \quad 3: 25
\] & pandemic & 156:6 \\
\hline option 88:14 & outline & \(4: 17,24\) & 19:12 & 172:3,7 \\
\hline 213:25 & 11:25 & \(6: 25 \quad 22: 18\) & panel 189:24 & 192:17 \\
\hline options & outlined & 41:21 & 190:12 & 200:7 \\
\hline 34:11 & 27:19 & 48:16 & 191:4 & 214:14,17 \\
\hline 138:18,22 & outlining & 67:21, 24 & 192:17 & 235:2 \\
\hline 155:16 & 25:11 & 67:25 & 194:15,17 & 243:19 \\
\hline 212:11 & Outlook & 125:7 & 195:2 & \(244: 25\) \\
\hline 218:19 & 30:13 & 129:5 & 251:23 & 253:9 \\
\hline 220:25 & output 43:4 & 131:16 & panels & 259:16 \\
\hline orally 39:22 & outside & 133:4,5,5 & 193:23 & 263:4 \\
\hline order 30:21 & 127:25 & 133:6 & 194:3,8 & participate \\
\hline 120:9,11 & overall & 136:9,16 & 251:17 & 103:21 \\
\hline 131:8 & 33:25 & 141:23 & paper 39:19 & 260:19 \\
\hline 164:24 & 52:24 & 142:14 & 112:16 & particip. \\
\hline 205:22 & 143:21 & 143:12,25 & 113:8 & 84:2 \\
\hline 206:4 & overlap & 144:12 & papers 129:7 & 177:16 \\
\hline 210:13 & 14:16 15:7 & \(146: 20\) & paragraph & 198:15 \\
\hline organiza... & 232:13 & 166:17 & 127:17 & 246:22 \\
\hline 14:3 15:1 & oversee & 168:25 & 156:22 & particular \\
\hline 51:7 & 11:22 & \[
169: 12,14
\] & 166:18 & 20:20 \\
\hline 247:23 & overview & 179:22 & paragraphs & \(63: 2464: 3\) \\
\hline organiza... & 3:11 & \[
189: 7,11
\] & 156:14 & \[
89: 7
\] \\
\hline 33:24 & 190:17 & \[
190: 25
\] & pardon 54:21 & 104:24 \\
\hline \(37: 12\) & 191:14 & 191:1,20 & parentheses & 105:4 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 141:4 & 85:17 & 114:4 & 69:25 & 215:4,5 \\
\hline 148:17 & 105:21 & 115:13 & 128:19 & 244:6 \\
\hline 197:8 & 119:12 & 123:23 & 228:14,16 & personally \\
\hline 201:3 & 131:17 & 128:4 & percentage & 50:1 59:18 \\
\hline 240:13 & 221:15 & 129:8 & 113:9 & 90:10 \\
\hline 246:17 & 222:25 & 135:19 & perception & 147:19 \\
\hline 248:1 & 232:5,14 & 136:3 & 194:25 & Pfizer \\
\hline particul. & 234:10 & 137:2 & performs & 156:25 \\
\hline 64:11 & 237:10 & 138:20 & 15:6 & Phoenix \\
\hline 163:24 & 257:15 & 146:16 & period 23:13 & 223:2 \\
\hline 200:2 & 259:2 & 149:17 & 30:6 52:4 & phone 20:14 \\
\hline parties 8:11 & Payton's & 151:2 & 54:15 & 29:20,25 \\
\hline 31:11 & 24:19 & 154:13 & 180:24 & \(30: 1\) 31:14 \\
\hline 270:12 & 86:14 & 155:17 & 183:8 & \(35: 21\) 36:1 \\
\hline partner & 119:10 & 162:2,15 & 218:15,16 & \(36: 6\) 44:14 \\
\hline 111:3 & Payton/G & 162:24 & periodic & 56:20 \\
\hline 206:22 & 87:8 & 164:6,12 & 17:4 & 86:20 \\
\hline 211:21,24 & @f & 168:4,6,11 & periodic. & 102:15 \\
\hline 213:9 & 24:9 & 170:16 & 117:20 & 117:11 \\
\hline partnering & PCR 220:11 & 177:9,13 & 167:21 & 120:1 \\
\hline 79:23 & pdfs 41:6 & 181:6,15 & periods & 173:7 \\
\hline partnership & Peck 261 :17 & 181:18 & 61:13 & 197:21 \\
\hline 84:5 87:5 & pediatric & 185:24 & perjury & 198:18 \\
\hline partners & 158:12 & 186:15 & 273:12 & photo 227:20 \\
\hline 84:11 & 253:11 & 188:21 & Perron 50:25 & photos 54:2 \\
\hline parts 13:25 & penalty & 189:22 & 60:11,17 & physical \\
\hline 68:10 & 273:12 & 191:20 & 61:22 & 39:19 \\
\hline 110:19 & people 15:22 & 192:12 & 63:15 & physicians \\
\hline pasted 76:10 & 18:20 & 194:6 & 141:21 & 123:11 \\
\hline 76:14 82:2 & 20:14 & 204:17 & person 20:10 & 143:15 \\
\hline 82:13 & 23:22 29:6 & 210:21 & 25:16 & pick 9:17 \\
\hline 190:15 & 39:5,20 & 217:3 & 50:20 & 186:18, 21 \\
\hline patience & 41:17 & 222:15 & \(66: 15\) 75:2 & 187:5 \\
\hline 177:1 & 42:22,23 & 223:10 & 79:16,18 & picked 46:23 \\
\hline patients & 43:17 47:3 & 228:14,16 & 83:16 92:4 & 143:22 \\
\hline 113:9 & 48:22 & 228:17 & 107:18 & picture 76:1 \\
\hline 123:2 & 50:15 53:5 & 233:11,16 & 114:14 & 81:11 \\
\hline Payton 20:25 & 54:16 & 233:19,21 & 115:3 & 263:12,23 \\
\hline 23:4 24:7 & 56:16 & 244:21 & 123:24 & pictures \\
\hline 24:10 25:3 & 59:23 & 252:6 & 133:15 & 149:6 \\
\hline 26:11, 25 & 61:15 & 258:25 & 198:4 & piece 135:17 \\
\hline 27:5 28:11 & 68:24 & 259:2 & 238:16 & 190:7,13 \\
\hline 28:14,21 & \(70: 20 \quad 72: 5\) & 263:9 & 241:2 & pieces 39:19 \\
\hline \(30: 4\) 35:12 & 83:19 88:9 & 266:18 & 249:1 & 166:12 \\
\hline \(36: 11\) & 89:1 96:22 & peoples' & 250:14 & Pinterest \\
\hline 37:14 & 96:22,23 & 88:13 97:8 & personal & 180:24 \\
\hline 50:16, 24 & 97:4,20 & 212:16 & 24:3 35:23 & pipe 227:10 \\
\hline 63:11 & 98:11, 21 & percent & 62:12 & piped 133:23 \\
\hline 79:22 & 107:1 & 46:13 & 143:11 & 265:19 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 309 of 334 PageID \#: 11253
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline place 12:19 & 187:18 & 247:19 & point 20:24 & 105:17 \\
\hline 23:18 & 188:25 & 249:3 & 28:10,22 & 157:2,10 \\
\hline 95:21 & 196:15 & 253:18 & 31:20 35:3 & 158:3 \\
\hline 111:8 & 200:15 & 266:18 & 61:11 83:1 & 159:8 \\
\hline 115:25 & 205:19 & 267:10 & 89:5 92:22 & 160:2 \\
\hline 151:5,7 & 219:19 & player 28:16 & 99:11,13 & 162:11 \\
\hline 156:10 & 221:3 & players & 106:20 & 167:4 \\
\hline 178:1 & 226:4,6 & 43:16 & 107:21 & 169:8 \\
\hline 192:12 & 237:2 & 180:2 & 108:17 & 170:5,8 \\
\hline 194:18,20 & 239:16 & please 8:11 & 114:9 & 234:21 \\
\hline 215:22 & 241:17 & 9:4 11:1 & 119:11 & policy 4:3,5 \\
\hline 219:7 & 247:7 & 21:15 & 127:14,15 & 103:21 \\
\hline 225:15 & 249:7 & 27:12 & 127:16,24 & 104:2,9 \\
\hline 248:16 & 254:4 & 64:16 & 128:7 & 139:6 \\
\hline places 248:9 & 257:4 & 118:25 & 142:3 & 140:3 \\
\hline plaintiff & plan 34:15 & 119:17 & 153:10,24 & 150:14 \\
\hline 6:1 144:22 & 70:5 73:6 & 133:11 & 190:9 & 151:23 \\
\hline plaintiffs & 84:8 & 141:8,12 & 198:1 & 154:3 \\
\hline 1:5 6:6 & 182:20 & 144:7 & 199:21 & 156:2 \\
\hline 8:14 269:5 & 207:25 & 145:3,5 & 205:1 & 158:11 \\
\hline plaintiffs' & 263:15 & 152:12 & 207:21 & 159:21 \\
\hline 2:5 5:21 & planning & 155:21 & 223:1 & 163:18 \\
\hline 21:12 22:8 & 228:2 & 166:18 & 242:24 & 168:3 \\
\hline 31:7,9,12 & plans 230:15 & 167:5 & 249:2 & 169:20 \\
\hline 33:4 38:18 & platform & 169:23 & 254:15 & 170:14,17 \\
\hline 43:10 49:1 & 17:23 18:2 & 170:2 & pointed & 170:20 \\
\hline 60:3 67:12 & 18:13 & 176:23 & 89:16 & 211:19 \\
\hline 85:6 91:1 & 162:15 & 188:1 & 107:5 & 220:21 \\
\hline 102:16,18 & 228:17 & 200:17 & pointing & 255:2 \\
\hline 102:22 & 243:5 & 221:11 & 88:2,16 & politicians \\
\hline 112:5 & 245:25 & 226:7,8 & 89:20 & 148:22 \\
\hline 113:3,5 & 266:19 & 242:8 & 90:18 & poorly \(260: 4\) \\
\hline 118:7 & platforms & 247:10 & 195:6 & pop-ups \\
\hline 126:8 & 17:5 18:15 & 249:17 & points 3:23 & 157:8 \\
\hline 135:1 & 21:11 & 254:8 & 20:17,20 & populate \\
\hline 136:6 & 29:14 & 255:18 & 21:1 39:21 & 196:11 \\
\hline 138:23 & 50:12 88:7 & 271:10,13 & 60:20 & populated \\
\hline 141:6 & 154:1,16 & 271:16 & 63:20 82:2 & 191:16 \\
\hline 145:1 & 154:19 & pleased & 127:7 & populations \\
\hline 150:6,9 & 155:2 & 162:2 & 128:11,22 & 3:10 45:24 \\
\hline 152:16 & 161:15 & plus 46:4 & 134:10 & 46:6,7 \\
\hline 155:7 & 162:4 & 230:7 & polices & portal 91:24 \\
\hline 163:13 & 180:12 & 255:5 & 157:6 & 206:22 \\
\hline 164:17 & 208:10 & PM 247 :16 & policies & 211:22,25 \\
\hline 166:2 & 209:23 & POC 35:3, 4 & 15:24 & 212: 6 \\
\hline 171:15 & 220:16 & POCs 174:11 & 103:14,17 & 213: 6,6,10 \\
\hline 173:20 & 242:11 & 198:7 & 104:24 & 213:14,16 \\
\hline 179:9 & 243:25 & 242:15,22 & 105:4,6,9 & 214:14 \\
\hline 187:9,11 & 245:15 & 245:19 & 105:12,16 & 215:11,13 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 215:14 & 229:10,15 & 182:5 & 182:12 & 138:21 \\
\hline 217:24 & 229:17 & pregnant & 183:2 & 151:11 \\
\hline 218:21 & 230:20 & 46:4 & 199:3 & 173:17 \\
\hline 236:8,13 & 264:24 & preparation & 209:15 & 189:15 \\
\hline portals & posting & 93:9 94:15 & 258:4 & 197:21 \\
\hline 213:18 & 129:4 & presence & 261:19 & 200:7 \\
\hline 217:3 & 253:14 & 11:15,16 & previously & 209:11 \\
\hline portfolio & postings & present 7:5 & 78:1 80:17 & 212:11 \\
\hline 32:19 & 237:15 & 7:21 8:10 & 142:11,21 & 215:10 \\
\hline portion & posts 35:18 & 18:1 26:2 & 174:18 & 219:12 \\
\hline 80:20 & 53:1,14,22 & 37:16 73:6 & 209:12 & 221:15 \\
\hline 174:4 & 58:6 81:4 & presented & 211:13 & 223:4,11 \\
\hline portions & 89:8,14 & 7:21 & primarily & 235:12 \\
\hline 64:8,10 & 90:16 & 138:23 & 113:17 & 245:2 \\
\hline pos-236:17 & 92:17 & 141:6 & 156:5 & 255:22 \\
\hline positions & 103:15 & 172:17 & primary & problem 4:18 \\
\hline 39:21 & 135:16 & presents & 20:24 & 4:21 \\
\hline positive & 149:6,19 & 194:23 & Prion's & 168:22 \\
\hline 63:22 & 155:19 & President & 122:3 & 196:20 \\
\hline 66:16 & 157:9 & 1:9 271:8 & prior 13:16 & 201:20 \\
\hline possible & 168:3,5 & 272:3 & 19:1,6 & 204:5 \\
\hline 120:20 & 170:15 & press 125:24 & 29:15,19 & 215:6,7,19 \\
\hline 139:15,16 & 207:15,24 & 160:19,20 & 58:4 209:4 & 219:8 \\
\hline 174:24 & 212:14 & presume & 209:6 & 238:12,17 \\
\hline 177:3 & 220:14 & 91:12 & 212:23 & problematic \\
\hline 188:2 & 258:7,9 & pretty 34:16 & priority & 197:6 \\
\hline 242:13 & 265:3 & 37:7 46:24 & 215:9,17 & 201:1 \\
\hline 243:2 & 266:4 & 90:20 & privilege & 212:5 \\
\hline possibly & potential & 119:3 & 93:22 & problems \\
\hline 34:25 & 53:15 & 121:13 & 94:22 & 219:10 \\
\hline 51:17 & 182:24 & 141:20 & Priya 50:22 & proceed 9:9 \\
\hline 58:16 & 184:8 & 159:11 & 50:23 & proceeding \\
\hline 140:8 & potentially & 179:6 & proactively & 7:22 \\
\hline post 76:4 & 132:11 & 181:16 & 262:24 & process \\
\hline 104:24 & 155:19 & 190:4 & probably & 10:14 \\
\hline 105:4 & power 153:9 & 192:6 & 29:10 & 92:23 93:2 \\
\hline 135:18,20 & PowerPoint & 258:13 & 30:13 & 127:20 \\
\hline 149:7 & 199:1,2 & Prevention & 35:19 37:8 & 128:1,2 \\
\hline 157: 6 & 210:23 & 1:17 6:16 & 39:25 42:4 & 129:15,17 \\
\hline 162:24 & practice & 7:6,12 & 56:16 61:1 & 131:11 \\
\hline 207:25 & 93:13 & previous & 61:13 69:3 & 216:21 \\
\hline 227:22 & 154:23 & 16:8 41:7 & \(70: 872: 5\) & 242:13 \\
\hline 229:6 & practices & 67:22 68:4 & 82:13 & 243:2 \\
\hline post-vac. & 34:18 & 102:17 & 83:13 & processes \\
\hline 62:8 63:22 & 253:22 & 119:21 & 90:20 & 131:1 \\
\hline 65:4 & preference & 138:19 & 108:14,15 & produce \\
\hline posted 59:13 & 43:3 & 140:19 & 115:15 & 84:19 \\
\hline 109:4 & preferred & 147:24 & 120:5,17 & produced \\
\hline 212:5 & 180:1 & 161:2 & 121:13 & 46:3 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 311 of 334 PageID \#: 11255
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline product & 245:23 & 161:23 & 214:11 & 251:15 \\
\hline 221:19 & proposal & 166:22 & 251:3 & 254:3 \\
\hline products & 84:4 & 183:10 & purposes & 256:19 \\
\hline 195:19 & proposals & 194:8 & 16:24 22:7 & 263:24 \\
\hline professi & 27:25 28:1 & 222:1 & 32:2 57:22 & 268:21 \\
\hline 203:15 & 132:5,14 & 261:4 & 147:1 & puts 123:7 \\
\hline progeste & 132:19,22 & provides & pursuant & 212:6 \\
\hline 255:9,14 & 165:19 & 11:14 & 7:19 21:21 & Putting \\
\hline program & propose & 227:5 & 102:16 & 168:20 \\
\hline 172:11,13 & 208:12 & providing & put 22:2 & \\
\hline programs & 209:17 & 51:23 52:2 & 30:21 & Q \\
\hline 71:8 & proposed & 54:13 & 32:23 & Q\&A 34:10,25 \\
\hline project 4:12 & 27:20 & 128:13 & 39:19 & 36:17,25 \\
\hline 46:9,15 & 69:20 & 161:23 & 40:16 43:8 & 37:6 \\
\hline 48:18 & 122:3 & 167:20 & 48:13 & Qs 70:10 \\
\hline 55:23 & 252:9 & PS 170:22 & 52:15 60:1 & question \\
\hline 70:16,18 & protection & public 12:5 & 85:4 90:24 & 10:1,3,11 \\
\hline 173:25 & 164:9 & 12:19,23 & 92:20 93:5 & 14:23 \\
\hline 174:22 & proteins & 13:8,10 & 100:12,19 & 39:15 41:9 \\
\hline 175:15,17 & 139:13 & 14:10 15:4 & 115:9 & 48:15 \\
\hline 176:12,18 & protocols & 18:13 19:9 & 118:5 & 66:25 \\
\hline 176:22 & 65:4 & 29:22 32:7 & 126:6 & 67:19 \\
\hline projects & prove 122:16 & 32:18 & 130:23 & 71:22 \\
\hline 48:3,10 & provide & 33:25 & 132:24,25 & 73:15 \\
\hline 221:20 & 11:15,18 & 143:15 & 144:25 & 74:21,22 \\
\hline 224:13 & 15:15,15 & 144:21 & 149:6,18 & 75:5,7,13 \\
\hline promote & 15:17 & 222:23 & 149:19 & 78:7,12,13 \\
\hline 81:22 & 27:15 & 237:17 & 153:9 & 79:15,17 \\
\hline 232:10 & 48:21 & 270:23 & 162:23 & 81:5 90:3 \\
\hline promoted & 50:21 51:2 & 271:14 & 171:11,13 & 93:7,8,20 \\
\hline 228:10 & 51:12,13 & 273:23 & 175:8 & 98:6,7 \\
\hline promotion & 52:7 72:17 & publicly & 179:7 & 99:8 \\
\hline 227:1,3 & 92:2 & 72:3 & 187:4,7 & 100:24 \\
\hline 228:3,5,7 & 105:17 & publicly. & 194:19 & 105:1 \\
\hline 228:13,24 & 106:21,22 & 59:9 & 196:13 & 106:15 \\
\hline 230:10 & 116:10 & pull 177:2,8 & 199:20 & 111:17,25 \\
\hline 233:14 & 128:11 & 230:12 & 200:14 & 112:11 \\
\hline promotions & 138:10 & pulled 48:3 & 201:11 & 118:11 \\
\hline 234:16 & 158:17 & 222:2 & 202:22 & 120:18 \\
\hline prompted & 159:10 & pulling & 205:2 & 126:5 \\
\hline 230:19 & 160:9 & 92:22 & 219:17 & 128:22 \\
\hline proof 146:1 & 220:13,16 & 236:7 & 221:2 & 129:12 \\
\hline properly & 238:18 & Pundit & 224:17 & 135:8 \\
\hline 216:22 & 259:24 & 264:15 & 226:2 & 146:5 \\
\hline properties & provided & purpose & 231:9 & 148:24 \\
\hline 50:4,5,7,8 & 29:21 & 57:23 & 236:24 & 156:17 \\
\hline 154:25 & \(71: 15\) & 110:20,22 & 239:12 & 158:9 \\
\hline 155:1 & 90:22 & 145:21 & 247:5 & 159:1 \\
\hline property & 113:13 & 147:7 & 249:5 & 164:1 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 312 of 334 PageID \#: 11256
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 181:5 & question... & re-reading & 200:22 & 160:7 \\
\hline 183:22 & 75:3 & 125:22 & 201:23 & 168:24 \\
\hline 185:17 & quick 27:22 & reach 2:13 & 205:14,14 & 178:21 \\
\hline 186:13 & 28:23 & 2:16 17:5 & 207:19,21 & 200:11 \\
\hline 188:1 & 135:6 & 17:6 39:9 & 208:6,8 & 228:7 \\
\hline 224:4 & 211:12 & 43:21 & 216:18 & 235:9 \\
\hline 235:24 & Quicker & 44:10 & 217:13 & reads 22:20 \\
\hline 236:5 & 23:23 & 228:14 & 218:12 & 23:20 \\
\hline 240:12 & quickly & reaction & 221:7,11 & ready 206:12 \\
\hline 248:18 & 173:5,16 & 168:12 & 226:7,8 & 206:13 \\
\hline 251:6 & quite 111:10 & reactions & 227:6 & 229:21 \\
\hline 259:19 & 190:24 & 164:13 & 228:20 & 239:23,24 \\
\hline questioning & quote 103:14 & read 8:20 & 229:2,22 & real 135: 6 \\
\hline 31:21 & 120:12 & 22:10 23:2 & 229:23 & realize \\
\hline questions & 129:1 & 25:4,20,21 & 230:3,5,7 & 219:3 \\
\hline 4:9 10:1 & 146:1 & 27:8,11,13 & 234:11,12 & realized \\
\hline 68:16,20 & quotes 226:9 & 46:19 & 237:5,12 & 41:6 \\
\hline 69:5,5,10 & & 52:17 & 239:18,19 & 205:23 \\
\hline 69:14,20 & R & 65:22 & 241:20 & really 9:22 \\
\hline 69:22 73:9 & R1:7 8:5 & 68:11 70:3 & 242:8,9 & 12:7 29:9 \\
\hline 73:19 & 270:1 & 85:14,15 & 245:13 & 32:15,16 \\
\hline 74:13 75:1 & 271:7 & 91:3 103:3 & 247:11,17 & 38:13 64:5 \\
\hline 79:18,25 & 272:2 & 112:8 & 252:12,18 & 92:21 \\
\hline 113:20,25 & Rachel & 127:4 & 252:24 & 101:24 \\
\hline 120:8 & 254:14,25 & 136:8,25 & 253:10 & 110:24 \\
\hline 128:12,15 & 256:7 & 145:5,8,10 & 254:12,13 & 130:20 \\
\hline 129:19 & Raena 222:10 & 152:19,21 & 254:24 & 138:8,9 \\
\hline 139:18 & raise 95:10 & 153:2 & 255:8,13 & 143:1,4 \\
\hline 144:5 & \(\operatorname{ran} 154: 12\) & 155:24 & 257:7 & 189:20 \\
\hline 152:1,4 & 175:12 & 156:13,23 & 260:15 & 207:17 \\
\hline 156:20 & 210:11 & 162:10 & 261:12,17 & 234:3 \\
\hline 161:1 & 265:12,13 & 163:16,17 & 262:13,23 & 236:13 \\
\hline 163:24 & 267:14 & 166:5,9,9 & 268:5 & reask 14:22 \\
\hline 166:7,10 & range 169:25 & 166:18,20 & 271:13 & 71:22 \\
\hline 167:21 & 187:4 & 168:2 & 272:6,10 & 158:9 \\
\hline 171:23 & rare 164:13 & 170:13 & 272:14,18 & reason 25:14 \\
\hline 172:17 & rarely 21:8 & 171:18 & 272:22 & 36:20 76:8 \\
\hline 173:5 & 128:3 & 173:22,23 & 273:6 & 82:7 185:6 \\
\hline 181:11 & 195:9 & 173:24 & readily & 272:7,11 \\
\hline 188:4,20 & 225:18 & 174:15,17 & 108:14 & 272:15,19 \\
\hline 224:2,9 & rate 3:9 & 176:7,23 & reading & 272:23 \\
\hline 229:1 & 111:20 & 179:11,22 & 26:13 & reasons 59:6 \\
\hline 247:21 & 113:9 & 182:14,17 & 42:11 & 142:10 \\
\hline 255:18 & 122:14 & 187:13,25 & 47:11 & recall 17:17 \\
\hline 263:25 & rates 122:19 & 188:1 & 50:19 & 17:21 \\
\hline 264:25 & 169:5 & 189:6 & 51:10 & 19:19 \\
\hline 267:12,17 & re-ask 251: 6 & 196:18,19 & 67:15 & 20:20 \\
\hline 267:22 & re-evalu. & 197:2 & 70:12 75:8 & 21:10 \\
\hline 268:1,3 & 76:7 & 200:17,18 & 77:2 91:22 & 29:11,17 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 313 of 334 PageID \#: 11257
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 30:5,14 & 198:16 & recipient & record 8:1 & 127:18 \\
\hline 32:14 & 199:1 & 60:10,12 & 9:19,21 & 175:10,14 \\
\hline \(35: 15\) 36:6 & 201:8 & 220:2 & 11:1 30:17 & 180:5 \\
\hline 36:11 & 202:7 & recognize & \(30: 2431: 3\) & 255:22 \\
\hline \(37: 13\) 38:1 & 213:7,15 & 22:11 33:8 & 37:21 & 256:15 \\
\hline 38: 4, 6,9 & 217:1 & 49:6 67:14 & 52:16 55:8 & reference \\
\hline 38:11 39:2 & 219:14 & 67:21 & 69:19 & 34:14 \\
\hline 39:13 & 222:9,11 & 97:19 & 92:19 93:1 & 55:15 69:3 \\
\hline 46:23 & 223:1 & 174:9 & 97:24,25 & \(70: 279: 22\) \\
\hline 51:11 57:4 & 224:18 & 206:18 & 98:1,2,3 & 80:11 \\
\hline 57:17, 20 & 225:21 & 222:15 & 102:9,11 & 81:14 \\
\hline 58:10,11 & 230:18,23 & 249:22 & 150:2,5 & 129:10 \\
\hline 61:11 & 234:2 & recollec. & 156:15 & 130:12 \\
\hline 65:19,21 & 235:3, 4, 21 & 18:1,4 & 203:12 & 183:23 \\
\hline 66:2,8 & 235:23 & 26:2 29:21 & 205:8, 9, 11 & 184:14,15 \\
\hline 68:23,24 & 236:10 & 32:23 & 225:17 & 185:21 \\
\hline \(71: 20 \quad 72: 1\) & 240:16,18 & 37:13,16 & 236:2 & 195:24 \\
\hline \(72: 283: 8\) & 240:22 & 40:11 & 241:8 & 208:23 \\
\hline 88:5 89:13 & 241:10 & \(42: 20 \quad 46: 9\) & 245:13 & references \\
\hline 89:15 & 244:19 & 48:18 52:8 & 247:17 & 72:21 \\
\hline 92:23 93:1 & 246:14 & 68:4 72:16 & 256:24,25 & 243:7 \\
\hline 99:13,14 & 256:16 & 75:13 & 257:2 & referencing \\
\hline 99:21 & 260:6 & \(76: 12\) & 261:2 & 149:16 \\
\hline 104:25 & 264:23 & \(87: 1788: 6\) & 265:5 & 196:9 \\
\hline 109:3 & 267:9,23 & 90:18 92:4 & 268:10,21 & 243:9 \\
\hline 110:25 & recalled & 94:1,7 & 269:18 & 258:3 \\
\hline 111:18 & 32:5 & 95:15 & 270:10 & 266:15 \\
\hline 115:24 & receive & 96:13 & recorded & referring \\
\hline 116:1,2 & 71:12 & 100:7 & 31:14 85:1 & 12:25 \\
\hline 119:23 & received & 106:23 & 102:19 & 34:12 \\
\hline 125:9 & 59:4 64:7 & 116:6 & recordings & \(36: 15\) 42:8 \\
\hline 136:4 & 97:15 & 125:22 & 84:25 & 42:10 \\
\hline 140:13,15 & 143:7 & 142:13 & 225:16 & 48:10 55:1 \\
\hline 142:8 & 158:15 & 143:10 & records & 56:14 \\
\hline 144:11 & 164:15 & 152:3 & 30:11,18 & 91:21 \\
\hline 150:20 & 198:1 & 159:18 & 56:19 & 116:13 \\
\hline 151:17 & 238:23,24 & 216:24 & 116:16 & 118:20,22 \\
\hline 152:11 & receiving & 217:1 & reduce & 129:3 \\
\hline 153:4 & 57:23 & 235:1 & 103:16 & 142:19 \\
\hline 154:7, 9, 12 & 76:17 & 242:18 & 138:20 & 143:9 \\
\hline 155:6 & 82:18 & 246:1 & reel 227:11 & 144:21 \\
\hline 177:25 & 137:2 & recollec... & 229:9 & 165:16 \\
\hline 178:9 & 142:3 & 117:24 & reestabl. & 175:9,11 \\
\hline 182:7 & 154:8 & Recommend & 102:14 & 175:20 \\
\hline 183:11 & recess 31:1 & 41:24 & reevaluated & 176:21 \\
\hline 184:5 & 102:10 & recommen. . . & 82:6 & 191:7 \\
\hline 185:8,10 & 150:3 & 29:10 & refer 39:12 & 196:10 \\
\hline 193:18 & 205:10 & reconsider & 72:1,21 & refers 56:20 \\
\hline 197:16 & 257:1 & 169:8 & 113:23 & 56:20 \\
\hline
\end{tabular}

LEXITAS LEGAL

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 68:21 82:8 & 174:24 & 222:24 & 196:8 & 162:25 \\
\hline 100:1 & 178:23 & relation... & 198:8,17 & 168:4 \\
\hline 125:8 & 179:3,24 & 112:16,18 & 200:5 & 212:12 \\
\hline reflect & 180: 4,11 & relative & 202:4 & 257:9,19 \\
\hline 195:19 & 180:16,17 & 65:16 & 203:19 & 258:8,11 \\
\hline 196:9 & 180:23 & 156:21 & 213:11,19 & 262:24 \\
\hline 236:2 & 181:2 & relayed & 215:19 & 263:11 \\
\hline reflected & 184:17 & 45:23 & 225:24,25 & removing \\
\hline 263:8 & 188:9,12 & 239:1 & 227:9,13 & 38:5 81:8 \\
\hline reflecting & 197:5 & relevant & 232:2 & 88:13 \\
\hline 162:1 & 198:12,13 & 219:6 & 233:9 & 155:19 \\
\hline refresh & 198:16 & religious & 241:15 & 162:14,21 \\
\hline 93:25 94:6 & 200:25 & 146:16 & 244:17 & renamed \\
\hline 106:14 & 215:11 & remember & 246:11 & 231:4 \\
\hline refreshed & 244:22 & 25:9 26:6 & 265:2 & render 273:9 \\
\hline 31:24 & regularly & 38:1,7,12 & remembered & reoorg 19:6 \\
\hline refresher & 21:11 37:8 & 41:3,20 & 68:3 245:5 & reorg 19:4 \\
\hline 262:16 & 70:9 & 51:14 & remembering & reorgani. \\
\hline refusal & 174:23 & 64:17 & 81:21 & 13:13,22 \\
\hline 63:21 & 175:16 & 73:14 & remind 203:1 & 16:9 19:2 \\
\hline 170:1 & 179:6 & 80:10 & 211:20 & rep 260:19 \\
\hline refusals & 185:11 & 82:21 & 217:5 & 261:17 \\
\hline 156:19 & 222:23 & 83:20 & 246:24 & repeat 12:21 \\
\hline 157:17,25 & 240:11 & 84:13 89:9 & reminds & 67:19 \\
\hline 164:3 & Regulations & 92:17,21 & 216:20 & 74:21 \\
\hline refusing & 7:20 & 92:25 & Remotely & 245:8 \\
\hline 53:17 58:6 & Reingold & 98:16,25 & 31:16 & repeatedly \\
\hline regarding & 96:23 & 109:5 & removal & 157:5 \\
\hline 57:16 & 100:22 & 111:21 & 220:25 & rephrase \\
\hline 58:20 83:3 & 101:1,8 & 117:4,6,9 & removals & 10:2,11 \\
\hline 99:19 & 217:7 & 117:10 & 75:5,7,12 & 78:7 90:3 \\
\hline 107:23 & rel 1:3 & 125:17 & 80:13,15 & 178:7 \\
\hline 154:14 & 271:7 & 130:15 & remove 33:25 & 204:10 \\
\hline 160:11 & 272:2 & 133:19 & 37:12 & replace \\
\hline 161:1 & related & 136:23 & 75:19 & 29:13 \\
\hline 167:5 & 92:22 & 140:20 & 90:11 & 42:22 \\
\hline 182:24 & 110:5,10 & 149:5 & 103:16 & replaced \\
\hline 184:8 & 185:23 & 151:6,25 & 138:21 & 254:16,18 \\
\hline 199:2 & 223:5 & 153:15 & 157:2 & replicate \\
\hline 207:15 & 232:12 & 160:11 & 159:21 & 110:21 \\
\hline 219:13 & 245:22 & 171:3 & 162:11 & replied \\
\hline 224:22 & 266:6 & 173:13 & 168:3 & 248:6 \\
\hline 234:12 & 270:11 & 174:11 & 170:15 & reply 34:6 \\
\hline 249:19 & relating & 177:17,24 & 220:24 & 216:8,17 \\
\hline regular & 105:8 & 183:22 & 258:16 & report 18:23 \\
\hline 16:13 17:8 & relation & 184:2,4 & removed 5:18 & 18:24 19:1 \\
\hline 74:3,5 & 210:7 & 188:19,23 & 75:25 76:6 & 19:6,12,14 \\
\hline 107:22 & 261:9 & 193:17 & 81:2,4 & 19:17 \\
\hline 167:2 & relations & 195:23 & 103:15 & 51:12 52:1 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 52:21 & 60:21 66:1 & 175:12 & reserved & 66:14 70:3 \\
\hline 54:13 & 91:9,24 & 204:6 & 269:20 & 72:13 \\
\hline 55:14 58:8 & 97:2 & 212:9 & resolve & 106:5,16 \\
\hline 59:9 60:19 & 101:18 & 230:1 & 182:11 & 107:7,20 \\
\hline 60:22,25 & 122:24 & 250:13 & resolved & 114:4 \\
\hline 62:1,14 & 141:21 & 258:5,6 & 185:15 & 117:6 \\
\hline 63:16 & 142:10 & 262:17,20 & respect & 123:24 \\
\hline 64:18 & 158:3 & 262:25 & 128:23 & 136:3 \\
\hline 65:15 & 169:5 & 263:7,12 & respective & 140:17 \\
\hline 66:12 & 214:10 & represent & 259:3 & 160:23 \\
\hline 76:16 81:1 & 218:19 & 8:12,14 & Respiratory & 164:14 \\
\hline 81:3 91:25 & 229:20 & 9:1,2 & 107:14 & 165:5 \\
\hline 95:22 & 234:17,19 & 112:12 & 160:22 & 170:22 \\
\hline 96:15 & 234:22 & 164:20 & respond 28:3 & 176:7,24 \\
\hline 98:19,23 & reports \(2: 18\) & represen. & 121:22 & 177:19 \\
\hline 99:3 123:1 & 2:20 3:17 & 8:18,23 & 122:4 & 182:15 \\
\hline 123:10 & 3:20 49:13 & request 4:18 & 124:9 & 197:3 \\
\hline 143:5,23 & 50:21 51:2 & 4:20 27:3 & 132:9 & 200:23 \\
\hline 144:6 & 51:4,18,20 & 31:7 78:24 & 160:14 & 211:1 \\
\hline 149:4 & 52:9,9,10 & 84:20 93:4 & 171:1 & 216:10 \\
\hline 152:5 & 53:1,16,25 & 141:4 & 184:19 & 230:3,5 \\
\hline 164:20 & 54:2,22 & 196:20 & 186:8 & 232:19 \\
\hline 212:4 & 55:7 56:18 & 200:22 & 201:7 & 234:11 \\
\hline 213:18 & 57:6,12,14 & 201:19 & 214:3 & 237:24 \\
\hline 260:15 & 57:16,18 & 242:6 & 235:15 & responses \\
\hline 261:14 & 57:23 58:5 & requested & 255:20 & 124:8 \\
\hline report/file & 58:7,22,24 & 47:25 & 259:6 & 129:23 \\
\hline 259:18 & 58:25 59:4 & 216:19 & 261:12,16 & 171:10 \\
\hline reported & 59:14,17 & requesting & 262:21 & responsi \\
\hline 19:8 24:16 & 59:19,22 & 255:2 & responded & 212:19 \\
\hline 92:16 & 60:7,18 & requests & 108:24 & responsible \\
\hline 123:18 & 61:24 62:7 & 140:17 & 164:5 & 26:9 95:13 \\
\hline 135:2 & 62:12 & 221:19 & 165:14 & rest 163:17 \\
\hline reporter & 63:25 & 234:14 & 186:7 & restful \\
\hline 1:19 9:4,8 & 66:17 & 250:3 & 238:3 & 126:20 \\
\hline 9:16 & \(71: 1672: 3\) & required & 245:3 & restrict. \\
\hline 171:25 & 72:4 75:24 & 115:6 & responding & 148:23 \\
\hline 256:18 & 77:11,13 & requirement & 27:3 28:8 & result \\
\hline 268:25 & 81:1 & 138:2 & 218:1 & 151:11 \\
\hline 270:5 & 141:10,24 & reread 74:19 & responds & 156:24 \\
\hline reporter's & 142:2 & rereading & 192:21,22 & 160:5 \\
\hline 5:21 8:8 & 143:20 & 91:19 & 214:8 & 166:24 \\
\hline 26:22 & 145:6,14 & research & 251:25 & 167:18,19 \\
\hline 97:22 & 146:23 & 59:2 72:6 & 258:15 & 250:4 \\
\hline 118:12 & 147:5,13 & 72:9,10 & response & results \\
\hline reporting & 147:18,19 & 81:1 & 2:11 4:7 & 189:22 \\
\hline 3:3 7:20 & 147:23 & 147:16 & 33:12 59:2 & 191:11 \\
\hline 51:24 & 148:2,9,11 & 258:6 & 59:6 61:15 & 192:16 \\
\hline 58:10 & 154:13 & reserve 8:19 & 61:16 & 195:4 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 316 of 334 PageID \#: 11260
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 251:19 & 35:2 36:25 & 111:23 & 175:2,14 & 243:15,18 \\
\hline return & 37:10,19 & 112:15 & 176:5,23 & 244:8,14 \\
\hline 146:16 & 38:16,22 & 113:14 & 177:1,7,22 & 245:21 \\
\hline 173:17 & \(38: 24\) 39:4 & 114:3,14 & 177:25 & 246:6,9,21 \\
\hline 271:16 & 39:11,18 & 115:8 & 178:12,16 & 247:5 \\
\hline reversing & 40:6, 9, 20 & 116:25 & 179:21 & 248:2,14 \\
\hline 255:9,14 & 40:22 41:1 & 119:2,4 & 180:20 & 248:23 \\
\hline review 5:15 & 41:1,5,19 & 120:6,10 & 181:19 & 249:22 \\
\hline 8:20,20 & 41:21 & 120:15 & 183:13,24 & 250:6,17 \\
\hline 38:25 & 42:12,16 & 121:23,24 & 184:6 & 251:1,23 \\
\hline 47:25 & 43:2,4,17 & 122:5,5,10 & 185:16 & 251:25 \\
\hline 93:10 & 45:15,20 & 123:14 & 186:16 & 252:4 \\
\hline 124:22 & \(46: 8\) 48:1 & 124:4,12 & 189:2,10 & 253:1, 4, 22 \\
\hline 145:9 & 48:9 49:6 & 124:23,24 & 190:10,23 & 254:22,24 \\
\hline 211:14 & 49:14,15 & 126:6,25 & 191:1 & 255:17 \\
\hline 212:7 & 49:22,24 & 127:2 & 192:22 & 256:17 \\
\hline 250:3 & 53:13,17 & 128:9,18 & 194:15 & 257:6,13 \\
\hline 254:11 & 54:21 60:1 & 129:11 & 195:15 & 258:16 \\
\hline reviewed & 60:5,8,13 & 130:25 & 196:23,25 & 259:6,14 \\
\hline 93:11,24 & 60:15 61:3 & 131:18,25 & 197:13 & 259:21 \\
\hline 94:4,10,14 & \(61: 962: 4\) & 132:25 & 201:16 & 260:14 \\
\hline 118:2 & 62:5,7 & 133:16 & 202:14 & 261: 6 \\
\hline 131:10 & 63:4 64:14 & 134:18 & 204:3, 8 & 262:2,8,11 \\
\hline 206:23 & 66:6,13 & 136:5 & 206:1,8,14 & 264:17,19 \\
\hline 211:13,23 & 67:14,18 & 137:11 & 207:20 & 266:7 \\
\hline 255:4 & 68:11,21 & 139:4,11 & 208:15,21 & 267:25 \\
\hline reviewing & 69:15 71:7 & 139:19 & 210:10 & 268:5,8 \\
\hline 31:24 & \(72: 14 \quad 74: 2\) & 143:7 & 211:3,9 & risk 42:23 \\
\hline 97:10 & \(75: 276: 2\) & 144:12 & 213:13 & 156:18 \\
\hline 118:19 & \(77: 25 \quad 79: 9\) & 145:25 & 214:6,21 & risks 53:15 \\
\hline right 8:20 & 79:16,17 & 146:6 & 215:22 & Road 1:17 \\
\hline 9:15 10:22 & 81:7,16,25 & 150:11,17 & 219:7,17 & role 11: 13 \\
\hline 11:1 15:10 & 85:14 86:2 & 156:8,10 & 220:5 & 12:18 15:1 \\
\hline 16:24 & 86:9,16,22 & 156:13 & 221:13 & 16:1,8 \\
\hline 17:10 & 87:7,11 & 157:12,17 & 222:5,14 & 18:23,24 \\
\hline 19:11,19 & 88:19,23 & 157:19 & 224:12, 25 & 24:24 32:8 \\
\hline 20:1 21:19 & 89:13 & 159:22 & 225:5 & 40:19 \\
\hline 21:23 22:2 & 91:12,17 & 160:5 & 226:13,22 & 86:13 \\
\hline 22:13,19 & 92:3,19 & 161:3,11 & 226:25 & 115:18 \\
\hline 23:1 24:6 & 93:3,14 & 161:15 & 227:5 & 161:21,21 \\
\hline 24:19, 23 & 95:9,13 & 163:5,8,23 & 230:16 & 183: 6 \\
\hline 25:7 26:5 & 96:20 97:2 & 164:3,6,14 & 233:16,23 & 220:12 \\
\hline 26:20 27:1 & 97:4,18 & 165:25 & 234:4,9 & roles 15:5 \\
\hline 27:24 28:3 & 98:6 99:12 & 166:15 & 235:15,16 & 31:25 \\
\hline 28:6 30:1 & 102:1,24 & 167:10,23 & 236:21,24 & 107:19 \\
\hline 30:19 & 103:15 & 168:8,12 & 240:3,7,12 & 223:11 \\
\hline 31:23 & 107:4 & 170:16, 24 & 241:24 & rollout 53:3 \\
\hline \(32: 21\) & 109:7 & 172:2,4,14 & 242:6,17 & room 97:23 \\
\hline \(33: 13\) 34:2 & 111:7,12 & 172:22 & 242:22,24 & 133:15 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline rose 151: 1 & SARS-CoV-2 & 24:12 26:5 & 223:18 & 167:20 \\
\hline Rosie 107:25 & 3:7,8 & 33:16,17 & 227:1 & 169:10 \\
\hline 114:22 & Sauer 6:2 & 33:23 34:5 & 228:2,12 & 170:20 \\
\hline 115:10 & 26:22 & 40:8,10,23 & 228:20 & 266:19 \\
\hline 120:2 & 30:19 & 41:24 42:8 & 229:14 & scientif. \\
\hline 124:1,9 & 267:20 & 44:9 45:22 & 238:11 & 162:22 \\
\hline 133:22 & 268:12,16 & 47:8 48:2 & 247:15 & scientist \\
\hline 135:21 & 268:24 & 51:3,21,22 & 257:18 & 108:12 \\
\hline rotate 28:25 & 269:4 & 52:3,25 & 260:15,20 & 129:20 \\
\hline round 31:20 & save 182:22 & 53:13,19 & \(\boldsymbol{\operatorname { s c a n }} 85: 20\) & 168:18 \\
\hline routinely & 184:7 & 55:3,4,21 & 211:12 & scientists \\
\hline 77:17 & saw 45:16 & 63:5,14,15 & scanned & 121:24 \\
\hline rudely 98:7 & 94:13 & 63:17 & 108:14 & 122:18 \\
\hline rules 7:19 & 98:22 & 65:14 & 141:13 & scope 19:25 \\
\hline 9:16 & 110:4 & 72:23 73:4 & schedule & scoping \\
\hline run 77:11 & 120:7,23 & 74:12,14 & 177:3 & 105:23 \\
\hline 147:13 & 130:15 & 80:12 82:6 & 198:17 & screen \\
\hline 195:9 & 132:15,25 & 87:7 91:9 & 232:24 & 237:15 \\
\hline 222:21 & 149:11 & 96:21 & 234:18 & screening \\
\hline 224:9 & 191:21 & 103:16 & 235:12,14 & 237:17 \\
\hline 227:2,24 & 203:25 & 105:22 & Scheer 239:5 & screenshot \\
\hline 228:13 & 209:8 & 119:13 & Schmitt 1:3 & 186:19 \\
\hline running & 220:13 & 120:12,18 & 149:1 & 190:11 \\
\hline 261:25 & 227:4 & 122:16,20 & 265:8 & 191:9 \\
\hline & 251:22 & 128:16 & 271:7 & 195:5 \\
\hline S & saying 38:11 & 133:10 & 272:2 & 214:16 \\
\hline S 1:3,20 7:5 & 51:12 & 134:24 & school 12:3 & screenshots \\
\hline 270:4,22 & 75:10,11 & 139: 6 & science & 251:14 \\
\hline 271:7 & 76:9 83:23 & 144:4 & 106:12,20 & scrolling \\
\hline 272:2 & 98:21 & 148:21 & 108:13 & 228:11 \\
\hline s--174:7 & 99:14 & 159:20,25 & 114:13 & se \(213: 16\) \\
\hline S.W 7:3 & 121:13 & 166:17 & 123:20 & search 53:8 \\
\hline sacred & 141:23,24 & 167:25 & 132:11 & 154:19,24 \\
\hline 194:11 & 147:24 & 168:2,25 & 170:21 & 188:23 \\
\hline Saddler & 149:17 & 169:17 & 210:21 & 189:22 \\
\hline 222:10 & 153:10 & 172:7 & sciences & 191:5,8,21 \\
\hline safe 157: 4 & 162:7 & 184:6 & 12:16 & 192:16 \\
\hline 161:14 & 169:7 & 185:19,22 & scientific & 193:22 \\
\hline 162:3,13 & 170:11 & 190:16 & 87:20 & 194:3,11 \\
\hline 255:9 & 172:7 & 193:10 & 105:17 & 194:12,13 \\
\hline safety 33:24 & 178:22 & 195:17 & 112:15,20 & 194:19 \\
\hline 68:25 & 195:22 & 197:24 & 113:8 & 195:4,7 \\
\hline 103:9 & 196:1 & 200:1 & 121:18 & 222:1 \\
\hline Sam 86:16,19 & 200:7 & 211:2,20 & 124:22 & 250:4 \\
\hline 125:8,10 & 203:9 & 214:9,20 & 129:7,17 & 251:19 \\
\hline 125:11,12 & 218:24 & 216:18 & 131:11 & searched \\
\hline samples & 225:18 & 217:10 & 140:2 & 147:17 \\
\hline 149:15 & 243:5 & 218:14,16 & 159:9,10 & searches \\
\hline SARS 112:17 & says 22:23 & 218:17 & 161:22,24 & 77:12 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 318 of 334 PageID \#: 11262
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 148:11,12 & 111:14 & 99:15 & 244:5 & 190:6 \\
\hline 190:4 & 114:19 & 106:12 & 247:24 & 192:9 \\
\hline 195:1,10 & 119:17 & 117:9 & 259:18 & 196:21 \\
\hline searching & 121:17 & 125:6 & sending & 198:25 \\
\hline 190:5 & 124:16 & 153:5 & 35:13 & 199:1,13 \\
\hline 192:12 & 126:21 & 190:8 & 44:18 79:6 & 201:8 \\
\hline season 29:19 & 131:24 & 200:10 & 87:22 & 202:3 \\
\hline second 14:22 & 140:9 & 207:22 & 121:1,2 & 205:21 \\
\hline 33:6 72:24 & 142:17 & 258:20 & 141:24 & 209:5 \\
\hline 73:2 99:24 & 146:13 & seek 266:18 & 145:15 & 216:15 \\
\hline 106:14 & 147:22 & seen 21:16 & 146:22 & 219:25 \\
\hline 112:10 & 153:7 & 47:4,5 & 147:4 & 221:10 \\
\hline 125:6 & 154:24 & 50:2 88:17 & 171:8 & 226:10 \\
\hline 133: 6 & 156:11 & 105:5 & 189:17 & 238:2 \\
\hline 136:9 & 157:8 & 110:3 & 208:25 & 241:22 \\
\hline 156:22 & 160:24 & 112:13,14 & 230:1 & 243:12,21 \\
\hline 160:15 & 161:8 & 113: 6 & 244:1 & 246:14 \\
\hline 169:12 & 166:14 & 117:21 & 245:10 & 248:1,8,9 \\
\hline 212:23 & 169:21 & 130:17 & 248:24 & 248:22 \\
\hline 267:19 & 172:9,11 & 165:2 & 251:2,11 & 249:20 \\
\hline second-t. & 172:13,19 & 179:3 & 257:23 & 252:19 \\
\hline 131:16 & 172:25 & 207:6 & 262:17 & 256:4,9,10 \\
\hline secondhand & 179:17 & 209:15 & sends 64:23 & 262:19 \\
\hline 54:1,22 & 185:22 & 218:13 & 131:17 & 265:3 \\
\hline 55:7 & 186:2 & 220:1 & 133:2 & sentence \\
\hline seconds & 190:25 & 239:25 & 144:1 & 29:12 \\
\hline 262:22 & 198:7 & selected & 146:14 & 41:25 \\
\hline section & 211:2 & 97:20 98:9 & 250:18 & 167:13 \\
\hline 14:15 & 212:13,17 & Seman 45:12 & sense 204:25 & separate \\
\hline see 10:13 & 214:12 & send 35:21 & sent 41:7,16 & 66:3 \\
\hline 21:3 22:23 & 215:2,13 & 55:20,20 & 52:9 62:24 & 185:22 \\
\hline 24:9 26:25 & 215:16 & 57:7,11,13 & 66:2 73:21 & 225:1 \\
\hline 34:4 35:4 & 216:3 & 114:10,15 & 73:22 & 240:2 \\
\hline 44:11 & 218:19 & 114:17 & 77:13 & 258:18 \\
\hline 45:15 & 222:6,6 & 115:4 & 115:5 & separately \\
\hline 46:21 & 227:12 & 124:7,8 & 117:11 & 173:15 \\
\hline 49:22 & 229:13 & 129:20 & 120:9 & 209:20 \\
\hline 51:21 & 232:12 & 130:11,12 & 121:9 & 210:22 \\
\hline 53:24 54:4 & 240:12 & 135:11,13 & 124:23 & 247:24 \\
\hline 63:10 65:6 & 250:24 & 135:18,19 & 133:21 & September \\
\hline 65:13 66:7 & 252:10 & 146:10 & 137:1 & 3:7 152:25 \\
\hline 70:10 & 258:9 & 153:17 & 139:18 & 219:25 \\
\hline 72:25 73:5 & 261:18 & 189:14 & 147:20 & 250:8 \\
\hline 75:24 & 262:23 & 192:12 & 148:18 & series 79:5 \\
\hline 86:19 & seeing 69:10 & 194:17 & 153:14 & served 32:8 \\
\hline 92:14 & 71:16,25 & 199:5 & 157:20 & servers \\
\hline 96:24 & 72:17 & 208:1 & 186:9 & 217:21 \\
\hline 97:16 & 76:15 87:9 & 214:5 & 187:19 & service \\
\hline 103:19 & 87:19 93:1 & 242:5,19 & 189:7,12 & 103:25 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline services 7:1 & 84:5,11 & 265:23 & 189:19 & SMEs 114: 4 \\
\hline 7:2,9 & 211:7 & showing & 197:18 & 116:12 \\
\hline 11:19 & she'd 124:7 & 186:23 & 212:3,10 & 123:25 \\
\hline 146:16 & 172:17 & shown 94:8 & 232:14 & 124:3 \\
\hline serving 32:6 & shedding & 94:10,21 & 243:21 & 135:23 \\
\hline 107:19 & 87:10 & 94:25 95:3 & 266:1 & 136:1 \\
\hline session & 90:15 & shows 53:5 & simpler & 188:3 \\
\hline 151:8 & 207:11,16 & 211:12 & 241:16 & Smith 181:10 \\
\hline 152:6 & 207:23 & sic 19:13 & simply 143:5 & 250:11,12 \\
\hline set \(82: 21\) & 208:1 & 21:8 24:13 & Sincerely & 252:4,7 \\
\hline 84:5,11 & 209:7 & 120:15 & 271:20 & snippets \\
\hline 161:2 & 265:24 & 133:5 & Singapore & 227:12 \\
\hline 167:6,15 & sheet 115:23 & 253:3 & 151:7 & Snow 6:18 \\
\hline 170:3 & 134:16 & side 54:1 & sir \(269: 13\) & 8:17,17 \\
\hline 198:11,14 & 272:1 & 58:8 65:5 & site 113:18 & 10:7 30:23 \\
\hline 213:2 & sheets & \(76: 580: 2\) & 129:10 & 31:4,6,18 \\
\hline 270:8,15 & 271:12,14 & 80:4 81:18 & 191:13,13 & \(33: 3\) 36:18 \\
\hline setting & 271:16 & 139:15,16 & 231:7,8,14 & 47:14 54:8 \\
\hline 34:17 & Shelley & 164:8,9,12 & 232:6 & \(57: 876: 21\) \\
\hline 197:4 & 25:15 & sidebar & sites 46:19 & 78:3,17 \\
\hline 200:25 & shooting & 216:19 & sitting 43:2 & 79:1 80:16 \\
\hline 236:16 & 208:10 & 217:2 & 236:22 & 80:23 \\
\hline 260:16 & Shopkorn & sign 8:20 & situation & 82:20 86:5 \\
\hline seven 136:8 & 83:23 & 128: 4 & 248:13 & 89:24 \\
\hline severe 41:25 & 86:24 & 196:5 & situations & 93:16,18 \\
\hline 42:23 & short 33:5 & 271:14 & 192:8 & 93:20 94:2 \\
\hline 53:25 58:8 & 132:3 & signature & six 32 : 8 & 94:6,11,14 \\
\hline share 51:25 & 149:24 & 269:20 & 165:13,19 & 94:17,19 \\
\hline 65:18 & 180:24 & 271:12,14 & skip 166:1 & 96:3,7 \\
\hline 71:18,21 & 227:25 & 271:17 & skipped & 99:4 \\
\hline 71:23 & 228:1 & 272:25 & 167:14 & 100:14 \\
\hline 125:10 & 247:20 & signs 42:9 & 269:7 & 101:2,6,20 \\
\hline 144:7 & 262:25 & 42:19 & Skype 241:16 & 102:13 \\
\hline 156:23 & 266:11 & 156:9 & slash 225:3 & 105:10 \\
\hline 160:4 & shorthanded & 164:8 & slide 149:19 & 106:6 \\
\hline 166:23 & 111:5 & Silling 7:14 & 210:17 & 110:7 \\
\hline 182:20 & shortly & 8:9 & 265:18,22 & 112:22 \\
\hline 230:14 & 207:25 & Silver 45:4 & 266:5 & 115:12 \\
\hline 235:11 & shot 29:13 & similar & slides & 121:5 \\
\hline 260:19,22 & shots 5:15 & 18:14 & 246:20 & 123:3 \\
\hline 261:3 & 249:19,20 & 44:22 & slightly & 126:12 \\
\hline shared 31:12 & show 52:11 & 46:17 & 47:21 65:3 & 131:6 \\
\hline 33:18 & 81:3 88:12 & 59:24 & small 95:15 & 132:6,21 \\
\hline 51:18 72:8 & 149:20 & 128:15,15 & 154:10 & 134:22 \\
\hline 102:15,17 & 214:16 & 135:21 & SME 108:7 & 137:22 \\
\hline 102:18 & showed 44:1 & 153:23 & 116:14 & 138:5 \\
\hline 144:8 & 117:10 & 157:19,22 & 130:19,21 & 142:24 \\
\hline sharing 54:2 & 210:18 & 180:11 & 135:12,15 & 143:16 \\
\hline 72:2,2 & 246:7 & 185:14 & 152:1 & 152:22 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 320 of 334 PageID \#: 11264
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 158:5,21 & 150:22 & 118:23 & speaking & 249:24 \\
\hline 158:23 & 154:21,22 & 124:19 & 17:14 & specifics \\
\hline 159:14 & 155:1 & 126:15 & 20:13 & 27:19 \\
\hline 161:16 & 181:7 & 136:15 & 104:14 & 38:12 \\
\hline 162:5,16 & 198:22 & 144:14 & 232:18 & 140:15 \\
\hline 163:1,9 & 207:7 & 145:11 & special & speculate \\
\hline 165:7 & 212:19 & 152:10 & 214:10 & 28:22 \\
\hline 168:13 & 220:2 & 153:18 & specific & 37:15 90:9 \\
\hline 171:20 & 227:10,20 & 156:6 & 29:10 30:5 & 131:12 \\
\hline 176:1 & 234:6 & 158:22 & 30:9 35:15 & 158:14 \\
\hline 178:2,5 & 237:14,19 & 163:12 & 57:4 82:21 & speculating \\
\hline 179:18 & 248:9 & 167:15 & 83:14 & 70:23 \\
\hline 193:13,24 & 264:3 & 178:5 & 84:13 88:5 & 143:1 \\
\hline 199:6 & 267:10 & 187:15 & 92:1 & speculation \\
\hline 205:3,17 & software & 216:2 & 113:12 & 76:22 78:4 \\
\hline 205:22 & 71:8 & 237:7,22 & 116:1 & 89:25 \\
\hline 206:3,7,9 & Sokler 87:3 & 239:24 & 117:4,7 & 101:21 \\
\hline 231:15 & 87:4 & 240:20 & 128:1 & 112:23 \\
\hline 238:13 & solely 256 : 6 & 255:12 & 129:4,13 & 121:6 \\
\hline 251:4 & solve 238:11 & sort 65:1 & 144:5 & 123:4 \\
\hline 259:25 & solving & 69:13 & 160:10,11 & 138:6 \\
\hline 260:25 & 215:19 & 149:10 & 175:10 & 142:25 \\
\hline 266:24 & somebody & 154:15 & 192:1 & 159:15 \\
\hline 268:2,6 & 114:12 & 207:13 & 225:25 & 163:2 \\
\hline 269:9,12 & something's & 209:9 & 234:14 & 193:14 \\
\hline 269:16 & 148:6 & sound 102:3 & 251:18 & 231:16 \\
\hline 271:4,9 & & sounds & 261:24 & 251:5 \\
\hline social 11:16 & 174:7 & 142:20 & 264:24 & 260:1 \\
\hline 12:6 15:6 & soon 55:22 & 177:20 & specific. & spelled \\
\hline 15:16 17:1 & 88:18 & 178:17 & 56:13 & 211:3 \\
\hline 19:20 20:3 & 127:13 & 200:9,12 & 58:11 & 244:7 \\
\hline 20:16 24:3 & 128:9 & source 140:7 & 68:23 & spike 139:13 \\
\hline 24:16,25 & 131:23 & 233:5 & 77:18 & split 45:20 \\
\hline 35:9 36:5 & 134:9,25 & 238:5 & 79:21 89:9 & 224:13,14 \\
\hline 50:3 52:10 & 268:12 & sourced & 90:12 & spoke 18:2 \\
\hline 52:11 53:8 & sorry 3:12 & 46:20 & 117:12 & 21:8 36:11 \\
\hline 54:14,17 & 3:13 13:4 & sources & 121:9 & 66:8 \\
\hline 57:25 59:3 & 14:5 28:6 & 46:24 59:5 & 133:19 & 166:23 \\
\hline 72:2,12 & 28:17 & 222:3 & 140:20 & spoken 33:14 \\
\hline 90:21 92:7 & 32:14 & 237:15,21 & 143:23 & 64:11 \\
\hline 104:5,24 & 63:10 & span 253:16 & 151:25 & spread \\
\hline 105:1,3 & 67:17,17 & Spanish & 158:14 & 161:24 \\
\hline 113:11 & 67:25 & 65:16,20 & 171:6 & spreadsheet \\
\hline 114:8 & 73:15 & 70:24 & 182:19 & 201:12 \\
\hline 117:2,8,17 & 74:21 & speak 10:15 & 183:11 & 202:2,3,13 \\
\hline 124: 6 & 85:21 & 20:15 27:9 & 191:22 & 202:23 \\
\hline 143:6,21 & 93:17 96:7 & 29:9 & 198:3 & 211:23 \\
\hline 143:24 & 96:8 & speakers & 211:17 & spreadsh. \\
\hline 148:13 & 103:12 & 97:23 & 232:2 & 202:19 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline spring 17:11 & 131:16 & 272:3 & 68:5 85:12 & submit 219:5 \\
\hline 20:1 68:15 & 174:24 & statistic & 91:5,9 & subscribe \\
\hline Spur 4:7 & 197:20 & 190:17 & 103:1,2 & 273:11 \\
\hline St 271:18 & 206:25 & 191:15 & 108:8 & subsequent \\
\hline stack 268:25 & 237:9 & statistics & 113:24 & 134:4 \\
\hline staff 18:21 & 242:14 & 185:24 & 118:18 & 146:6 \\
\hline 18:21 & 253:13 & status & 123:20 & substance \\
\hline 99:18 & started 12:2 & 221:22 & 126:11 & 273:8 \\
\hline 160:17,18 & 16:12,13 & 225:7 & 127:18 & substantial \\
\hline 215:12 & 18:5 25:25 & staying & 129:20 & 194:25 \\
\hline stamp 124:18 & 32:16 61:7 & 166:21 & 130:10 & successful \\
\hline 136:14,19 & 77:12 & 172:8 & 132:17 & 53:1 \\
\hline 146:11 & 171:7 & Steele & 133:17 & successf. \\
\hline stamped & 188:14,15 & 254:17,18 & 137:3 & 212:2 \\
\hline 136:9 & starting & stems 137:5 & 138:25 & Sudevi 7: 6 \\
\hline 169:13 & 66:18 & step 242:14 & 141:8 & suggest 42:1 \\
\hline stamps & 248:18 & steps 182:24 & 145:4 & 57:21 \\
\hline 205:25 & starts 44:25 & 184:8 & 150:12,14 & 194:3 \\
\hline stand 208:18 & 250:7 & stop 70:13 & 152:7,20 & suggesting \\
\hline standards & state 1:3 & 127:8 & 152:24 & 56:6 \\
\hline 103:25 & 6:1 8:4 & 234:23 & 156:1,6 & suggestion \\
\hline 234:21 & 11:1 12:11 & stories & 163:16 & 87:18 \\
\hline standing & 25:2,11,16 & 76:18,20 & 166:5 & 184:16 \\
\hline 72:6 208:8 & 234:15 & 82:18 & 171:17 & 256:15 \\
\hline standpoint & 237:23 & storm 122:4 & 173:23 & Suite 6:11 \\
\hline 34:19 & 238:20 & story 3:8 & 179:12,14 & summaries \\
\hline Stanley & 254:8 & 229:8,9 & 181:14,18 & 72:12 \\
\hline 174:6,10 & 270:2,5,24 & straight & 184:20 & 147:11 \\
\hline 174:13 & 271:7 & 153:14 & 187:12,14 & summarized \\
\hline 176:7 & 272:2 & strategists & 189:5,7 & 60:20 62:2 \\
\hline 189:16 & 273:1 & 47:9 & 196:18,20 & summarizes \\
\hline 193:1 & stated 39:22 & strategy & 200:18 & 65:3 \\
\hline 195:12 & 110:11 & 11:22 & 201:18,19 & summarizing \\
\hline 250:10 & 147:21 & Street 6:3 & 201:23 & 61:23 \\
\hline 251:2 & 203:25 & 6:10,20 & 205:14,20 & summary 40:1 \\
\hline 252:7 & statement & 271:5,18 & 206:16 & 53:9 59:5 \\
\hline 253:3 & 37:11 & stress 41:25 & 219:22,24 & 60:17,25 \\
\hline 254:18 & 162:24,25 & string 43:20 & 221:6,8 & 61:24 \\
\hline Stanley's & 203:22 & 44:6 83:3 & 223:18 & 62:17,19 \\
\hline 250:25 & statements & 83:6 & 226:7,9 & 63:19 72:7 \\
\hline Stanley/Jan & 106:11 & structure & 237:5,7 & 144:2 \\
\hline 174:16 & 143:15,19 & 185:14 & 239:19 & 148:19 \\
\hline stapled & 144:21 & studied & 241:20,21 & supervisor \\
\hline 205:22 & states 1:1 & 108:12 & 247:10,12 & 234:7 \\
\hline 239:14 & 1:10 & stuff 121:15 & 249:18,19 & support \\
\hline start 11:24 & 228:17 & subject 2:8 & 254:9,11 & 15:17 \\
\hline 55:22 & 239:9 & 33:10 39:7 & 257:8,9 & 27:14 \\
\hline 58:19 & 254:2 & 43:19 44:9 & subjects & 33:19,25 \\
\hline 119:6 & 271:8 & 51:3 60:5 & 181:21 & 206:22 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 322 of 334 PageID \#: 11266
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 211:21,24 & 190:4,24 & 270:9 & 38:23 & talk 9:21 \\
\hline 213:10 & 192:1 & symptom & 43:12,12 & 20:19 \\
\hline supported & 195:25 & 191:15 & 47:22 49:3 & 21:11 37:9 \\
\hline 146:7 & 202:24 & symptoms & 60:8 61:17 & 39:4 49:14 \\
\hline supports & 205:5,5,23 & 183:16 & 74:11,24 & 69:1 72:4 \\
\hline 218:1 & 206:4 & 190:18 & 84:20 85:2 & 77:20 \\
\hline supposed & 212:11,12 & 191:15 & 86:8 & 116:12 \\
\hline 125:1 & 212:14 & sync 5:4 & 100:15 & 124:4,5 \\
\hline 215:4 & 216:11,22 & 221:8 & 105:20 & 167:7,9,15 \\
\hline Supreme 6:3 & 217:13 & 223:21,23 & 116:18 & 172:11,13 \\
\hline sure 14:13 & 223:10 & 239:21 & 118:25 & 172:25 \\
\hline 33:21 37:9 & 228:6 & synced & 129:23,23 & 178:19 \\
\hline 40:21 & 229:25 & 268:14,16 & 135:5 & 182:10 \\
\hline 44:24 & 235:6 & 269:11 & 136:5 & 183:20 \\
\hline 46:13,24 & 240:1 & synchron. & 141:12 & 185:2 \\
\hline 48:12 & 251:23 & 223:22 & 146:21 & 210:10 \\
\hline 55:13 & 256:16 & syncs 268:16 & 149:24,25 & 227:18 \\
\hline 61:12 & 257:10 & syndrome & 150:1 & 237:22,23 \\
\hline 64:17,19 & 266:16,20 & 139:14 & 159:13 & 243:6 \\
\hline 64:22 & surface & system 15:24 & 160:17 & 249:2 \\
\hline 68:19 69:1 & 68:16 69:4 & 44:21 & 161:5 & talked 37:7 \\
\hline 69:6,25 & surprisi & 92:14 & 174:3 & 43:17 \\
\hline 73:24 75:2 & 127:11 & 122:24 & 176:5 & 54:14 \\
\hline 79:15 & survey & 123:5,7 & 179:12 & 61:10 \\
\hline 80:11 & 221:21,21 & 164:1 & 187:3 & 106:25 \\
\hline 82:13 & 224:25 & 212:6 & 193:2 & 125:14 \\
\hline 88:25 & 225:3 & 233:12 & 205:3,16 & 197:14 \\
\hline 96:18 & surveying & systems & 206:24 & 210:17 \\
\hline 108:25 & 224:21 & 17:14 & 211:15 & 213:9,13 \\
\hline 110:11 & surveys & & 225:12 & 217:7 \\
\hline 113:18 & 131:4 & T & 229:24 & 222:22 \\
\hline 116:4 & survival & T 270:1,1 & 234:9 & 224:10 \\
\hline 120:3 & 111:20 & table 207:15 & 238:17 & 226:18 \\
\hline 121:10,13 & 113:9 & 207:18,20 & 241:9 & 227:19 \\
\hline 121:14 & 122:14,19 & 211:9 & 249:18 & 244:23 \\
\hline 125:25 & suspect & 265:23 & 253:1 & 267:15 \\
\hline 127:21 & 56:16 72:7 & 266:1,8 & 256:18 & talking 3:22 \\
\hline 128:19 & 213:4 & tabs 183:15 & taken 76:7 & 18:5 19:19 \\
\hline 130:15 & 219:13 & 189:25 & 82:7 & 53:5 72:5 \\
\hline 141:20 & 231:12 & 190:12 & 116:19 & 78:22 83:1 \\
\hline 143:3 & suspected & 196:12 & 149:14 & 83:20 \\
\hline 151:8 & 231:23 & tactics & 162:4 & 121:11 \\
\hline 160:25 & suspense & 27:20 & 201:16 & 124:2 \\
\hline 173:10 & 67:10 & \(\operatorname{tag} 88: 9\) & 204:3,12 & 127:14,15 \\
\hline 182:12 & swap 191:23 & tagged 157:8 & 270:6 & 127:16,24 \\
\hline 183:12,23 & swear 9:4 & take 18:16 & 271:11 & 128:11 \\
\hline 184:13 & switch & 21:14 & 272:4 & 134:10 \\
\hline 188:16 & 192:19 & 30:20 33:5 & takes 144:1 & 149:18,20 \\
\hline 189:21 & sworn 9:6 & 33:6 35:22 & 171:11 & 226:21 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 323 of 334 PageID \#: 11267
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 233:20 & 228:2 & 67:23 & 39:21 & 25:15 \\
\hline Tangle 60:7 & 233:12 & 72:24 & 87:25 & thank 10:20 \\
\hline target 45:23 & 234:18 & 84:15 85:9 & 134:11,12 & 15:7 22:2 \\
\hline task 42:5,5 & 255:2 & 85:10 86:2 & 193:16 & 24:23 27:7 \\
\hline tasked & 263:1,21 & 87:13 & 217:14 & 28:12 \\
\hline 248:23 & team's 68:19 & 103:1,7 & terms 25:13 & 31:18 32:4 \\
\hline team 41:12 & 69:5 80:12 & 112:13 & 43:5 64:18 & 32:21 \\
\hline 45:23 & 119:14 & 119:13 & 69:10 & 48:25 \\
\hline 51:24 & 124:13 & 126:10 & 98:25 & 50:13 \\
\hline 52:22 59:2 & teams 27:9 & 138:25 & 103:25 & 55:17 \\
\hline 66:18 & 27:13 52:3 & 150:11 & 151:1 & 64:23 \\
\hline 68:16,17 & 52:10 & 154:18 & 191:21 & 66:24 67:6 \\
\hline 69:1 72:10 & 68:25 & 157:15 & 194:19 & 67:10 \\
\hline 74:14 & 80:25 & 158:19 & terrible & 69:17 \\
\hline 75:11 76:7 & 147:18 & 159:3 & 247:2 & 83:25 \\
\hline 77:5,15,17 & 164:15 & 162:14 & testified & 84:22 \\
\hline 78:16 82:7 & 220:21,22 & 166:4 & 9:7 65:11 & 85:21 \\
\hline 82:9,11 & 220:22,23 & 170:14 & 96:5 & 90:25 \\
\hline 84:7 87:2 & 241:1,3,6 & 171:17 & 145:22 & 96:21 \\
\hline 90:16 92:7 & 258:4 & 187:12 & 148:7 & 104:21 \\
\hline 103:9,9 & tech 114:14 & 189:4 & 220:6 & 117:22 \\
\hline 105:25 & 208:10,17 & 206:12 & testify & 124:13,16 \\
\hline 107:10 & technical & 207:14 & 10:24 & 132:13 \\
\hline 110:14 & 181:10,11 & 208:15 & testifying & 133:7 \\
\hline 119:10 & 181:20 & 209:22 & 104:18 & 135:4 \\
\hline 125:13 & 215:7 & 210:15 & testimony & 138:24 \\
\hline 135:16 & 224:9 & 216:6 & 47:15 54:9 & 144:15 \\
\hline 139:7,10 & 250:14 & 219:2,21 & 57:9 64:2 & 149:21 \\
\hline 140:6 & technically & 221:6 & 65:7 76:22 & 152:17 \\
\hline 147:16 & 120:20 & 223:13 & 89:25 & 156:19 \\
\hline 151:8,22 & technique & 229:16 & 101:3 & 158:15 \\
\hline 151:23 & 213:17 & 237:4 & 120:19 & 161:9 \\
\hline 154:5,22 & technolo. & 238:21 & 125:20,25 & 165:20 \\
\hline 166:20 & 34:19 & 239:23 & 126:1 & 166:21 \\
\hline 172:8 & technology & 247:10 & 132:7 & 170:23 \\
\hline 174:21,23 & 16:5 & 257:8 & 143:17 & 171:13 \\
\hline 175:16 & tee 75:5 & 267:14 & 161:17 & 176:25 \\
\hline 177:10,11 & telephone & telling & 162: 6 & 187:7 \\
\hline 182:25 & 64:12 & 89:23 & 178:3 & 189:3 \\
\hline 184:9 & telephonic & 153:6 & 199:7 & 204:15 \\
\hline 192:24 & 20:8,12 & 158:11 & 266:25 & 234:12 \\
\hline 193:2 & telephon... & 168:19 & 270:10 & 236:24 \\
\hline 197:5 & 20:15 & 199:24 & testing & 265:11 \\
\hline 201:1,11 & tell 20:4 & 220:9 & 63:21 & 269:17 \\
\hline 203:14 & 30:3 32:24 & 243:24 & 220:11 & thanks 66:13 \\
\hline 208:2,4 & 33:10 & 258:1 & texting & 107:7 \\
\hline 211:14 & 36:20 & tells 55:17 & 36:10 & 119:14 \\
\hline 216:22 & 43:19 & 170:5 & TF 42:5 & 156:16 \\
\hline 227:2 & 55:17 & term 11:11 & Thakral & 185:19 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 324 of 334 PageID \#: 11268
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 192:24 & 12:7 16:17 & think 10:3 & 133:16,21 & 218:21,23 \\
\hline 197:13 & 30:21 & 16:19 & 138:18 & 218:24 \\
\hline 211:6 & 38:11 & 21:17 23:7 & 142:2 & 219:9,10 \\
\hline 230:10 & 46:17 & 23:8 28:20 & 143:23 & 220:1,12 \\
\hline 242:16 & 54:19 58:2 & 28:20 32:8 & 147:13,17 & 221:15 \\
\hline 253:7 & 58:24 62:5 & 37:24 & 153:9 & 222:5,10 \\
\hline theme 266:2 & 62:6 64:10 & 38:14 39:5 & 156:4 & 222:23 \\
\hline 266:3,6 & 64:19 66:9 & 40:3,12,17 & 157:23 & 224:3,16 \\
\hline themes 5:17 & 79:24 & 43:16,23 & 158:1,18 & 224:20,20 \\
\hline 52:11 & 83:12 & 46:2,14 & 159:19 & 225:2 \\
\hline 53:14 59:3 & 88:12 89:3 & 48:6,7 & 160:14,25 & 226:17 \\
\hline 59:10 & 90:8 91:25 & 49:18 & 161:25 & 227:11 \\
\hline 62:17 & 99:7,9 & 50:15,19 & 162:7 & 229:18 \\
\hline 72:17 & 105:19 & 52:14 63:7 & 163:6,11 & 230:8,9 \\
\hline 75:18, 25 & 106:11 & 63:12 & 165:11 & 231:6 \\
\hline 76:15 & 113:12,14 & 66:16 69:3 & 167:12,14 & 232:23 \\
\hline 87:20 & 113:17 & 69:6,9,22 & 171:5,5,9 & 233:18 \\
\hline 90:19 & 114:10 & 75:1,14 & 172:2,25 & 236:21 \\
\hline 257:9,18 & 117:20 & 77:1 79:10 & 173:10,11 & 238:8 \\
\hline 258:8 & 122:2,3 & 79:13,14 & 173:13,14 & 239:25 \\
\hline 264:3 & 128:3,13 & 80:24 & 173:16 & 242:2 \\
\hline theoreti & 129:6 & 81:21,23 & 175:20 & 243:6,9 \\
\hline 187:3 & 130:23 & 82:12 & 178:22,25 & 244:1 \\
\hline theory 122: 8 & 135:22 & 83:23 & 180:6,8 & 246:3 \\
\hline thereon & 151:1 & 86:14 & 184:14,23 & 247:5 \\
\hline 273:10 & 152:5 & 88:10,10 & 186:9,19 & 248:6,8,11 \\
\hline they'd76:4 & 167:1 & 90:12 & 186:23 & 248:13,16 \\
\hline 130:5,23 & 170:11 & 91:19,20 & 188:14,15 & 248:18 \\
\hline 157:9 & 171:8 & 91:21 & 190:16 & 250:6,17 \\
\hline 246:17 & 179:25 & 92:16 97:5 & 192:9 & 251:20 \\
\hline 260:22 & 180:10 & 99:22 & 193:5,5,9 & 253:22 \\
\hline thing 25:20 & 181:23 & 103:17 & 194:21 & 255:21 \\
\hline 34:4 35:2 & 182:4 & 105:22 & 195:2,8,11 & 256:7,13 \\
\hline 49:24 & 183:17 & 106:25 & 195:22,25 & 256:14,23 \\
\hline 65:10 & 188:20 & 109:2 & 197:16 & 257:19 \\
\hline 123:17 & 189:22 & 110:23 & 198:5,24 & 258:18 \\
\hline 126:3 & 191:14 & 113:17 & 198:25 & 259:16 \\
\hline 137:25 & 194:23 & 115:15 & 203:11 & 260:4,7,13 \\
\hline 155:15 & 199:24 & 117:3,19 & 204:25 & 261:10 \\
\hline 179:11 & 203:24 & 119:2 & 206:3 & 263:14,19 \\
\hline 189:20 & 209:2 & 120:1,22 & 207:2, 6 & 263:21 \\
\hline 204:13 & 217:21 & 121:15 & 208:22 & 264:19 \\
\hline 225:7,8 & 218:24 & 123:17 & 209:6 & 267:15,24 \\
\hline 231:8 & 219:5 & 125:24 & 210:3 & 268:16,19 \\
\hline 240:10 & 224:16 & 128:20,23 & 213:2,17 & thinking \\
\hline 248:12 & 232:4,14 & 129:3,9 & 214:4,16 & 28:14 64:5 \\
\hline 260:14 & 247:2 & 130:14 & 215:20 & 69:7 \\
\hline 266:15 & 251:18 & 131:13 & 216:5,12 & 128:10 \\
\hline things 9:20 & 263:11 & 132:9 & 217:25 & 172:23,25 \\
\hline
\end{tabular}

LEXITAS LEGAL

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 325 of 334 PageID \#: 11269
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 215:10 & 92:18 & 97:12 & 268:1 & 216:15,17 \\
\hline 230:21 & 98:22 & 107:21 & timeline & 218:1,14 \\
\hline 243:8 & 212:5 & 111:10 & 16:18 & 219:2 \\
\hline 259:17 & 218:23 & 130:1 & timelines & 248:1 \\
\hline 263:10 & three 13:18 & 132:1,3,10 & 29:11 & Todd's \\
\hline 269:7 & 13:23 & 135:3 & timely 27:15 & 197:25 \\
\hline third 247:20 & 14:15 & 137:18 & times 29:1 & 216:10 \\
\hline 248:20 & 27:25 & 140:11 & 65:19 & told 12:20 \\
\hline Thombley 7:7 & 31:12 & 141:20 & 72:18 & 12:22 \\
\hline Thornton & 92:16,17 & 142:6,9 & 106:24 & 14:15 26:4 \\
\hline 222:25 & 115:16 & 144:8 & 129:25 & 63:9 73:5 \\
\hline thought 52:2 & 120:3 & 145:25 & 130:8 & 78:1 82:1 \\
\hline 65:17 88:6 & 140:16 & 151:7 & 133:21 & 86:25 97:5 \\
\hline 90:10 & 167:1,4,25 & 156:9 & 226:21 & 114:17 \\
\hline 91:21 & 228:13 & 157:22,24 & 235:11 & 131:22 \\
\hline 97:10,15 & Thursday & 160:20 & 241:16 & 210:24 \\
\hline 97:17 & 73:6 84:7 & 167:6,9,15 & 243:7 & 213:25 \\
\hline 107:2 & 84:9,11 & 170:3 & timetable & 235:22 \\
\hline 108:14 & 105:23 & 171:11 & 192:7 & tomorrow \\
\hline 109:13 & 119:18,20 & 174:25 & timing 70:1 & 27:22 \\
\hline 125:5 & 119:21 & 175:9 & title 11: 6 & 230:12 \\
\hline 133:24 & 263:16 & 179:2,6 & 193:9 & tomorrow's \\
\hline 153:24 & tie 10:19 & 180:24 & 198:2 & 188:2 \\
\hline 156:6 & tied 122:21 & 183:3,8,18 & 223:7 & tons 192:10 \\
\hline 173:6 & time 8:2 & 183:18 & 261:24 & tool 50:4 \\
\hline 176:21 & 17:25 & 185:9,19 & titled 3:9 & 234:20,22 \\
\hline 186:12 & 19:24 & 189:21 & titles & tools 90:21 \\
\hline 192:11,19 & 20:13 & 192:9 & 177:14 & 148:13 \\
\hline 194:7 & 28:10,18 & 197:17 & today 10:24 & 154:21 \\
\hline 202:16 & 28:20 29:3 & 198:11,15 & 21:19 & 234:16 \\
\hline 210:19 & 29:8 30:6 & 198:25 & 27:22 93:9 & top 36:15 \\
\hline 215:11 & 32:5 36:6 & 200:13 & 94:9,10,13 & 39:8 41:5 \\
\hline 220:15 & 36:12 37:8 & 201:7 & 94:22 95:1 & 47:7 52:23 \\
\hline 223:5 & \(37: 15\) 38:6 & 210:4 & 95:3 & 136:2 \\
\hline 236:18 & 38:10 & 212:13 & 109:16 & 141:14,15 \\
\hline 249:13 & 39:18 & 220:6 & 116:25 & 151:1 \\
\hline 256:7 & 40:12 & 226:17,18 & 193:1,11 & 172:6 \\
\hline 266:18 & 42:25 & 227:14,25 & Today's 8:2 & 173:8 \\
\hline 267:16 & 49:15 52:4 & 230:20 & Todd 21:7 & 187:20 \\
\hline thoughts & 54:15 & 232:13,13 & 196:23,24 & 191:3 \\
\hline 27:20 70:8 & 58:13 59:8 & 236:12,14 & 197:14,18 & 196:2,24 \\
\hline 121:19 & 61:7,13 & 238:5 & 197:23 & 219:23 \\
\hline thousands & 65:2,21 & 244:13 & 198: 6 & 237:25 \\
\hline 34:25 & 68:7,17 & 245:6 & 199:21 & topic 107:24 \\
\hline 168:20 & 71:2 73:11 & 249:14 & 202:4 & 124:1 \\
\hline thousand. & 77:7 78:9 & 252:18 & 207:4 & 144:22 \\
\hline 168:1 & 89:12 & 261:25 & 211:5,16 & 150:21 \\
\hline threats & 90:17 & 262:20 & 214:3 & 154:14 \\
\hline 91:25 & 92:13,16 & 263:13 & 216:5,12 & 174:25 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 177:5 & 141:23 & 215:18 & 249:2 & 84:2 \\
\hline 184:18 & travel 46:14 & trying 17:6 & Twitter's & 106:18 \\
\hline 198:1 & 48:20 & 26:1 29:25 & 206:22 & 178:14 \\
\hline 256:8 & traveler's & 34:15 & Twitter.com & 181:9,17 \\
\hline topics 54:14 & 45:10,10 & 36:22 & 197:24 & 181:20 \\
\hline 77:24 & travelers & \(39: 23\) 40:2 & two 3:1 & typo 257:10 \\
\hline 107:3 & 2:13,16 & \(78: 2179: 4\) & 20:25 22:7 & 260:5 \\
\hline 140:13 & 39:10 & 89:5 114:7 & 58:24 77:9 & \\
\hline 144:9 & 43:22 & 121:15 & 83:20 84:7 & U \\
\hline 181:20 & \(44: 10 \quad 45: 6\) & 129:8 & 85:12 87:8 & U.S 6:19 7:1 \\
\hline 187:23 & 45:8,13 & 183:12 & 87:23 & \(7: 2,88: 5\) \\
\hline 188:6 & 46:5 54:23 & 188:22 & 89:11 & 65:16 71:9 \\
\hline 195:8,9 & treatment & 189:21 & 92:16,17 & 71:12,19 \\
\hline 243:11,12 & 183:16 & 194:16 & 109:23 & 71:24 \\
\hline 256:6 & 188:3 & 213:8 & 110:19 & 101:19 \\
\hline tossed & trends & 219:3 & 120:4 & 192:25 \\
\hline 165:11 & 143:24 & 232:9,12 & 131:25 & 193:10 \\
\hline totally & 197:6 & TTS 169:5 & 132:8 & 228:15 \\
\hline 152:9 & 201:2 & Tuesday & 151:20 & 233:12,16 \\
\hline town 173:13 & 211:11 & 61:18 & 156:14 & 271:5 \\
\hline 250:16,21 & 262:14 & 161:7 & 198:24 & unanswered \\
\hline TP 127:12,13 & tried 244:5 & turn 10:17 & 207:16,21 & 70:11 \\
\hline 127:22 & true 106:11 & 143:25 & two-page & unclear \\
\hline 128:9,11 & 108:22 & 144:12 & 40:1 & 216:1,9 \\
\hline 128:16 & 116:8 & turn.io 70:7 & 153:10 & 219:4 \\
\hline track 71:9 & 120:14 & 70:15 & two-week & uncommon \\
\hline tracker & 139:24 & Turner 35:6 & 66:1 & 188:19 \\
\hline 186:14 & 158:19 & 37:2,20 & Tyler 66:15 & 232:3 \\
\hline tracking & 159:4 & Twitter 16:5 & 141:17,19 & uncredible \\
\hline 192:25 & 164:24 & 21:7,9 & 141:20,24 & 266:22 \\
\hline 193:10 & 170:12 & 180:13 & 144:1,13 & 267:4,7 \\
\hline 195:18 & 255:5 & 181:1 & 145:15,18 & underlying \\
\hline 196:5 & 270:9 & 197:24,25 & 146:10,22 & 185:25 \\
\hline trail 114:7 & 273:9,13 & 198:12,14 & type 16:11 & understand \\
\hline training & trust 68:25 & 199:5,21 & 40:13 & 10:1, 3, 4 \\
\hline 98:13,16 & 103:9 & 200:20 & 106:24 & 10:14,15 \\
\hline 99:19 & 174:23 & 202:12 & 151:23 & 14:13 \\
\hline 234:18,25 & 175:16 & 206:23 & 222:24 & 36:21,22 \\
\hline 235:1,5,7 & 177:10 & 209:2,19 & 227:22 & 41:2 57:24 \\
\hline 235:13,22 & 220:21 & 211:17 & 253:18 & 78:21,21 \\
\hline 236:15,16 & trusted & 212:8,13 & typed 26:16 & 79:5 92:15 \\
\hline 236:17 & 135:19 & 212:17,18 & types 20:2 & 104:19 \\
\hline transcript & truth/da. & 212:20,21 & 99:2 & 109:10 \\
\hline 5:23 8:21 & 140:7 & 213:15,20 & 227:19 & 129:9 \\
\hline 125:11,19 & truthfully & 214:11,13 & 258:7,16 & 139:10 \\
\hline 126:2 & 10:24 & 214:25 & typical & 148:14 \\
\hline 268:17,22 & try 9:21 & 218:17 & 194:22 & 155:19 \\
\hline 271:13 & 106:18 & 220:8,10 & typically & 162:21 \\
\hline transfer & 179:11 & 248:2 & 52:10 57:2 & 168:19 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 327 of 334 PageID \#: 11271
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 169:1,17 & 224:19 & 193:20,21 & 156:25 & 58:6,8 \\
\hline 174:21 & 228:18 & 193:22 & 160:1 & 59:9,12 \\
\hline 190:23 & 251:10 & 194:2 & 169:18,23 & 63:21 65:4 \\
\hline 193:16 & 255:25 & 195:19 & 174:25 & 65:5 70:24 \\
\hline 194:1,17 & 258:24 & 221:21,21 & 213:5,6,24 & 72:4 76:17 \\
\hline 194:21 & 261:6 & 225:2,3 & 215:10 & 81:1,22,23 \\
\hline 195:21 & understood & 228:22 & 236:13 & 82:18 \\
\hline 217:16 & 91:20 & 229:11,19 & useful & 87:10 \\
\hline 224:1 & 140:4 & updated & 173:19 & 108:2 \\
\hline 232:10 & undertaking & 143:14,19 & user 24:22 & 111:13 \\
\hline 265:5,5 & 69:12 & 157:1 & 97:8 & 115:19 \\
\hline understa & unfolding & 159:20 & user's 228:9 & 119:15 \\
\hline 14:6 24:10 & 3:8 & 160:2 & users 27:15 & 121:4 \\
\hline 26:17 & unfortun. & 162:10 & 54:2 89:6 & 122:2,23 \\
\hline 35:13 & 196:7 & 240:10 & 228:11 & 123:15 \\
\hline 36:14 & unit 40:15 & updates 4:3 & uses 55:4 & 124:14 \\
\hline 37:10 & 40:15 & 4:5 156:2 & 136:18 & 126:22 \\
\hline 40:22 41:1 & 42:13 45:9 & 163:18 & usual 206:24 & 137:19 \\
\hline 42:17 & United 1: 1,9 & 166:24 & usually 93:8 & 138:2 \\
\hline 44:20 64:8 & 228:17 & 192:2 & 98:22 & 140:7,13 \\
\hline 69:8 74:17 & 271:8 & 250:2 & 109:25 & 143:8 \\
\hline 79:19 80:8 & 272:3 & 253:15 & 115:6 & 156:18,21 \\
\hline 95:17 & units 40:15 & updates/ & 123:24 & 156:25 \\
\hline 96:11 & 46:11 & 221:19 & 127:17,24 & 157:3, 4, 7 \\
\hline 103:8 & 47:21,23 & updating & 144:17 & 157:17,25 \\
\hline 109:20 & 48:19,21 & 192:8 & 181: 6,13 & 159:5 \\
\hline 111:1 & University & upgraded & 227:20 & 160:17,18 \\
\hline 114:5 & 12:10,10 & 267:5 & 250:14 & 160:22 \\
\hline 120:24 & unknown & uptick 146:1 & & 161:14 \\
\hline 122:25 & 170:12 & urgency 48:4 & V & 162:3,12 \\
\hline 137:16 & unmarked & url 229:14 & v 271:7 & 162:13 \\
\hline 138:15 & 67:8 & Ursula 223:2 & 272:2 & 164:2,8 \\
\hline 139:22,23 & unproven & 223:11 & vac-231:5 & 166:7 \\
\hline 143:8 & 108:22 & Ursula's & vaccinated & 169:19,23 \\
\hline 150:17 & 120:13 & 223:8 & 143:13 & 170:1 \\
\hline 158:2,10 & unsupported & use 15:20 & 165:15 & 171:22 \\
\hline 159:2 & 108:22 & 18:13 29:2 & 168:7 & 172:11,13 \\
\hline 163:4 & 120:13 & 29:4,5 & vaccination & 174:20 \\
\hline 167:17 & unvaccin. & 35:23 36:2 & 53:3 62:12 & 175:5 \\
\hline 168:20 & 146:3 & 39:20 & 66:4,6 & 176:17 \\
\hline 177:6 & up-to-date & 40:17 59:5 & 71:13 & 182:19,20 \\
\hline 184:10 & 228:21 & 67:8 70:20 & 142:16 & 182:22 \\
\hline 193:12 & upcoming & 71:7 96:15 & 164:6 & 183:9,25 \\
\hline 201:19 & 224: 6 & 105:18 & 169:3,6 & 197:9 \\
\hline 204:4 & update 59:12 & 128:21 & vaccinat. & 201:5 \\
\hline 210:6,9 & 75:16 & 134:11,12 & 53:1 & 207:16,23 \\
\hline 212:1 & 148:15 & 137:10,12 & 148:23 & 207:25 \\
\hline 213:23 & 170:23 & 139:15 & vaccine 4:8 & 209:7 \\
\hline 217:17,19 & 183:18 & 147:23 & 53:17,25 & 231:11 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 328 of 334 PageID \#: 11272
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 234:15 & 231:3,5 & vary 181: 8 & 106:7 & 196:16 \\
\hline 237:16 & 232:10 & VC 5: 4,9 & 110:9 & 199:9 \\
\hline 258:5 & 233:10 & 223:18 & 111:24 & 200:14,16 \\
\hline 263:1,7,21 & 234:1,13 & VC-Facebook & 112:3,7,24 & 203:13 \\
\hline vaccine- & 251:22 & 221:8 & 113:4 & 205:5,12 \\
\hline 52:24 & VAERS 3:22 & 239:20 & 115:13,17 & 205:18,25 \\
\hline 53:22 58:7 & 122:21,22 & VECCHIOINE & 118:8,14 & 206:6,11 \\
\hline 140:8 & 122:23 & 10:8 & 118:16,21 & 219:17,20 \\
\hline 227:3 & 150:14,18 & Vecchione & 121:7 & 221:2,4 \\
\hline vaccine.gov & 150:21,21 & 2:4 6:8 & 123: 6 & 226:2,5 \\
\hline 230:14 & 150:23,24 & 8:13,13 & 126:6,9,13 & 231:17,24 \\
\hline 231:1,4 & 150:25 & 9:11 21:13 & 131:7 & 236:2,4,20 \\
\hline 232:6 & 151:3,9,19 & 22:4,9 & 132:12,23 & 237:3 \\
\hline 233:15 & 151:20 & 26:24 & 133:5,8,9 & 238:15 \\
\hline 234:13 & 152:2,5,8 & 30:19 31:5 & 134:23 & 239:12,17 \\
\hline vaccinef & 201:15 & 31:16,22 & 135:4,7 & 241:14,18 \\
\hline 230:14 & 204:3,5,12 & 33:1,5,7 & 136:20,23 & 247:3,8 \\
\hline 231:1,2,7 & vague 36:18 & 36:19 & 136:24 & 249:5,8,10 \\
\hline vaccinef. & 36:21 & 38:19 & 137:24 & 249:15,16 \\
\hline 231:4 & 48:23 78:3 & 43:11 & 138:11 & 251:7 \\
\hline vaccines 3:7 & 96:13 99:4 & 47:16 & 143:2,18 & 254:5 \\
\hline 3:8 64:20 & 101:6,20 & 48:25 49:2 & 144:25 & 256:17,22 \\
\hline 70:21 86:3 & 105:10 & 54:10 & 145:2 & 257:5 \\
\hline 87:14 & 115:12 & 57:10 60:1 & 149:22,25 & 260:2 \\
\hline 89:12 & 117:24 & 60:4 67:2 & 150:7 & 261:1 \\
\hline 115:22 & 131:6 & 67:5,11,13 & 152:14,18 & 267:1,20 \\
\hline 124:2 & 132:21 & 76:24 78:5 & 152:23 & 267:21,25 \\
\hline 127:10 & 134:22 & 78:19 79:3 & 153:3 & 268:4,8,19 \\
\hline 128:8 & 176:1 & 80:18 81:6 & 155:8 & 269:6 \\
\hline 131:5 & vaguely & 82:24 & 158:7,24 & verbal 9:17 \\
\hline 137:3,6 & 154:12 & 84:18,22 & 159:16 & verifiable \\
\hline 139:14,17 & vagueness & 84:23 85:4 & 161:18 & 237:20 \\
\hline 144:20 & 176:15 & 85:7 86:1 & 162:9,19 & 238:4 \\
\hline 158: 4,12 & valid 237:17 & 86:7 90:1 & 163:3,14 & version \\
\hline 163:25 & variant & 91:2,8,11 & 164:18 & 227:23 \\
\hline 164:13,23 & 190:25 & 93:4,6,23 & 165:8,18 & versus 8:5 \\
\hline 167:5 & 191:1 & 94:3,8,13 & 165:21,24 & 217:3 \\
\hline 168:1,4,11 & variants & 94:16,18 & 166:3 & video 21:18 \\
\hline 169:1,15 & 190:21 & 94:21 95:2 & 168:16 & 54:3 \\
\hline 169:21 & 191:17,20 & 95:6,12 & 171:16,21 & 227:12,23 \\
\hline 170:15 & varied & 96:5,9 & 172:1 & 227:24 \\
\hline 183:16 & 130:14 & 97:25 98:5 & 173:18,21 & 268:10,12 \\
\hline 201:14 & variety 88:8 & 99:5 & 176:2 & 268:16 \\
\hline 203:20,22 & various & 100:12,17 & 178:7,8 & 269:10 \\
\hline 204:1,18 & 54:24 & 100:18 & 179:7,10 & video-re. \\
\hline 231:5,10 & 55:11 & 101:4,7,22 & 179:20 & 8:3 \\
\hline 253:11 & 122:2 & 102:1,8,21 & 187:7,10 & videogra... \\
\hline 256:1,3 & 155:16 & 102:23 & 189:1 & 7:14 8:1,9 \\
\hline vaccines. & 227:19 & 105:11 & 193:15,25 & 9:3,9 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 329 of 334 PageID \#: 11273
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 30:24 31:2 & want 23:6 & 160:4 & way 22 : 18 & 76:15 \\
\hline 31:17 98:1 & 27:11 29:1 & 166:23,25 & 42:1 71:12 & 121:13 \\
\hline 98:3 102:9 & 33:17,18 & 183:18 & 99:10 & 148:18 \\
\hline 102:11 & 34:9 36:24 & 186:22 & 110:14 & 165:22,25 \\
\hline 150:2,4 & 46:18 47:4 & 188:11 & 119:22 & 166:1 \\
\hline 205:9,11 & 55:25 & 190:13 & 134:3 & 169:7 \\
\hline 256:25 & 68:18 & 191:22 & 140:4 & 172:23 \\
\hline 257:2 & 70:12 & 199:20 & 147:7,10 & 173:12,16 \\
\hline 268:9,14 & 76:19 & 204:25 & 147:20,24 & 182:3 \\
\hline 268:18 & 77:16,24 & 207:21 & 148:12 & 192:7 \\
\hline 269:2,11 & 78:24 79:9 & 209:20,23 & 155:22 & 200:10 \\
\hline 269:13,15 & 80:7 85:22 & 215:16 & 162:23 & 203:9 \\
\hline 269:17 & 126:20 & 217:2 & 181:5 & 205:6 \\
\hline VIDEOTAPED & 131:12 & 224:5,6,22 & 194:22 & 208:8,8 \\
\hline 1:13 & 175:1 & 228:20 & 197:19 & 256:6 \\
\hline view 29:8 & 176:9 & 230:22,22 & 199:20 & 268:20 \\
\hline 146:7 & 178:18,19 & 242:14 & 209:24 & 269:4 \\
\hline 164:23 & 186:19 & 251:23 & 211:22 & we've 31:7 \\
\hline 209:19,22 & 191:23,25 & 259:16 & 216:8 & 33:14 47:4 \\
\hline viewpoint & 192:14,19 & 260:7 & 224:14 & 60:13 \\
\hline 71:12,24 & 200:10 & 267:5 & 240:16 & 66:14,19 \\
\hline viewpoints & 205:16,23 & wanting & 252:23 & 78:11 \\
\hline 71:9,19,24 & 205:24 & 106:10 & 264:25 & 102:14 \\
\hline violate & 206:4 & 171:8 & 270:13 & 114:12 \\
\hline 157:9 & 215:10,13 & wants 66:21 & ways \(2: 13,16\) & 133:10 \\
\hline violates & 217:10 & 187: 4 & 39:9 43:21 & 141:1 \\
\hline 157:6 & 226:24 & warning 4:7 & 44:10 & 145:13 \\
\hline virus 190:16 & 234:16 & 42:8,19 & 81:13 & 148: 4 \\
\hline visit 218:17 & 240:1 & Washington & 87:16 88:8 & 157:11 \\
\hline visual 11:19 & 245:18 & 6:12,21 & we'll 21:3 & 167:1 \\
\hline visualize & 262:23 & 7:3 271:6 & 48:2 55:21 & 179:3 \\
\hline 262:14 & 267:3 & wasn't 37:21 & 84:20 & 180:12 \\
\hline voice 223:19 & 268:7,12 & 81:7 96:15 & 95:10 & 189:19 \\
\hline volume 53:9 & 268:14 & 110:1 & 100:14,15 & 207:6 \\
\hline 89:20 & 269:2 & 128:2 & 107:5 & 208: 4 \\
\hline 151:2 & wanted 18:13 & 131:11 & 116:12 & 209:15 \\
\hline voluntar. & 31:6,19,20 & 152:2 & 121:19 & 220:1 \\
\hline 138:4 & 48:22 & 180:1 & 133:17 & 222:10 \\
\hline vote 253:12 & 51:25 & 188:19 & 185:1 & 226:17 \\
\hline vs 1: 6 & 66:12 & 190:12 & 187:23 & 229:17 \\
\hline & 68:16 & 194:5 & 188:6 & 234:15 \\
\hline W & 77:23 & 215:10,14 & 235:12 & 239:25 \\
\hline W 6:3 & 82:16 & 215:17,22 & 256:23 & 240:5 \\
\hline Wait 10:10 & 87:10 & 250:16 & we're \(21: 24\) & 242:2,22 \\
\hline Walensky & 98:23 & 260:15 & 21:24 36:7 & 247:2 \\
\hline 120:23,25 & 123:11 & watching & 39:16 & 257:19 \\
\hline 125:20 & 144:9 & 143:10 & 45:23 & 268:20 \\
\hline walkthrough & 147:8 & 196:6 & 49:15 & weaken \\
\hline 234:22 & 156:23 & wave 46:1 & 54:19 & 163:25 \\
\hline
\end{tabular}
\begin{tabular}{|c|c|c|c|c|}
\hline wear 29:6 & 195:23 & WhatsApp & 9:24 22:6 & words 52:14 \\
\hline web 11:15 & 196:8 & 70:17,19 & \(31: 19\) 33:1 & 55:4 64:21 \\
\hline 12:6 15:6 & 197:12 & \(70: 25\) & 66:20 & 133:15 \\
\hline 15:21, 21 & 226:25 & 137:9 & 80:21 & 145:8 \\
\hline 15:23 & 229:21 & White 230:13 & 93:22 & 149:12 \\
\hline 87:21 & 253:11,18 & 230:24,25 & 102:4,5,7 & 227:21 \\
\hline 109:9 & 257:23 & 231:12,19 & 118:13,14 & 251:21 \\
\hline 127:22 & 260:18,18 & 232:1,4,7 & 149:23 & work 11:5, 21 \\
\hline 128:14,16 & week's \(2: 23\) & 232:22 & 150:1 & 11:22 12:2 \\
\hline 128:21 & 5:6 68:6 & 233:2,8,11 & 179:17 & 14:1 19:25 \\
\hline 129:1 & 76:5 & 233:18,19 & 205:13 & 25:12 \\
\hline 134:11,14 & 226:10,16 & 233:21 & 236:1, 3 & 33:19 \\
\hline 134:15,16 & weekend & 234:4,5,14 & 269:1 & 34:20,23 \\
\hline 134:17 & 126:20 & 259:10,22 & 270:7,10 & \(35: 22\) 36:8 \\
\hline 135:16 & 186:8 & 260:9,17 & 270:15 & 40:12 73:7 \\
\hline 192:8 & weekly 5:4 & 261:8,19 & 271:13 & 100:4 \\
\hline website & 68:9 69:2 & 263:4 & 272:1,25 & 109:24 \\
\hline 15:15,23 & 221:8 & whitelist & witnesses & 156:24 \\
\hline 45:10 & 223:21 & 217:22 & 49:23 & 159:19 \\
\hline 47:20,22 & 226:19,21 & whitelisted & women 46:4 & 160:5,9,16 \\
\hline 59:13 & 239:21 & 217:11,11 & wondered & 160:22 \\
\hline 106:13 & 260:11,13 & 217:15,17 & 176:15 & 164:13 \\
\hline 108:4,16 & 262:5 & whitelis.. & 248:12 & 166:24 \\
\hline 109:4 & weeks 27:18 & 217:20 & wonderful & 167:18,19 \\
\hline 113:15,22 & 51:23 & wide 55:24 & 55:20 & 175:6,7 \\
\hline 114:16,17 & 56:21 84:8 & 56:7,11 & wondering & 177:21 \\
\hline 114:20 & 132:8 & 58:21 & 75:15 81:2 & 181:12 \\
\hline 115:22 & 151:13 & 59:15 & 140:6 & 200:7 \\
\hline 130:23 & 169:20 & widely & 200:9 & 209:24 \\
\hline 183:17 & 228:13 & 150:22 & 204:23 & 213:18 \\
\hline 187:3 & weeks' & 153:25 & 258:6 & 214:1 \\
\hline 194:20 & 131:25 & 154:23 & 263:7 & 224:11 \\
\hline websites & weigh 230:7 & widespread & Woods 66:15 & 235:12 \\
\hline 233:17 & Weir 223:2 & 29:1 & 141:17,19 & 237:19 \\
\hline Wednesday & went 12:3 & Wilhelm & 141:21 & 258:21 \\
\hline 247:15 & 63:8 70:11 & 263:1,5 & 144:1,13 & 262:3 \\
\hline week 3:5 & 187:2 & willing & 145:15,18 & worked 24:15 \\
\hline 46:2 48:2 & 219:4 & 35:10 & 146:22 & 40:25 \\
\hline 65:14 68:8 & 236:6,11 & 173:1 & word 15:20 & \(75: 23\) \\
\hline 103:4 & 265:18 & 228:22 & 19:2 74:15 & 186:17 \\
\hline 118:24 & weren't 81:8 & 263:2 & 85:3 195:2 & 192:18 \\
\hline 119:21 & 115:3 & withdraw & 201:18 & 214:20 \\
\hline 126:16 & 185:5 & 74:22 & 225:20 & Worker-c. . . \\
\hline 156:18,20 & 212:15 & 100:24 & 241:12 & 55:5 \\
\hline 157:1 & 240:10 & 127:16 & worded 260:4 & workers \\
\hline 161:6 & 248:19 & 139:22 & wording & 53:17 58:6 \\
\hline 177:3 & 267:12 & withdrawn & 42:14,15 & 66:5 \\
\hline 180:20 & Western 1:1 & 247:25 & 110:25 & working 12:5 \\
\hline 185:20 & 8:6 & witness 9:4 & 149:12 & 27:9,14 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 331 of 334 PageID \#: 11275
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 28:19 & 258:10 & 22:15 & YouTube & 211:6 \\
\hline 56:17 & Wright 50:17 & 25:22 & 175:16 & 212:23 \\
\hline 58:19 & write 23:23 & 28:12 & 185:13 & 241:22 \\
\hline 70:17 & 39:18 43:7 & 44:18 55:9 & 227:25 & 10 (B) 7:19 \\
\hline 77:21 80:8 & 55:18 & 67:2 74:8 & 244:18,20 & 10/28/2021 \\
\hline 84:4 87:5 & 115:21 & 75:9 78:8 & 244:21,22 & 249:20 \\
\hline 89:22 & 131:21 & 85:16 & 244:24 & 10/28/21 \\
\hline 101:10 & 230:19 & 86:19 90:5 & 245:2,18 & 5:14 \\
\hline 111:9 & 237:10,11 & 92:12 94:2 & 245:21,22 & 10:09 31: 1,3 \\
\hline 114:23 & writes 36:23 & 94:16 & 245:23 & 10:38189:12 \\
\hline 135:13,15 & 74:25 84:4 & 95:21 & 255:2 & \(10046: 13\) \\
\hline 174:18 & 126:18 & 124:20,21 & 97:7 & 69:25 \\
\hline 175:3 & 145:18 & 128:10 & & 128:19 \\
\hline 177:5 & 156:14 & 136:16 & Z & 1023 : 4 \\
\hline 189:20 & 166:14 & 149:15 & 35:6 & 10th 63:17 \\
\hline 195:15 & 195:12 & 158:10 & ZIP 70:20 & 213:3 \\
\hline 232:4,8 & 197:2 & 159:2 & 231:9 & 214:8 \\
\hline 234:15 & 211:5 & 165:12 & Zoom 7:7,11 & 242:3 \\
\hline 236:9 & 226:24 & 173:19 & 31:8,11,13 & 257:15 \\
\hline 262:15 & 252:5,7 & 179:5 & 102:14,18 & 259:7 \\
\hline works 22:18 & writing 93:5 & 186:23 & 102:19,19 & 261:13 \\
\hline 24:15 & written 7:22 & 187:15 & 240:25 & 113:4 102:2 \\
\hline 44:20 & 163:7 & 199:17 & 241:6 & 102:22,25 \\
\hline 216:6,8 & wrong 41:1 & 206:7,9 & Zuckerberg & 108:19 \\
\hline World 51:7 & 96:16 & 212:19 & 33:22 & 112:19 \\
\hline worldwide & 124:19 & 214:23 & & 114:22 \\
\hline 164:23 & 194:18,20 & 222:18 & & 115:8 \\
\hline worried & 203:10 & 223:9 & 35:7 & 118:5 \\
\hline 34:24 & 216:1 & 225:9 & @CDC.gov & 11-year \\
\hline 214:1 & 245:9 & 230:6 & 35:8 & 163:19 \\
\hline 258:9 & wrote \(26: 13\) & 245:5 & 1 & 11-year-. \\
\hline 263:9 & 34:6 87:11 & 249:19 & \(\frac{1}{12: 75121}\) & 156:3 \\
\hline worth 88:16 & 122:8 & 250:19 & & 11/2 160:14 \\
\hline 89:20
258.18 & \(174: 14,15\)
\(231: 18\) & \(252: 21\)
\(254: 6\) & \(21: 12,14\)
\(40: 15\)
\(55: 3\) & 11/2/21 4:2 \\
\hline \(258: 18\)
wouldn't & 231:18 & 254:6
269:9,16 & 40:15 \(55: 3\)
\(55: 4\) & \(11 / 8 / 214: 5\)
\(11: 27100: 1\) \\
\hline 53:7 & WY 5:7 & year 4:3,6 & 252:24 & 11:5198:1 \\
\hline 101:24 & Wyoming & 174:22 & 270:8 & 11:5398:4 \\
\hline 106:21 & 237:7,12 & 175:15 & 1.5235:12 & 11:59102:9 \\
\hline 110:23 & 237:18 & 214:21 & 1/26/21 2:17 & 102:10 \\
\hline 113:1 & 239:3 & years 12:3 & 1:22156:15 & 1100 6:20 \\
\hline 116:23 & & 169:16,22 & 1:50 207:3 & 271:5 \\
\hline 131:3,12 & X & yellow 70:7 & 1:57119:7 & 112 3: 6, 7 \\
\hline 144:24 & xlsx 200:20 & yesterday & 124:12,17 & 113 3:9 \\
\hline 146:5 & & 100:3 & 103:2 91:1 & 1183:11 \\
\hline 149:3,13 & Y & 109:15,16 & 91:7,8,10 & 11th 271:18 \\
\hline 180:9 & Y 22:24 34:6 & 120:19 & 100:19 & 123:6 100:3 \\
\hline 218:10 & y'all 99:15 & Young 11:3 & 102:2 & 112:3,3,5 \\
\hline 244:12 & yeah 12:22 & youth 45:24 & 207:3 & 112:15 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 332 of 334 PageID \#: 11276
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 115:9 & 271:3 & 150:6,9 & 207:3 & 237:10 \\
\hline 208:10 & 171 4:10 & 266:12 & 211:6 & 244:7 5:22 \\
\hline 12/21/21 & 173 4:11 & 273:15 & 216:4 & 28:9 63:17 \\
\hline 4:17 & 179 4:13 & 200 4:20 7:3 & 218:13 & 119:7 \\
\hline 12:51 102:10 & 17th 61:18 & 20036 6:12 & 219:25 & 124:12 \\
\hline 102:12 & 100:3 & 2019 16:20 & 221:10 & 164:17,19 \\
\hline 1225 6:10 & 146:21,25 & 2026:14 & 237:8 & 2415:10 \\
\hline 126 3:13 & \(183: 1612: 2\) & 202-353- & 239:22 & 2440146:12 \\
\hline 13 3:7 112:5 & 141:6,7,9 & 6:22 & 241:22 & 2475:12 \\
\hline 112:17 & 144:13 & \(202016: 21\) & 242:3 & 2495:14 \\
\hline 138 3:14 & 174:4,14 & 16:22 & 247:15 & 24th 119:19 \\
\hline 143:9 112:4 & 187 4:15 & 17:11 18:6 & 250:8 & 124:17 \\
\hline 113:3,5,6 & 188 4:17 & 20:2 22:15 & 252:22 & 216:4,14 \\
\hline 115:9 & 18th 99:23 & 34:5 38:8 & 257:15 & \(25166: 1\) \\
\hline 119:4 & 270:16 & 43:24 & 2022 1:14 & 269:7 \\
\hline 270:25 & 193:19 & 77:13 & 8:2 13:3,4 & 2545:15 \\
\hline 141 3:16 & 21:25 & 147:14 & 13:14 15:2 & 2575:17 \\
\hline 145 3:19 & 145:1,4 & 175:19 & 16:2 166:8 & 25th 49:21 \\
\hline 151:14 3:11 & 148:19 & 210:7 & 166:15 & 50:14 \\
\hline 8:2 64:23 & 196 4:18 & 20201 7:3 & 171:23 & 65:24 \\
\hline 65:14 & 19th 6:10 & 2021 3: 6, 7 & 270:16 & 264:8 5:22 \\
\hline 118:7,9,20 & 105:22 & 49:16,19 & 271:3,11 & 49:18 \\
\hline 118:22 & 131:18 & 60:9 61:18 & 272:4 & 139:3 \\
\hline 125:8 & 1st 63:2,14 & 68:13 & 2024 270:25 & 165:25 \\
\hline 131:13 & 126:18 & 73:16 82:1 & 205 5:1 & 166:2,6 \\
\hline 133:1,1,5 & 152:25 & 85:13 & 20th 103:5 & 172:9 \\
\hline 133:8 & & 91:10 & 119:20 & 269 270:8 \\
\hline 221:10 & 2 & 100:1 & 146:11 & 26th 55:18 \\
\hline 271:11 & 22:8 22:5,8 & 117:8 & \(212: 74: 1\) & 27 4:10 \\
\hline 272:4 & 32:1,3 & 118:24 & 21:24 60:9 & 171:15,21 \\
\hline 150 3:22 & 40:15 55:4 & 124:17 & 103:5 & 173:9 \\
\hline 152 4:1 & 169:15 & 126:18,24 & 152:16,22 & 27th 44:25 \\
\hline 155 4:2 & 2/3/22 4:8 & 131:21 & 152:23 & 47:1 \\
\hline 163:13 & 2/4/22 4:10 & 134:21 & 189:7,12 & 218:12 \\
\hline 61:18 & 2/7/20 2:8 & 135:1 & 195:23 & 284:11 \\
\hline 126:8,12 & 2:06150:2,3 & 139:3 & 2195:2 & 173:20,23 \\
\hline 126:14 & 2:0776:3 & 142:9,15 & 21st195:11 & 252:22 \\
\hline 131:20 & 82:1,4 & 146:11,25 & 222:8 4:2 & 28th 230:4 \\
\hline 133:1 & 2:1884:3 & 150:15 & 155:7,9,22 & 238:7 \\
\hline 135:1, 8 & 2:19150:3,5 & 156:1 & \(2215: 4\) 6:3 & 253:4 \\
\hline 136:6,11 & 2:28216:4 & 163:20 & 226 5:5 & 29 4:13 \\
\hline 16001 : 17 & 2:30218:13 & 174:4 & 22nd 144:2 & 179:9,11 \\
\hline 163 4:5 & 2:32 230:3 & 176:6 & 23 4:5 & 179:23 \\
\hline 164 4:7 & 2:4268:13 & 179:5 & 163:13,15 & 187:18 \\
\hline 166 4:8 & 2:54:26 & 185:17 & 163:23 & 234:10 \\
\hline 1684 169:13 & 160:15 & 187:15 & 165:18 & 29530 6:21 \\
\hline 17 3:14 & 2:57131:21 & 189:8,12 & 237 5:7 & 271:6 \\
\hline 135:4 & \(203: 22\) & 190:5 & 2395:8 & 29th 182:16 \\
\hline 138:23,24 & 149:22,23 & 196:21,25 & 23rd 176: 6 & 2nd 118:24 \\
\hline
\end{tabular}

Case 3:22-cv-01213-TAD-KDM Document 205-1 Filed 03/03/23 Page 333 of 334 PageID \#: 11277
CAROL CRAWFORD 11/15/2022
\begin{tabular}{|c|c|c|c|c|}
\hline 126:24 & 112:2 & 4/12/21 4:15 & 5:10 & 65 42:24 \\
\hline 156:1,14 & 188:25 & 187:15 & 5/20/21 3: 4 & 65101 6:4 \\
\hline 185:17 & 189:2,4 & 4/14/2021 & 5/26/21 2:19 & \(672: 22\) \\
\hline 219:25 & 31st 40:4 & 200:21 & 5/6/21 3:1 & 682 241:25 \\
\hline 253:13 & 44:1 76:3 & 4/14/21 4:20 & 5:8 & 696-6775 6:5 \\
\hline 3 & 76:13 & 4/15/21 5:4 & 5:07256:25 & 7 \\
\hline 32:10 32:1 & 82:4 84:3 & 226:11 & 5:11253:4 & 72:19 60:3 \\
\hline 33:2,4 & 324 : 18 & 4/29/215:5 & 5:19257:1,3 & 100:1 \\
\hline 55:3, 4, 6 & 196:15,17 & 4/30/215:7 & 5:21172:10 & 136:25 \\
\hline 128:23 & 196:18 & 4/5/2021 & 5:2666:14 & 7 (a) 137:4 \\
\hline 3/10/2021 & 332:10 4:20 & 179:16 & 5:331:15 & 7/20/21 3:16 \\
\hline 257:11 & 200:15,17 & 4/5/21 4:13 & 269:18,19 & 141:11 \\
\hline 3/10/21 5:17 & 200:19 & 4/9/21 4:18 & 5:4763:14 & 7/26/2021 \\
\hline 3/23/2021 & \(345: 112: 3\) & 4:00180:4,7 & @CDC.gov & 139:2 \\
\hline 173:25 & 205:18,19 & 4:19105:22 & 24:14 & 7/26/21 3:14 \\
\hline 3/23/21 4:11 & 206:14 & 4:23247:16 & 500206:2 & 7:3873:16 \\
\hline 3/30/20 2:15 & 211:6 & 4:36166:15 & \(533136: 9,12\) & 80:3 \\
\hline 3/31/20 2:12 & 355:2 & 4:43144:2 & \(539124: 18\) & 7:4674:24 \\
\hline 3/31/21 2:22 & 219:19,21 & 405:10 & 5th 186:7 & 79:14 \\
\hline 3/5/20 2:10 & 219:21 & 241:14,17 & & 711 271:17 \\
\hline 3:01 47:1 & 365:4 221:3 & 241:19 & 6 & \\
\hline 3:0870:4 & 221:5,6 & 40-49185:25 & 62:17 49:1 & 8 \\
\hline 3:10263:15 & 375:5 226:4 & 415 : 12 & 49:4,5 & 82:22 67:12 \\
\hline 3:1673:4 & 226:6,7 & 247:7,9 & 85:13 & 67:14 85:4 \\
\hline 74:12 & \(382: 12\) 5:7 & 42 5:14 67:5 & 128:23 & 85:5 \\
\hline 3:22-cv- & 237:2,4 & 249:7,9 & 169:22 & 8.15_AH \\
\hline 1:5 & 395:8 & \(432: 15\) 5:15 & 239:22 & 3:23 \\
\hline 3:3070:6 & 239:13,16 & 249:11 & 240:24 & 8/18/21 3:19 \\
\hline 177:21 & 239:18 & 254:4,7,8 & 6/10/2021 & 145:6 \\
\hline 3:30-4:30 & 3rd 46:2 & 445:17,22 & 247:13 & 8/19 150:15 \\
\hline 44:9 & 126:16 & 256:21 & 6/10/21 5:12 & 8/19/21 3:22 \\
\hline 3:35 27:5 & 131:20 & 257:4,7 & 6/2/21 3:11 & 8:13142:15 \\
\hline 3:37205:9 & 134:21 & 450 6:11 & 6/29/2022 & 8:39 60:9 \\
\hline 205:10 & 135:1,9 & 492 17 & 254:11 & 8:49126:19 \\
\hline 3:51205:10 & 145:17,18 & \(496206: 1\) & 6/29/22 5:15 & 8:51214:9 \\
\hline 205:11 & 166:8,15 & \(497206: 1\) & 6/3/21 3:13 & 8:5534:5 \\
\hline 304:15 47:7 & 172:10 & \(498206: 1\) & 6/30/2021 & 80228:14,16 \\
\hline 187:9,11 & 253:14 & 499 206:1 & 205:21 & 800-number \\
\hline 216:16 & & 4pm 179:24 & 206:17 & 11:17 \\
\hline 271:17 & 4 & 4th 171:23 & 6/30/21 5:1 & 15:18 \\
\hline 30th 43:23 & 42:12 38:18 & & 6:16145:19 & 853 : 1 \\
\hline 68:13 73:3 & 38:20 44:1 & 5 & 6:1964:24 & 869-5210 \\
\hline 73:16 & 49:4 & 52:15 4:10 & 6:23234:10 & 6:14 \\
\hline 74:24 & 128:23 & 34:5 43:10 & 6:37238:7 & 877 6:5 \\
\hline 79:14 80:3 & 169:22 & 156:2 & 6:58126:25 & 899 6:4 \\
\hline 237:8 & 187:15 & 163:19 & 602:19 & 8th 142:15 \\
\hline 250:8 & 4-13-21 & 5-11 4:3,6 & 228:14,16 & 163:20 \\
\hline 314:17 & 200:20 & 5/10/21 3:2 & \(63101271: 18\) & 196:25 \\
\hline
\end{tabular}

CAROL CRAWFORD 11/15/2022
```

